AstraZeneca

Abbreviated Clinical Study Report

Drug Substance	Fostamatinib
Study Code	D4302C00001
Edition Number	1
Date	15 January 2014

A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Study dates:
First patient enrolled: 18 January 2012
Last patient last visit: 3 patients are ongoing
Data cut-off for this report: 30 October 2013

Phase of development:
II

Co-ordinating Investigator:
Ian W Flinn, MD, PhD
Sarah Cannon Research Institute (SCRI)
3322 West End Ave., Suite 900
Nashville, TN 37203
1-877-MY-1-SCRI
asksarah@scresearch.net

Sponsor's Responsible Medical Officer:
Jeffrey Skolnik, MD
AstraZeneca, LP
Oncology, Clinical Development
1800 Concord Pike
Wilmington, DE 19850
1-302-885-7686

Contract Research Organization:
Sarah Cannon Research Institute (SCRI)
Development Innovations, LLC
3322 West End Ave., Suite 900
Nashville, TN 37203
1-877-MY-1-SCRI
asksarah@scresearch.net

This study was performed in compliance with Good Clinical Practice, including the archiving of essential documents

TABLE OF CONTENTS PAGE

LIST OF TABLES

LIST OF APPENDICES

If required by a regulatory agency, Appendices 12.3 Case Report Forms and 12.4 Patient Data (listings) will be included in the appropriate section of the application.

LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

The following abbreviations and special terms are used in this study report.

Abbreviation or special term	Explanation
aCSR	Abbreviated clinical study report
AE	Adverse event
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
ANC	Absolute neutrophil count
AST	Aspartate aminotransferase
BCA	B-Cell receptor activation
CI	Confidence interval
CRF	Case report form
CSP	Clinical study protocol
CT	Computerized tomography (scan)
CTCAE	Common Terminology Criteria for Adverse Events
CV	Cardiovascular
CVAC	Cardiovascular Adjudication Committee
DBL	Data base lock
DLBCL	Diffuse large B-cell lymphoma
DILI	Drug-induced liver injury
DoR	Duration of response
DRR	Durable response rate
ECG	Electrocardiogram
ECOG	Eastern Cooperative Oncology Group
Endpoint	A status of the patient that constitutes the ‘endpoint’ of a patient’s participation in a clinical study and that is used as the final outcome.
GCP	Good Clinical Practice
ICH	International Conference on Harmonisation
IEC	Independent Ethics Committee
IRB	Institutional Review Board
ITT	Intent-to-treat
LVEF	Left ventricular ejection fraction
ORR	Overall response rate
PGx	Pharmacogenetic

Abbreviation or special term	Explanation
PHC	Personalized healthcare
PFS	Progression-free survival
PK	Pharmacokinetic
PRO	Patient-reported outcomes
PT	Preferred term
SAE	Serious adverse event
SAP	Statistical Analysis Plan
SCRI	Sarah Cannon Research Institute
SOC	System organ class
StD	Standard deviation
Patient identifier	Only one variable is used to identify each patient within the reporting database. This identifier is a combination of the Study Number, and the enrolment Code. Within this study report, the enrolment code alone (eg, 3000001) is used to reference individual patients in-text within the CSR and in tables and listings.

1. ETHICS

See Section 8.1 of the clinical study protocol (CSP) in Appendix 12.1.1.

2. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

See Section 9 of the CSP in Appendix 12.1.1.

3. INTRODUCTION

This study is being submitted as an abbreviated clinical study report (aCSR) because AstraZeneca (AZ) returned the rights to fostamatinib to Rigel Pharmaceuticals, who decided not to progress development in diffuse large B-cell lymphoma (DLBCL). The decision to stop development of fostamatinib was not due to any clinical safety reason. Patient enrolment was completed on 14 June 2013. However three patients, considered by the Investigator to still be receiving clinical benefit, continue to receive fostamatinib.

This report presents the data of the 68 patients with DLBCL treated with fostamatinib.

This study was conducted at 23 study centres in the United States and 2 study centres in the United Kingdom (see Appendix 12.1.4.1).

See Section 1 of the CSP in Appendix 12.1.1 for further information.

4. STUDY OBJECTIVES

Please see Section 2 of the CSP in Appendix 12.1.1 for more details.

5. STUDY PLAN AND PROCEDURES

5.1 Overall study design

This study was originally designed as a randomised, two-arm double-blind, multi-centre study of two doses of fostamatinib, 100 mg and 200 mg bid, in patients with relapsed or refractory DLBCL. Anti-tumour activity had been observed in patients with DLBCL when given 200 mg bid fostamatinib in a previous study by Rigel Pharmaceuticals (C935788-009). Since the 100 mg bid dose was felt likely to be better tolerated for long-term administration, and had not been previously tested in lymphoma trials, the lower dose was included in the initial design of this study. The aim of the study was to evaluate the efficacy and tolerability of both doses of fostamatinib, and to select a dose for further study. With the implementation of Protocol Amendment 1, treatment with lower dose fostamatinib (100 mg bid) was stopped and

the higher dose of fostamatinib (200 mg bid) was given to enrolling patients. Treatment assignment was no longer blinded. Thirty additional patient who were biologically evaluable (defined as patients with adequate fresh tumour biopsy material) were planned for this portion of the study.

The primary objective of this study was to evaluate the efficacy of fostamatinib in patients with relapsed or refractory DLBCL by assessing the overall response rate (ORR). In addition, patients in whom fostamatinib was thought to demonstrate efficacy (both frequency and duration of response [DoR]) were explored by sub-classification into B-cell receptor activation positive and negative (BCA +/-) segments. The hypothesis explored was that patients whose tumours demonstrated B-cell signalling were more likely to respond, or would respond for longer duration, to fostamatinib.

In order to adequately assess the relevance of responses in the study (and responses in BCA+ and BCA- patient subgroups), the durable response rate (DRR) had to be assessed (defined as the number [%] of patients having complete remission [CR] or partial remission [PR] with a DoR of at least 24 weeks), and the DoR for patients.

Consent was obtained from patients to provide a sample of archival tumour biopsy material for molecular analysis, and one fresh pre-treatment biopsy in this study, to: a) support generation of BCA+ and BCA- signatures for future selection of responding patients, b) confirm pathway inhibition by analysis of relevant biomarkers, and c) help inform the dose selection for future studies. In addition, optional tumour biopsies were requested from consenting patients at progression.

Blood samples for pharmacogenetic (PGx) analysis, for the determination of *UGT1A1* genotype and for other exploratory analyses, were collected during the study.

The CSP was amended because of a lack of an objective response in the first 35 patients evaluated. Toxicity profiles of both doses were reviewed in a blinded fashion and were found to be acceptable and similar to those reported in the previous Rigel Pharmaceuticals, Inc Phase II study. The lower fostamatinib dose (100 mg bid) was omitted from the study, and all subsequent patients received the higher dose (200 mg bid). In addition, patients previously randomised and receiving blinded treatment were unblinded, and if assigned 100 mg bid, were offered dose escalation. The two patients still on study at the time of the amendment were unblinded; one patient (7808001) had their dose escalated from 100 mg bid to 200 mg bid at the time of the implementation of CSP Amendment 1 (see Appendix 12.2.11). This patient was analysed with the 100 mg bid group.

For additional details see CSP Amendment #1 in Appendix 12.1.1.

5.2 Rationale for study design, doses, and control groups

See Section 1.3 of the CSP in Appendix 12.1.1.

5.3 Selection of study population

See Section 4 of the CSP in Appendix 12.1.1.

5.4 Treatments

Fostamatinib and matching placebo were administered orally as oval blue film-coated tablets containing 50 mg or excipient, respectively.

- 100 mg = 2 fostamatinib tablets twice daily plus 2 placebo tablets twice daily (removed with CSP Amendment #1 [see Appendix 12.1.1])
- 200 mg = 4 fostamatinib tablets twice daily

A listing of batch numbers is presented in Appendix 12.1.6.

5.5 Measurements of study variables and definitions of outcome variables

See Section 11.1 of the CSP in Appendix 12.1.1.

5.6 Data management and quality assurance

Quality of study data was assured through planned monitoring of investigational sites, provision of appropriate training for study personnel, and use of data management procedures, as detailed in Sections 9 and 10 of the CSP (see Appendix 12.1.1).

5.7 Statistical methods and determination of sample size

See Section 12 of the CSP in Appendix 12.1.1 and Section 4 of the Statistical Analysis Plan (SAP) in Appendix 12.1.9 for further information.

5.8 Clinical study protocol amendments and other changes in the conduct of the study or planned analyses

5.8.1 Changes in the conduct of the study

There were 2 amendments to the CSP made after the start of patient recruitment. The major changes made by the amendments are presented in Table 1.

Table 1 Protocol amendments

Number	Date of Amendment Approval	Key details of amendment
Amendments made after the start of patient recruitment		
1[a]	29 January 2013	Overall study design changed. Randomisation of patients to one of two treatment arms was discontinued. Treatment with lower dose fostamatinib (100 mg bid) was stopped and the higher dose of fostamatinib (200 mg bid) was given to enrolling patients. Treatment assignment no longer blinded. Any patient previously randomised and receiving blinded treatment was unblinded and given the opportunity to dose escalate, if previously assigned to the fostamatinib 100 mg bid dose. References to two doses of fostamatinib were removed. Reference to matching placebo was removed. Reference to methods for ensuring blinding and method for unblinding were removed. The study design was amended to enrol an additional 30 biologically evaluable patients to fostamatinib 200 mg bid.
2[a]	03 October 2013	Protocol Sections 3.1, 5.5.4, 5.6, 5.7, 5.8, 6.1, 6.2.9, 6.4.4, 9.5, 12.2.6, and 13.2 were revised to identify database lock (DBL) as the end of the study. The amendment included patient care instructions for the continuation of treatment after DBL, and investigator reporting of serious adverse events (SAEs).

a This protocol amendment was approved by AZ before being submitted to a regulatory authority and/or an Institutional Review Board (IRB)/Independent Ethics Committee (IEC).

5.8.2 Changes to planned analyses

See the CSP Amendment 1 in Appendix 12.1.1.

6. STUDY PATIENTS

6.1 Disposition

Patients were randomly assigned treatment with either 100 mg bid or 200 mg bid fostamatinib according to the original protocol design. Prior to the implementation of CSP Amendment 1, 21 and 22 patients had been randomized to the 100 and 200 mg groups, respectively. After the implementation of that amendment (see Appendix 12.1.1), it was recommended that patients previously randomised and receiving blinded treatment be unblinded. The two patients still on study at the time of the amendment were unblinded; the first patient's dose was escalated to 200 mg bid (Patient 7808001), and it was determined that the second patient

required a dose reduction (Patient 2813002) (see Appendix 12.2.11). These patients were not included in the additional 30 patient count that was to be enrolled to evaluate the activity of fostamatinib 200 mg bid in this patient population.

Informed consent was received from 102 patients, 3 of whom were not screened. There were 31 screen failures. The reasons for screen failure are presented in Appendix 12.2.2.1. Of the 68 patients treated, 21 were in the 100 mg group and 47 were in the 200 mg group. Fifty-eight patients (85.3%) completed the study (ended study treatment only due to objective or subjective disease progression) and 7 patients (10.3%) were withdrawn due to adverse events (AEs) (5 [7.4%]), subject decision (1 [1.5%]), or another reason (switched to a different chemotherapy treatment; 1 [1.5%])(see Table 11.1.1 and Appendix 12.2.1.2). Three patients (4.4%) continue to receive treatment with fostamatinib at the time of this report (see Appendix 12.2.1.1).

Objective disease progression and subjective disease progression were the major reasons for discontinuation of study treatment (44 [64.7%] and 13 [19.1%], respectively)(see Table 11.1.1).

6.2 Protocol deviations

Protocol deviations occurred intermittently during the study with 136 reported. The majority of the deviations were for laboratory and study assessments (83%) that were not collected or were not collected at the time, or as required, in the CSP. For example, of the study assessment deviations, 16% were blood pressure readings that were not obtained according to the CSP, 21% were creatine kinase samples that were not collected, and 9% were electrocardiograms (ECGs) that were not obtained according to the CSP. In addition, reporting or procedure errors (12%) occurred, such as using the incorrect gauge needle for tumour biopsy, and patient non-compliance (4%).

One site reported an SAE for Patient 7808001 greater than 24 hours after notification of the event. The site was first notified of the SAE on 01 April 2013 and SCRI Innovations Safety Department did not receive the SAE report until 03 April 2013. The site was subsequently re-trained on SAE reporting procedures, and the violation was reported to the IRB.

The following CSP deviations were noted:

- Patient 7815002 was enrolled into the study at the screening visit with an Eastern Cooperative Oncology Group (ECOG) Performance Status of 1. However, the ECOG value captured on Day 1 of Cycle 1 was 2.
- Patient 7808007 enrolled into the trial with a blood pressure of 155/85 mmHg. The treating investigator did not consider this to meet the exclusion criteria of uncontrolled hypertension.

Of the CSP deviations identified, none affected the overall safety or conduct of the study.

The details of these CSP deviations are noted in the monitoring reports contained in the Master Study File.

6.3 Patients analysed (analysis sets)

There were 4 study populations defined for this study:

- The full analysis set consisted of all randomised or dosed patients on the basis of randomised or assigned treatment, regardless of the treatment actually received. Patients who were randomised but did not subsequently go on to receive study treatment were included in the full analysis set.
- The safety analysis set consisted of all patients who received at least 1 dose of randomised study treatment irrespective of follow-up.
- The pharmacokinetic (PK) analysis set consisted of patients who received at least one dose of fostamatinib and who had at least one plasma concentration variable above the lower limit of quantitation (results presented in a separate report).
- The personalised healthcare (PHC) biomarkers analysis set consisted of patients from whom a pre-treatment fresh tumour biopsy and/or archival tumour biopsy were obtained. These samples had to have passed appropriate quality control (QC) checks to generate valid gene expression data. The results were not analysed for this aCSR.

Each patient received the dose level that they were intended to receive upon randomization before CSP Amendment 1 was implemented (after which randomisation was not necessary). Therefore, each patient was assigned to the same dose arm (either 100 mg BID or 200 mg BID) in both the full analysis set and the safety set populations.

Details of analysis sets are present in Table 11.1.2.

6.4 Demographic and other patient characteristics

All patients entering this study had relapsed or refractory DLBCL and had received previous chemotherapy (see Table 11.1.5). The majority of patients had received 2 or 3 (30.9% and 27.9%, respectively) previous chemotherapy treatments with R-CHOP or an equivalent chemo-immunotherapy (see Table 11.1.8).

Most patients were Caucasian (91.2%) and male (69.1%). The mean age (±standard deviation [StD]) was 63.6 ±12.6 years. The youngest patient was 29 years-of-age and the oldest was 86 years-of-age. The majority of patients were ≥50 and <75 years of age.

The demographic and key baseline characteristics of study patients are listed in Table 11.1.3, Table 11.1.4, and Appendix 12.2.4.1. Pre-existing and current medical histories are presented in Table 11.1.9.1, Table 11.1.9.2, and Appendix 12.2.4.2. Relevant surgical history is presented in Table 11.1.10 and Appendix 12.2.4.3. Disease characteristics and extent of disease are presented in Table 11.1.11, Table 11.1.12, and Appendix 12.2.4.4. Time from most recent disease progression to randomisation is presented in Table 11.1.13. A summary of descriptive statistics for biomarker baseline assessments is presented in Table 11.1.17.

6.5 Use of concomitant medication and treatment compliance

6.5.1 Concomitant medication after study entry

Summaries of allowed and disallowed concomitant medication use during the study are presented in Table 11.1.14 and Table 11.1.15, respectively. No patient took any disallowed medication.

6.5.2 Treatment compliance

Fostamatinib is an oral medication that was taken at home by the study participants who were to report any missed doses. Compliance was determined by the following formula: 100 x (total number of study drug tablets dispensed) - (total number study drug tablets returned)/(total number study drug tablets dispensed).

Details of study drug compliance are presented in Table 11.1.16 and Appendix 12.2.5.4.

6.6 Conclusions on study patients

The patients treated in this study represented the planned target population. The data for 68 patients is presented in this aCSR. Fifty-eight patients completed the study, 7 were withdrawn due to AEs, subject decision, or another reason, and 3 patients continue to receive treatment with fostamatinib at the time of this report. Most patients were male Caucasians aged between 50 and 75 years.

Disease progression was the major reason for discontinuation of study treatment. The usage of concomitant medication was reasonable in the context of this study.

7. EFFICACY EVALUATION

7.1 Efficacy results

The primary objective of this study was to evaluate the efficacy of fostamatinib in patients with relapsed or refractory DLBCL by assessing the ORR.

The best overall tumour response during the study was one patient (4.8%) with a complete response and one patient (4.8%) with a partial response, both in the 100 mg fostamatinib group. In addition, stable disease was demonstrated by 2 patients (9.5%) in the 100 mg group and 5 patients (10.6%) in the 200 mg group. Response assessments were performed at scheduled time points throughout the study as detailed in the study plan (see Section 12.2.1 of the CSP in Appendix 12.1.1).

Patients were assessed using the revised response criteria for malignant lymphoma (Cheson et al 2007). Patients were assessed for response, with CT and FDG-PET scans at 8 weeks, then every 12 weeks until radiological progression by clinical CT. A summary of best objective response is presented in Table 11.2.2.1. The ORR rates observed were 9.52% (95% confidence intervals [CIs]: 1.17, 30.38) in the 100 mg group and 0.00% (95% CIs: 0.00,7.55) in the 200 mg group. The primary and secondary analyses of ORR are presented in Table 11.2.2.2 and Table 11.2.2.3, respectively. Progression status is presented in Table 11.2.2.4. Patients censored for progression at more than 8 weeks before the data cut-off

are presented in Table 11.2.2.9. Median progression-free survival (PFS) and a Kaplan-Meier plot of PFS are presented in Table 11.2.2.5 and Figure 11.2.2.1, respectively. Details of overall response are presented in Appendix 12.2.6.2.8.

A summary of target lesion size by percentage change from baseline is presented in Table 11.2.2.6. Lists of target lesions, non-target lesions, and new lesions are presented in Appendix 12.2.6.2.1.1-2, Appendix 12.2.6.2.2.1-2, Appendix 12.2.6.2.3, and Appendix 12.2.6.2.4, respectively. Subsequent cancer therapy relative to progression is presented in Table 11.2.2.7. Days between tumour assessments is presented in Table 11.2.2.8.

7.2 Pharmacokinetic results

The results of the PK analyses are reported outside of this aCSR. Please see Section 11.2.1 for the table and figures included in this report. A listing of the fostamatinib (R406 metabolite) plasma concentration PK data is presented in (Appendix 12.2.6.1.1).

7.3 Pharmacodynamic results

Overall patient response to fostamatinib was limited, precluding biomarker development.

7.4 Pharmacokinetic/pharmacodynamic relationship

Not applicable

7.5 Pharmacogenetic results

Exploratory PGx research from the optional pre-treatment blood samples will be reported outside of this aCSR.

7.6 Potential issues affecting efficacy, pharmacokinetic, pharmacodynamics, and pharmacogenetic results

Not applicable

7.7 Efficacy evaluation conclusions

There were few overall responses across both doses (0 in the 200 mg bid group and 2 in 100 mg bid group) leading to an overall proportion of 4.2%, comparing this to standard of case in this population of 30% (Coiffer et al 1998, Gottlieb et al 1973, and Jones et al 1972). It does not appear that either dose will be efficacious in late-line DLBCL.

8. SAFETY EVALUATION

8.1 Extent of exposure

Treatment compliance was calculated to be 66.5% (±20.6%) for the 100 mg group and 73.4% (±18.5% for the 200 mg bid group (see Table 11.1.16). The mean of actual treatment duration for the 100 mg bid and 200 mg bid groups was 69.0 days and 33.8 days, respectively. The maximum numbers of days that any patient was on treatment were 407 days and 118 days, respectively. The summary table of extent of exposure is presented in Table 11.3.1.1.

Listings of active treatment and dose modifications are presented in Table 11.3.1.2, Appendix 12.2.5.1, and Appendix 12.2.5.3. Cumulative exposure is presented in Table 11.3.1.3. Dose intensity of fostamatinib is presented in Table 11.3.1.4.

8.2 Adverse events

8.2.1 Categories of adverse events

There were 2 deaths related to SAEs, 13 patients experienced SAEs that did not lead to death, and 2 patients experienced AEs and 3 patients experienced SAEs leading to discontinuations due to fostamatinib. Every patient in the 100 mg bid group experienced at least 1 AE and 93.6% of patients in the 200 mg bid group experienced at least 1 AE. Adverse events by category are presented in Table 11.3.2.1.

8.2.2 Adverse events by system organ class and preferred term

The majority of patients experienced AEs in the gastrointestinal disorders system organ class (SOC) (57.1% in the 100 mg group and 68.1% in the 200 mg group). At least 40% of total patients experienced AEs in the general disorders, investigations, and blood and lymphatic system disorders SOCs (48.5%, 48.5%, and 44.1%, respectively) (see Table 11.3.2.2).

In general, the numbers of patients in the 100 mg bid and 200 mg bid dosing groups who experienced AEs in any one SOC were similar with the exception of nervous system disorders (14.3% versus 36.2%, respectively), metabolism and nutrition disorders (9.5% versus 31.9%, respectively), skin and subcutaneous tissue disorders (14.3% versus 27.7%), and psychiatric disorders (9.5% versus 19.1%).

A summary of AEs and event rates by SOC and preferred term (PT) is presented in Table 11.3.2.2 and listed in Appendix 12.2.7.1.1 and Appendix 12.2.7.1.2. Adverse events by SOC, PT, and maximum reported Common Terminology Criteria for Adverse Events (CTCAE) grade) are presented in Table 11.3.2.3. Adverse events of CTCAE Grade 3 or higher by SOC and PT are presented in Table 11.3.2.4. Causally-related AEs as determined by the Investigator by SOC and PT and by PT, presented by maximum reported CTCAE grade, are presented in Table 11.3.2.5 and Table 11.3.2.6, respectively.

8.3 Deaths, serious adverse events, discontinuation of investigational product due to adverse events, and other significant adverse events

8.3.1 Deaths

There were a total number of 18 deaths during the study, 16 of which were related to the disease under investigation. Two AEs had an outcome of death. Full narratives of these 2 events are presented in Section 11.4 for Patient 7815008 (pneumonitis; possibly related to fostamatinib) and Patient 7822003 (pneumonia; not related to fostamatinib).

A table of all deaths, a listing of deaths, and key patient information for AEs with an outcome of death are presented in Table 11.3.3.1, Table 11.3.3.2.1, and Table 11.3.3.2.2, respectively). Adverse events with an outcome of death by SOC and PT and AEs with outcome of death, Investigator-determined causally-related to study treatment, by SOC and PT are presented in Table 11.3.3.3 and Table 11.3.3.4, respectively.

8.3.2 Serious adverse events

Fifteen patients (22.1%) experienced at least 1 SAE during the study. Full narratives for these events are presented in Section 11.4.

Serious AEs by SOC and PT and key patient information by SAE are presented in Table 11.3.4.1 and Table 11.3.4.2, respectively. Serious AEs causally-related to study treatment as determined by the Investigator are presented by SOC and PT in Table 11.3.4.3.

There are 3 AEs marked "serious" in the clinical database that were initially reported as SAEs, but subsequently retracted as SAEs. These events were overlooked during the final safety/clinical database reconciliation. All events have been researched and confirmed to not meet "serious" criteria. Footnotes in the data listings reflect where these events are presented.

- Patient 7815010: Brain mass; this event was retracted as an SAE on 15 October 2013. This patient was a screen failure.
- Patient 7801007: Cellulitis; this event was retracted as an SAE on 5 October 2012.
- Patient 7801007: Seizure; this event was amended to Vasovagal Syncope on 4 October 2012, but was later incorrectly added back to the EDC as an SAE.

8.3.3 Adverse events leading to treatment discontinuation or dose modification

Five patients experienced AEs or SAEs that led to treatment discontinuation. Adverse events leading to discontinuation of fostamatinib by SOC and PT and key patient information by AE are presented in Table 11.3.5.1.1 and Table 11.3.5.1.2, respectively. Adverse events leading to discontinuation causally-related to study treatment as determined by the Investigator are presented by SOC and PT in Table 11.3.5.1.3. Full narratives for patients experiencing SAEs that led to treatment discontinuation are presented in Section 11.4.

Adverse events leading to dose modification and dose reduction are presented by SOC and PT in Table 11.3.5.2.1 and Table 11.3.5.2.2, respectively.

8.3.4 Other significant adverse events

No AEs were classified as "other significant AEs" in this study (see Table 11.3.6.1.1).

8.4 Clinical laboratory evaluation

Summary tables pertaining to this section are presented in Section 11.3.7.

Haematology and clinical chemistry laboratory variables over time, as change from baseline over time, and as change from baseline to maximum observation on treatment are presented in Table 11.3.7.1.1, Table 11.3.7.1.2, and Table 11.3.7.1.3, respectively. Haematology and clinical chemistry, CTCAE grade changes from baseline to maximum values during treatment are presented in Table 11.3.7.1.4.

Clinical chemistry, CTCAE grade changes from baseline to maximum values during treatment for electrolytes are presented in Table 11.3.7.1.5. Individual patient data for ALT or AST, and bilirubin, elevations at any time are presented in Table 11.3.7.2.

Urinalysis laboratory variables over time are presented in Table 11.3.7.1.6.

Haematology and clinical chemistry figures are presented from Figure 11.3.7.1.1.1 through Figure 11.3.7.1.28.3.

8.5 Vital signs, electrocardiograms, physical findings and other observations related to safety

Summary tables pertaining to this section are presented in Section 11.3.8.

Vital signs variables over time, as change from baseline over time, as change from baseline to maximum value during treatment, and as changes outside predefined criteria are presented in Table 11.3.8.1.1, Table 11.3.8.1.2, Table 11.3.8.1.3, and Table 11.3.8.1.4, respectively. Figures of vital signs data are presented from Figure 11.3.8.1.5.1 through Figure 11.3.8.1.8.2.

Electrocardiogram variables over time, as change from baseline over time, and as change from baseline to maximum value during treatment are presented in Table 11.3.8.2.1, Table 11.3.8.2.2, and Table 11.3.8.2.3, respectively. QTcF and QTcF intervals outside of defined criteria, at any observation on treatment, are presented in Table 11.3.8.2.4. Figures of electrocardiogram data are presented from Figure 11.3.8.2.1 through Figure 11.3.8.7.2.

World Health Organization (WHO) performance status, baseline values versus last observation on treatment values are presented in Table 11.3.8.3.

8.6 Cardiovascular events evaluation and adjudication

As required in the Rheumatoid Arthritis program, AZ required utilization of a Cardiovascular Adjudication Committee (CVAC) for this trial. The CVAC was an independent expert advisory group responsible for reviewing data to confirm diagnoses of potential cardiovascular (CV) events, and was comprised of a chair and 2 additional members, all whom had a specialty in cardiovascular medicine and oncology. The CVAC was required to adjudicate all deaths reported as SAEs, as well as all specified nonfatal CV events reported as an SAE, including but not limited to: myocardial infarction, stroke, transient ischemic attack, and hospitalization for unstable angina, hospitalization for heart failure, cardiac arrhythmias, venous and peripheral arterial thromboembolic events and serious hypertensive events. Only those events occurring in patients receiving at least one dose of fostamatinib were adjudicated.

There were 15 events adjudicated for this trial. Three events (20%) were determined to be CV events (Patient 7801007: vasovagal syncope; Patient 7810001: supraventricular tachycardia; and Patient 7817005: sinus ventricular tachycardia), 5 events (33%) were considered disease progression, 3 events (20%) were of unknown etiology, and the remainder of the 4 events (27%) were considered related to other intercurrent illnesses. One event was left to be adjudicated at the end of study, however, information requested from the site to perform adjudication was not received after multiple attempts to receive this information and the decision was made by AZ and SCRI Innovations to not move forward with the adjudication.

8.7 Safety evaluation conclusions

Fostamatinib was generally well tolerated in this patient population.

9. DISCUSSION AND OVERALL CONCLUSIONS

AstraZeneca returned the rights to fostamatinib to Rigel Pharmaceuticals, Inc who decided not to progress development in DLBCL. This decision was not due to any fostamatinib clinical safety reason. This report presents the safety data and minimal efficacy data of the 68 patients with DLBCL treated with fostamatinib in this clinical trial. The PK data are described in a stand-alone report.

Overall conclusions of this study are:

- Fostamatinib was generally well tolerated in this patient population.
- One CR and one PR were seen in this study.

10. REFERENCE LIST

Cheson et al 2007
Cheson BD, Pfistner B, Malik E, et al. Revised Response Criteria for Malignant Lymphoma. J Clin Oncol. 2007;25:579-86.

Coiffer et al 1998
Coiffer B, Haioun C, Engert A et al. Rituximab (Anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II trial. Blood. 1998. 92; 1927-32.

Gottlieb et al 1973
Gottlieb JA, Gutterman JU, McCredie KB, Rodriguez V and Frei E III. Chemotherapy of malignant lymphomas with adriamycin. Cancer Research. 1973;33:3024-8.

Jones et al 1972
Jones SE, Rosenberg SA Kaplan HS, Kadin ME and Dorfman RF. Non Hodgkin's Lymphoma II. Single Agent chemotherapy. Cancer. 1972;30:31-8.

11. SUMMARY TABLES AND FIGURES, LISTINGS, AND NARRATIVES

11.1 Demographic, baseline, concomitant medication, and other patient-specific characteristics

11.2 Efficacy and pharmacokinetic data

11.2.1 Pharmacokinetic data

Pharmacokinetic data will be described in a separate report outside of this aCSR.

11.2.2 Efficacy data

11.3 Safety evaluation data

11.3.1 Exposure

11.3.2 All adverse events

11.3.3 Deaths

11.3.4 Serious adverse events

11.3.5 Discontinuation of investigational product due to adverse events

11.3.6 Other significant adverse events

Not done

11.3.7 Clinical laboratory evaluation

11.3.8 Vital signs, ECGs, physical findings, and other observations

11.4 Patient safety narratives

The patient safety narratives for patients with SAEs or AEs leading to treatment discontinuation are presented in this section.

Table 11.1.1 Patient Disposition
(All Patients)

	Number (%) of patients		
	100mg BID	**200mg BID**	**Total**
Patients enrolled[a]			102
Patients randomized	21 (100.0)	47 (100.0)	68 (100.0)
Patients who were not randomized			34
Full analysis set	21 (100.0)	47 (100.0)	68 (100.0)
Patients who received treatment	21 (100.0)	47 (100.0)	68 (100.0)
Patients who did not receive treatment	0 (0.0)	0 (0.0)	0 (0.0)
Patients who discontinued treatment	19 (90.5)	46 (97.9)	65 (95.6)
Subject Decision	0 (0.0)	1 (2.1)	1 (1.5)
Adverse Event	1 (4.8)	4 (8.5)	5 (7.4)
Objective Disease Progression (Condition Under Investigation Worsened)	14 (66.7)	30 (63.8)	44 (64.7)
Subjective Disease Progression	4 (19.0)	9 (19.1)	13 (19.1)
Other	0 (0.0)	2 (4.3)	2 (2.9)
Patients ongoing study	2 (9.5)	1 (2.1)	3 (4.4)
Patients who completed study	18 (85.7)	40 (85.1)	58 (85.3)
Patients withdrawn from study	1 (4.8)	6 (12.8)	7 (10.3)
Subject Decision	0 (0.0)	1 (2.1)	1 (1.5)
Adverse Event	1 (4.8)	4 (8.5)	5 (7.4)
Other	0 (0.0)	1 (2.1)	1 (1.5)

[a] Informed consent received.

Program Name: RTTDEM010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.2 Analysis sets

	Number of patients		
	100mg BID	200mg BID	Total
Patients randomized	21	47	68
Patients included in full analysis set	21	47	68
Patients included in safety analysis set	21	47	68
Patients excluded from safety analysis set	0	0	0
Did not receive treatment	0	0	0
Other reason for exclusion	0	0	0
Patients included in PK analysis set	20	45	65
Patients excluded from PK analysis set	1	2	3
No PK data available	1	2	3
No plasma concentration variable above LOQ	0	0	0
Other reason for exclusion	0	0	0
Patients included in PHC biomarker analysis set	0	0	0
Patients excluded from PHC biomarker analysis set	21	47	68
No pre-treatment fresh tumour biopsy nor archival tumour biopsy obtained	21	47	68
Other reason for exclusion	0	0	0

Full analysis set - all randomized patients analysed on an ITT basis.
Safety analysis set - all patients who received at least one dose of study treatment.
PK analysis set - all patients who received at least one dose of fostamatinib and who have at least one plasma concentration variable above the LOQ.
PHC biomarker analysis set - all patients for whom pre-treatment fresh tumour biopsy and/or archival tumour biopsy have been obtained and these samples have passed the appropriate quality control (QC) checks to generate valid gene expression data.
Note: PHC biomarker results were not provided and therefore not analysed for this abbreviated Clinical Study Report.

Program Name: RTTDEM030.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.3 Demographic Characteristics
(Full analysis set)

Demographic characteristic		100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Age (years)	n	21	47	68
	Mean	62.9	63.9	63.6
	SD	12.38	12.78	12.57
	Median	64.0	67.0	65.0
	Min	31	29	29
	Max	84	86	86
Age group (years) n (%)	>=18 - <50	2 (9.5)	6 (12.8)	8 (11.8)
	>=50 - <65	9 (42.9)	15 (31.9)	24 (35.3)
	>=65 - <75	6 (28.6)	15 (31.9)	21 (30.9)
	>=75	4 (19.0)	11 (23.4)	15 (22.1)
	Total	21 (100.0)	47 (100.0)	68 (100.0)
Sex n (%)	Female	9 (42.9)	12 (25.5)	21 (30.9)
	Male	12 (57.1)	35 (74.5)	47 (69.1)
	Total	21 (100.0)	47 (100.0)	68 (100.0)
Race n (%)	Asian	0 (0.0)	2 (4.3)	2 (2.9)
	Black Or African American	2 (9.5)	0 (0.0)	2 (2.9)
	Other	0 (0.0)	2 (4.3)	2 (2.9)
	White	19 (90.5)	43 (91.5)	62 (91.2)
	Total	21 (100.0)	47 (100.0)	68 (100.0)
Ethnic group n (%)	Hispanic Or Latino	0 (0.0)	3 (6.4)	3 (4.4)
	Not Hispanic Or Latino	21 (100.0)	44 (93.6)	65 (95.6)
	Total	21 (100.0)	47 (100.0)	68 (100.0)

n Number of patients in category or analysis. N Number of patients in treatment group. SD Standard deviation. Min Minimum. Max Maximum.

Program Name: RTTDEM040.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.4 Patient characteristics
(Full analysis set)

Patient Characteristic		100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Height (cm)	n	20	47	67
	Mean	168.87	170.90	170.29
	SD	8.340	10.150	9.629
	Median	170.19	172.20	171.00
	Min	155.0	142.0	142.0
	Max	184.9	187.6	187.6
Weight (kg)	n	19	47	66
	Mean	77.27	80.46	79.54
	SD	17.133	20.808	19.743
	Median	78.93	78.84	78.89
	Min	47.5	47.2	47.2
	Max	106.0	139.3	139.3

n Number of patients in category or analysis. N Number of patients in treatment group. SD Standard deviation. Min Minimum. Max Maximum.

Program Name: RTTDEM045.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.5 Previous disease-related treatment modalities and therapies
(Full analysis set)

	Number (%) of patients		
Previous treatment modalities	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
CHEMOTHERAPY	21 (100.0%)	47 (100.0%)	68 (100.0%)
RADIOTHERAPY	6 (28.6%)	19 (40.4%)	25 (36.8%)
IMMUNOTHERAPY	7 (33.3%)	18 (38.3%)	25 (36.8%)
HORMONAL THERAPY	0 (0.0%)	0 (0.0%)	0 (0.0%)
OTHER SYSTEMIC ANTICANCER THERAPY	11 (52.4%)	23 (48.9%)	34 (50.0%)

N Number of patients in treatment group.

Program Name: RTTDEM060
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.6 Post-discontinuation disease-related anticancer therapy
(Full analysis set)

	Number (%) of patients		
Anticancer therapy [a]	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
Total number of patients	0 (0.0%)	2 (4.3%)	2 (2.9%)
BENDAMUSTINE-FLUDARABINE-RITUXIMAB	0 (0.0%)	1 (2.1%)	1 (1.5%)
CYCLOPHOSPHAMIDE-VINCRISTINE	0 (0.0%)	1 (2.1%)	1 (1.5%)
PREDNISONE	0 (0.0%)	1 (2.1%)	1 (1.5%)

N Number of patients in treatment group.
[a] Therapies post discontinuation of study treatment
Program Name: RTTDEM180
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.7 Number of regimens of previous chemotherapy at baseline
(Full analysis set)

	Number (%) of patients		
Number of regimens	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
1	3 (14.3%)	8 (17.0%)	11 (16.2%)
2	6 (28.6%)	15 (31.9%)	21 (30.9%)
3	7 (33.3%)	12 (25.5%)	19 (27.9%)
4	3 (14.3%)	7 (14.9%)	10 (14.7%)
5	0 (0.00%)	3 (6.4%)	3 (4.4%)
6	1 (4.8%)	2 (4.3%)	3 (4.4%)
8	1 (4.8%)	0 (0.00%)	1 (1.5%)
n	21	47	68
Mean	3	2.7	2.8
SD	1.66	1.33	1.43
Median	3	3	3

n Number of patients in category or analysis. N Number of patients in treatment group. SD Standard deviation.
Patients in the unknown category are not included in the calculation of n or the associated summary statistics

Program Name: RTTDEM070
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.8 Previous disease-related chemotherapy treatments
(Full analysis set)

Number of prior regimens	Previous treatment	Number (%) of patients 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Any	CYCLOPHOSPHAMIDE	20 (95.2%)	46 (97.9%)	66 (97.1%)
	DOXORUBICIN	19 (90.5%)	42 (89.4%)	61 (89.7%)
	RITUXIMAB	15 (71.4%)	34 (72.3%)	49 (72.1%)
	ETOPOSIDE	15 (71.4%)	28 (59.6%)	43 (63.2%)
	VINCRISTINE	11 (52.4%)	28 (59.6%)	39 (57.4%)
	IFOSFAMIDE	15 (71.4%)	22 (46.8%)	37 (54.4%)
	CARBOPLATIN	13 (61.9%)	19 (40.4%)	32 (47.1%)
	PREDNISONE	8 (38.1%)	20 (42.6%)	28 (41.2%)
	VINCRISTINE SULFATE	9 (42.9%)	19 (40.4%)	28 (41.2%)
	CYTARABINE	7 (33.3%)	18 (38.3%)	25 (36.8%)
	CISPLATIN	5 (23.8%)	11 (23.4%)	16 (23.5%)
	OXALIPLATIN	4 (19.0%)	10 (21.3%)	14 (20.6%)
	GEMCITABINE	5 (23.8%)	8 (17.0%)	13 (19.1%)
	CARMUSTINE	4 (19.0%)	8 (17.0%)	12 (17.6%)
	MELPHALAN	4 (19.0%)	8 (17.0%)	12 (17.6%)
	DEXAMETHASONE	4 (19.0%)	7 (14.9%)	11 (16.2%)
	BENDAMUSTINE	3 (14.3%)	6 (12.8%)	9 (13.2%)
	METHOTREXATE	1 (4.8%)	6 (12.8%)	7 (10.3%)
	GEMCITABINE HYDROCHLORIDE	0 (0.00%)	5 (10.6%)	5 (7.4%)
	PREDNISOLONE	3 (14.3%)	2 (4.3%)	5 (7.4%)
	DOXORUBICIN HYDROCHLORIDE	0 (0.00%)	3 (6.4%)	3 (4.4%)
	INVESTIGATIONAL DRUG	0 (0.00%)	3 (6.4%)	3 (4.4%)
	BORTEZOMIB	0 (0.00%)	2 (4.3%)	2 (2.9%)
	ANTINEOPLASTIC AGENTS	0 (0.00%)	1 (2.1%)	1 (1.5%)
	BENDAMUSTINE HYDROCHLORIDE	0 (0.00%)	1 (2.1%)	1 (1.5%)
	BLEOMYCIN	0 (0.00%)	1 (2.1%)	1 (1.5%)
	CHLORAMBUCIL	1 (4.8%)	0 (0.00%)	1 (1.5%)
	EPIRUBICIN	1 (4.8%)	0 (0.00%)	1 (1.5%)

N Number of patients in treatment group.
Patients who received disease related prior therapy will be counted at least once under the category of any and at least once under the relevant number of regimens.
Patients may appear under more than one previous treatment type, if they received more than one regimen.

Program Name: RTTDEM080
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.8 Previous disease-related chemotherapy treatments
(Full analysis set)

		Number (%) of patients		
Number of prior regimens	Previous treatment	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	FLUDARABINE	0 (0.00%)	1 (2.1%)	1 (1.5%)
	IBRITUMOMAB TIUXETAN	1 (4.8%)	0 (0.00%)	1 (1.5%)
	IFOSFAMIDE+MESNA	0 (0.00%)	1 (2.1%)	1 (1.5%)
	LENALIDOMIDE	0 (0.00%)	1 (2.1%)	1 (1.5%)
	METHYLPREDNISOLONE	0 (0.00%)	1 (2.1%)	1 (1.5%)
	MITOGUAZONE	0 (0.00%)	1 (2.1%)	1 (1.5%)
	MITOXANTRONE	0 (0.00%)	1 (2.1%)	1 (1.5%)
	PROCARBAZINE	0 (0.00%)	1 (2.1%)	1 (1.5%)
	TEMSIROLIMUS	0 (0.00%)	1 (2.1%)	1 (1.5%)
	VINORELBINE	0 (0.00%)	1 (2.1%)	1 (1.5%)
	VINORELBINE DITARTRATE	0 (0.00%)	1 (2.1%)	1 (1.5%)

N Number of patients in treatment group.
Patients who received disease related prior therapy will be counted at least once under the category of any and at least once under the relevant number of regimens.
Patients may appear under more than one previous treatment type, if they received more than one regimen.

Program Name: RTTDEM080
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.9.1 Disease related medical history - Past
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
Patients with any relevant medical history	16 (76.2%)	40 (85.1%)	56 (82.4%)
INFECTIONS AND INFESTATIONS	7 (33.3%)	13 (27.7%)	20 (29.4%)
PNEUMONIA	3 (14.3%)	1 (2.1%)	4 (5.9%)
CELLULITIS	1 (4.8%)	2 (4.3%)	3 (4.4%)
HERPES ZOSTER	1 (4.8%)	1 (2.1%)	2 (2.9%)
UPPER RESPIRATORY TRACT INFECTION	1 (4.8%)	1 (2.1%)	2 (2.9%)
ACUTE SINUSITIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
CANDIDA INFECTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
CLOSTRIDIUM DIFFICILE COLITIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
CLOSTRIDIUM DIFFICILE INFECTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
HEPATITIS B	0 (0.0%)	1 (2.1%)	1 (1.5%)
HEPATITIS C	1 (4.8%)	0 (0.0%)	1 (1.5%)
HEPATITIS VIRAL	0 (0.0%)	1 (2.1%)	1 (1.5%)
ORAL HERPES	0 (0.0%)	1 (2.1%)	1 (1.5%)
PSEUDOMONAL BACTERAEMIA	1 (4.8%)	0 (0.0%)	1 (1.5%)
SINUSITIS	1 (4.8%)	0 (0.0%)	1 (1.5%)
URINARY TRACT INFECTION	1 (4.8%)	0 (0.0%)	1 (1.5%)
VARICELLA	0 (0.0%)	1 (2.1%)	1 (1.5%)
GASTROINTESTINAL DISORDERS	7 (33.3%)	10 (21.3%)	17 (25.0%)
ABDOMINAL PAIN	0 (0.0%)	3 (6.4%)	3 (4.4%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.1 Disease related medical history - Past
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
DIVERTICULUM	2 (9.5%)	0 (0.0%)	2 (2.9%)
GASTROINTESTINAL HAEMORRHAGE	1 (4.8%)	1 (2.1%)	2 (2.9%)
HAEMORRHOIDS	2 (9.5%)	0 (0.0%)	2 (2.9%)
NAUSEA	0 (0.0%)	2 (4.3%)	2 (2.9%)
ABDOMINAL DISTENSION	0 (0.0%)	1 (2.1%)	1 (1.5%)
CAECITIS	1 (4.8%)	0 (0.0%)	1 (1.5%)
CONSTIPATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
DIARRHOEA	1 (4.8%)	0 (0.0%)	1 (1.5%)
DYSPEPSIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
ENTEROCOLITIS	1 (4.8%)	0 (0.0%)	1 (1.5%)
GASTRIC ULCER	0 (0.0%)	1 (2.1%)	1 (1.5%)
GASTRITIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
HIATUS HERNIA	1 (4.8%)	0 (0.0%)	1 (1.5%)
INGUINAL HERNIA	1 (4.8%)	0 (0.0%)	1 (1.5%)
IRRITABLE BOWEL SYNDROME	1 (4.8%)	0 (0.0%)	1 (1.5%)
OESOPHAGEAL STENOSIS	1 (4.8%)	0 (0.0%)	1 (1.5%)
PEPTIC ULCER	1 (4.8%)	0 (0.0%)	1 (1.5%)
PNEUMATOSIS INTESTINALIS	1 (4.8%)	0 (0.0%)	1 (1.5%)
RECTAL HAEMORRHAGE	1 (4.8%)	0 (0.0%)	1 (1.5%)
RECTAL PERFORATION	0 (0.0%)	1 (2.1%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.1 Disease related medical history - Past
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
VOMITING	1 (4.8%)	0 (0.0%)	1 (1.5%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	3 (14.3%)	9 (19.1%)	12 (17.6%)
PROSTATE CANCER	0 (0.0%)	3 (6.4%)	3 (4.4%)
B-CELL LYMPHOMA	0 (0.0%)	1 (2.1%)	1 (1.5%)
BASAL CELL CARCINOMA	0 (0.0%)	1 (2.1%)	1 (1.5%)
BREAST CANCER	0 (0.0%)	1 (2.1%)	1 (1.5%)
COLON ADENOMA	1 (4.8%)	0 (0.0%)	1 (1.5%)
HODGKIN'S DISEASE	0 (0.0%)	1 (2.1%)	1 (1.5%)
LIP SQUAMOUS CELL CARCINOMA	1 (4.8%)	0 (0.0%)	1 (1.5%)
LIPOMA	0 (0.0%)	1 (2.1%)	1 (1.5%)
SQUAMOUS CELL CARCINOMA	1 (4.8%)	0 (0.0%)	1 (1.5%)
URETERIC CANCER	0 (0.0%)	1 (2.1%)	1 (1.5%)
WALDENSTROM'S MACROGLOBULINAEMIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
SURGICAL AND MEDICAL PROCEDURES	2 (9.5%)	9 (19.1%)	11 (16.2%)
ANKLE OPERATION	0 (0.0%)	2 (4.3%)	2 (2.9%)
CHOLECYSTECTOMY	1 (4.8%)	1 (2.1%)	2 (2.9%)
STEM CELL TRANSPLANT	0 (0.0%)	2 (4.3%)	2 (2.9%)
ADENOIDECTOMY	0 (0.0%)	1 (2.1%)	1 (1.5%)
CAESAREAN SECTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
COLON POLYPECTOMY	1 (4.8%)	0 (0.0%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.1 Disease related medical history - Past
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
HERNIA REPAIR	0 (0.0%)	1 (2.1%)	1 (1.5%)
JOINT INJECTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
KNEE ARTHROPLASTY	1 (4.8%)	0 (0.0%)	1 (1.5%)
TONSILLECTOMY	0 (0.0%)	1 (2.1%)	1 (1.5%)
UMBILICAL HERNIA REPAIR	0 (0.0%)	1 (2.1%)	1 (1.5%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	4 (19.0%)	5 (10.6%)	9 (13.2%)
PANCYTOPENIA	1 (4.8%)	2 (4.3%)	3 (4.4%)
FEBRILE NEUTROPENIA	2 (9.5%)	0 (0.0%)	2 (2.9%)
THROMBOCYTOPENIA	0 (0.0%)	2 (4.3%)	2 (2.9%)
ANAEMIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
COAGULOPATHY	1 (4.8%)	0 (0.0%)	1 (1.5%)
LEUKOCYTOSIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
LYMPH NODE PAIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
LYMPHADENOPATHY	0 (0.0%)	1 (2.1%)	1 (1.5%)
NEUTROPENIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
SPLEEN DISORDER	1 (4.8%)	0 (0.0%)	1 (1.5%)
METABOLISM AND NUTRITION DISORDERS	3 (14.3%)	5 (10.6%)	8 (11.8%)
DECREASED APPETITE	0 (0.0%)	2 (4.3%)	2 (2.9%)
HYPOKALAEMIA	0 (0.0%)	2 (4.3%)	2 (2.9%)
VITAMIN B12 DEFICIENCY	1 (4.8%)	1 (2.1%)	2 (2.9%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.1 Disease related medical history - Past
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
DEHYDRATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
HYPERCALCAEMIA	1 (4.8%)	0 (0.0%)	1 (1.5%)
HYPOALBUMINAEMIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
HYPOCALCAEMIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
HYPOMAGNESAEMIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
MALNUTRITION	1 (4.8%)	0 (0.0%)	1 (1.5%)
NERVOUS SYSTEM DISORDERS	4 (19.0%)	4 (8.5%)	8 (11.8%)
BURNING SENSATION	1 (4.8%)	0 (0.0%)	1 (1.5%)
DIZZINESS	0 (0.0%)	1 (2.1%)	1 (1.5%)
DYSGEUSIA	1 (4.8%)	0 (0.0%)	1 (1.5%)
HEADACHE	0 (0.0%)	1 (2.1%)	1 (1.5%)
RESTLESS LEGS SYNDROME	1 (4.8%)	0 (0.0%)	1 (1.5%)
SCIATICA	0 (0.0%)	1 (2.1%)	1 (1.5%)
SPINAL CORD COMPRESSION	1 (4.8%)	0 (0.0%)	1 (1.5%)
VOCAL CORD PARALYSIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	0 (0.0%)	7 (14.9%)	7 (10.3%)
CONTUSION	0 (0.0%)	1 (2.1%)	1 (1.5%)
LOWER LIMB FRACTURE	0 (0.0%)	1 (2.1%)	1 (1.5%)
LUMBAR VERTEBRAL FRACTURE	0 (0.0%)	1 (2.1%)	1 (1.5%)
MENISCUS INJURY	0 (0.0%)	1 (2.1%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.1 Disease related medical history - Past
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
PNEUMOTHORAX TRAUMATIC	0 (0.0%)	1 (2.1%)	1 (1.5%)
SPORTS INJURY	0 (0.0%)	1 (2.1%)	1 (1.5%)
TENDON RUPTURE	0 (0.0%)	1 (2.1%)	1 (1.5%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	3 (14.3%)	4 (8.5%)	7 (10.3%)
PLEURAL EFFUSION	1 (4.8%)	2 (4.3%)	3 (4.4%)
PNEUMOTHORAX	0 (0.0%)	2 (4.3%)	2 (2.9%)
RESPIRATORY FAILURE	0 (0.0%)	2 (4.3%)	2 (2.9%)
ATELECTASIS	1 (4.8%)	0 (0.0%)	1 (1.5%)
DYSPNOEA	1 (4.8%)	0 (0.0%)	1 (1.5%)
PULMONARY MASS	1 (4.8%)	0 (0.0%)	1 (1.5%)
PULMONARY OEDEMA	0 (0.0%)	1 (2.1%)	1 (1.5%)
CARDIAC DISORDERS	2 (9.5%)	4 (8.5%)	6 (8.8%)
BUNDLE BRANCH BLOCK LEFT	1 (4.8%)	0 (0.0%)	1 (1.5%)
CARDIAC ARREST	0 (0.0%)	1 (2.1%)	1 (1.5%)
CARDIAC FAILURE CONGESTIVE	0 (0.0%)	1 (2.1%)	1 (1.5%)
CARDIOMYOPATHY	0 (0.0%)	1 (2.1%)	1 (1.5%)
PERICARDIAL EFFUSION	1 (4.8%)	0 (0.0%)	1 (1.5%)
TACHYCARDIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
VENTRICULAR FIBRILLATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	3 (14.3%)	3 (6.4%)	6 (8.8%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.1 Disease related medical history - Past
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
FATIGUE	2 (9.5%)	1 (2.1%)	3 (4.4%)
PYREXIA	0 (0.0%)	2 (4.3%)	2 (2.9%)
INDURATION	1 (4.8%)	0 (0.0%)	1 (1.5%)
MUCOSAL ULCERATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
OEDEMA	1 (4.8%)	0 (0.0%)	1 (1.5%)
INVESTIGATIONS	1 (4.8%)	5 (10.6%)	6 (8.8%)
WEIGHT DECREASED	1 (4.8%)	1 (2.1%)	2 (2.9%)
ARTHROSCOPY	0 (0.0%)	1 (2.1%)	1 (1.5%)
BIOPSY LYMPH GLAND	0 (0.0%)	1 (2.1%)	1 (1.5%)
BRONCHOSCOPY	0 (0.0%)	1 (2.1%)	1 (1.5%)
LOW DENSITY LIPOPROTEIN INCREASED	0 (0.0%)	1 (2.1%)	1 (1.5%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	1 (4.8%)	5 (10.6%)	6 (8.8%)
BACK PAIN	1 (4.8%)	2 (4.3%)	3 (4.4%)
JOINT SWELLING	0 (0.0%)	1 (2.1%)	1 (1.5%)
MUSCULAR WEAKNESS	0 (0.0%)	1 (2.1%)	1 (1.5%)
MYALGIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
RHEUMATIC FEVER	0 (0.0%)	1 (2.1%)	1 (1.5%)
PSYCHIATRIC DISORDERS	1 (4.8%)	4 (8.5%)	5 (7.4%)
ANXIETY	1 (4.8%)	2 (4.3%)	3 (4.4%)
DEPRESSION	0 (0.0%)	2 (4.3%)	2 (2.9%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.1 Disease related medical history - Past
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
RENAL AND URINARY DISORDERS	0 (0.0%)	5 (10.6%)	5 (7.4%)
HYDRONEPHROSIS	0 (0.0%)	2 (4.3%)	2 (2.9%)
NEPHROLITHIASIS	0 (0.0%)	2 (4.3%)	2 (2.9%)
RENAL CYST	0 (0.0%)	1 (2.1%)	1 (1.5%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	2 (9.5%)	1 (2.1%)	3 (4.4%)
BENIGN PROSTATIC HYPERPLASIA	1 (4.8%)	0 (0.0%)	1 (1.5%)
BREAST CYST	1 (4.8%)	0 (0.0%)	1 (1.5%)
PELVIC PAIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	2 (9.5%)	1 (2.1%)	3 (4.4%)
ALOPECIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
NIGHT SWEATS	1 (4.8%)	0 (0.0%)	1 (1.5%)
RASH MACULAR	1 (4.8%)	0 (0.0%)	1 (1.5%)
SOCIAL CIRCUMSTANCES	0 (0.0%)	3 (6.4%)	3 (4.4%)
TOBACCO USER	0 (0.0%)	2 (4.3%)	2 (2.9%)
SUBSTANCE USE	0 (0.0%)	1 (2.1%)	1 (1.5%)
EAR AND LABYRINTH DISORDERS	1 (4.8%)	1 (2.1%)	2 (2.9%)
DEAFNESS BILATERAL	1 (4.8%)	0 (0.0%)	1 (1.5%)
VERTIGO	0 (0.0%)	1 (2.1%)	1 (1.5%)
HEPATOBILIARY DISORDERS	1 (4.8%)	1 (2.1%)	2 (2.9%)
CHOLELITHIASIS	1 (4.8%)	1 (2.1%)	2 (2.9%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.1 Disease related medical history - Past
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
IMMUNE SYSTEM DISORDERS	0 (0.0%)	2 (4.3%)	2 (2.9%)
DRUG HYPERSENSITIVITY	0 (0.0%)	2 (4.3%)	2 (2.9%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	0 (0.0%)	1 (2.1%)	1 (1.5%)
ICHTHYOSIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
EYE DISORDERS	1 (4.8%)	0 (0.0%)	1 (1.5%)
CONJUNCTIVITIS	1 (4.8%)	0 (0.0%)	1 (1.5%)
VASCULAR DISORDERS	1 (4.8%)	0 (0.0%)	1 (1.5%)
HYPOTENSION	1 (4.8%)	0 (0.0%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.2 Disease related medical history - Current
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
Patients with any relevant medical history	21 (100.0%)	45 (95.7%)	66 (97.1%)
GASTROINTESTINAL DISORDERS	13 (61.9%)	27 (57.4%)	40 (58.8%)
GASTROOESOPHAGEAL REFLUX DISEASE	7 (33.3%)	10 (21.3%)	17 (25.0%)
CONSTIPATION	3 (14.3%)	11 (23.4%)	14 (20.6%)
NAUSEA	2 (9.5%)	6 (12.8%)	8 (11.8%)
ABDOMINAL PAIN	2 (9.5%)	5 (10.6%)	7 (10.3%)
DIARRHOEA	1 (4.8%)	4 (8.5%)	5 (7.4%)
DYSPEPSIA	1 (4.8%)	3 (6.4%)	4 (5.9%)
ABDOMINAL DISTENSION	3 (14.3%)	0 (0.0%)	3 (4.4%)
ABDOMINAL DISCOMFORT	0 (0.0%)	2 (4.3%)	2 (2.9%)
HAEMORRHOIDS	2 (9.5%)	0 (0.0%)	2 (2.9%)
HIATUS HERNIA	0 (0.0%)	2 (4.3%)	2 (2.9%)
VOMITING	0 (0.0%)	2 (4.3%)	2 (2.9%)
ABDOMINAL PAIN LOWER	0 (0.0%)	1 (2.1%)	1 (1.5%)
ABDOMINAL TENDERNESS	1 (4.8%)	0 (0.0%)	1 (1.5%)
ASCITES	1 (4.8%)	0 (0.0%)	1 (1.5%)
BARRETT'S OESOPHAGUS	0 (0.0%)	1 (2.1%)	1 (1.5%)
COLITIS ULCERATIVE	1 (4.8%)	0 (0.0%)	1 (1.5%)
CROHN'S DISEASE	0 (0.0%)	1 (2.1%)	1 (1.5%)
DENTAL CARIES	0 (0.0%)	1 (2.1%)	1 (1.5%)
DIVERTICULUM INTESTINAL	0 (0.0%)	1 (2.1%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090_2
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.2 Disease related medical history - Current
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
DRY MOUTH	0 (0.0%)	1 (2.1%)	1 (1.5%)
GASTRITIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
GINGIVAL DISCOLOURATION	1 (4.8%)	0 (0.0%)	1 (1.5%)
OESOPHAGITIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
RECTAL DISCHARGE	0 (0.0%)	1 (2.1%)	1 (1.5%)
TOOTHACHE	0 (0.0%)	1 (2.1%)	1 (1.5%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	7 (33.3%)	26 (55.3%)	33 (48.5%)
FATIGUE	5 (23.8%)	19 (40.4%)	24 (35.3%)
OEDEMA PERIPHERAL	0 (0.0%)	5 (10.6%)	5 (7.4%)
PAIN	1 (4.8%)	4 (8.5%)	5 (7.4%)
AXILLARY PAIN	0 (0.0%)	2 (4.3%)	2 (2.9%)
CHILLS	0 (0.0%)	2 (4.3%)	2 (2.9%)
GAIT DISTURBANCE	1 (4.8%)	1 (2.1%)	2 (2.9%)
PYREXIA	0 (0.0%)	2 (4.3%)	2 (2.9%)
CHEST PAIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
DRUG INTOLERANCE	0 (0.0%)	1 (2.1%)	1 (1.5%)
INFLUENZA LIKE ILLNESS	0 (0.0%)	1 (2.1%)	1 (1.5%)
LOCAL SWELLING	0 (0.0%)	1 (2.1%)	1 (1.5%)
NODULE	0 (0.0%)	1 (2.1%)	1 (1.5%)
OEDEMA	1 (4.8%)	0 (0.0%)	1 (1.5%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	9 (42.9%)	20 (42.6%)	29 (42.6%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090_2
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.2 Disease related medical history - Current
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
BACK PAIN	3 (14.3%)	8 (17.0%)	11 (16.2%)
ARTHRALGIA	2 (9.5%)	5 (10.6%)	7 (10.3%)
OSTEOARTHRITIS	2 (9.5%)	3 (6.4%)	5 (7.4%)
OSTEOPOROSIS	2 (9.5%)	1 (2.1%)	3 (4.4%)
MUSCULOSKELETAL CHEST PAIN	1 (4.8%)	1 (2.1%)	2 (2.9%)
OSTEOPENIA	2 (9.5%)	0 (0.0%)	2 (2.9%)
PAIN IN EXTREMITY	0 (0.0%)	2 (4.3%)	2 (2.9%)
BONE PAIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
GROIN PAIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
MUSCLE SPASMS	0 (0.0%)	1 (2.1%)	1 (1.5%)
MUSCULAR WEAKNESS	0 (0.0%)	1 (2.1%)	1 (1.5%)
MUSCULOSKELETAL PAIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
OSTEITIS DEFORMANS	0 (0.0%)	1 (2.1%)	1 (1.5%)
OSTEOCHONDROSIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
POLYMYALGIA RHEUMATICA	1 (4.8%)	0 (0.0%)	1 (1.5%)
RHEUMATOID ARTHRITIS	1 (4.8%)	0 (0.0%)	1 (1.5%)
NERVOUS SYSTEM DISORDERS	6 (28.6%)	17 (36.2%)	23 (33.8%)
NEUROPATHY PERIPHERAL	1 (4.8%)	7 (14.9%)	8 (11.8%)
PERIPHERAL SENSORY NEUROPATHY	2 (9.5%)	5 (10.6%)	7 (10.3%)
DIZZINESS	1 (4.8%)	2 (4.3%)	3 (4.4%)
HEADACHE	1 (4.8%)	1 (2.1%)	2 (2.9%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090_2
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.2 Disease related medical history - Current
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
CEREBRAL CALCIFICATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
DIZZINESS POSTURAL	0 (0.0%)	1 (2.1%)	1 (1.5%)
DYSGRAPHIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
HYPOAESTHESIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
MEMORY IMPAIRMENT	0 (0.0%)	1 (2.1%)	1 (1.5%)
MIGRAINE	0 (0.0%)	1 (2.1%)	1 (1.5%)
PARKINSONISM	1 (4.8%)	0 (0.0%)	1 (1.5%)
POST HERPETIC NEURALGIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
RESTLESS LEGS SYNDROME	1 (4.8%)	0 (0.0%)	1 (1.5%)
SENSORY LOSS	0 (0.0%)	1 (2.1%)	1 (1.5%)
SINUS HEADACHE	0 (0.0%)	1 (2.1%)	1 (1.5%)
VASOGENIC CEREBRAL OEDEMA	0 (0.0%)	1 (2.1%)	1 (1.5%)
IMMUNE SYSTEM DISORDERS	6 (28.6%)	16 (34.0%)	22 (32.4%)
DRUG HYPERSENSITIVITY	5 (23.8%)	12 (25.5%)	17 (25.0%)
SEASONAL ALLERGY	1 (4.8%)	6 (12.8%)	7 (10.3%)
HYPOGAMMAGLOBULINAEMIA	1 (4.8%)	1 (2.1%)	2 (2.9%)
CONTRAST MEDIA ALLERGY	0 (0.0%)	1 (2.1%)	1 (1.5%)
FOOD ALLERGY	0 (0.0%)	1 (2.1%)	1 (1.5%)
PSYCHIATRIC DISORDERS	9 (42.9%)	11 (23.4%)	20 (29.4%)
INSOMNIA	5 (23.8%)	5 (10.6%)	10 (14.7%)
DEPRESSION	3 (14.3%)	6 (12.8%)	9 (13.2%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090_2
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.2 Disease related medical history - Current
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
ANXIETY	2 (9.5%)	6 (12.8%)	8 (11.8%)
NERVOUSNESS	0 (0.0%)	1 (2.1%)	1 (1.5%)
OBSESSIVE-COMPULSIVE DISORDER	0 (0.0%)	1 (2.1%)	1 (1.5%)
TOBACCO ABUSE	0 (0.0%)	1 (2.1%)	1 (1.5%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	8 (38.1%)	11 (23.4%)	19 (27.9%)
ANAEMIA	6 (28.6%)	9 (19.1%)	15 (22.1%)
THROMBOCYTOPENIA	2 (9.5%)	2 (4.3%)	4 (5.9%)
LYMPH NODE PAIN	1 (4.8%)	1 (2.1%)	2 (2.9%)
LYMPHADENOPATHY	1 (4.8%)	1 (2.1%)	2 (2.9%)
COLD TYPE HAEMOLYTIC ANAEMIA	1 (4.8%)	0 (0.0%)	1 (1.5%)
IRON DEFICIENCY ANAEMIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
LEUKOPENIA	1 (4.8%)	0 (0.0%)	1 (1.5%)
NEUTROPENIA	1 (4.8%)	0 (0.0%)	1 (1.5%)
PANCYTOPENIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
METABOLISM AND NUTRITION DISORDERS	5 (23.8%)	13 (27.7%)	18 (26.5%)
DECREASED APPETITE	2 (9.5%)	4 (8.5%)	6 (8.8%)
HYPOKALAEMIA	1 (4.8%)	3 (6.4%)	4 (5.9%)
GOUT	0 (0.0%)	3 (6.4%)	3 (4.4%)
HYPERPHOSPHATAEMIA	1 (4.8%)	1 (2.1%)	2 (2.9%)
HYPOALBUMINAEMIA	0 (0.0%)	2 (4.3%)	2 (2.9%)
HYPONATRAEMIA	0 (0.0%)	2 (4.3%)	2 (2.9%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090_2
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.2 Disease related medical history - Current
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
MALNUTRITION	0 (0.0%)	2 (4.3%)	2 (2.9%)
APPETITE DISORDER	1 (4.8%)	0 (0.0%)	1 (1.5%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	6 (28.6%)	11 (23.4%)	17 (25.0%)
DYSPNOEA	2 (9.5%)	4 (8.5%)	6 (8.8%)
COUGH	1 (4.8%)	2 (4.3%)	3 (4.4%)
DYSPNOEA EXERTIONAL	0 (0.0%)	3 (6.4%)	3 (4.4%)
SLEEP APNOEA SYNDROME	2 (9.5%)	1 (2.1%)	3 (4.4%)
OROPHARYNGEAL PAIN	0 (0.0%)	2 (4.3%)	2 (2.9%)
RHINITIS ALLERGIC	1 (4.8%)	1 (2.1%)	2 (2.9%)
SINUS CONGESTION	1 (4.8%)	1 (2.1%)	2 (2.9%)
ASTHMA	1 (4.8%)	0 (0.0%)	1 (1.5%)
ASTHMA EXERCISE INDUCED	0 (0.0%)	1 (2.1%)	1 (1.5%)
HICCUPS	1 (4.8%)	0 (0.0%)	1 (1.5%)
NASAL CONGESTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
ORTHOPNOEA	0 (0.0%)	1 (2.1%)	1 (1.5%)
PULMONARY CALCIFICATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
PULMONARY MASS	1 (4.8%)	0 (0.0%)	1 (1.5%)
RHINORRHOEA	0 (0.0%)	1 (2.1%)	1 (1.5%)
WHEEZING	0 (0.0%)	1 (2.1%)	1 (1.5%)
YAWNING	1 (4.8%)	0 (0.0%)	1 (1.5%)
INFECTIONS AND INFESTATIONS	5 (23.8%)	7 (14.9%)	12 (17.6%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090_2
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.2 Disease related medical history - Current
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
DIVERTICULITIS	2 (9.5%)	1 (2.1%)	3 (4.4%)
RHINITIS	1 (4.8%)	1 (2.1%)	2 (2.9%)
SINUSITIS	1 (4.8%)	1 (2.1%)	2 (2.9%)
CANDIDA INFECTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
CELLULITIS	1 (4.8%)	0 (0.0%)	1 (1.5%)
GASTRITIS VIRAL	1 (4.8%)	0 (0.0%)	1 (1.5%)
HERPES SIMPLEX	0 (0.0%)	1 (2.1%)	1 (1.5%)
NASOPHARYNGITIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
ORAL HERPES	1 (4.8%)	0 (0.0%)	1 (1.5%)
UPPER RESPIRATORY TRACT INFECTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	6 (28.6%)	6 (12.8%)	12 (17.6%)
ALOPECIA	1 (4.8%)	3 (6.4%)	4 (5.9%)
NIGHT SWEATS	1 (4.8%)	1 (2.1%)	2 (2.9%)
PRURITUS	1 (4.8%)	1 (2.1%)	2 (2.9%)
PSORIASIS	1 (4.8%)	1 (2.1%)	2 (2.9%)
ALOPECIA TOTALIS	1 (4.8%)	0 (0.0%)	1 (1.5%)
BLISTER	0 (0.0%)	1 (2.1%)	1 (1.5%)
DERMATITIS CONTACT	1 (4.8%)	0 (0.0%)	1 (1.5%)
DRY SKIN	1 (4.8%)	0 (0.0%)	1 (1.5%)
PETECHIAE	1 (4.8%)	0 (0.0%)	1 (1.5%)
SWELLING FACE	1 (4.8%)	0 (0.0%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090_2
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.2 Disease related medical history - Current
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	2 (9.5%)	9 (19.1%)	11 (16.2%)
BENIGN PROSTATIC HYPERPLASIA	1 (4.8%)	5 (10.6%)	6 (8.8%)
ERECTILE DYSFUNCTION	1 (4.8%)	1 (2.1%)	2 (2.9%)
ENDOMETRIOSIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
PELVIC PAIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
PROSTATITIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
ENDOCRINE DISORDERS	4 (19.0%)	6 (12.8%)	10 (14.7%)
HYPOTHYROIDISM	1 (4.8%)	4 (8.5%)	5 (7.4%)
ADRENAL INSUFFICIENCY	0 (0.0%)	1 (2.1%)	1 (1.5%)
ANDROGEN DEFICIENCY	1 (4.8%)	0 (0.0%)	1 (1.5%)
DIABETES INSIPIDUS	1 (4.8%)	0 (0.0%)	1 (1.5%)
HYPERPARATHYROIDISM PRIMARY	1 (4.8%)	0 (0.0%)	1 (1.5%)
HYPERTHYROIDISM	0 (0.0%)	1 (2.1%)	1 (1.5%)
CARDIAC DISORDERS	2 (9.5%)	6 (12.8%)	8 (11.8%)
CORONARY ARTERY DISEASE	1 (4.8%)	2 (4.3%)	3 (4.4%)
TACHYCARDIA	1 (4.8%)	1 (2.1%)	2 (2.9%)
ARRHYTHMIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
CARDIOMEGALY	0 (0.0%)	1 (2.1%)	1 (1.5%)
SINUS BRADYCARDIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
INVESTIGATIONS	3 (14.3%)	5 (10.6%)	8 (11.8%)
WEIGHT DECREASED	0 (0.0%)	3 (6.4%)	3 (4.4%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090_2
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.2 Disease related medical history - Current
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
ASPARTATE AMINOTRANSFERASE INCREASED	1 (4.8%)	0 (0.0%)	1 (1.5%)
BLOOD CHLORIDE INCREASED	1 (4.8%)	0 (0.0%)	1 (1.5%)
BLOOD CREATININE	1 (4.8%)	0 (0.0%)	1 (1.5%)
BODY TEMPERATURE NORMAL	0 (0.0%)	1 (2.1%)	1 (1.5%)
CARDIAC MURMUR	1 (4.8%)	0 (0.0%)	1 (1.5%)
INTERNATIONAL NORMALISED RATIO INCREASED	1 (4.8%)	0 (0.0%)	1 (1.5%)
PLATELET COUNT	1 (4.8%)	0 (0.0%)	1 (1.5%)
WHITE BLOOD CELL COUNT DECREASED	0 (0.0%)	1 (2.1%)	1 (1.5%)
EYE DISORDERS	0 (0.0%)	7 (14.9%)	7 (10.3%)
CATARACT	0 (0.0%)	3 (6.4%)	3 (4.4%)
DRY EYE	0 (0.0%)	2 (4.3%)	2 (2.9%)
VISION BLURRED	0 (0.0%)	2 (4.3%)	2 (2.9%)
GLAUCOMA	0 (0.0%)	1 (2.1%)	1 (1.5%)
HYPERMETROPIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
EAR AND LABYRINTH DISORDERS	1 (4.8%)	4 (8.5%)	5 (7.4%)
DEAFNESS UNILATERAL	0 (0.0%)	2 (4.3%)	2 (2.9%)
HYPOACUSIS	0 (0.0%)	2 (4.3%)	2 (2.9%)
VERTIGO	1 (4.8%)	0 (0.0%)	1 (1.5%)
VASCULAR DISORDERS	2 (9.5%)	3 (6.4%)	5 (7.4%)
LYMPHOEDEMA	1 (4.8%)	1 (2.1%)	2 (2.9%)
ARTERIOSCLEROSIS	1 (4.8%)	0 (0.0%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090_2
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.2 Disease related medical history - Current
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
GRANULOMATOSIS WITH POLYANGIITIS	0 (0.0%)	1 (2.1%)	1 (1.5%)
PHLEBITIS SUPERFICIAL	0 (0.0%)	1 (2.1%)	1 (1.5%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	2 (9.5%)	2 (4.3%)	4 (5.9%)
COMPRESSION FRACTURE	1 (4.8%)	0 (0.0%)	1 (1.5%)
ILIUM FRACTURE	0 (0.0%)	1 (2.1%)	1 (1.5%)
POST PROCEDURAL HYPOTHYROIDISM	1 (4.8%)	0 (0.0%)	1 (1.5%)
SPINAL COMPRESSION FRACTURE	0 (0.0%)	1 (2.1%)	1 (1.5%)
RENAL AND URINARY DISORDERS	1 (4.8%)	3 (6.4%)	4 (5.9%)
POLLAKIURIA	0 (0.0%)	2 (4.3%)	2 (2.9%)
INCONTINENCE	1 (4.8%)	0 (0.0%)	1 (1.5%)
MICTURITION URGENCY	0 (0.0%)	1 (2.1%)	1 (1.5%)
SINGLE FUNCTIONAL KIDNEY	0 (0.0%)	1 (2.1%)	1 (1.5%)
SURGICAL AND MEDICAL PROCEDURES	0 (0.0%)	3 (6.4%)	3 (4.4%)
CARDIAC PACEMAKER INSERTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
CENTRAL VENOUS CATHETERISATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
IMPLANTABLE DEFIBRILLATOR INSERTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
TRACHEOSTOMY	0 (0.0%)	1 (2.1%)	1 (1.5%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	1 (4.8%)	1 (2.1%)	2 (2.9%)
DIFFUSE LARGE B-CELL LYMPHOMA	0 (0.0%)	1 (2.1%)	1 (1.5%)
GASTRIC NEOPLASM	1 (4.8%)	0 (0.0%)	1 (1.5%)
METASTASES TO BREAST	0 (0.0%)	1 (2.1%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090_2
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.9.2 Disease related medical history - Current
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
SOCIAL CIRCUMSTANCES	0 (0.0%)	2 (4.3%)	2 (2.9%)
TOBACCO USER	0 (0.0%)	2 (4.3%)	2 (2.9%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM090_2
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.10 Relevant surgical history
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
Patients with any relevant surgical history	17 (81.0%)	37 (78.7%)	54 (79.4%)
SURGICAL AND MEDICAL PROCEDURES	14 (66.7%)	33 (70.2%)	47 (69.1%)
STEM CELL TRANSPLANT	2 (9.5%)	6 (12.8%)	8 (11.8%)
TONSILLECTOMY	3 (14.3%)	4 (8.5%)	7 (10.3%)
HYSTERECTOMY	3 (14.3%)	2 (4.3%)	5 (7.4%)
APPENDICECTOMY	1 (4.8%)	2 (4.3%)	3 (4.4%)
CATARACT OPERATION	1 (4.8%)	2 (4.3%)	3 (4.4%)
CATHETER PLACEMENT	1 (4.8%)	2 (4.3%)	3 (4.4%)
CHOLECYSTECTOMY	2 (9.5%)	1 (2.1%)	3 (4.4%)
HERNIA REPAIR	1 (4.8%)	2 (4.3%)	3 (4.4%)
INGUINAL HERNIA REPAIR	0 (0.0%)	3 (6.4%)	3 (4.4%)
KNEE ARTHROPLASTY	1 (4.8%)	2 (4.3%)	3 (4.4%)
KNEE OPERATION	1 (4.8%)	2 (4.3%)	3 (4.4%)
SPLENECTOMY	1 (4.8%)	2 (4.3%)	3 (4.4%)
THYROIDECTOMY	0 (0.0%)	3 (6.4%)	3 (4.4%)
BREAST LUMP REMOVAL	0 (0.0%)	2 (4.3%)	2 (2.9%)
CENTRAL VENOUS CATHETERISATION	1 (4.8%)	1 (2.1%)	2 (2.9%)
CORONARY ARTERIAL STENT INSERTION	1 (4.8%)	1 (2.1%)	2 (2.9%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM100
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.10 Relevant surgical history
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
HAEMORRHOID OPERATION	1 (4.8%)	1 (2.1%)	2 (2.9%)
HIP ARTHROPLASTY	1 (4.8%)	1 (2.1%)	2 (2.9%)
LYMPHADENECTOMY	0 (0.0%)	2 (4.3%)	2 (2.9%)
ORCHIDECTOMY	1 (4.8%)	1 (2.1%)	2 (2.9%)
SALPINGO-OOPHORECTOMY BILATERAL	0 (0.0%)	2 (4.3%)	2 (2.9%)
ABDOMINAL HERNIA REPAIR	0 (0.0%)	1 (2.1%)	1 (1.5%)
AUTOLOGOUS BONE MARROW TRANSPLANTATION THERAPY	0 (0.0%)	1 (2.1%)	1 (1.5%)
BLADDER OPERATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
BREAST CYST EXCISION	1 (4.8%)	0 (0.0%)	1 (1.5%)
BREAST PROSTHESIS IMPLANTATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
CARPAL TUNNEL DECOMPRESSION	0 (0.0%)	1 (2.1%)	1 (1.5%)
CATHETER REMOVAL	1 (4.8%)	0 (0.0%)	1 (1.5%)
CHEST TUBE INSERTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
COLECTOMY	0 (0.0%)	1 (2.1%)	1 (1.5%)
COLOSTOMY	0 (0.0%)	1 (2.1%)	1 (1.5%)
CRANIOTOMY	0 (0.0%)	1 (2.1%)	1 (1.5%)
CYST REMOVAL	0 (0.0%)	1 (2.1%)	1 (1.5%)
DENTAL IMPLANTATION	0 (0.0%)	1 (2.1%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM100
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.10 Relevant surgical history
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
EXPLORATIVE LAPAROTOMY	0 (0.0%)	1 (2.1%)	1 (1.5%)
HYDROCELE OPERATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
IMPLANTABLE DEFIBRILLATOR INSERTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
IMPLANTABLE PLEURAL CATHETER INSERTION	1 (4.8%)	0 (0.0%)	1 (1.5%)
INTRAOCULAR LENS EXTRACTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
LIPOMA EXCISION	0 (0.0%)	1 (2.1%)	1 (1.5%)
MITRAL VALVE REPAIR	1 (4.8%)	0 (0.0%)	1 (1.5%)
MOLE EXCISION	0 (0.0%)	1 (2.1%)	1 (1.5%)
OESOPHAGEAL DILATION PROCEDURE	1 (4.8%)	0 (0.0%)	1 (1.5%)
ORTHOPAEDIC PROCEDURE	0 (0.0%)	1 (2.1%)	1 (1.5%)
PAPILLOMA EXCISION	0 (0.0%)	1 (2.1%)	1 (1.5%)
PERICARDIAL EXCISION	1 (4.8%)	0 (0.0%)	1 (1.5%)
PROSTATECTOMY	0 (0.0%)	1 (2.1%)	1 (1.5%)
RADICAL PROSTATECTOMY	0 (0.0%)	1 (2.1%)	1 (1.5%)
ROTATOR CUFF REPAIR	0 (0.0%)	1 (2.1%)	1 (1.5%)
SKIN NEOPLASM EXCISION	0 (0.0%)	1 (2.1%)	1 (1.5%)
SMALL INTESTINAL RESECTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
SPINAL FUSION SURGERY	1 (4.8%)	0 (0.0%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM100
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.10 Relevant surgical history
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
SPINAL LAMINECTOMY	1 (4.8%)	0 (0.0%)	1 (1.5%)
SPINAL NERVE STIMULATOR IMPLANTATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
STENT PLACEMENT	0 (0.0%)	1 (2.1%)	1 (1.5%)
THORACIC OPERATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
TOOTH EXTRACTION	1 (4.8%)	0 (0.0%)	1 (1.5%)
TRACHEOSTOMY	0 (0.0%)	1 (2.1%)	1 (1.5%)
VASECTOMY	0 (0.0%)	1 (2.1%)	1 (1.5%)
VENA CAVA FILTER INSERTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
WRIST SURGERY	0 (0.0%)	1 (2.1%)	1 (1.5%)
INVESTIGATIONS	9 (42.9%)	12 (25.5%)	21 (30.9%)
BIOPSY LYMPH GLAND	6 (28.6%)	6 (12.8%)	12 (17.6%)
BIOPSY BONE MARROW	4 (19.0%)	2 (4.3%)	6 (8.8%)
ARTHROSCOPY	1 (4.8%)	1 (2.1%)	2 (2.9%)
BIOPSY LIVER	0 (0.0%)	2 (4.3%)	2 (2.9%)
ASPIRATION BONE MARROW	0 (0.0%)	1 (2.1%)	1 (1.5%)
ASPIRATION PLEURAL CAVITY	1 (4.8%)	0 (0.0%)	1 (1.5%)
BIOPSY	0 (0.0%)	1 (2.1%)	1 (1.5%)
BIOPSY BLADDER	0 (0.0%)	1 (2.1%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM100
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.10 Relevant surgical history
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
BIOPSY BRAIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
BIOPSY BREAST	0 (0.0%)	1 (2.1%)	1 (1.5%)
BIOPSY CHEST WALL	0 (0.0%)	1 (2.1%)	1 (1.5%)
BIOPSY SPLEEN	1 (4.8%)	0 (0.0%)	1 (1.5%)
BIOPSY STOMACH	1 (4.8%)	0 (0.0%)	1 (1.5%)
MEDIASTINOSCOPY	1 (4.8%)	0 (0.0%)	1 (1.5%)
GASTROINTESTINAL DISORDERS	0 (0.0%)	3 (6.4%)	3 (4.4%)
ABDOMINAL MASS	0 (0.0%)	1 (2.1%)	1 (1.5%)
LARGE INTESTINE POLYP	0 (0.0%)	1 (2.1%)	1 (1.5%)
OESOPHAGEAL DILATATION	0 (0.0%)	1 (2.1%)	1 (1.5%)
RETROPERITONEAL MASS	0 (0.0%)	1 (2.1%)	1 (1.5%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	1 (4.8%)	2 (4.3%)	3 (4.4%)
MEDIASTINAL MASS	0 (0.0%)	2 (4.3%)	2 (2.9%)
PNEUMOTHORAX	1 (4.8%)	0 (0.0%)	1 (1.5%)
TRACHEAL MASS	0 (0.0%)	1 (2.1%)	1 (1.5%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	0 (0.0%)	2 (4.3%)	2 (2.9%)
AXILLARY MASS	0 (0.0%)	1 (2.1%)	1 (1.5%)
LOWER EXTREMITY MASS	0 (0.0%)	1 (2.1%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM100
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.10 Relevant surgical history
(Full analysis set)

	Number (%) of patients		
System organ class / MedDRA Preferred term	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
UPPER EXTREMITY MASS	0 (0.0%)	1 (2.1%)	1 (1.5%)
ENDOCRINE DISORDERS	1 (4.8%)	0 (0.0%)	1 (1.5%)
THYROID CYST	1 (4.8%)	0 (0.0%)	1 (1.5%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	0 (0.0%)	1 (2.1%)	1 (1.5%)
PELVIC MASS	0 (0.0%)	1 (2.1%)	1 (1.5%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	0 (0.0%)	1 (2.1%)	1 (1.5%)
BURNS THIRD DEGREE	0 (0.0%)	1 (2.1%)	1 (1.5%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	0 (0.0%)	1 (2.1%)	1 (1.5%)
DIFFUSE LARGE B-CELL LYMPHOMA	0 (0.0%)	1 (2.1%)	1 (1.5%)
NERVOUS SYSTEM DISORDERS	0 (0.0%)	1 (2.1%)	1 (1.5%)
CEREBROSPINAL FLUID LEAKAGE	0 (0.0%)	1 (2.1%)	1 (1.5%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	0 (0.0%)	1 (2.1%)	1 (1.5%)
OVARIAN CYST	0 (0.0%)	1 (2.1%)	1 (1.5%)
SOCIAL CIRCUMSTANCES	0 (0.0%)	1 (2.1%)	1 (1.5%)
ORGAN DONOR	0 (0.0%)	1 (2.1%)	1 (1.5%)

N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
Number (%) of patients are sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Program Name: RTTDEM100
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca **Page 6 of 6**

Table 11.1.11 Disease characteristics
(Full analysis set)

	Number (%) of patients		
	100mg BID (N=21)	**200mg BID (N=47)**	**Total (N=68)**
Ann Arbor lymphoma staging at diagnosis			
Stage I	0(0.00)	3(6.38)	3(4.41)
Stage IE	1(4.76)	0(0.00)	1(1.47)
Stage II	2(9.52)	8(17.02)	10(14.71)
Stage IIE	0(0.00)	1(2.13)	1(1.47)
Stage III	5(23.81)	9(19.15)	14(20.59)
Stage IIIE	0(0.00)	1(2.13)	1(1.47)
Stage IV	11(52.38)	20(42.55)	31(45.59)
Missing	2(9.52)	5(10.64)	7(10.29)
Ann Arbor lymphoma symptoms			
A	11(52.38)	27(57.45)	38(55.88)
B	7(33.33)	15(31.91)	22(32.35)
Missing	3(14.29)	5(10.64)	8(11.76)
WHO Performance Status at diagnosis			
0	7(33.33)	9(19.15)	16(23.53)
1	10(47.62)	22(46.81)	32(47.06)
2	0(0.00)	1(2.13)	1(1.47)
3	1(4.76)	1(2.13)	2(2.94)
4	0(0.00)	0(0.00)	0(0.00)
Missing	3(14.29)	14(29.79)	17(25.00)

WHO=World Health Organization
N Number of patients in treatment group.
Program Name: RTTDEM110
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.11 Disease characteristics
(Full analysis set)

	Number (%) of patients		
	100mg BID (N=21)	**200mg BID (N=47)**	**Total (N=68)**
Primary tumor location			
Lymph Nodes	21(100.00)	47(100.00)	68(100.00)
Missing	0(0.00)	0(0.00)	0(0.00)
Number of extra nodal sites,category			
0	9(42.86)	24(51.06)	33(48.53)
1-2	9(42.86)	19(40.43)	28(41.18)
3-6	3(14.29)	4(8.51)	7(10.29)
>6	0(0.00)	0(0.00)	0(0.00)
Missing	0(0.00)	0(0.00)	0(0.00)
Time from initial diagnosis to treatment start			
<=6 months	14(66.67)	33(70.21)	47(69.12)
6-<=12 months	4(19.05)	5(10.64)	9(13.24)
12-<=36 months	1(4.76)	2(4.26)	3(4.41)
>36 months	1(4.76)	2(4.26)	3(4.41)
Missing	1(4.76)	5(10.64)	6(8.82)

WHO=World Health Organization
N Number of patients in treatment group.
Program Name: RTTDEM110
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.12 Extent of disease at baseline
(Full analysis set)

	Number (%) of patients		
Extra nodal sites of disease	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
Total	12 (57.1%)	23 (48.9%)	35 (51.5%)
Bone Marrow	2 (9.5%)	8 (17.0%)	10 (14.7%)
Hepatic (Including Gall Bladder)	2 (9.5%)	3 (6.4%)	5 (7.4%)
Spleen	5 (23.8%)	7 (14.9%)	12 (17.6%)
Brain/CNS	0 (0.0%)	0 (0.0%)	0 (0.0%)
CNS/Left Meninges	0 (0.0%)	0 (0.0%)	0 (0.0%)
Bone	2 (9.5%)	5 (10.6%)	7 (10.3%)
Pleural Effusion	3 (14.3%)	2 (4.3%)	5 (7.4%)
Ascites	1 (4.8%)	0 (0.00%)	1 (1.5%)
Other Extra Nodal Sites	5 (23.8%)	14 (29.8%)	19 (27.9%)
Abdomen	1 (4.8%)	0 (0.00%)	1 (1.5%)
At Right Neck And Inguinal Area (Per Patie	0 (0.00%)	1 (2.1%)	1 (1.5%)
Duodenum And Mesentery	0 (0.00%)	1 (2.1%)	1 (1.5%)
In Chest	0 (0.00%)	1 (2.1%)	1 (1.5%)
Kidney	0 (0.00%)	1 (2.1%)	1 (1.5%)
Left Costal Margin Soft Tissue Mass; Lobul	0 (0.00%)	1 (2.1%)	1 (1.5%)
Left Upper Lobe Of The Lung	0 (0.00%)	1 (2.1%)	1 (1.5%)

Table 11.1.12 Extent of disease at baseline
(Full analysis set)

	Number (%) of patients		
Extra nodal sites of disease	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
Lt Breast, Lt Flank, Fifth To Seventh Ribs	0 (0.00%)	1 (2.1%)	1 (1.5%)
Lung	0 (0.00%)	1 (2.1%)	1 (1.5%)
Messenteric Mass	0 (0.00%)	1 (2.1%)	1 (1.5%)
Neck-- Right Submandibular Region	1 (4.8%)	0 (0.00%)	1 (1.5%)
No Data Is Available At The Moment. It Is	1 (4.8%)	0 (0.00%)	1 (1.5%)
Pancreas	1 (4.8%)	0 (0.00%)	1 (1.5%)
Pancreas, Small Bowel Loop	0 (0.00%)	1 (2.1%)	1 (1.5%)
Pericardial Effusion	0 (0.00%)	1 (2.1%)	1 (1.5%)
Retroperitoneal Lymphadenopathy	0 (0.00%)	1 (2.1%)	1 (1.5%)
Skin	1 (4.8%)	0 (0.00%)	1 (1.5%)
Stomach And The Terminal Ileum	0 (0.00%)	1 (2.1%)	1 (1.5%)
Stomach, Transverse Colon	0 (0.00%)	1 (2.1%)	1 (1.5%)

Table 11.1.13 Time from most recent disease progression to treatment start
(Full analysis set)

Time(days)		100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Most recent progression to treatment start	n	15	32	47
	Mean	86.5	49.5	136.0
	SD	101.31	34.68	135.99
	Median	43.0	41.0	84.0
	Min	9	12	21
	Max	375	167	542

n Number of patients in category or analysis. N Number of patients in treatment group. SD Standard deviation. Min Minimum. Max Maximum
Program Name: RTTDEM200
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.14 All allowed concomitant medications during study treatment
(Full analysis set)

ATC classification / Generic term	Number (%) of patients		
	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Number of patients with allowed concomitant medication	12 (57.1%)	38 (80.9%)	50 (73.5%)
NATURAL OPIUM ALKALOIDS	3 (14.3%)	12 (25.5%)	15 (22.1%)
HYDROCODONE+PARACETAMOL	1 (4.8%)	0 (0.0%)	1 (1.5%)
HYDROMORPHONE HYDROCHLORIDE	1 (4.8%)	1 (2.1%)	2 (2.9%)
MORPHINE	1 (4.8%)	2 (4.3%)	3 (4.4%)
MORPHINE SULFATE	0 (0.0%)	3 (6.4%)	3 (4.4%)
OXYCODONE	0 (0.0%)	4 (8.5%)	4 (5.9%)
OXYCODONE HYDROCHLORIDE	0 (0.0%)	2 (4.3%)	2 (2.9%)
ELECTROLYTE SOLUTIONS	1 (4.8%)	9 (19.1%)	10 (14.7%)
POTASSIUM CHLORIDE	0 (0.0%)	1 (2.1%)	1 (1.5%)
SODIUM CHLORIDE	1 (4.8%)	8 (17.0%)	9 (13.2%)
GLUCOCORTICOIDS	2 (9.5%)	5 (10.6%)	7 (10.3%)
DEXAMETHASONE	0 (0.0%)	1 (2.1%)	1 (1.5%)
METHYLPREDNISOLONE SODIUM SUCCINATE	1 (4.8%)	1 (2.1%)	2 (2.9%)
PREDNISOLONE	0 (0.0%)	1 (2.1%)	1 (1.5%)
PREDNISONE	1 (4.8%)	2 (4.3%)	3 (4.4%)
PHENYLPIPERIDINE DERIVATIVES	1 (4.8%)	6 (12.8%)	7 (10.3%)
FENTANYL	1 (4.8%)	6 (12.8%)	7 (10.3%)
POTASSIUM	1 (4.8%)	6 (12.8%)	7 (10.3%)
POTASSIUM	1 (4.8%)	0 (0.0%)	1 (1.5%)
POTASSIUM CHLORIDE	0 (0.0%)	5 (10.6%)	5 (7.4%)

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Program Name: RTTCON020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.14 All allowed concomitant medications during study treatment
(Full analysis set)

ATC classification / Generic term	Number (%) of patients 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
POTASSIUM PHOSPHATE MONOBASIC	0 (0.0%)	1 (2.1%)	1 (1.5%)
DIHYDROPYRIDINE DERIVATIVES	1 (4.8%)	5 (10.6%)	6 (8.8%)
AMLODIPINE	1 (4.8%)	5 (10.6%)	6 (8.8%)
OTHER ANTIEMETICS	1 (4.8%)	5 (10.6%)	6 (8.8%)
PROCHLORPERAZINE	0 (0.0%)	4 (8.5%)	4 (5.9%)
PROCHLORPERAZINE EDISYLATE	1 (4.8%)	1 (2.1%)	2 (2.9%)
BENZODIAZEPINE DERIVATIVES	1 (4.8%)	4 (8.5%)	5 (7.4%)
ALPRAZOLAM	1 (4.8%)	0 (0.0%)	1 (1.5%)
LORAZEPAM	0 (0.0%)	4 (8.5%)	4 (5.9%)
FLUOROQUINOLONES	2 (9.5%)	3 (6.4%)	5 (7.4%)
CIPROFLOXACIN	1 (4.8%)	0 (0.0%)	1 (1.5%)
LEVOFLOXACIN	0 (0.0%)	2 (4.3%)	2 (2.9%)
MOXIFLOXACIN	1 (4.8%)	1 (2.1%)	2 (2.9%)
MAGNESIUM	1 (4.8%)	4 (8.5%)	5 (7.4%)
MAGNESIUM	1 (4.8%)	0 (0.0%)	1 (1.5%)
MAGNESIUM OXIDE	0 (0.0%)	2 (4.3%)	2 (2.9%)
MAGNESIUM SULFATE	0 (0.0%)	2 (4.3%)	2 (2.9%)
PROTON PUMP INHIBITORS	2 (9.5%)	3 (6.4%)	5 (7.4%)
DEXLANSOPRAZOLE	0 (0.0%)	1 (2.1%)	1 (1.5%)
OMEPRAZOLE	1 (4.8%)	0 (0.0%)	1 (1.5%)
PANTOPRAZOLE	1 (4.8%)	2 (4.3%)	3 (4.4%)

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Program Name: RTTCON020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.14 All allowed concomitant medications during study treatment
(Full analysis set)

	Number (%) of patients		
ATC classification / Generic term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
SEROTONIN (5HT3) ANTAGONISTS	1 (4.8%)	4 (8.5%)	5 (7.4%)
ONDANSETRON	1 (4.8%)	2 (4.3%)	3 (4.4%)
ONDANSETRON HYDROCHLORIDE	0 (0.0%)	2 (4.3%)	2 (2.9%)
SULFONAMIDES, PLAIN	2 (9.5%)	3 (6.4%)	5 (7.4%)
FUROSEMIDE	1 (4.8%)	3 (6.4%)	4 (5.9%)
METOLAZONE	1 (4.8%)	0 (0.0%)	1 (1.5%)
NUCLEOSIDE/NUCLEOTIDE EXCL REVERSE TRANS INHIBITOR	0 (0.0%)	4 (8.5%)	4 (5.9%)
ACICLOVIR	0 (0.0%)	4 (8.5%)	4 (5.9%)
OTHER BLOOD PRODUCTS	2 (9.5%)	2 (4.3%)	4 (5.9%)
PLATELETS, HUMAN BLOOD	1 (4.8%)	0 (0.0%)	1 (1.5%)
RED BLOOD CELLS, CONCENTRATED	1 (4.8%)	2 (4.3%)	3 (4.4%)
SOFTENERS, EMOLLIENTS	0 (0.0%)	4 (8.5%)	4 (5.9%)
DOCUSATE	0 (0.0%)	1 (2.1%)	1 (1.5%)
DOCUSATE SODIUM	0 (0.0%)	3 (6.4%)	3 (4.4%)
TRIAZOLE DERIVATIVES	1 (4.8%)	3 (6.4%)	4 (5.9%)
FLUCONAZOLE	1 (4.8%)	3 (6.4%)	4 (5.9%)
AMIDES	3 (14.3%)	0 (0.0%)	3 (4.4%)
LIDOCAINE	1 (4.8%)	0 (0.0%)	1 (1.5%)
LIDOCAINE HYDROCHLORIDE	1 (4.8%)	0 (0.0%)	1 (1.5%)
LIDOCAINE+PRILOCAINE	1 (4.8%)	0 (0.0%)	1 (1.5%)

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Program Name: RTTCON020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.14 All allowed concomitant medications during study treatment
(Full analysis set)

ATC classification / Generic term	Number (%) of patients 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
AMINOALKYL ETHERS	2 (9.5%)	1 (2.1%)	3 (4.4%)
DIPHENHYDRAMINE	1 (4.8%)	1 (2.1%)	2 (2.9%)
DIPHENHYDRAMINE HYDROCHLORIDE	1 (4.8%)	0 (0.0%)	1 (1.5%)
ANILIDES	1 (4.8%)	2 (4.3%)	3 (4.4%)
PARACETAMOL	1 (4.8%)	2 (4.3%)	3 (4.4%)
ANTIPROPULSIVES	2 (9.5%)	1 (2.1%)	3 (4.4%)
DIPHENOXYLATE	1 (4.8%)	0 (0.0%)	1 (1.5%)
LOPERAMIDE HYDROCHLORIDE	1 (4.8%)	1 (2.1%)	2 (2.9%)
FIRST-GENERATION CEPHALOSPORINS	1 (4.8%)	2 (4.3%)	3 (4.4%)
CEFALEXIN	1 (4.8%)	2 (4.3%)	3 (4.4%)
H2-RECEPTOR ANTAGONISTS	1 (4.8%)	2 (4.3%)	3 (4.4%)
FAMOTIDINE	1 (4.8%)	0 (0.0%)	1 (1.5%)
RANITIDINE	0 (0.0%)	2 (4.3%)	2 (2.9%)
THIRD-GENERATION CEPHALOSPORINS	1 (4.8%)	2 (4.3%)	3 (4.4%)
CEFTAZIDIME	1 (4.8%)	0 (0.0%)	1 (1.5%)
CEFTRIAXONE	0 (0.0%)	2 (4.3%)	2 (2.9%)
ACE INHIBITORS, PLAIN	0 (0.0%)	2 (4.3%)	2 (2.9%)
LISINOPRIL	0 (0.0%)	1 (2.1%)	1 (1.5%)
RAMIPRIL	0 (0.0%)	1 (2.1%)	1 (1.5%)

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Table 11.1.14 All allowed concomitant medications during study treatment
(Full analysis set)

	Number (%) of patients		
ATC classification / Generic term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
ALPHA AND BETA BLOCKING AGENTS	1 (4.8%)	1 (2.1%)	2 (2.9%)
CARVEDILOL	1 (4.8%)	0 (0.0%)	1 (1.5%)
LABETALOL	0 (0.0%)	1 (2.1%)	1 (1.5%)
ANTACIDS WITH ANTIFLATULENTS	0 (0.0%)	2 (4.3%)	2 (2.9%)
ALUMINIUM+MAGNESIUM HYDROXIDE+SIMETICONE	0 (0.0%)	1 (2.1%)	1 (1.5%)
SIMETICONE	0 (0.0%)	1 (2.1%)	1 (1.5%)
BETA BLOCKING AGENTS, SELECTIVE	0 (0.0%)	2 (4.3%)	2 (2.9%)
ATENOLOL	0 (0.0%)	1 (2.1%)	1 (1.5%)
METOPROLOL TARTRATE	0 (0.0%)	1 (2.1%)	1 (1.5%)
COLONY STIMULATING FACTORS	2 (9.5%)	0 (0.0%)	2 (2.9%)
FILGRASTIM	1 (4.8%)	0 (0.0%)	1 (1.5%)
PEGFILGRASTIM	1 (4.8%)	0 (0.0%)	1 (1.5%)
COMB/COMPLEXES ALUMINIUM, CALCIUM, MAGNESIUM COMPS	1 (4.8%)	1 (2.1%)	2 (2.9%)
ALUMINIUM HYDROXIDE+MAGNESIUM HYDROXIDE	1 (4.8%)	1 (2.1%)	2 (2.9%)
CONTACT LAXATIVES	0 (0.0%)	2 (4.3%)	2 (2.9%)
SENNA ALEXANDRINA	0 (0.0%)	2 (4.3%)	2 (2.9%)
DIGITALIS GLYCOSIDES	1 (4.8%)	1 (2.1%)	2 (2.9%)
DIGOXIN	1 (4.8%)	1 (2.1%)	2 (2.9%)
GLYCOPEPTIDE ANTIBACTERIALS	1 (4.8%)	1 (2.1%)	2 (2.9%)
VANCOMYCIN	1 (4.8%)	1 (2.1%)	2 (2.9%)

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Program Name: RTTCON020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.14 All allowed concomitant medications during study treatment
(Full analysis set)

ATC classification / Generic term	Number (%) of patients		
	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
HMG COA REDUCTASE INHIBITORS	2 (9.5%)	0 (0.0%)	2 (2.9%)
PRAVASTATIN	1 (4.8%)	0 (0.0%)	1 (1.5%)
SIMVASTATIN	1 (4.8%)	0 (0.0%)	1 (1.5%)
OSMOTICALLY ACTING LAXATIVES	0 (0.0%)	2 (4.3%)	2 (2.9%)
MACROGOL	0 (0.0%)	2 (4.3%)	2 (2.9%)
OTHER OPIOIDS	0 (0.0%)	2 (4.3%)	2 (2.9%)
TAPENTADOL	0 (0.0%)	1 (2.1%)	1 (1.5%)
TRAMADOL	0 (0.0%)	1 (2.1%)	1 (1.5%)
OTHER PLAIN VITAMIN PREPARATIONS	1 (4.8%)	1 (2.1%)	2 (2.9%)
PYRIDOXINE HYDROCHLORIDE	0 (0.0%)	1 (2.1%)	1 (1.5%)
TOCOPHEROL	1 (4.8%)	0 (0.0%)	1 (1.5%)
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN	2 (9.5%)	0 (0.0%)	2 (2.9%)
ACETYLSALICYLIC ACID	1 (4.8%)	0 (0.0%)	1 (1.5%)
CLOPIDOGREL SULFATE	1 (4.8%)	0 (0.0%)	1 (1.5%)
PROPULSIVES	1 (4.8%)	1 (2.1%)	2 (2.9%)
METOCLOPRAMIDE	1 (4.8%)	0 (0.0%)	1 (1.5%)
METOCLOPRAMIDE HYDROCHLORIDE	0 (0.0%)	1 (2.1%)	1 (1.5%)
ACE INHIBITORS AND DIURETICS	1 (4.8%)	0 (0.0%)	1 (1.5%)
HYDROCHLOROTHIAZIDE+LISINOPRIL	1 (4.8%)	0 (0.0%)	1 (1.5%)

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Table 11.1.14 All allowed concomitant medications during study treatment
(Full analysis set)

	Number (%) of patients		
ATC classification / Generic term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
ALDOSTERONE ANTAGONISTS	0 (0.0%)	1 (2.1%)	1 (1.5%)
SPIRONOLACTONE	0 (0.0%)	1 (2.1%)	1 (1.5%)
ANGIOTENSIN II ANTAGONISTS AND DIURETICS	0 (0.0%)	1 (2.1%)	1 (1.5%)
HYDROCHLOROTHIAZIDE+OLMESARTAN MEDOXOMIL	0 (0.0%)	1 (2.1%)	1 (1.5%)
ANGIOTENSIN II ANTAGONISTS, PLAIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
LOSARTAN	0 (0.0%)	1 (2.1%)	1 (1.5%)
ANTIINFECTIVE/ANTISEPTICS FOR LOCAL ORAL TREATMENT	0 (0.0%)	1 (2.1%)	1 (1.5%)
NYSTATIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
BETA-LACTAMASE RESISTANT PENICILLINS	0 (0.0%)	1 (2.1%)	1 (1.5%)
FLUCLOXACILLIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
BIGUANIDES	1 (4.8%)	0 (0.0%)	1 (1.5%)
METFORMIN	1 (4.8%)	0 (0.0%)	1 (1.5%)
BISPHOSPHONATES	0 (0.0%)	1 (2.1%)	1 (1.5%)
ZOLEDRONIC ACID	0 (0.0%)	1 (2.1%)	1 (1.5%)
CALCITONIN PREPARATIONS	0 (0.0%)	1 (2.1%)	1 (1.5%)
CALCITONIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
CALCIUM	0 (0.0%)	1 (2.1%)	1 (1.5%)
CALCIUM GLUCONATE	0 (0.0%)	1 (2.1%)	1 (1.5%)

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Program Name: RTTCON020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.14 All allowed concomitant medications during study treatment
(Full analysis set)

	Number (%) of patients		
ATC classification / Generic term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
CALCIUM, COMBINATIONS WITH VITD AND/OR OTHER DRUGS	0 (0.0%)	1 (2.1%)	1 (1.5%)
CALCIUM+ERGOCALCIFEROL	0 (0.0%)	1 (2.1%)	1 (1.5%)
CARBOHYDRATES	1 (4.8%)	0 (0.0%)	1 (1.5%)
GLUCOSE OXIDASE	1 (4.8%)	0 (0.0%)	1 (1.5%)
COMBS OF PENICILLINS INCL BETA-LACTAMASE INHIBITOR	0 (0.0%)	1 (2.1%)	1 (1.5%)
AMOXICILLIN+CLAVULANIC ACID	0 (0.0%)	1 (2.1%)	1 (1.5%)
DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT	0 (0.0%)	1 (2.1%)	1 (1.5%)
RASBURICASE	0 (0.0%)	1 (2.1%)	1 (1.5%)
DOPAMINE AGONISTS	1 (4.8%)	0 (0.0%)	1 (1.5%)
PRAMIPEXOLE	1 (4.8%)	0 (0.0%)	1 (1.5%)
FOLIC ACID ANALOGUES	0 (0.0%)	1 (2.1%)	1 (1.5%)
METHOTREXATE SODIUM	0 (0.0%)	1 (2.1%)	1 (1.5%)
IMIDAZOLE AND TRIAZOLE DERIVATIVES	1 (4.8%)	0 (0.0%)	1 (1.5%)
FLUCONAZOLE	1 (4.8%)	0 (0.0%)	1 (1.5%)
INFLUENZA VACCINES	1 (4.8%)	0 (0.0%)	1 (1.5%)
INFLUENZA VIRUS VACCINE POLYVALENT	1 (4.8%)	0 (0.0%)	1 (1.5%)
LIVER THERAPY	0 (0.0%)	1 (2.1%)	1 (1.5%)
SILYBUM MARIANUM	0 (0.0%)	1 (2.1%)	1 (1.5%)

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Table 11.1.14 All allowed concomitant medications during study treatment
(Full analysis set)

	Number (%) of patients		
ATC classification / Generic term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
MACROLIDES	1 (4.8%)	0 (0.0%)	1 (1.5%)
AZITHROMYCIN	1 (4.8%)	0 (0.0%)	1 (1.5%)
MAGNESIUM COMPOUNDS	0 (0.0%)	1 (2.1%)	1 (1.5%)
MAGNESIUM HYDROXIDE	0 (0.0%)	1 (2.1%)	1 (1.5%)
MINERALOCORTICOIDS	0 (0.0%)	1 (2.1%)	1 (1.5%)
FLUDROCORTISONE	0 (0.0%)	1 (2.1%)	1 (1.5%)
NITROFURAN DERIVATIVES	1 (4.8%)	0 (0.0%)	1 (1.5%)
NITROFURANTOIN	1 (4.8%)	0 (0.0%)	1 (1.5%)
NITROGEN MUSTARD ANALOGUES	1 (4.8%)	0 (0.0%)	1 (1.5%)
CYCLOPHOSPHAMIDE	1 (4.8%)	0 (0.0%)	1 (1.5%)
OTHER ANTIDEPRESSANTS	1 (4.8%)	0 (0.0%)	1 (1.5%)
TRAZODONE	1 (4.8%)	0 (0.0%)	1 (1.5%)
OTHER ANTIHISTAMINES FOR SYSTEMIC USE	0 (0.0%)	1 (2.1%)	1 (1.5%)
LORATADINE	0 (0.0%)	1 (2.1%)	1 (1.5%)
OTHER ANTITHROMBOTIC AGENTS	1 (4.8%)	0 (0.0%)	1 (1.5%)
FONDAPARINUX	1 (4.8%)	0 (0.0%)	1 (1.5%)
OTHER LIPID MODIFYING AGENTS	0 (0.0%)	1 (2.1%)	1 (1.5%)
FISH OIL	0 (0.0%)	1 (2.1%)	1 (1.5%)

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Program Name: RTTCON020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.1.14 All allowed concomitant medications during study treatment
(Full analysis set)

	Number (%) of patients		
ATC classification / Generic term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
OTHER NASAL PREPARATIONS	0 (0.0%)	1 (2.1%)	1 (1.5%)
MUPIROCIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
PARAMAGNETIC CONTRAST MEDIA	0 (0.0%)	1 (2.1%)	1 (1.5%)
GADOBENIC ACID	0 (0.0%)	1 (2.1%)	1 (1.5%)
PENICILLINS WITH EXTENDED SPECTRUM	0 (0.0%)	1 (2.1%)	1 (1.5%)
AMOXICILLIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
PHENOTHIAZINE DERIVATIVES	0 (0.0%)	1 (2.1%)	1 (1.5%)
PROMETHAZINE HYDROCHLORIDE	0 (0.0%)	1 (2.1%)	1 (1.5%)
PHENOTHIAZINES WITH ALIPHATIC SIDE-CHAIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
CHLORPROMAZINE HYDROCHLORIDE	0 (0.0%)	1 (2.1%)	1 (1.5%)
PODOPHYLLOTOXIN DERIVATIVES	1 (4.8%)	0 (0.0%)	1 (1.5%)
ETOPOSIDE	1 (4.8%)	0 (0.0%)	1 (1.5%)
PREPARATIONS INHIBITING URIC ACID PRODUCTION	0 (0.0%)	1 (2.1%)	1 (1.5%)
ALLOPURINOL	0 (0.0%)	1 (2.1%)	1 (1.5%)
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS	0 (0.0%)	1 (2.1%)	1 (1.5%)
LEVOSALBUTAMOL	0 (0.0%)	1 (2.1%)	1 (1.5%)
SOLUTIONS AFFECTING THE ELECTROLYTE BALANCE	0 (0.0%)	1 (2.1%)	1 (1.5%)
GLUCOSE+SODIUM CHLORIDE	0 (0.0%)	1 (2.1%)	1 (1.5%)

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Table 11.1.14 All allowed concomitant medications during study treatment
(Full analysis set)

	Number (%) of patients		
ATC classification / Generic term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
SYNTHETIC ANTICHOLINERGIC,QUATERNARY AMMONIUM COMP	0 (0.0%)	1 (2.1%)	1 (1.5%)
GLYCOPYRRONIUM	0 (0.0%)	1 (2.1%)	1 (1.5%)
TETRACYCLINES	1 (4.8%)	0 (0.0%)	1 (1.5%)
DOXYCYCLINE	1 (4.8%)	0 (0.0%)	1 (1.5%)
THIAZIDES, PLAIN	0 (0.0%)	1 (2.1%)	1 (1.5%)
HYDROCHLOROTHIAZIDE	0 (0.0%)	1 (2.1%)	1 (1.5%)
THYROID HORMONES	1 (4.8%)	0 (0.0%)	1 (1.5%)
LEVOTHYROXINE	1 (4.8%)	0 (0.0%)	1 (1.5%)

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Program Name: RTTCON020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.15 Disallowed concomitant medications during study treatment
(Full analysis set)

ATC classification / Generic term	Number (%) of patients		
	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)

No Data

Includes medications that began prior to randomization but were ongoing after randomization.
Number (%) of patients are sorted by ATC classification in descending order of total frequency and Generic term within the ATC classification in descending order of total frequency.
Patients with multiple Generic terms in the same ATC classification are counted only once in that category.
Patients with Generic terms in more than 1 ATC classification are counted once in each of those categories.AZ Drug Dictionary version 12.2

Program Name: RTTCON010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.16 Study treatment compliance
(Full analysis set)

Compliance (%) with study treatment	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
n	21	47	68
Mean	66.52	73.42	71.29
SD	20.558	18.477	19.258
Median	72.98	80.88	76.10
Min	20.6	22.1	20.6
Max	100.0	100.0	100.0

Compliance = 100 * (total study drug dispensed) - (total study drug returned)/(total study drug dispensed).
n Number of patients in category or analysis. N Number of patients in treatment group. SD Standard Deviation. Min Minimum. Max Maximum.

Program Name: RTCOM010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.1.17 Summary of descriptive statistics for baseline assessments - biomarkers
(Full analysis set)

Fostamatinib assigned starting dose	Biomarker category	n	Number (%) of patients with the biomarker assessment at baseline						
			Negative	Heterozygous	Homozygous	No valid result	Other	Not Analyzed	No Sample Received
100mg BID(N=21)	UGT1A1*6	13	3(23.1)	2(15.4)	3(23.1)	2(15.4)	0(0.0)	3(23.1)	0(0.0)
	UGT1A1*28	13	1(7.7)	2(15.4)	5(38.5)	0(0.0)	1(7.7)	4(30.8)	0(0.0)
	UGT1A1*60	13	3(23.1)	0(0.0)	0(0.0)	1(7.7)	0(0.0)	9(69.2)	0(0.0)
200mg BID(N=47)	UGT1A1*6	31	7(22.6)	5(16.1)	3(9.7)	1(3.2)	0(0.0)	13(41.9)	2(6.5)
	UGT1A1*28	30	5(16.7)	12(40.0)	8(26.7)	0(0.0)	0(0.0)	5(16.7)	0(0.0)
	UGT1A1*60	30	5(16.7)	0(0.0)	2(6.7)	0(0.0)	0(0.0)	21(70.0)	2(6.7)

n Number of patients in the biomarker category at baseline
Baseline is defined as the last result obtained prior to the start of study treatment.
Percentages have been calculated using each biomarker category assessment n as denominator

Program Name: RT_LB250
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.2.1.1 Summary of plasma concentrations (ng/mL) of fostamatinib (metabolite R406) (PK analysis set)

Visit	Protocol schedule time	Summary statistic	100mg BID (N=20)	200mg BID (N=45)
WEEK 0	PRE-DOSE	n	19	44
		n below LOQ	18	44
		Geometric mean	3.21	2.50
		CV(%)	372.957	0.000
		Arithmetic mean	17.32	2.50
		SD	64.581	0.000
		Median	2.50	2.50
		Min	2.5	2.5
		Max	284.0	2.5
	POST-DOSE 1 H	n	14	41
		n below LOQ	2	4
		Geometric mean	46.33	113.91
		CV(%)	120.166	126.116
		Arithmetic mean	140.39	348.02
		SD	168.700	438.916
		Median	93.60	129.00
		Min	2.5	2.5
		Max	611.0	1820.0
	POST-DOSE 2 H	n	14	41
		n below LOQ	0	1
		Geometric mean	136.71	354.31
		CV(%)	59.355	75.011
		Arithmetic mean	182.59	531.75
		SD	108.373	398.872
		Median	163.00	456.00
		Min	10.4	2.5
		Max	365.0	1600.0

Note: Patients who chose to receive 200mg BID dose following the protocol amendment will be included in the dose group corresponding to the dose level actually received on Cycle 1 Day 1.
Level of quantification (LOQ): 2.5 ng/mL. Values below the LOQ have been set to 2.5 ng/mL for the analysis.
CV Coefficient of variation. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group.
PK Pharmacokinetics. SD Standard deviation.
Program Name: RT_TPC201
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.2.1.1 Summary of plasma concentrations (ng/mL) of fostamatinib (metabolite R406) (PK analysis set)

Visit	Protocol schedule time	Summary statistic	100mg BID (N=20)	200mg BID (N=45)
WEEK 0	POST-DOSE 4 H	n	14	41
		n below LOQ	0	1
		Geometric mean	152.99	340.10
		CV(%)	66.769	52.406
		Arithmetic mean	186.72	429.67
		SD	124.672	225.173
		Median	137.00	446.00
		Min	45.5	2.5
		Max	490.0	1040.0
	POST-DOSE 8 H	n	14	38
		n below LOQ	0	0
		Geometric mean	103.77	250.88
		CV(%)	50.872	49.007
		Arithmetic mean	118.09	284.25
		SD	60.072	139.301
		Median	111.00	257.00
		Min	42.7	90.5
		Max	219.0	670.0
WEEK 1	PRE-DOSE	n	16	39
		n below LOQ	0	0
		Geometric mean	284.34	652.14
		CV(%)	39.921	64.763
		Arithmetic mean	305.75	810.04
		SD	122.057	524.604
		Median	295.50	684.00
		Min	121.0	63.4
		Max	603.0	2730.0

Note: Patients who chose to receive 200mg BID dose following the protocol amendment will be included in the dose group corresponding to the dose level actually received on Cycle 1 Day 1.
Level of quantification (LOQ): 2.5 ng/mL. Values below the LOQ have been set to 2.5 ng/mL for the analysis.
CV Coefficient of variation. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group.
PK Pharmacokinetics. SD Standard deviation.
Program Name: RT_TPC201
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.2.1.1 Summary of plasma concentrations (ng/mL) of fostamatinib (metabolite R406) (PK analysis set)

Visit	Protocol schedule time	Summary statistic	100mg BID (N=20)	200mg BID (N=45)
WEEK 1	POST-DOSE 1 H	n	11	36
		n below LOQ	0	0
		Geometric mean	595.31	975.49
		CV(%)	41.266	70.443
		Arithmetic mean	654.64	1216.69
		SD	270.141	857.073
		Median	685.00	933.00
		Min	203.0	191.0
		Max	1110.0	4430.0
	POST-DOSE 2 H	n	12	37
		n below LOQ	0	0
		Geometric mean	526.67	1115.00
		CV(%)	35.297	62.274
		Arithmetic mean	555.92	1337.41
		SD	196.225	832.850
		Median	559.00	1170.00
		Min	331.0	207.0
		Max	982.0	3890.0
	POST-DOSE 4 H	n	12	36
		n below LOQ	0	0
		Geometric mean	389.53	951.79
		CV(%)	33.951	50.577
		Arithmetic mean	410.33	1076.39
		SD	139.311	544.400
		Median	429.00	905.00
		Min	215.0	204.0
		Max	752.0	3050.0

Note: Patients who chose to receive 200mg BID dose following the protocol amendment will be included in the dose group corresponding to the dose level actually received on Cycle 1 Day 1.
Level of quantification (LOQ): 2.5 ng/mL. Values below the LOQ have been set to 2.5 ng/mL for the analysis.
CV Coefficient of variation. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group.
PK Pharmacokinetics. SD Standard deviation.
Program Name: RT_TPC201
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.2.1.1 Summary of plasma concentrations (ng/mL) of fostamatinib (metabolite R406) (PK analysis set)

Visit	Protocol schedule time	Summary statistic	100mg BID (N=20)	200mg BID (N=45)
WEEK 1	POST-DOSE 8 H	n	12	35
		n below LOQ	0	0
		Geometric mean	285.81	731.95
		CV(%)	43.046	54.250
		Arithmetic mean	308.83	840.34
		SD	132.941	455.884
		Median	301.50	807.00
		Min	132.0	193.0
		Max	656.0	2330.0
WEEK 4	PRE-DOSE	n	12	19
		n below LOQ	0	0
		Geometric mean	340.76	584.43
		CV(%)	58.805	81.136
		Arithmetic mean	407.40	740.26
		SD	239.572	600.622
		Median	380.50	541.00
		Min	97.8	186.0
		Max	937.0	2400.0
	POST-DOSE 1 H	n	9	18
		n below LOQ	0	0
		Geometric mean	604.57	820.36
		CV(%)	46.472	78.438
		Arithmetic mean	701.00	1073.22
		SD	325.765	841.813
		Median	772.00	896.50
		Min	155.0	206.0
		Max	1150.0	3220.0

Note: Patients who chose to receive 200mg BID dose following the protocol amendment will be included in the dose group corresponding to the dose level actually received on Cycle 1 Day 1.
Level of quantification (LOQ): 2.5 ng/mL. Values below the LOQ have been set to 2.5 ng/mL for the analysis.
CV Coefficient of variation. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group.
PK Pharmacokinetics. SD Standard deviation.
Program Name: RT_TPC201
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.2.1.1 Summary of plasma concentrations (ng/mL) of fostamatinib (metabolite R406) (PK analysis set)

Visit	Protocol schedule time	Summary statistic	100mg BID (N=20)	200mg BID (N=45)
WEEK 4	POST-DOSE 2 H	n	9	19
		n below LOQ	0	0
		Geometric mean	502.08	929.90
		CV(%)	41.120	98.738
		Arithmetic mean	547.78	1256.00
		SD	225.248	1240.149
		Median	536.00	987.00
		Min	184.0	285.0
		Max	1010.0	5410.0
	POST-DOSE 4 H	n	9	18
		n below LOQ	0	0
		Geometric mean	365.25	765.49
		CV(%)	40.290	73.332
		Arithmetic mean	397.11	947.00
		SD	159.996	694.452
		Median	431.00	798.50
		Min	149.0	246.0
		Max	687.0	2700.0
	POST-DOSE 8 H	n	9	16
		n below LOQ	0	0
		Geometric mean	304.75	628.43
		CV(%)	52.625	89.063
		Arithmetic mean	349.67	823.69
		SD	184.014	733.603
		Median	345.00	557.00
		Min	103.0	253.0
		Max	703.0	2860.0

Note: Patients who chose to receive 200mg BID dose following the protocol amendment will be included in the dose group corresponding to the dose level actually received on Cycle 1 Day 1.
Level of quantification (LOQ): 2.5 ng/mL. Values below the LOQ have been set to 2.5 ng/mL for the analysis.
CV Coefficient of variation. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group.
PK Pharmacokinetics. SD Standard deviation.
Program Name: RT_TPC201
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.2.1.1 Summary of plasma concentrations (ng/mL) of fostamatinib (metabolite R406) (PK analysis set)

Visit	Protocol schedule time	Summary statistic	100mg BID (N=20)	200mg BID (N=45)
WEEK 12		n	0	0
		n below LOQ	0	0
		Geometric mean	-	-
		CV(%)	-	-
		Arithmetic mean	-	-
		SD	-	-
		Median	-	-
		Min	-	-
		Max	-	-
WEEK 16		n	2	1
		n below LOQ	0	1
		Geometric mean	197.14	2.50
		CV(%)	72.405	0.000
		Arithmetic mean	229.50	2.50
		SD	166.170	0.000
		Median	229.50	2.50
		Min	112.0	2.5
		Max	347.0	2.5
WEEK 20		n	0	0
		n below LOQ	0	0
		Geometric mean	-	-
		CV(%)	-	-
		Arithmetic mean	-	-
		SD	-	-
		Median	-	-
		Min	-	-
		Max	-	-

Note: Patients who chose to receive 200mg BID dose following the protocol amendment will be included in the dose group corresponding to the dose level actually received on Cycle 1 Day 1.
Level of quantification (LOQ): 2.5 ng/mL. Values below the LOQ have been set to 2.5 ng/mL for the analysis.
CV Coefficient of variation. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group.
PK Pharmacokinetics. SD Standard deviation.
Program Name: RT_TPC201
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.2.1.1 Summary of plasma concentrations (ng/mL) of fostamatinib (metabolite R406) (PK analysis set)

Visit	Protocol schedule time	Summary statistic	100mg BID (N=20)	200mg BID (N=45)
WEEK 24		n	1	0
		n below LOQ	0	0
		Geometric mean	378.00	-
		CV(%)	0.000	-
		Arithmetic mean	378.00	-
		SD	0.000	-
		Median	378.00	-
		Min	378.0	-
		Max	378.0	-
WEEK 28		n	2	0
		n below LOQ	0	0
		Geometric mean	191.93	-
		CV(%)	68.617	-
		Arithmetic mean	219.50	-
		SD	150.614	-
		Median	219.50	-
		Min	113.0	-
		Max	326.0	-
WEEK 32		n	0	0
		n below LOQ	0	0
		Geometric mean	-	-
		CV(%)	-	-
		Arithmetic mean	-	-
		SD	-	-
		Median	-	-
		Min	-	-
		Max	-	-

Note: Patients who chose to receive 200mg BID dose following the protocol amendment will be included in the dose group corresponding to the dose level actually received on Cycle 1 Day 1.
Level of quantification (LOQ): 2.5 ng/mL. Values below the LOQ have been set to 2.5 ng/mL for the analysis.
CV Coefficient of variation. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group.
PK Pharmacokinetics. SD Standard deviation.
Program Name: RT_TPC201
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.2.1.1 Summary of plasma concentrations (ng/mL) of fostamatinib (metabolite R406) (PK analysis set)

Visit	Protocol schedule time	Summary statistic	100mg BID (N=20)	200mg BID (N=45)
WEEK 36		n	1	0
		n below LOQ	0	0
		Geometric mean	561.00	-
		CV(%)	0.000	-
		Arithmetic mean	561.00	-
		SD	0.000	-
		Median	561.00	-
		Min	561.0	-
		Max	561.0	-
WEEK 40		n	0	0
		n below LOQ	0	0
		Geometric mean	-	-
		CV(%)	-	-
		Arithmetic mean	-	-
		SD	-	-
		Median	-	-
		Min	-	-
		Max	-	-
WEEK 44		n	1	0
		n below LOQ	0	0
		Geometric mean	915.00	-
		CV(%)	0.000	-
		Arithmetic mean	915.00	-
		SD	0.000	-
		Median	915.00	-
		Min	915.0	-
		Max	915.0	-

Note: Patients who chose to receive 200mg BID dose following the protocol amendment will be included in the dose group corresponding to the dose level actually received on Cycle 1 Day 1.
Level of quantification (LOQ): 2.5 ng/mL. Values below the LOQ have been set to 2.5 ng/mL for the analysis.
CV Coefficient of variation. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group.
PK Pharmacokinetics. SD Standard deviation.
Program Name: RT_TPC201
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.2.1.1 Summary of plasma concentrations (ng/mL) of fostamatinib (metabolite R406) (PK analysis set)

Visit	Protocol schedule time	Summary statistic	100mg BID (N=20)	200mg BID (N=45)
WEEK 48		n	0	0
		n below LOQ	0	0
		Geometric mean	-	-
		CV(%)	-	-
		Arithmetic mean	-	-
		SD	-	-
		Median	-	-
		Min	-	-
		Max	-	-
DISCONTINUATION		n	1	0
		n below LOQ	0	0
		Geometric mean	408.00	-
		CV(%)	0.000	-
		Arithmetic mean	408.00	-
		SD	0.000	-
		Median	408.00	-
		Min	408.0	-
		Max	408.0	-

Note: Patients who chose to receive 200mg BID dose following the protocol amendment will be included in the dose group corresponding to the dose level actually received on Cycle 1 Day 1.
Level of quantification (LOQ): 2.5 ng/mL. Values below the LOQ have been set to 2.5 ng/mL for the analysis.
CV Coefficient of variation. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group.
PK Pharmacokinetics. SD Standard deviation.
Program Name: RT_TPC201
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.2.2.1 Best objective response
(Full analysis set)

Response status	Best objective response	Number (%) of patients 100mg BID (N=21)	200mg BID (N=47)
Response	Total	2 (9.5)	0 (0.0)
	Complete response [a]	1 (4.8)	0 (0.0)
	Partial response [a]	1 (4.8)	0 (0.0)
Non-response	Total	19 (90.5)	47 (100.0)
	Stable disease	2 (9.5)	5 (10.6)
	Progression	13 (61.9)	31 (66.0)
	Not evaluable	4 (19.0)	10 (21.3)
	Missing	0 (0.0)	1 (2.1)

[a] Response does not require confirmation
N Number of patients in treatment group.

Program Name: RTTEFF110.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.2.2.2 Objective response rate analysis, exact binomial test, primary analysis (Full analysis set)

Group	N	Number of patients with response [a]	Response Rate (%)	Response rate confidence intervals		Test of null hypothesis: Response rate <= 10% 1-sided p-value
				80% CI	95% CI	
100mg BID	21	2	9.52	2.56, 23.40	1.17, 30.38	0.6353
200mg BID	47	0	0.00	0.00, 4.78	0.00, 7.55	1.0000

CI Confidence interval. N Number of patients in treatment group.
The analysis was performed using the exact binomial test.
CI calculated using Clopper-Pearson method for response rate.
[a] Response does not require confirmation
Cheson criteria

Program Name: RTTEFF140_PRI.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.2.2.3 Objective response rate analysis, Fisher's exact test, Fostamatinib 100mg BID vs 200mg BID secondary analysis (Full analysis set)

				Comparison between groups		
Group	N	Number of patients with response [a]	Response Rate (%)	Odds ratio	95% CI	2-sided p-value
100mg BID	21	2	9.52	0.00	0.00, 1.52	0.0922
200mg BID	47	0	0.00			

CI Confidence interval. N Number of patients in treatment group.
The analysis was performed using Fisher's exact test.
An odds ratio > 1 favours Fostamatinib 200 BID.
CI calculated using Thomas exact algorithm for odds ratio.
[a] Response does not require confirmation
Cheson criteria

Program Name: RTTEFF140_SECARM.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.2.2.4 Progression status
(Full analysis set)

Progression status	Type of event	Number (%) of patients 100mg BID (N=21)	200mg BID (N=47)
Progression	Total	18 (85.7)	39 (83.0)
	Cheson progression [a]	14 (66.7)	31 (66.0)
	Death [b]	4 (19.0)	8 (17.0)
No Progression	Total	3 (14.3)	8 (17.0)
	Progression free at time of analysis [c]	3 (14.3)	4 (8.5)
	Censored Cheson progression [d]	0 (0.0)	0 (0.0)
	Censored death [d]	0 (0.0)	0 (0.0)
	Censor due to insufficient data [e]	0 (0.0)	4 (8.5)

Note: progression status was assigned regardless whether the patient withdrew from randomised therapy or received another anti-lymphoma therapy.
[a] Patient relapsed/progressed, after none or one missed visit, was an event on the earliest evaluation date that triggered the outcome.
[b] Patient died in the absence of relapse/progression, within two visits of baseline or after none or one missed visit, was an event on the date of death.
[c] Patient known to be relapse-free/progression-free and alive was censored at the date of the latest assessment from their last evaluable scan.
[d] Patient relapsed/progressed or died after two or more missed visits was censored at the date of the latest assessment from their previous evaluable scan.
[e] Patient who was alive but had no evaluable visits or did not have baseline data was censored at day 0.

Program Name: RTTEFF010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca **Page 1 of 1**

Table 11.2.2.5 Median progression free survival
(Full analysis set)

	100mg BID (N=21)	200mg BID (N=47)
Total number of events [a]	18	39
Median progression free survival (weeks) [b]	7.3	5.3
95% CI for median progression free survival	4.1, 7.9	3.7, 6.1
Range for progression free survival (weeks)	0.4, 57.4	0.0, 19.9

Progression includes deaths in the absence of Cheson progression.
[a] Patients who relapsed/progressed or died after two or more missed visits were censored at the date of the latest assessment from their previous evaluable scan (or randomisation) and therefore excluded in the number of events.
[b] Calculated using the Kaplan-Meier technique.
CI Confidence interval. N Number of patients in treatment group.

Program Name: RTTEFF030_PFS.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.2.2.6 Target Lesion size, percentage change from baseline
(Full analysis set)

			Target lesion size (mm^2)						Percentage change (post-baseline)				
Fostamatinib, assigned starting dose	Site location	Time point	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
100mg BID (N=21)	LIVER	Baseline	2	1646.5	501.34	1292.0	1646.5	2001.0						
		DISCONTINUATION	1	2760.0		2760.0	2760.0	2760.0	1	113.6		113.6	113.6	113.6
	LYMPH NODE	Baseline	21	3173.4	4127.53	99.0	1799.0	18677.0						
		WEEK 2	1	1833.0		1833.0	1833.0	1833.0	1	36.4		36.4	36.4	36.4
		WEEK 8	4	2584.5	3632.50	661.0	823.0	8031.0	4	-12.7	23.69	-40.5	-11.5	12.7
		WEEK 20	2	660.5	253.85	481.0	660.5	840.0	2	-28.7	29.63	-49.6	-28.7	-7.7
		WEEK 32	2	457.5	53.03	420.0	457.5	495.0	2	-51.0	4.03	-53.8	-51.0	-48.1
		WEEK 48	1	12.0		12.0	12.0	12.0	1	-98.7		-98.7	-98.7	-98.7
		DISCONTINUATION	10	3773.3	2387.21	1339.0	2994.0	8441.0	10	361.6	736.41	-30.6	123.8	2433.3
	SPLEEN	Baseline	1	1170.0		1170.0	1170.0	1170.0						
		DISCONTINUATION	1	2116.0		2116.0	2116.0	2116.0	1	80.9		80.9	80.9	80.9

A negative change denotes a reduction in target lesion size.
Any changes in target lesion size that are imputed (rules defined in SAP) are included.
NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. SD Standard deviation.
Cheson criteria
Program Name: RTTEFF200.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.2.2.6 Target Lesion size, percentage change from baseline
(Full analysis set)

			Target lesion size (mm^2)						Percentage change (post-baseline)					
Fostamatinib, assigned starting dose	Site location	Time point	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
200mg BID (N=47)	LIVER	Baseline	5	2404.2	2446.52	352.0	1978.0	6584.0						
		DISCONTINUATION	3	2531.3	1735.17	550.0	3264.0	3780.0	3	125.5	91.34	56.3	91.1	229.0
	LYMPH NODE	Baseline	47	4757.1	5557.14	168.0	2895.0	27438.0						
		WEEK 8	3	1079.3	607.00	487.0	1051.0	1700.0	3	-14.4	18.91	-31.2	-18.0	6.1
		WEEK 20	1	760.0		760.0	760.0	760.0	1	-40.7		-40.7	-40.7	-40.7
		DISCONTINUATION	26	6805.8	6537.84	434.0	4797.0	30866.0	26	100.1	154.20	-55.2	55.3	713.9
		FOLLOW-UP	1	9285.0		9285.0	9285.0	9285.0	1	293.4		293.4	293.4	293.4
	SPLEEN	Baseline	2	1143.0	640.64	690.0	1143.0	1596.0						
		DISCONTINUATION	2	1276.0	808.93	704.0	1276.0	1848.0	2	8.9	9.76	2.0	8.9	15.8

A negative change denotes a reduction in target lesion size.
Any changes in target lesion size that are imputed (rules defined in SAP) are included.
NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. SD Standard deviation.
Cheson criteria
Program Name: RTTEFF200.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.2.2.7 Subsequent cancer therapy relative to progression
(Full analysis set)

	Number (%) of patients	
	100mg BID (N=21)	**200mg BID (N=47)**
Received further therapy for cancer	1(4.8)	1(2.1)
After progression	1(4.8)	0(0.0)
Before progression	0(0.0)	0(0.0)
No progression	0(0.0)	1(2.1)
No further therapy for cancer recorded	20(95.2)	46(97.9)

Progression includes deaths in the absence of Cheson progression.
However, patients who relapsed/progressed or died after two or more missed visits were censored at the date of the latest assessment from their previous evaluable scan (or randomisation) and therefore categorised as 'No progression'.
N Number of patients in treatment group.
Cheson criteria

Program Name: RT_EFF170
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.2.2.8 Days between Cheson assessments
(Full analysis set)

Number of days	100mg BID (N=21)	200mg BID (N=47)
n	17	35
Mean	47.8	37.1
SD	17.67	16.62
Median	54.0	37.0
Min	14	12
Max	80	70

The number of days is calculated from the latest scan dates at each assessment compared to the next assessment and averaged for a patient.The first post baseline assessment is compared to the date of randomisation.
n is the number of patients with at least one post baseline Cheson assessment scan.
Max Maximum. Min Minimum. N Number of patients in treatment group. SD Standard deviation.
Program Name: RTTEFF530
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.2.2.9 Patients censored for progression at more than 8 weeks before the data cut-off (Full analysis set)

	Number (%) of patients	
Censored patients	**100mg BID (N=21)**	**200mg BID (N=47)**
Censored > 8 weeks before DCO	0(0.0)	2(4.3)
Censored <= 8 weeks before DCO	0(0.0)	6(12.8)

DCO = Data cut-off
Patients without a progression event or who do not progress within 8 weeks of the last evaluable assessment (or randomisation).
N Number of patients in treatment group.
Program Name: RTTEFF510
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.1.1 Duration of exposure
(Safety analysis set)

Treatment duration (days)		100mg BID (N=21)	200mg BID (N=47)
Total treatment duration (days) [a]	n	21	47
	Mean	70.7	35.4
	SD	96.74	25.93
	Median	54.0	28.0
	Minimum	4	4
	Maximum	407	142
	Total treatment days	1484	1662
Actual treatment duration (days) [b]	n	21	47
	Mean	69.0	33.8
	SD	94.95	23.80
	Median	54.0	28.0
	Minimum	4	4
	Maximum	407	118
	Total treatment days	1449	1587

N Number of patients in treatment group. n Number of patients included in analysis. SD Standard deviation
[a] Total treatment duration = (last dose - first dose +1).
[b] Actual treatment duration = total treatment duration, excluding dose interruptions and planned 'no dose' periods for intermittent dosing.

Program Name: RTTEXP010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.1.2 Dose interruptions and dose reductions of fostamatinib
(Safety analysis set)

	Number (%) of patients	
	100mg BID (N=21)	**200mg BID (N=47)**
Received planned starting dose: YES	21(100.0)	47(100.0)
NO	0(0.0)	0(0.0)
No interruption	19(90.5)	37(78.7)
Number of patients with an interruption	2(9.5)	10(21.3)
No dose reduction	19(90.5)	47(100.0)
Number of patients with a dose reduction	2(9.5)	0(0.0)
No dose escalation	21(100.0)	47(100.0)
Number of patients with a dose escalation	0(0.0)	0(0.0)
No dose modification	19(90.5)	37(78.7)
Number of patients with a dose modification[a]	2(9.5)	10(21.3)
Number of patients with both an interruption and a dose reduction	2(9.5)	0(0.0)

[a] Number of patients with either an interruption and/or a dose reduction.
N Number of patients in treatment group

Program Name: RTTEXP020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.1.3 Cumulative exposure over time
(Safety analysis set)

	Number (%) of patients	
Treatment day	100mg BID (N=21)	200mg BID (N=47)
1	21(100.0)	47(100.0)
29	14(66.7)	23(48.9)
57	5(23.8)	4(8.5)
85	3(14.3)	2(4.3)
>85	3(14.3)	2(4.3)

Rows are cumulative and subjects are included if they have taken treatment up to that day
N Number of patients in treatment group.
Program Name: RTTEXP070
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.1.4 Dose intensity of fostamatinib
(Safety analysis set)

		100mg BID (N=21)	200mg BID (N=47)
Relative dose intensity (RDI)	n	21	47
	Mean	95.97	97.14
	SD	14.858	7.502
	Median	100.00	100.00
	Minimum	32.3	60.0
	Q1	100.00	98.00
	Q3	100.00	100.00
	Maximum	100.0	100.0
Percentage intended dose (PID)	n	21	47
	Mean	87.17	86.46
	SD	21.603	20.133
	Median	99.42	97.06
	Minimum	32.3	29.7
	Q1	87.50	79.08
	Q3	100.00	100.00
	Maximum	100.0	100.0

N Number of patients in treatment group. n Number of patients included in analysis. Q1 Lower quartile Q3 Upper quartile SD Standard deviation

Relative dose intensity (RDI) is the percentage of the actual dose intensity delivered relative to the intended dose intensity through treatment discontinuation. RDI = 100% * d/D, where d is the actual cumulative dose delivered up to the earlier of progression (or a censoring event) or the actual last day of dosing, and D is the intended cumulative dose up to the earlier of progression (or a censoring event) or the actual last day of dosing.

Percentage intended dose (PID) is the percentage of the actual dose delivered relative to the intended dose through progression. PID = 100% * d/D, where d is the actual cumulative dose delivered up to progression (or a censoring event), and D is the intended cumulative dose up to progression (or a censoring event). D is the total dose that would be delivered, if there were no modification to dose or schedule.

Program Name: RTTEXP100.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.1 Adverse Events in any category - patient level
(Safety analysis set)

	Number (%) of patients [a]		
AE category	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
Any AE	21 (100.0)	44 (93.6)	65 (95.6)
Any AE causally related [b]	13 (61.9)	34 (72.3)	47 (69.1)
Any AE of CTCAE grade 3 or higher	10 (47.6)	25 (53.2)	35 (51.5)
Any AE of CTCAE grade 3 or higher, causally related [b]	5 (23.8)	14 (29.8)	19 (27.9)
Any AE with outcome = death	0 (0.0)	2 (4.3)	2 (2.9)
Any AE with outcome = death, causally related [b]	0 (0.0)	1 (2.1)	1 (1.5)
Any SAE (including events with outcome = death)	3 (14.3)	12 (25.5)	15 (22.1)
Any SAE (including events with outcome = death), causally related [b]	1 (4.8)	2 (4.3)	3 (4.4)
Any AE leading to dose modification	4 (19.0)	10 (21.3)	14 (20.6)
Any AE leading to discontinuation of fostamatinib	1 (4.8)	4 (8.5)	5 (7.4)
Any AE leading to discontinuation of fostamatinib, causally related [b]	1 (4.8)	2 (4.3)	3 (4.4)
Any AE leading to withdrawal from study	1 (4.8)	5 (10.6)	6 (8.8)
Any SAE (including events with outcome = death) leading to withdrawal from study	0 (0.0)	2 (4.3)	2 (2.9)
Any AE with AE leading to dose reduction of fostamatinib	1 (4.8)	0 (0.0)	1 (1.5)

[a] Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

[b] As assessed by the Investigator.

[c] Significant AEs, other than SAEs and those AEs leading to discontinuation of study treatment, which are of particular clinical importance, are identified and classified as other significant AEs (OAEs).

AE Adverse Avent. IP Investigational product N Number of patients in treatment group. SAE Serious AE

There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT_AE010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

	100mg BID (N=21)		200mg BID (N=47)		Total (N=68)	
System organ class / MedDRA Preferred term	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]
Patients with any AE	21 (100.0)	512.20	44 (93.6)	956.52	65 (95.6)	755.81
GASTROINTESTINAL DISORDERS	12 (57.1)	292.68	32 (68.1)	695.65	44 (64.7)	511.63
DIARRHOEA	3 (14.3)	73.17	16 (34.0)	347.83	19 (27.9)	220.93
CONSTIPATION	4 (19.0)	97.56	12 (25.5)	260.87	16 (23.5)	186.05
NAUSEA	4 (19.0)	97.56	12 (25.5)	260.87	16 (23.5)	186.05
VOMITING	0 (0.0)	0.00	9 (19.1)	195.65	9 (13.2)	104.65
ABDOMINAL PAIN	1 (4.8)	24.39	4 (8.5)	86.96	5 (7.4)	58.14
ABDOMINAL DISTENSION	2 (9.5)	48.78	2 (4.3)	43.48	4 (5.9)	46.51
DYSPEPSIA	0 (0.0)	0.00	4 (8.5)	86.96	4 (5.9)	46.51
ABDOMINAL PAIN LOWER	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
ABDOMINAL PAIN UPPER	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
DYSPHAGIA	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
ABDOMINAL DISCOMFORT	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
ABDOMINAL TENDERNESS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
ASCITES	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
BOWEL MOVEMENT IRREGULARITY	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
DRY MOUTH	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
EPIGASTRIC DISCOMFORT	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
FLATULENCE	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
GASTROOESOPHAGEAL REFLUX DISEASE	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.
The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

System organ class / MedDRA Preferred term	100mg BID (N=21) Number (%) of patients [a]	100mg BID (N=21) Event rate (per 100 pt years) [b]	200mg BID (N=47) Number (%) of patients [a]	200mg BID (N=47) Event rate (per 100 pt years) [b]	Total (N=68) Number (%) of patients [a]	Total (N=68) Event rate (per 100 pt years) [b]
GINGIVAL DISCOLOURATION	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
HAEMATEMESIS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HAEMATOCHEZIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HYPOAESTHESIA ORAL	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
LIP SWELLING	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
PALATAL OEDEMA	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
PROCTALGIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
STOMATITIS	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	9 (42.9)	219.51	24 (51.1)	521.74	33 (48.5)	383.72
FATIGUE	4 (19.0)	97.56	13 (27.7)	282.61	17 (25.0)	197.67
PYREXIA	4 (19.0)	97.56	10 (21.3)	217.39	14 (20.6)	162.79
OEDEMA PERIPHERAL	2 (9.5)	48.78	3 (6.4)	65.22	5 (7.4)	58.14
ASTHENIA	0 (0.0)	0.00	3 (6.4)	65.22	3 (4.4)	34.88
PAIN	1 (4.8)	24.39	2 (4.3)	43.48	3 (4.4)	34.88
EARLY SATIETY	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
CATHETER SITE PAIN	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
CHEST DISCOMFORT	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
CHILLS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
FEELING COLD	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.
The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

	100mg BID (N=21)		200mg BID (N=47)		Total (N=68)	
System organ class / MedDRA Preferred term	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]
INFLUENZA LIKE ILLNESS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
LOCAL SWELLING	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
MALAISE	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
MUCOSAL INFLAMMATION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
TENDERNESS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
INVESTIGATIONS	13 (61.9)	317.07	20 (42.6)	434.78	33 (48.5)	383.72
ASPARTATE AMINOTRANSFERASE INCREASED	4 (19.0)	97.56	8 (17.0)	173.91	12 (17.6)	139.53
BLOOD ALKALINE PHOSPHATASE INCREASED	5 (23.8)	121.95	5 (10.6)	108.70	10 (14.7)	116.28
BLOOD CREATININE INCREASED	3 (14.3)	73.17	3 (6.4)	65.22	6 (8.8)	69.77
ALANINE AMINOTRANSFERASE INCREASED	3 (14.3)	73.17	2 (4.3)	43.48	5 (7.4)	58.14
BLOOD LACTATE DEHYDROGENASE INCREASED	1 (4.8)	24.39	4 (8.5)	86.96	5 (7.4)	58.14
WHITE BLOOD CELL COUNT DECREASED	1 (4.8)	24.39	3 (6.4)	65.22	4 (5.9)	46.51
BLOOD BILIRUBIN INCREASED	3 (14.3)	73.17	0 (0.0)	0.00	3 (4.4)	34.88
BLOOD UREA INCREASED	2 (9.5)	48.78	1 (2.1)	21.74	3 (4.4)	34.88
WEIGHT DECREASED	1 (4.8)	24.39	2 (4.3)	43.48	3 (4.4)	34.88
BLOOD POTASSIUM DECREASED	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
LIPASE INCREASED	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
LYMPHOCYTE COUNT DECREASED	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
NEUTROPHIL COUNT DECREASED	2 (9.5)	48.78	0 (0.0)	0.00	2 (2.9)	23.26

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.
The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

	100mg BID (N=21)		200mg BID (N=47)		Total (N=68)	
System organ class / MedDRA Preferred term	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
BLOOD ALBUMIN DECREASED	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
BLOOD ALBUMIN INCREASED	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
BLOOD ALKALINE PHOSPHATASE	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
BLOOD CREATINE PHOSPHOKINASE INCREASED	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
BLOOD LACTIC ACID INCREASED	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
BLOOD MAGNESIUM DECREASED	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
BLOOD UREA NITROGEN/CREATININE RATIO INCREASED	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
BREATH SOUNDS ABNORMAL	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
ELECTROCARDIOGRAM ABNORMAL	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HAEMATOCRIT DECREASED	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
PLATELET COUNT DECREASED	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
TRANSAMINASES INCREASED	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
URINE BILIRUBIN INCREASED	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
BLOOD AND LYMPHATIC SYSTEM DISORDERS	8 (38.1)	195.12	22 (46.8)	478.26	30 (44.1)	348.84
ANAEMIA	2 (9.5)	48.78	12 (25.5)	260.87	14 (20.6)	162.79
THROMBOCYTOPENIA	5 (23.8)	121.95	7 (14.9)	152.17	12 (17.6)	139.53
NEUTROPENIA	5 (23.8)	121.95	5 (10.6)	108.70	10 (14.7)	116.28

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.
The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

System organ class / MedDRA Preferred term	100mg BID (N=21) Number (%) of patients [a]	100mg BID (N=21) Event rate (per 100 pt years) [b]	200mg BID (N=47) Number (%) of patients [a]	200mg BID (N=47) Event rate (per 100 pt years) [b]	Total (N=68) Number (%) of patients [a]	Total (N=68) Event rate (per 100 pt years) [b]
LEUKOPENIA	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
HYPOPROTHROMBINAEMIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
LYMPH NODE PAIN	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
LYMPHADENOPATHY	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
PANCYTOPENIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	8 (38.1)	195.12	16 (34.0)	347.83	24 (35.3)	279.07
DYSPNOEA	3 (14.3)	73.17	4 (8.5)	86.96	7 (10.3)	81.40
COUGH	4 (19.0)	97.56	2 (4.3)	43.48	6 (8.8)	69.77
NASAL CONGESTION	1 (4.8)	24.39	2 (4.3)	43.48	3 (4.4)	34.88
HYPOXIA	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
PLEURAL EFFUSION	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
ALLERGIC SINUSITIS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
DYSPNOEA AT REST	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
DYSPNOEA EXERTIONAL	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
EPISTAXIS	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
HICCUPS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
OROPHARYNGEAL PAIN	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
PNEUMONITIS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
PULMONARY EMBOLISM	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.
The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

	100mg BID (N=21)		200mg BID (N=47)		Total (N=68)	
System organ class / MedDRA Preferred term	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]
PULMONARY MASS	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
RALES	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
RESPIRATORY TRACT CONGESTION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
SINUS CONGESTION	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
VASCULAR DISORDERS	6 (28.6)	146.34	15 (31.9)	326.09	21 (30.9)	244.19
HYPERTENSION	1 (4.8)	24.39	9 (19.1)	195.65	10 (14.7)	116.28
HYPOTENSION	2 (9.5)	48.78	3 (6.4)	65.22	5 (7.4)	58.14
LYMPHOEDEMA	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
DEEP VEIN THROMBOSIS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
FLUSHING	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HAEMATOMA	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
HOT FLUSH	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
PALLOR	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	7 (33.3)	170.73	13 (27.7)	282.61	20 (29.4)	232.56
BACK PAIN	4 (19.0)	97.56	5 (10.6)	108.70	9 (13.2)	104.65
ARTHRALGIA	2 (9.5)	48.78	2 (4.3)	43.48	4 (5.9)	46.51
MYALGIA	1 (4.8)	24.39	3 (6.4)	65.22	4 (5.9)	46.51
GROIN PAIN	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.
The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

	100mg BID (N=21)		200mg BID (N=47)		Total (N=68)	
System organ class / MedDRA Preferred term	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]
MUSCULOSKELETAL CHEST PAIN	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
MUSCULOSKELETAL PAIN	2 (9.5)	48.78	0 (0.0)	0.00	2 (2.9)	23.26
BONE PAIN	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
MUSCULAR WEAKNESS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
PAIN IN EXTREMITY	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
NERVOUS SYSTEM DISORDERS	3 (14.3)	73.17	17 (36.2)	369.57	20 (29.4)	232.56
HEADACHE	2 (9.5)	48.78	5 (10.6)	108.70	7 (10.3)	81.40
SYNCOPE	0 (0.0)	0.00	3 (6.4)	65.22	3 (4.4)	34.88
DIZZINESS	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
PERIPHERAL MOTOR NEUROPATHY	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
TREMOR	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
ATAXIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
BALANCE DISORDER	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
CONVULSION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
DYSARTHRIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
DYSGEUSIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
ENCEPHALOPATHY	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HYPERSOMNIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
NEUROPATHY PERIPHERAL	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
PERIPHERAL SENSORY NEUROPATHY	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.

Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.

[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.

The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.

AE Adverse event. N Number of patients in treatment group.

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

	100mg BID (N=21)		200mg BID (N=47)		Total (N=68)	
System organ class / MedDRA Preferred term	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]
METABOLISM AND NUTRITION DISORDERS	2 (9.5)	48.78	15 (31.9)	326.09	17 (25.0)	197.67
HYPONATRAEMIA	1 (4.8)	24.39	5 (10.6)	108.70	6 (8.8)	69.77
DECREASED APPETITE	0 (0.0)	0.00	5 (10.6)	108.70	5 (7.4)	58.14
HYPOKALAEMIA	0 (0.0)	0.00	4 (8.5)	86.96	4 (5.9)	46.51
HYPOPHOSPHATAEMIA	1 (4.8)	24.39	2 (4.3)	43.48	3 (4.4)	34.88
DEHYDRATION	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
HYPERCALCAEMIA	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
HYPERGLYCAEMIA	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
HYPOCALCAEMIA	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
HYPOCHLORAEMIA	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
HYPOMAGNESAEMIA	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
FAILURE TO THRIVE	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HYPERKALAEMIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HYPERMAGNESAEMIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HYPERURICAEMIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HYPOALBUMINAEMIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HYPOGLYCAEMIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	3 (14.3)	73.17	13 (27.7)	282.61	16 (23.5)	186.05
NIGHT SWEATS	0 (0.0)	0.00	4 (8.5)	86.96	4 (5.9)	46.51

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.

Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.

[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.

The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.

AE Adverse event. N Number of patients in treatment group.

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

	100mg BID (N=21)		200mg BID (N=47)		Total (N=68)	
System organ class / MedDRA Preferred term	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]
RASH	1 (4.8)	24.39	2 (4.3)	43.48	3 (4.4)	34.88
ERYTHEMA	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
DERMATITIS ALLERGIC	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
DRY SKIN	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
DYSHIDROTIC ECZEMA	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
HYPERHIDROSIS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
SCAB	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
SKIN EXFOLIATION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
SKIN INDURATION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
SKIN MASS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
INFECTIONS AND INFESTATIONS	4 (19.0)	97.56	7 (14.9)	152.17	11 (16.2)	127.91
PNEUMONIA	0 (0.0)	0.00	3 (6.4)	65.22	3 (4.4)	34.88
UPPER RESPIRATORY TRACT INFECTION	1 (4.8)	24.39	2 (4.3)	43.48	3 (4.4)	34.88
CELLULITIS	0 (0.0)	0.00	2 (4.3)	43.48	2 (2.9)	23.26
URINARY TRACT INFECTION	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
CLOSTRIDIUM DIFFICILE INFECTION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
FUNGAL SKIN INFECTION	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
HERPES ZOSTER	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
LOCALISED INFECTION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
NASOPHARYNGITIS	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.

Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.

[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.

The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.

AE Adverse event. N Number of patients in treatment group.

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

	100mg BID (N=21)		200mg BID (N=47)		Total (N=68)	
System organ class / MedDRA Preferred term	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]
NEUTROPENIC SEPSIS	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
SEPSIS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
PSYCHIATRIC DISORDERS	2 (9.5)	48.78	9 (19.1)	195.65	11 (16.2)	127.91
ANXIETY	2 (9.5)	48.78	4 (8.5)	86.96	6 (8.8)	69.77
CONFUSIONAL STATE	0 (0.0)	0.00	3 (6.4)	65.22	3 (4.4)	34.88
AGITATION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
DEPRESSION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
INSOMNIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
MENTAL STATUS CHANGES	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
RENAL AND URINARY DISORDERS	2 (9.5)	48.78	8 (17.0)	173.91	10 (14.7)	116.28
RENAL FAILURE ACUTE	0 (0.0)	0.00	4 (8.5)	86.96	4 (5.9)	46.51
BLADDER PAIN	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
CHROMATURIA	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
HAEMATURIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
MICTURITION URGENCY	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
POLLAKIURIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
PROTEINURIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
PYURIA	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
RENAL FAILURE	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.
The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

	100mg BID (N=21)		200mg BID (N=47)		Total (N=68)	
System organ class / MedDRA Preferred term	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]	Number (%) of patients [a]	Event rate (per 100 pt years) [b]
URINARY INCONTINENCE	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
URINARY RETENTION	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
CARDIAC DISORDERS	2 (9.5)	48.78	7 (14.9)	152.17	9 (13.2)	104.65
SINUS TACHYCARDIA	1 (4.8)	24.39	2 (4.3)	43.48	3 (4.4)	34.88
TACHYCARDIA	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
ACUTE MYOCARDIAL INFARCTION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
CARDIAC ARREST	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
CARDIAC FAILURE CONGESTIVE	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
SUPRAVENTRICULAR TACHYCARDIA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HEPATOBILIARY DISORDERS	2 (9.5)	48.78	1 (2.1)	21.74	3 (4.4)	34.88
JAUNDICE	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
BILE DUCT OBSTRUCTION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
HYPERBILIRUBINAEMIA	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	0 (0.0)	0.00	3 (6.4)	65.22	3 (4.4)	34.88
BREAST DISCOMFORT	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
BREAST PAIN	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
SCROTAL OEDEMA	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.
The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.2 Adverse Events and event rates by system organ class and preferred term (Safety analysis set)

System organ class / MedDRA Preferred term	100mg BID (N=21) Number (%) of patients [a]	100mg BID (N=21) Event rate (per 100 pt years) [b]	200mg BID (N=47) Number (%) of patients [a]	200mg BID (N=47) Event rate (per 100 pt years) [b]	Total (N=68) Number (%) of patients [a]	Total (N=68) Event rate (per 100 pt years) [b]
EYE DISORDERS	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
EYE PAIN	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
VISION BLURRED	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
FALL	1 (4.8)	24.39	1 (2.1)	21.74	2 (2.9)	23.26
EYE CONTUSION	1 (4.8)	24.39	0 (0.0)	0.00	1 (1.5)	11.63
EAR AND LABYRINTH DISORDERS	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63
EAR CONGESTION	0 (0.0)	0.00	1 (2.1)	21.74	1 (1.5)	11.63

[a] Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
[b] Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.
The total duration of treatment across all patients in 100mg BID arm = 4.1 years; in 200mg BID arm = 4.6 years.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Patients with any AE	TOTAL	21 (100.0)	44 (93.6)	65 (95.6)
	MILD	4 (19.0)	1 (2.1)	5 (7.4)
	MODERATE	7 (33.3)	18 (38.3)	25 (36.8)
	SEVERE	8 (38.1)	17 (36.2)	25 (36.8)
	LIFE THREATENING	2 (9.5)	6 (12.8)	8 (11.8)
	DEATH	0 (0.0)	2 (4.3)	2 (2.9)
GASTROINTESTINAL DISORDERS	TOTAL	12 (57.1)	32 (68.1)	44 (64.7)
	MILD	10 (47.6)	22 (46.8)	32 (47.1)
	MODERATE	2 (9.5)	9 (19.1)	11 (16.2)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
DIARRHOEA	TOTAL	3 (14.3)	16 (34.0)	19 (27.9)
	MILD	3 (14.3)	11 (23.4)	14 (20.6)
	MODERATE	0 (0.0)	4 (8.5)	4 (5.9)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
CONSTIPATION	TOTAL	4 (19.0)	12 (25.5)	16 (23.5)
	MILD	4 (19.0)	9 (19.1)	13 (19.1)
	MODERATE	0 (0.0)	3 (6.4)	3 (4.4)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
NAUSEA	TOTAL	4 (19.0)	12 (25.5)	16 (23.5)
	MILD	4 (19.0)	9 (19.1)	13 (19.1)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
VOMITING	TOTAL	0 (0.0)	9 (19.1)	9 (13.2)
	MILD	0 (0.0)	7 (14.9)	7 (10.3)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)
ABDOMINAL PAIN	TOTAL	1 (4.8)	4 (8.5)	5 (7.4)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	1 (4.8)	1 (2.1)	2 (2.9)
	SEVERE	0 (0.0)	2 (4.3)	2 (2.9)
ABDOMINAL DISTENSION	TOTAL	2 (9.5)	2 (4.3)	4 (5.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	1 (4.8)	1 (2.1)	2 (2.9)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)
DYSPEPSIA	TOTAL	0 (0.0)	4 (8.5)	4 (5.9)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
ABDOMINAL PAIN LOWER	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
ABDOMINAL PAIN UPPER	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)
DYSPHAGIA	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MODERATE	1 (4.8)	1 (2.1)	2 (2.9)
ABDOMINAL DISCOMFORT	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
ABDOMINAL TENDERNESS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
ASCITES	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
BOWEL MOVEMENT IRREGULARITY	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
DRY MOUTH	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
EPIGASTRIC DISCOMFORT	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
FLATULENCE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
GASTROOESOPHAGEAL REFLUX DISEASE	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
GINGIVAL DISCOLOURATION	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
HAEMATEMESIS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
HAEMATOCHEZIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HYPOAESTHESIA ORAL	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
LIP SWELLING	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
PALATAL OEDEMA	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
PROCTALGIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
STOMATITIS	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	TOTAL	9 (42.9)	24 (51.1)	33 (48.5)
	MILD	8 (38.1)	12 (25.5)	20 (29.4)
	MODERATE	1 (4.8)	8 (17.0)	9 (13.2)
	SEVERE	0 (0.0)	4 (8.5)	4 (5.9)
FATIGUE	TOTAL	4 (19.0)	13 (27.7)	17 (25.0)
	MILD	4 (19.0)	3 (6.4)	7 (10.3)
	MODERATE	0 (0.0)	6 (12.8)	6 (8.8)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	SEVERE	0 (0.0)	4 (8.5)	4 (5.9)
PYREXIA	TOTAL	4 (19.0)	10 (21.3)	14 (20.6)
	MILD	4 (19.0)	8 (17.0)	12 (17.6)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)
OEDEMA PERIPHERAL	TOTAL	2 (9.5)	3 (6.4)	5 (7.4)
	MILD	2 (9.5)	3 (6.4)	5 (7.4)
ASTHENIA	TOTAL	0 (0.0)	3 (6.4)	3 (4.4)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
PAIN	TOTAL	1 (4.8)	2 (4.3)	3 (4.4)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
EARLY SATIETY	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)
CATHETER SITE PAIN	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
CHEST DISCOMFORT	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
CHILLS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
FEELING COLD	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
INFLUENZA LIKE ILLNESS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
LOCAL SWELLING	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
MALAISE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
MUCOSAL INFLAMMATION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
TENDERNESS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
INVESTIGATIONS	TOTAL	13 (61.9)	20 (42.6)	33 (48.5)
	MILD	8 (38.1)	14 (29.8)	22 (32.4)
	MODERATE	1 (4.8)	4 (8.5)	5 (7.4)
	SEVERE	4 (19.0)	2 (4.3)	6 (8.8)
ASPARTATE AMINOTRANSFERASE INCREASED	TOTAL	4 (19.0)	8 (17.0)	12 (17.6)
	MILD	3 (14.3)	5 (10.6)	8 (11.8)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)
	SEVERE	1 (4.8)	1 (2.1)	2 (2.9)
BLOOD ALKALINE PHOSPHATASE INCREASED	TOTAL	5 (23.8)	5 (10.6)	10 (14.7)
	MILD	2 (9.5)	4 (8.5)	6 (8.8)
	MODERATE	2 (9.5)	1 (2.1)	3 (4.4)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)
BLOOD CREATININE INCREASED	TOTAL	3 (14.3)	3 (6.4)	6 (8.8)
	MILD	2 (9.5)	1 (2.1)	3 (4.4)
	MODERATE	1 (4.8)	2 (4.3)	3 (4.4)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
ALANINE AMINOTRANSFERASE INCREASED	TOTAL	3 (14.3)	2 (4.3)	5 (7.4)
	MILD	2 (9.5)	0 (0.0)	2 (2.9)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	1 (4.8)	1 (2.1)	2 (2.9)
BLOOD LACTATE DEHYDROGENASE INCREASED	TOTAL	1 (4.8)	4 (8.5)	5 (7.4)
	MILD	1 (4.8)	2 (4.3)	3 (4.4)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)
WHITE BLOOD CELL COUNT DECREASED	TOTAL	1 (4.8)	3 (6.4)	4 (5.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	1 (4.8)	2 (4.3)	3 (4.4)
BLOOD BILIRUBIN INCREASED	TOTAL	3 (14.3)	0 (0.0)	3 (4.4)
	MILD	2 (9.5)	0 (0.0)	2 (2.9)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)
BLOOD UREA INCREASED	TOTAL	2 (9.5)	1 (2.1)	3 (4.4)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)
WEIGHT DECREASED	TOTAL	1 (4.8)	2 (4.3)	3 (4.4)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)
BLOOD POTASSIUM DECREASED	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)
LIPASE INCREASED	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	SEVERE	0 (0.0)	2 (4.3)	2 (2.9)
LYMPHOCYTE COUNT DECREASED	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	LIFE THREATENING	0 (0.0)	1 (2.1)	1 (1.5)
NEUTROPHIL COUNT DECREASED	TOTAL	2 (9.5)	0 (0.0)	2 (2.9)
	SEVERE	2 (9.5)	0 (0.0)	2 (2.9)
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD ALBUMIN DECREASED	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
BLOOD ALBUMIN INCREASED	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
BLOOD ALKALINE PHOSPHATASE	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
BLOOD CREATINE PHOSPHOKINASE INCREASED	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD LACTIC ACID INCREASED	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
BLOOD MAGNESIUM DECREASED	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD UREA NITROGEN/CREATININE RATIO INCREASED	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
BREATH SOUNDS ABNORMAL	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
ELECTROCARDIOGRAM ABNORMAL	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HAEMATOCRIT DECREASED	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)
PLATELET COUNT DECREASED	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)
TRANSAMINASES INCREASED	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
URINE BILIRUBIN INCREASED	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	TOTAL	8 (38.1)	22 (46.8)	30 (44.1)
	MILD	3 (14.3)	7 (14.9)	10 (14.7)
	MODERATE	1 (4.8)	6 (12.8)	7 (10.3)
	SEVERE	4 (19.0)	8 (17.0)	12 (17.6)
	LIFE THREATENING	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
ANAEMIA	TOTAL	2 (9.5)	12 (25.5)	14 (20.6)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	1 (4.8)	5 (10.6)	6 (8.8)
	SEVERE	1 (4.8)	6 (12.8)	7 (10.3)
THROMBOCYTOPENIA	TOTAL	5 (23.8)	7 (14.9)	12 (17.6)
	MILD	2 (9.5)	2 (4.3)	4 (5.9)
	MODERATE	1 (4.8)	1 (2.1)	2 (2.9)
	SEVERE	2 (9.5)	3 (6.4)	5 (7.4)
	LIFE THREATENING	0 (0.0)	1 (2.1)	1 (1.5)
NEUTROPENIA	TOTAL	5 (23.8)	5 (10.6)	10 (14.7)
	MILD	2 (9.5)	2 (4.3)	4 (5.9)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)
	LIFE THREATENING	2 (9.5)	2 (4.3)	4 (5.9)
LEUKOPENIA	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	LIFE THREATENING	0 (0.0)	1 (2.1)	1 (1.5)
HYPOPROTHROMBINAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
LYMPH NODE PAIN	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
LYMPHADENOPATHY	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
PANCYTOPENIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	TOTAL	8 (38.1)	16 (34.0)	24 (35.3)
	MILD	4 (19.0)	9 (19.1)	13 (19.1)
	MODERATE	4 (19.0)	3 (6.4)	7 (10.3)
	SEVERE	0 (0.0)	4 (8.5)	4 (5.9)
DYSPNOEA	TOTAL	3 (14.3)	4 (8.5)	7 (10.3)
	MILD	1 (4.8)	2 (4.3)	3 (4.4)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MODERATE	2 (9.5)	1 (2.1)	3 (4.4)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
COUGH	TOTAL	4 (19.0)	2 (4.3)	6 (8.8)
	MILD	3 (14.3)	2 (4.3)	5 (7.4)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
NASAL CONGESTION	TOTAL	1 (4.8)	2 (4.3)	3 (4.4)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
HYPOXIA	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	SEVERE	0 (0.0)	2 (4.3)	2 (2.9)
PLEURAL EFFUSION	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
ALLERGIC SINUSITIS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
DYSPNOEA AT REST	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
DYSPNOEA EXERTIONAL	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
EPISTAXIS	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
HICCUPS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
OROPHARYNGEAL PAIN	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
PNEUMONITIS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
PULMONARY EMBOLISM	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
PULMONARY MASS	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
RALES	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
RESPIRATORY TRACT CONGESTION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
SINUS CONGESTION	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
VASCULAR DISORDERS	TOTAL	6 (28.6)	15 (31.9)	21 (30.9)
	MILD	5 (23.8)	3 (6.4)	8 (11.8)
	MODERATE	1 (4.8)	10 (21.3)	11 (16.2)
	SEVERE	0 (0.0)	2 (4.3)	2 (2.9)
HYPERTENSION	TOTAL	1 (4.8)	9 (19.1)	10 (14.7)
	MODERATE	1 (4.8)	7 (14.9)	8 (11.8)
	SEVERE	0 (0.0)	2 (4.3)	2 (2.9)
HYPOTENSION	TOTAL	2 (9.5)	3 (6.4)	5 (7.4)
	MILD	2 (9.5)	1 (2.1)	3 (4.4)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
LYMPHOEDEMA	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
DEEP VEIN THROMBOSIS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
FLUSHING	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HAEMATOMA	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
HOT FLUSH	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
PALLOR	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	TOTAL	7 (33.3)	13 (27.7)	20 (29.4)
	MILD	3 (14.3)	5 (10.6)	8 (11.8)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MODERATE	4 (19.0)	5 (10.6)	9 (13.2)
	SEVERE	0 (0.0)	3 (6.4)	3 (4.4)
BACK PAIN	TOTAL	4 (19.0)	5 (10.6)	9 (13.2)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
	MODERATE	4 (19.0)	2 (4.3)	6 (8.8)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
ARTHRALGIA	TOTAL	2 (9.5)	2 (4.3)	4 (5.9)
	MILD	2 (9.5)	0 (0.0)	2 (2.9)
	SEVERE	0 (0.0)	2 (4.3)	2 (2.9)
MYALGIA	TOTAL	1 (4.8)	3 (6.4)	4 (5.9)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
GROIN PAIN	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)
MUSCULOSKELETAL CHEST PAIN	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
MUSCULOSKELETAL PAIN	TOTAL	2 (9.5)	0 (0.0)	2 (2.9)
	MODERATE	2 (9.5)	0 (0.0)	2 (2.9)
BONE PAIN	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
MUSCULAR WEAKNESS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
PAIN IN EXTREMITY	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
NERVOUS SYSTEM DISORDERS	TOTAL	3 (14.3)	17 (36.2)	20 (29.4)
	MILD	2 (9.5)	12 (25.5)	14 (20.6)
	MODERATE	0 (0.0)	4 (8.5)	4 (5.9)
	SEVERE	1 (4.8)	1 (2.1)	2 (2.9)
HEADACHE	TOTAL	2 (9.5)	5 (10.6)	7 (10.3)
	MILD	2 (9.5)	3 (6.4)	5 (7.4)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
SYNCOPE	TOTAL	0 (0.0)	3 (6.4)	3 (4.4)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
DIZZINESS	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
PERIPHERAL MOTOR NEUROPATHY	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)
TREMOR	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
ATAXIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
BALANCE DISORDER	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
CONVULSION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
DYSARTHRIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
DYSGEUSIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
ENCEPHALOPATHY	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
HYPERSOMNIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
NEUROPATHY PERIPHERAL	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
PERIPHERAL SENSORY NEUROPATHY	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
METABOLISM AND NUTRITION DISORDERS	TOTAL	2 (9.5)	15 (31.9)	17 (25.0)
	MILD	2 (9.5)	8 (17.0)	10 (14.7)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MODERATE	0 (0.0)	4 (8.5)	4 (5.9)
	SEVERE	0 (0.0)	3 (6.4)	3 (4.4)
HYPONATRAEMIA	TOTAL	1 (4.8)	5 (10.6)	6 (8.8)
	MILD	1 (4.8)	4 (8.5)	5 (7.4)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
DECREASED APPETITE	TOTAL	0 (0.0)	5 (10.6)	5 (7.4)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
	MODERATE	0 (0.0)	3 (6.4)	3 (4.4)
HYPOKALAEMIA	TOTAL	0 (0.0)	4 (8.5)	4 (5.9)
	MILD	0 (0.0)	3 (6.4)	3 (4.4)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
HYPOPHOSPHATAEMIA	TOTAL	1 (4.8)	2 (4.3)	3 (4.4)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
DEHYDRATION	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
HYPERCALCAEMIA	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
HYPERGLYCAEMIA	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
HYPOCALCAEMIA	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
HYPOCHLORAEMIA	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
HYPOMAGNESAEMIA	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
FAILURE TO THRIVE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
HYPERKALAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HYPERMAGNESAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HYPERURICAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
HYPOALBUMINAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
HYPOGLYCAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	TOTAL	3 (14.3)	13 (27.7)	16 (23.5)
	MILD	2 (9.5)	9 (19.1)	11 (16.2)
	MODERATE	1 (4.8)	3 (6.4)	4 (5.9)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
NIGHT SWEATS	TOTAL	0 (0.0)	4 (8.5)	4 (5.9)
	MILD	0 (0.0)	3 (6.4)	3 (4.4)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
RASH	TOTAL	1 (4.8)	2 (4.3)	3 (4.4)
	MILD	1 (4.8)	2 (4.3)	3 (4.4)
ERYTHEMA	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MODERATE	1 (4.8)	1 (2.1)	2 (2.9)
DERMATITIS ALLERGIC	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
DRY SKIN	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
DYSHIDROTIC ECZEMA	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
HYPERHIDROSIS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
SCAB	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
SKIN EXFOLIATION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
SKIN INDURATION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
SKIN MASS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
INFECTIONS AND INFESTATIONS	TOTAL	4 (19.0)	7 (14.9)	11 (16.2)
	MILD	2 (9.5)	1 (2.1)	3 (4.4)
	MODERATE	1 (4.8)	2 (4.3)	3 (4.4)
	SEVERE	1 (4.8)	3 (6.4)	4 (5.9)
	DEATH	0 (0.0)	1 (2.1)	1 (1.5)
PNEUMONIA	TOTAL	0 (0.0)	3 (6.4)	3 (4.4)
	SEVERE	0 (0.0)	2 (4.3)	2 (2.9)
	DEATH	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
UPPER RESPIRATORY TRACT INFECTION	TOTAL	1 (4.8)	2 (4.3)	3 (4.4)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)
CELLULITIS	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
URINARY TRACT INFECTION	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
CLOSTRIDIUM DIFFICILE INFECTION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
FUNGAL SKIN INFECTION	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
HERPES ZOSTER	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
LOCALISED INFECTION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
NASOPHARYNGITIS	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
NEUTROPENIC SEPSIS	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)
SEPSIS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
PSYCHIATRIC DISORDERS	TOTAL	2 (9.5)	9 (19.1)	11 (16.2)
	MILD	1 (4.8)	6 (12.8)	7 (10.3)
	MODERATE	1 (4.8)	2 (4.3)	3 (4.4)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
ANXIETY	TOTAL	2 (9.5)	4 (8.5)	6 (8.8)
	MILD	1 (4.8)	3 (6.4)	4 (5.9)
	MODERATE	1 (4.8)	1 (2.1)	2 (2.9)
CONFUSIONAL STATE	TOTAL	0 (0.0)	3 (6.4)	3 (4.4)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
AGITATION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
DEPRESSION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
INSOMNIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
MENTAL STATUS CHANGES	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
RENAL AND URINARY DISORDERS	TOTAL	2 (9.5)	8 (17.0)	10 (14.7)
	MILD	1 (4.8)	3 (6.4)	4 (5.9)
	MODERATE	1 (4.8)	5 (10.6)	6 (8.8)
RENAL FAILURE ACUTE	TOTAL	0 (0.0)	4 (8.5)	4 (5.9)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
BLADDER PAIN	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
CHROMATURIA	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
HAEMATURIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
MICTURITION URGENCY	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
POLLAKIURIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
PROTEINURIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
PYURIA	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
RENAL FAILURE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
URINARY INCONTINENCE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
URINARY RETENTION	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
CARDIAC DISORDERS	TOTAL	2 (9.5)	7 (14.9)	9 (13.2)
	MILD	2 (9.5)	1 (2.1)	3 (4.4)
	SEVERE	0 (0.0)	4 (8.5)	4 (5.9)
	LIFE THREATENING	0 (0.0)	2 (4.3)	2 (2.9)
SINUS TACHYCARDIA	TOTAL	1 (4.8)	2 (4.3)	3 (4.4)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
	SEVERE	0 (0.0)	2 (4.3)	2 (2.9)
TACHYCARDIA	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
ACUTE MYOCARDIAL INFARCTION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
CARDIAC ARREST	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	LIFE THREATENING	0 (0.0)	1 (2.1)	1 (1.5)
CARDIAC FAILURE CONGESTIVE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	LIFE THREATENING	0 (0.0)	1 (2.1)	1 (1.5)
SUPRAVENTRICULAR TACHYCARDIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
HEPATOBILIARY DISORDERS	TOTAL	2 (9.5)	1 (2.1)	3 (4.4)
	MILD	2 (9.5)	0 (0.0)	2 (2.9)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
JAUNDICE	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)
BILE DUCT OBSTRUCTION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
HYPERBILIRUBINAEMIA	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	TOTAL	0 (0.0)	3 (6.4)	3 (4.4)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
BREAST DISCOMFORT	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
BREAST PAIN	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
SCROTAL OEDEMA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
EYE DISORDERS	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.3 Adverse Events by system organ class, preferred term and maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
EYE PAIN	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
VISION BLURRED	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)
FALL	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)
EYE CONTUSION	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
EAR AND LABYRINTH DISORDERS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
EAR CONGESTION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.4 Adverse Events of CTCAE grade 3 or higher by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Patients with AE of CTCAE grade 3 or higher	10 (47.6)	25 (53.2)	35 (51.5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	5 (23.8)	10 (21.3)	15 (22.1)
ANAEMIA	1 (4.8)	6 (12.8)	7 (10.3)
THROMBOCYTOPENIA	3 (14.3)	4 (8.5)	7 (10.3)
NEUTROPENIA	3 (14.3)	2 (4.3)	5 (7.4)
LEUKOPENIA	1 (4.8)	1 (2.1)	2 (2.9)
INVESTIGATIONS	5 (23.8)	5 (10.6)	10 (14.7)
ALANINE AMINOTRANSFERASE INCREASED	1 (4.8)	1 (2.1)	2 (2.9)
ASPARTATE AMINOTRANSFERASE INCREASED	1 (4.8)	1 (2.1)	2 (2.9)
LIPASE INCREASED	0 (0.0)	2 (4.3)	2 (2.9)
NEUTROPHIL COUNT DECREASED	2 (9.5)	0 (0.0)	2 (2.9)
BLOOD ALKALINE PHOSPHATASE INCREASED	1 (4.8)	0 (0.0)	1 (1.5)
BLOOD BILIRUBIN INCREASED	1 (4.8)	0 (0.0)	1 (1.5)
BLOOD UREA INCREASED	1 (4.8)	0 (0.0)	1 (1.5)
HAEMATOCRIT DECREASED	1 (4.8)	0 (0.0)	1 (1.5)
LYMPHOCYTE COUNT DECREASED	0 (0.0)	1 (2.1)	1 (1.5)
PLATELET COUNT DECREASED	1 (4.8)	0 (0.0)	1 (1.5)
WHITE BLOOD CELL COUNT DECREASED	0 (0.0)	1 (2.1)	1 (1.5)
CARDIAC DISORDERS	0 (0.0)	6 (12.8)	6 (8.8)
SINUS TACHYCARDIA	0 (0.0)	2 (4.3)	2 (2.9)

[a] Patients with multiple AEs of CTCAE grade 3 or higher are counted once for each preferred term.
Number (%) of patients with AEs of CTCAE grade 3 or higher, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE060
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.4 Adverse Events of CTCAE grade 3 or higher by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
ACUTE MYOCARDIAL INFARCTION	0 (0.0)	1 (2.1)	1 (1.5)
CARDIAC ARREST	0 (0.0)	1 (2.1)	1 (1.5)
CARDIAC FAILURE CONGESTIVE	0 (0.0)	1 (2.1)	1 (1.5)
SUPRAVENTRICULAR TACHYCARDIA	0 (0.0)	1 (2.1)	1 (1.5)
GASTROINTESTINAL DISORDERS	1 (4.8)	5 (10.6)	6 (8.8)
ABDOMINAL PAIN	0 (0.0)	2 (4.3)	2 (2.9)
ABDOMINAL DISTENSION	1 (4.8)	0 (0.0)	1 (1.5)
ASCITES	0 (0.0)	1 (2.1)	1 (1.5)
DIARRHOEA	0 (0.0)	1 (2.1)	1 (1.5)
NAUSEA	0 (0.0)	1 (2.1)	1 (1.5)
VOMITING	0 (0.0)	1 (2.1)	1 (1.5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	0 (0.0)	6 (12.8)	6 (8.8)
FATIGUE	0 (0.0)	4 (8.5)	4 (5.9)
ASTHENIA	0 (0.0)	1 (2.1)	1 (1.5)
PAIN	0 (0.0)	1 (2.1)	1 (1.5)
INFECTIONS AND INFESTATIONS	1 (4.8)	5 (10.6)	6 (8.8)
PNEUMONIA	0 (0.0)	3 (6.4)	3 (4.4)
CELLULITIS	0 (0.0)	1 (2.1)	1 (1.5)
CLOSTRIDIUM DIFFICILE INFECTION	0 (0.0)	1 (2.1)	1 (1.5)
NEUTROPENIC SEPSIS	1 (4.8)	0 (0.0)	1 (1.5)

[a] Patients with multiple AEs of CTCAE grade 3 or higher are counted once for each preferred term.
Number (%) of patients with AEs of CTCAE grade 3 or higher, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE060
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.2.4 Adverse Events of CTCAE grade 3 or higher by system organ class and preferred term (Safety analysis set)

System organ class / MedDRA Preferred term	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
SEPSIS	0 (0.0)	1 (2.1)	1 (1.5)
METABOLISM AND NUTRITION DISORDERS	0 (0.0)	6 (12.8)	6 (8.8)
FAILURE TO THRIVE	0 (0.0)	1 (2.1)	1 (1.5)
HYPERCALCAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
HYPERURICAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
HYPOALBUMINAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
HYPOKALAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
HYPONATRAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
HYPOPHOSPHATAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	0 (0.0)	5 (10.6)	5 (7.4)
HYPOXIA	0 (0.0)	2 (4.3)	2 (2.9)
DYSPNOEA	0 (0.0)	1 (2.1)	1 (1.5)
PLEURAL EFFUSION	0 (0.0)	1 (2.1)	1 (1.5)
PNEUMONITIS	0 (0.0)	1 (2.1)	1 (1.5)
PULMONARY EMBOLISM	0 (0.0)	1 (2.1)	1 (1.5)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	0 (0.0)	3 (6.4)	3 (4.4)
ARTHRALGIA	0 (0.0)	2 (4.3)	2 (2.9)
BACK PAIN	0 (0.0)	1 (2.1)	1 (1.5)
MYALGIA	0 (0.0)	1 (2.1)	1 (1.5)

[a] Patients with multiple AEs of CTCAE grade 3 or higher are counted once for each preferred term.
Number (%) of patients with AEs of CTCAE grade 3 or higher, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE060
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.4 Adverse Events of CTCAE grade 3 or higher by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
NERVOUS SYSTEM DISORDERS	1 (4.8)	1 (2.1)	2 (2.9)
ENCEPHALOPATHY	0 (0.0)	1 (2.1)	1 (1.5)
PERIPHERAL MOTOR NEUROPATHY	1 (4.8)	0 (0.0)	1 (1.5)
PSYCHIATRIC DISORDERS	0 (0.0)	2 (4.3)	2 (2.9)
CONFUSIONAL STATE	0 (0.0)	1 (2.1)	1 (1.5)
MENTAL STATUS CHANGES	0 (0.0)	1 (2.1)	1 (1.5)
VASCULAR DISORDERS	0 (0.0)	2 (4.3)	2 (2.9)
HYPERTENSION	0 (0.0)	2 (4.3)	2 (2.9)
HEPATOBILIARY DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
BILE DUCT OBSTRUCTION	0 (0.0)	1 (2.1)	1 (1.5)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
BREAST PAIN	0 (0.0)	1 (2.1)	1 (1.5)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
DERMATITIS ALLERGIC	0 (0.0)	1 (2.1)	1 (1.5)

[a] Patients with multiple AEs of CTCAE grade 3 or higher are counted once for each preferred term.
Number (%) of patients with AEs of CTCAE grade 3 or higher, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE060
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.5 Causally related Adverse Events, by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Patients with any causally related AE [b]	13 (61.9)	34 (72.3)	47 (69.1)
GASTROINTESTINAL DISORDERS	7 (33.3)	22 (46.8)	29 (42.6)
DIARRHOEA	0 (0.0)	14 (29.8)	14 (20.6)
NAUSEA	3 (14.3)	10 (21.3)	13 (19.1)
CONSTIPATION	2 (9.5)	6 (12.8)	8 (11.8)
VOMITING	0 (0.0)	6 (12.8)	6 (8.8)
DYSPEPSIA	0 (0.0)	3 (6.4)	3 (4.4)
ABDOMINAL DISTENSION	0 (0.0)	1 (2.1)	1 (1.5)
ABDOMINAL PAIN LOWER	0 (0.0)	1 (2.1)	1 (1.5)
BOWEL MOVEMENT IRREGULARITY	0 (0.0)	1 (2.1)	1 (1.5)
DRY MOUTH	1 (4.8)	0 (0.0)	1 (1.5)
DYSPHAGIA	1 (4.8)	0 (0.0)	1 (1.5)
FLATULENCE	0 (0.0)	1 (2.1)	1 (1.5)
HAEMATEMESIS	0 (0.0)	1 (2.1)	1 (1.5)
HAEMATOCHEZIA	0 (0.0)	1 (2.1)	1 (1.5)
HYPOAESTHESIA ORAL	0 (0.0)	1 (2.1)	1 (1.5)
LIP SWELLING	1 (4.8)	0 (0.0)	1 (1.5)
PALATAL OEDEMA	1 (4.8)	0 (0.0)	1 (1.5)
INVESTIGATIONS	7 (33.3)	12 (25.5)	19 (27.9)
ASPARTATE AMINOTRANSFERASE INCREASED	2 (9.5)	4 (8.5)	6 (8.8)
BLOOD ALKALINE PHOSPHATASE INCREASED	1 (4.8)	3 (6.4)	4 (5.9)
BLOOD CREATININE INCREASED	2 (9.5)	1 (2.1)	3 (4.4)

[a] Number (%) of patients with a causally related AE, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.

Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

[b] Causally related as assessed by the investigator.

Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.

AE Adverse event. N Number of patients in treatment group.

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE070
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.5 Causally related Adverse Events, by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
WHITE BLOOD CELL COUNT DECREASED	1 (4.8)	2 (4.3)	3 (4.4)
ALANINE AMINOTRANSFERASE INCREASED	2 (9.5)	0 (0.0)	2 (2.9)
BLOOD UREA INCREASED	1 (4.8)	1 (2.1)	2 (2.9)
NEUTROPHIL COUNT DECREASED	2 (9.5)	0 (0.0)	2 (2.9)
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD BILIRUBIN INCREASED	1 (4.8)	0 (0.0)	1 (1.5)
BLOOD LACTATE DEHYDROGENASE INCREASED	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD POTASSIUM DECREASED	0 (0.0)	1 (2.1)	1 (1.5)
ELECTROCARDIOGRAM ABNORMAL	0 (0.0)	1 (2.1)	1 (1.5)
LIPASE INCREASED	0 (0.0)	1 (2.1)	1 (1.5)
LYMPHOCYTE COUNT DECREASED	0 (0.0)	1 (2.1)	1 (1.5)
TRANSAMINASES INCREASED	1 (4.8)	0 (0.0)	1 (1.5)
WEIGHT DECREASED	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	7 (33.3)	11 (23.4)	18 (26.5)
THROMBOCYTOPENIA	4 (19.0)	5 (10.6)	9 (13.2)
NEUTROPENIA	4 (19.0)	4 (8.5)	8 (11.8)
ANAEMIA	1 (4.8)	5 (10.6)	6 (8.8)
LEUKOPENIA	1 (4.8)	1 (2.1)	2 (2.9)
PANCYTOPENIA	0 (0.0)	1 (2.1)	1 (1.5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	6 (28.6)	11 (23.4)	17 (25.0)
FATIGUE	3 (14.3)	9 (19.1)	12 (17.6)
PYREXIA	2 (9.5)	3 (6.4)	5 (7.4)

[a] Number (%) of patients with a causally related AE, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
[b] Causally related as assessed by the investigator.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE070
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.5 Causally related Adverse Events, by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
ASTHENIA	0 (0.0)	1 (2.1)	1 (1.5)
CHEST DISCOMFORT	1 (4.8)	0 (0.0)	1 (1.5)
EARLY SATIETY	0 (0.0)	1 (2.1)	1 (1.5)
FEELING COLD	0 (0.0)	1 (2.1)	1 (1.5)
MUCOSAL INFLAMMATION	0 (0.0)	1 (2.1)	1 (1.5)
OEDEMA PERIPHERAL	0 (0.0)	1 (2.1)	1 (1.5)
VASCULAR DISORDERS	2 (9.5)	8 (17.0)	10 (14.7)
HYPERTENSION	1 (4.8)	5 (10.6)	6 (8.8)
FLUSHING	0 (0.0)	1 (2.1)	1 (1.5)
HOT FLUSH	1 (4.8)	0 (0.0)	1 (1.5)
HYPOTENSION	0 (0.0)	1 (2.1)	1 (1.5)
LYMPHOEDEMA	0 (0.0)	1 (2.1)	1 (1.5)
METABOLISM AND NUTRITION DISORDERS	1 (4.8)	6 (12.8)	7 (10.3)
DECREASED APPETITE	0 (0.0)	3 (6.4)	3 (4.4)
HYPONATRAEMIA	1 (4.8)	2 (4.3)	3 (4.4)
HYPOCHLORAEMIA	0 (0.0)	2 (4.3)	2 (2.9)
HYPERCALCAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
HYPERGLYCAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
HYPERMAGNESAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
HYPOALBUMINAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
HYPOCALCAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
HYPOPHOSPHATAEMIA	0 (0.0)	1 (2.1)	1 (1.5)

[a] Number (%) of patients with a causally related AE, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
[b] Causally related as assessed by the investigator.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE070
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.5 Causally related Adverse Events, by system organ class and preferred term (Safety analysis set)

System organ class / MedDRA Preferred term	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
NERVOUS SYSTEM DISORDERS	0 (0.0)	6 (12.8)	6 (8.8)
ATAXIA	0 (0.0)	1 (2.1)	1 (1.5)
DYSGEUSIA	0 (0.0)	1 (2.1)	1 (1.5)
HEADACHE	0 (0.0)	1 (2.1)	1 (1.5)
PERIPHERAL SENSORY NEUROPATHY	0 (0.0)	1 (2.1)	1 (1.5)
SYNCOPE	0 (0.0)	1 (2.1)	1 (1.5)
TREMOR	0 (0.0)	1 (2.1)	1 (1.5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	1 (4.8)	5 (10.6)	6 (8.8)
COUGH	0 (0.0)	2 (4.3)	2 (2.9)
DYSPNOEA	1 (4.8)	1 (2.1)	2 (2.9)
DYSPNOEA EXERTIONAL	0 (0.0)	1 (2.1)	1 (1.5)
HYPOXIA	0 (0.0)	1 (2.1)	1 (1.5)
PNEUMONITIS	0 (0.0)	1 (2.1)	1 (1.5)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	0 (0.0)	4 (8.5)	4 (5.9)
BACK PAIN	0 (0.0)	1 (2.1)	1 (1.5)
BONE PAIN	0 (0.0)	1 (2.1)	1 (1.5)
MYALGIA	0 (0.0)	1 (2.1)	1 (1.5)
PAIN IN EXTREMITY	0 (0.0)	1 (2.1)	1 (1.5)
RENAL AND URINARY DISORDERS	0 (0.0)	4 (8.5)	4 (5.9)
MICTURITION URGENCY	0 (0.0)	1 (2.1)	1 (1.5)

[a] Number (%) of patients with a causally related AE, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
[b] Causally related as assessed by the investigator.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE070
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.5 Causally related Adverse Events, by system organ class and preferred term (Safety analysis set)

System organ class / MedDRA Preferred term	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
POLLAKIURIA	0 (0.0)	1 (2.1)	1 (1.5)
PROTEINURIA	0 (0.0)	1 (2.1)	1 (1.5)
RENAL FAILURE ACUTE	0 (0.0)	1 (2.1)	1 (1.5)
URINARY INCONTINENCE	0 (0.0)	1 (2.1)	1 (1.5)
PSYCHIATRIC DISORDERS	0 (0.0)	2 (4.3)	2 (2.9)
CONFUSIONAL STATE	0 (0.0)	1 (2.1)	1 (1.5)
INSOMNIA	0 (0.0)	1 (2.1)	1 (1.5)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	1 (4.8)	1 (2.1)	2 (2.9)
ERYTHEMA	1 (4.8)	0 (0.0)	1 (1.5)
NIGHT SWEATS	0 (0.0)	1 (2.1)	1 (1.5)
EYE DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
EYE PAIN	0 (0.0)	1 (2.1)	1 (1.5)
HEPATOBILIARY DISORDERS	1 (4.8)	0 (0.0)	1 (1.5)
HYPERBILIRUBINAEMIA	1 (4.8)	0 (0.0)	1 (1.5)
INFECTIONS AND INFESTATIONS	0 (0.0)	1 (2.1)	1 (1.5)
CELLULITIS	0 (0.0)	1 (2.1)	1 (1.5)

[a] Number (%) of patients with a causally related AE, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
[b] Causally related as assessed by the investigator.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE070
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Patients with any causally related AE	TOTAL	13 (61.9)	34 (72.3)	47 (69.1)
	MILD	3 (14.3)	1 (2.1)	4 (5.9)
	MODERATE	3 (14.3)	13 (27.7)	16 (23.5)
	SEVERE	5 (23.8)	14 (29.8)	19 (27.9)
	LIFE THREATENING	2 (9.5)	5 (10.6)	7 (10.3)
	DEATH	0 (0.0)	1 (2.1)	1 (1.5)
GASTROINTESTINAL DISORDERS	TOTAL	7 (33.3)	22 (46.8)	29 (42.6)
	MILD	6 (28.6)	18 (38.3)	24 (35.3)
	MODERATE	1 (4.8)	3 (6.4)	4 (5.9)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
DIARRHOEA	TOTAL	0 (0.0)	14 (29.8)	14 (20.6)
	MILD	0 (0.0)	10 (21.3)	10 (14.7)
	MODERATE	0 (0.0)	3 (6.4)	3 (4.4)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
NAUSEA	TOTAL	3 (14.3)	10 (21.3)	13 (19.1)
	MILD	3 (14.3)	8 (17.0)	11 (16.2)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
CONSTIPATION	TOTAL	2 (9.5)	6 (12.8)	8 (11.8)
	MILD	2 (9.5)	5 (10.6)	7 (10.3)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
VOMITING	TOTAL	0 (0.0)	6 (12.8)	6 (8.8)
	MILD	0 (0.0)	5 (10.6)	5 (7.4)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
DYSPEPSIA	TOTAL	0 (0.0)	3 (6.4)	3 (4.4)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
ABDOMINAL DISTENSION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
ABDOMINAL PAIN LOWER	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
BOWEL MOVEMENT IRREGULARITY	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
DRY MOUTH	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
DYSPHAGIA	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
FLATULENCE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HAEMATEMESIS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
HAEMATOCHEZIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HYPOAESTHESIA ORAL	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
LIP SWELLING	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
PALATAL OEDEMA	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
INVESTIGATIONS	TOTAL	7 (33.3)	12 (25.5)	19 (27.9)
	MILD	4 (19.0)	7 (14.9)	11 (16.2)
	MODERATE	1 (4.8)	4 (8.5)	5 (7.4)
	SEVERE	2 (9.5)	1 (2.1)	3 (4.4)
ASPARTATE AMINOTRANSFERASE INCREASED	TOTAL	2 (9.5)	4 (8.5)	6 (8.8)
	MILD	2 (9.5)	3 (6.4)	5 (7.4)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD ALKALINE PHOSPHATASE INCREASED	TOTAL	1 (4.8)	3 (6.4)	4 (5.9)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
	MODERATE	1 (4.8)	1 (2.1)	2 (2.9)
BLOOD CREATININE INCREASED	TOTAL	2 (9.5)	1 (2.1)	3 (4.4)
	MILD	2 (9.5)	1 (2.1)	3 (4.4)
WHITE BLOOD CELL COUNT DECREASED	TOTAL	1 (4.8)	2 (4.3)	3 (4.4)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	1 (4.8)	1 (2.1)	2 (2.9)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
ALANINE AMINOTRANSFERASE INCREASED	TOTAL	2 (9.5)	0 (0.0)	2 (2.9)
	MILD	2 (9.5)	0 (0.0)	2 (2.9)
BLOOD UREA INCREASED	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	1 (4.8)	1 (2.1)	2 (2.9)
NEUTROPHIL COUNT DECREASED	TOTAL	2 (9.5)	0 (0.0)	2 (2.9)
	SEVERE	2 (9.5)	0 (0.0)	2 (2.9)
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD BILIRUBIN INCREASED	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
BLOOD LACTATE DEHYDROGENASE INCREASED	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD POTASSIUM DECREASED	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
ELECTROCARDIOGRAM ABNORMAL	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
LIPASE INCREASED	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
LYMPHOCYTE COUNT DECREASED	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
TRANSAMINASES INCREASED	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
WEIGHT DECREASED	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	TOTAL	7 (33.3)	11 (23.4)	18 (26.5)
	MILD	3 (14.3)	3 (6.4)	6 (8.8)
	MODERATE	1 (4.8)	4 (8.5)	5 (7.4)
	SEVERE	3 (14.3)	3 (6.4)	6 (8.8)
	LIFE THREATENING	0 (0.0)	1 (2.1)	1 (1.5)
THROMBOCYTOPENIA	TOTAL	4 (19.0)	5 (10.6)	9 (13.2)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MILD	2 (9.5)	2 (4.3)	4 (5.9)
	MODERATE	1 (4.8)	1 (2.1)	2 (2.9)
	SEVERE	1 (4.8)	1 (2.1)	2 (2.9)
	LIFE THREATENING	0 (0.0)	1 (2.1)	1 (1.5)
NEUTROPENIA	TOTAL	4 (19.0)	4 (8.5)	8 (11.8)
	MILD	2 (9.5)	1 (2.1)	3 (4.4)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)
	LIFE THREATENING	1 (4.8)	2 (4.3)	3 (4.4)
ANAEMIA	TOTAL	1 (4.8)	5 (10.6)	6 (8.8)
	MODERATE	1 (4.8)	2 (4.3)	3 (4.4)
	SEVERE	0 (0.0)	3 (6.4)	3 (4.4)
LEUKOPENIA	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	SEVERE	1 (4.8)	0 (0.0)	1 (1.5)
	LIFE THREATENING	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
PANCYTOPENIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	TOTAL	6 (28.6)	11 (23.4)	17 (25.0)
	MILD	5 (23.8)	4 (8.5)	9 (13.2)
	MODERATE	1 (4.8)	5 (10.6)	6 (8.8)
	SEVERE	0 (0.0)	2 (4.3)	2 (2.9)
FATIGUE	TOTAL	3 (14.3)	9 (19.1)	12 (17.6)
	MILD	3 (14.3)	3 (6.4)	6 (8.8)
	MODERATE	0 (0.0)	4 (8.5)	4 (5.9)
	SEVERE	0 (0.0)	2 (4.3)	2 (2.9)
PYREXIA	TOTAL	2 (9.5)	3 (6.4)	5 (7.4)
	MILD	2 (9.5)	3 (6.4)	5 (7.4)
ASTHENIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
CHEST DISCOMFORT	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
EARLY SATIETY	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
FEELING COLD	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
MUCOSAL INFLAMMATION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
OEDEMA PERIPHERAL	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
VASCULAR DISORDERS	TOTAL	2 (9.5)	8 (17.0)	10 (14.7)
	MILD	1 (4.8)	2 (4.3)	3 (4.4)
	MODERATE	1 (4.8)	5 (10.6)	6 (8.8)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
HYPERTENSION	TOTAL	1 (4.8)	5 (10.6)	6 (8.8)
	MODERATE	1 (4.8)	4 (8.5)	5 (7.4)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
FLUSHING	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HOT FLUSH	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
HYPOTENSION	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
LYMPHOEDEMA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
METABOLISM AND NUTRITION DISORDERS	TOTAL	1 (4.8)	6 (12.8)	7 (10.3)
	MILD	1 (4.8)	5 (10.6)	6 (8.8)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
DECREASED APPETITE	TOTAL	0 (0.0)	3 (6.4)	3 (4.4)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
HYPONATRAEMIA	TOTAL	1 (4.8)	2 (4.3)	3 (4.4)
	MILD	1 (4.8)	2 (4.3)	3 (4.4)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
HYPOCHLORAEMIA	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
HYPERCALCAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HYPERGLYCAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HYPERMAGNESAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HYPOALBUMINAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
HYPOCALCAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
HYPOPHOSPHATAEMIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
NERVOUS SYSTEM DISORDERS	TOTAL	0 (0.0)	6 (12.8)	6 (8.8)
	MILD	0 (0.0)	4 (8.5)	4 (5.9)
	MODERATE	0 (0.0)	2 (4.3)	2 (2.9)
ATAXIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
DYSGEUSIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HEADACHE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
PERIPHERAL SENSORY NEUROPATHY	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
SYNCOPE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
TREMOR	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	TOTAL	1 (4.8)	5 (10.6)	6 (8.8)
	MILD	0 (0.0)	3 (6.4)	3 (4.4)
	MODERATE	1 (4.8)	1 (2.1)	2 (2.9)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
COUGH	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MILD	0 (0.0)	2 (4.3)	2 (2.9)
DYSPNOEA	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MODERATE	1 (4.8)	1 (2.1)	2 (2.9)
DYSPNOEA EXERTIONAL	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HYPOXIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
PNEUMONITIS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	TOTAL	0 (0.0)	4 (8.5)	4 (5.9)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

System organ class / MedDRA Preferred term	Maximum CTCAE grade	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
	MILD	0 (0.0)	3 (6.4)	3 (4.4)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
BACK PAIN	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
BONE PAIN	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
MYALGIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
PAIN IN EXTREMITY	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
RENAL AND URINARY DISORDERS	TOTAL	0 (0.0)	4 (8.5)	4 (5.9)
	MILD	0 (0.0)	3 (6.4)	3 (4.4)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
MICTURITION URGENCY	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
POLLAKIURIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
PROTEINURIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
RENAL FAILURE ACUTE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
URINARY INCONTINENCE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
PSYCHIATRIC DISORDERS	TOTAL	0 (0.0)	2 (4.3)	2 (2.9)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
CONFUSIONAL STATE	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	SEVERE	0 (0.0)	1 (2.1)	1 (1.5)
INSOMNIA	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	TOTAL	1 (4.8)	1 (2.1)	2 (2.9)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
ERYTHEMA	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MODERATE	1 (4.8)	0 (0.0)	1 (1.5)
NIGHT SWEATS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
EYE DISORDERS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
EYE PAIN	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
HEPATOBILIARY DISORDERS	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)
HYPERBILIRUBINAEMIA	TOTAL	1 (4.8)	0 (0.0)	1 (1.5)
	MILD	1 (4.8)	0 (0.0)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.2.6 Causally related Adverse Events, by preferred term presented by maximum reported CTCAE Grade (Safety analysis set)

		Number (%) of patients [a]		
System organ class / MedDRA Preferred term	Maximum CTCAE grade	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
INFECTIONS AND INFESTATIONS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)
CELLULITIS	TOTAL	0 (0.0)	1 (2.1)	1 (1.5)
	MILD	0 (0.0)	1 (2.1)	1 (1.5)

[a] Each patient has only been represented with the maximum reported CTCAE grade for each system organ class/preferred term.
[b] Each patient is counted only once within a treatment group in this overall summary, in the category of maximum reported CTCAE grade.
Number (%) of patients with AEs, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency and then maximum grade.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication. AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE = Common Terminology Criteria for Adverse Events (version 4).

Program Name: RT AE050a
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.3.1 All deaths
(Full analysis set)

	Number (%) of patients		
Category	**100mg BID (N=21)**	**200mg BID (N=47)**	**Total (N=68)**
Total number of deaths	5(23.8)	13(27.7)	18(26.5)
Death related to disease under investigation only	5(23.8)	11(23.4)	16(23.5)
AE with outcome of death only	0(0.0)	2(4.3)	2(2.9)
AE with outcome of death only(AE start date falling after 30 day follow up period)	0(0.0)	0(0.0)	0(0.0)
Number of patients with death related to disease and an AE with outcome of death	0(0.0)	0(0.0)	0(0.0)
Other deaths[a]	0(0.0)	0(0.0)	0(0.0)

[a] Patients who died and are not captured in earlier categories.
Death related to disease under investigation is determined by the investigator
Rows are mutually exclusive, patients are only reported in one category
AE Adverse event. N Number of patients in treatment group.

Program Name: RT_TDTH010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.3.2.1 Listing of Deaths
(Full analysis set)

Fostamatinib, assigned starting dose(mg)	Patient Identifier	Time from first dose (days)	Time from last dose to death (days)	Treatment period	Primary cause of death investigator text	Primary cause MedDRA preferred term	Secondary cause of death investigator text	Secondary cause MedDRA preferred term	Autopsy performed	Death related to disease under investigation
100mg	E7801003	71	16	F-U	Death is realted to disease Diffuse Large B-cell Lymphoma.	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)			NO	YES
	E7804003	21	9	F-U	Non Hodgkins Diffuse Large B Cell lymphoma	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)			NO	YES
	E7808004	34	21	F-U	disease progression	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS			NO	YES

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RL_TDTH040.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.3.2.1 Listing of Deaths
(Full analysis set)

Fostamatinib, assigned starting dose(mg)	Patient Identifier	Time from first dose (days)	Time from last dose to death (days)	Treatment period	Primary cause of death investigator text	Primary cause MedDRA preferred term	Secondary cause of death investigator text	Secondary cause MedDRA preferred term	Autopsy performed	Death related to disease under investigation
100mg	E7809003	44	16	F-U	progression of DLBCL	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)			NO	YES
	E7814002	12	6	F-U	Complications from Lymphoma	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)			NO	YES
200mg	E7801006	59	25	F-U	Diffuse Large B Cell Lymphoma	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)			NO	YES

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RL_TDTH040.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.3.2.1 Listing of Deaths
(Full analysis set)

Fostamatinib, assigned starting dose(mg)	Patient Identifier	Time from first dose (days)	Time from last dose to death (days)	Treatment period	Primary cause of death investigator text	Primary cause MedDRA preferred term	Secondary cause of death investigator text	Secondary cause MedDRA preferred term	Autopsy performed	Death related to disease under investigation
200mg	E7804002	44	28	F-U	B-Cell Lymphoma	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	Severe Thrombocytopenia	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	NO	YES
	E7805002	25	15	F-U	Diffuse Large B-Cell Lymphoma	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)			NO	YES
	E7806006	6	3	F-U	DIFFUSE LARGE B-CELL LYMPHOMA	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)			NO	YES

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RL_TDTH040.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.3.2.1 Listing of Deaths
(Full analysis set)

Fostamatinib, assigned starting dose(mg)	Patient Identifier	Time from first dose (days)	Time from last dose to death (days)	Treatment period	Primary cause of death investigator text	Primary cause MedDRA preferred term	Secondary cause of death investigator text	Secondary cause MedDRA preferred term	Autopsy performed	Death related to disease under investigation
200mg	E7808002	37	2	F-U	progressive disease related symptoms	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS			NO	YES
	E7808006	11	2	F-U	disease progression per PI	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS			NO	YES
	E7812003	54	27	F-U	progression of disease	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS			NO	YES

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RL_TDTH040.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.3.2.1 Listing of Deaths
(Full analysis set)

Fostamatinib, assigned starting dose(mg)	Patient Identifier	Time from first dose (days)	Time from last dose to death (days)	Treatment period	Primary cause of death investigator text	Primary cause MedDRA preferred term	Secondary cause of death investigator text	Secondary cause MedDRA preferred term	Autopsy performed	Death related to disease under investigation
200mg	E7815008	53	12	F-U	Pneumonitis	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS			YES	NO
	E7817007	39	26	F-U	Progression of disease	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS			NO	YES
	E7822001	23	16	F-U	diffuse large B-cell lymphoma	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)			YES	YES

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RL_TDTH040.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.3.2.1 Listing of Deaths
(Full analysis set)

Fostamatinib, assigned starting dose(mg)	Patient Identifier	Time from first dose (days)	Time from last dose to death (days)	Treatment period	Primary cause of death investigator text	Primary cause MedDRA preferred term	Secondary cause of death investigator text	Secondary cause MedDRA preferred term	Autopsy performed	Death related to disease under investigation
200mg	E7822003	19	8	F-U	Pneumonia	INFECTIONS AND INFESTATIONS			NO	NO
	E7822004	69	20	F-U	progressive diffuse large B cell lymphoma	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)			NO	YES
	E7822005	30	5	F-U	diffuse large B cell lymphoma	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)			NO	YES

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RL_TDTH040.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.3.2.2 Adverse events with outcome of death - key patient information
(Safety analysis set)
Arm = Fostamatinib 200mg BID

Patient Identifier	Sex	Age[a] (years)	Episode term as reported by investigator	Adverse event (MedDRA preferred term)	Time from first dose to AE (days)	Treatment Period	Last dose prior to death	Time from last dose to death (days)	Time from first dose to death (days)	Reasonable possibility AE causally related[b]
E7815008	M	86	PNEUMONITIS	PNEUMONITIS	43	F-U	0mg	11	52	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT
E7822003	M	81	PNEUMONIA	PNEUMONIA	13	F-U	0mg	7	18	NOT RELATED

[a] Age = at study entry
[b] As assessed by the investigator.
NA = Not applicable.
Includes adverse events with an onset date between the date of first dose and 30 days following the date of last dose of study medication.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT DTH050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.3.3 Adverse events with outcome of death by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N= 21)	200mg BID (N= 47)	Total (N= 68)
Patients with AE with outcome = death	0 (0.0)	2 (4.3)	2 (2.9)
INFECTIONS AND INFESTATIONS	0 (0.0)	1 (2.1)	1 (1.5)
PNEUMONIA	0 (0.0)	1 (2.1)	1 (1.5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
PNEUMONITIS	0 (0.0)	1 (2.1)	1 (1.5)

[a] Number (%) of patients with outcome of death, sorted by system organ class (SOC) in descending order and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT DTH020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.3.4 Adverse events with outcome of death, causally related to study treatment, by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N= 21)	200mg BID (N= 47)	Total (N= 68)
Patients with a causally related AE with outcome = death [b]	0 (0.0)	1 (2.1)	1 (1.5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
PNEUMONITIS	0 (0.0)	1 (2.1)	1 (1.5)

[a] Number (%) of patients with a causally related AE with outcome of death, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.

Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

[b] Causally related, as assessed by the investigator.

Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.

AE Adverse event. N Number of patients in treatment group.

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT DTH030
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.4.1 Serious adverse events by system organ class and preferred term
(Safety analysis set)

System organ class / MedDRA Preferred term	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Patients with any SAE	3 (14.3)	12 (25.5)	15 (22.1)
INFECTIONS AND INFESTATIONS	1 (4.8)	4 (8.5)	5 (7.4)
PNEUMONIA	0 (0.0)	2 (4.3)	2 (2.9)
CELLULITIS	0 (0.0)	1 (2.1)	1 (1.5)
CLOSTRIDIUM DIFFICILE INFECTION	0 (0.0)	1 (2.1)	1 (1.5)
NEUTROPENIC SEPSIS	1 (4.8)	0 (0.0)	1 (1.5)
CARDIAC DISORDERS	0 (0.0)	4 (8.5)	4 (5.9)
CARDIAC ARREST	0 (0.0)	1 (2.1)	1 (1.5)
CARDIAC FAILURE CONGESTIVE	0 (0.0)	1 (2.1)	1 (1.5)
SINUS TACHYCARDIA	0 (0.0)	1 (2.1)	1 (1.5)
SUPRAVENTRICULAR TACHYCARDIA	0 (0.0)	1 (2.1)	1 (1.5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	1 (4.8)	2 (4.3)	3 (4.4)
PYREXIA	1 (4.8)	1 (2.1)	2 (2.9)
FATIGUE	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	0 (0.0)	2 (4.3)	2 (2.9)
ANAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
PANCYTOPENIA	0 (0.0)	1 (2.1)	1 (1.5)

[a] Number (%) of patients with an SAE, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
SAE Serious adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE150
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.4.1 Serious adverse events by system organ class and preferred term
(Safety analysis set)

System organ class / MedDRA Preferred term	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
METABOLISM AND NUTRITION DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
HYPONATRAEMIA	0 (0.0)	1 (2.1)	1 (1.5)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	1 (4.8)	0 (0.0)	1 (1.5)
BACK PAIN	1 (4.8)	0 (0.0)	1 (1.5)
NERVOUS SYSTEM DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
CONVULSION	0 (0.0)	1 (2.1)	1 (1.5)
SYNCOPE	0 (0.0)	1 (2.1)	1 (1.5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
PNEUMONITIS	0 (0.0)	1 (2.1)	1 (1.5)

[a] Number (%) of patients with an SAE, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
SAE Serious adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE150
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.4.2 Serious adverse events-Key patient information
(Safety analysis set)
Arm = Fostamatinib 100mg BID

Patient Identifier	Sex/ Age (yrs)	Episode term as reported by investigator	Adverse event (MedDRA preferred term)	Time from start of treatment to onset of AE (days)/ Treatment period	Dose at time of AE	Time from last dose to onset of AE (days)[a]	Time from start of treatment to becoming serious (days)	Maximum CTC Grade	Outcome[b]/ Received treatment for AE	Action taken[c]	Reasonable possibility AE causally related[d]
E2818001	F/54	NEUTROPENIC SEPSIS	NEUTROPENIC SEPSIS	49/F-U	0mg	21	49	3	RECOVRD	NA	NOT RELATED
E7808001	F/71	BACK PAIN	BACK PAIN	235/On-trt	200mg BID	11	235	2	RECOVRD	DNC	NOT RELATED
E7809002	F/50	FEVER	PYREXIA	61/On-trt	0mg	5	64	1	RECOVRD	DNC	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT

Age = at study entry
[a] Calculated for AEs starting after the discontinuation of study treatment
[b] Outcome: RECOVRD = Recovered / Resolved; RECVRNG = Recovering / Resolving; RWS = Recovered / Resolved with sequelae; NRNR=Not recovered/Not resolved; F=Fatal
[c] Actions taken: DNC=Dose not changed DINC=Dose increased DR=Dose reduced DINT=Drug interrupted DPD=Drug permanently discontinued.
[d] As assessed by the investigator. IP = Investigational product NA = Not applicable NR = Not recorded.
Includes adverse events with an onset date between the date of first dose and 30 days following the date of last dose of study medication.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1 CTCAE=Common Terminology Criteria for Adverse Events(version 4).
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE180
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.4.2 Serious adverse events-Key patient information
(Safety analysis set)
Arm = Fostamatinib 200mg BID

Patient Identifier	Sex/ Age (yrs)	Episode term as reported by investigator	Adverse event (MedDRA preferred term)	Time from start of treatment to onset of AE (days)/ Treatment period	Dose at time of AE	Time from last dose to onset of AE (days)[a]	Time from start of treatment to becoming serious (days)	Maximum CTC Grade	Outcome[b]/ Received treatment for AE	Action taken[c]	Reasonable possibility AE causally related[d]
E2813001	M/76	FATIGUE	FATIGUE	39/F-U	0mg	1	39	3	RECOVRD	NA	NOT RELATED
E2813005	M/69	VF CARDIAC ARREST	CARDIAC ARREST	90/On-trt	0mg	1	90	4	RECVRNG	DINT	NOT RELATED
E7801007	F/81	VASOVAGAL SYNCOPE	SYNCOPE	8/On-trt	200mg BID	1	8	2	RECOVRD	DNC	NOT RELATED
E7801007	F/81	SEIZURE	CONVULSION	8/On-trt	200mg BID	1	8	2	RECOVRD	DNC	NOT RELATED
	F/81	CELLULITIS	CELLULITIS	46/On-trt	200mg BID	4	48	3	NRNR	DINT	NOT RELATED
E7806007	M/46	CONGESTIVE HEART FAILURE	CARDIAC FAILURE CONGESTIVE	89/On-trt	200mg BID	5	113	4	RECVRNG	DPC	NOT RELATED

Age = at study entry
[a] Calculated for AEs starting after the discontinuation of study treatment
[b] Outcome: RECOVRD = Recovered / Resolved; RECVRNG = Recovering / Resolving; RWS = Recovered / Resolved with sequelae; NRNR=Not recovered/Not resolved; F=Fatal
[c] Actions taken: DNC=Dose not changed DINC=Dose increased DR=Dose reduced DINT=Drug interrupted DPD=Drug permanently discontinued.
[d] As assessed by the investigator. IP = Investigational product NA = Not applicable NR = Not recorded.
Includes adverse events with an onset date between the date of first dose and 30 days following the date of last dose of study medication.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1 CTCAE=Common Terminology Criteria for Adverse Events(version 4).
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE180
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.4.2 Serious adverse events-Key patient information
(Safety analysis set)
Arm = Fostamatinib 200mg BID

Patient Identifier	Sex/ Age (yrs)	Episode term as reported by investigator	Adverse event (MedDRA preferred term)	Time from start of treatment to onset of AE (days)/ Treatment period	Dose at time of AE	Time from last dose to onset of AE (days)[a]	Time from start of treatment to becoming serious (days)	Maximum CTC Grade	Outcome[b]/ Received treatment for AE	Action taken[c]	Reasonable possibility AE causally related[d]
E7806008	F/61	INFECTIONS AND INFESTATIONS-CLOSTRIDIUM DIFFICILE INFECTION	CLOSTRIDIUM DIFFICILE INFECTION	13/On-trt	200mg QD	1	13	3	NRNR	DINT	NOT RELATED
E7809001	F/71	PROGRESSIVE DETERIORATION (CYTOPENIA)	PANCYTOPENIA	69/F-U	0mg	41	69	1	RECOVRD	NA	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT
E7809004	M/75	FEVER	PYREXIA	8/On-trt	0mg	1	8	1	RECOVRD	DINT	NOT RELATED
E7810001	M/74	SUPRAVENTRICULAR TACHYCARDIA	SUPRAVENTRICULAR TACHYCARDIA	8/On-trt	200mg QD	1	8	3	RECOVRD	DINT	NOT RELATED

Age = at study entry
[a] Calculated for AEs starting after the discontinuation of study treatment
[b] Outcome: RECOVRD = Recovered / Resolved; RECVRNG = Recovering / Resolving; RWS = Recovered / Resolved with sequelae; NRNR=Not recovered/Not resolved; F=Fatal
[c] Actions taken: DNC=Dose not changed DINC=Dose increased DR=Dose reduced DINT=Drug interrupted DPD=Drug permanently discontinued.
[d] As assessed by the investigator. IP = Investigational product NA = Not applicable NR = Not recorded.
Includes adverse events with an onset date between the date of first dose and 30 days following the date of last dose of study medication.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1 CTCAE=Common Terminology Criteria for Adverse Events(version 4).
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE180
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.4.2 Serious adverse events-Key patient information
(Safety analysis set)
Arm = Fostamatinib 200mg BID

Patient Identifier	Sex/ Age (yrs)	Episode term as reported by investigator	Adverse event (MedDRA preferred term)	Time from start of treatment to onset of AE (days)/ Treatment period	Dose at time of AE	Time from last dose to onset of AE (days)[a]	Time from start of treatment to becoming serious (days)	Maximum CTC Grade	Outcome[b]/ Received treatment for AE	Action taken[c]	Reasonable possibility AE causally related[d]
	M/74	ANEMIA	ANAEMIA	10/On-trt	200mg QD	1	10	3	RECOVRD	DNC	NOT RELATED
E7812003	M/53	HYPONATREMIA	HYPONATRAEMIA	10/On-trt	200mg BID	3	10	3	RECOVRD	DNC	NOT RELATED
	M/53	RIGHT LOWER LOBE PNEUMONIA	PNEUMONIA	31/F-U	0mg	10	31	3	NRNR	NA	NOT RELATED
E7815008	M/86	PNEUMONITIS	PNEUMONITIS	31/On-trt	200mg QD	3	32	3	RECOVRD	DINT	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT

Age = at study entry
[a] Calculated for AEs starting after the discontinuation of study treatment
[b] Outcome: RECOVRD = Recovered / Resolved; RECVRNG = Recovering / Resolving; RWS = Recovered / Resolved with sequelae; NRNR=Not recovered/Not resolved; F=Fatal
[c] Actions taken: DNC=Dose not changed DINC=Dose increased DR=Dose reduced DINT=Drug interrupted DPD=Drug permanently discontinued.
[d] As assessed by the investigator. IP = Investigational product NA = Not applicable NR = Not recorded.
Includes adverse events with an onset date between the date of first dose and 30 days following the date of last dose of study medication.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1 CTCAE=Common Terminology Criteria for Adverse Events(version 4).
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE180
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.4.2 Serious adverse events-Key patient information
(Safety analysis set)
Arm = Fostamatinib 200mg BID

Patient Identifier	Sex/ Age (yrs)	Episode term as reported by investigator	Adverse event (MedDRA preferred term)	Time from start of treatment to onset of AE (days)/ Treatment period	Dose at time of AE	Time from last dose to onset of AE (days)[a]	Time from start of treatment to becoming serious (days)	Maximum CTC Grade	Outcome[b]/ Received treatment for AE	Action taken[c]	Reasonable possibility AE causally related[d]
	M/86	PNEUMONITIS	PNEUMONITIS	43/F-U	0mg	1	43	5	F	DPC	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT
E7817005	M/56	SINUS TACHYCARDIA	SINUS TACHYCARDIA	50/On-trt	200mg BID	22	50	3	RECOVRD	DNC	NOT RELATED
E7822003	M/81	PNEUMONIA	PNEUMONIA	13/F-U	0mg	8	13	5	F	DPC	NOT RELATED

Age = at study entry
[a] Calculated for AEs starting after the discontinuation of study treatment
[b] Outcome: RECOVRD = Recovered / Resolved; RECVRNG = Recovering / Resolving; RWS = Recovered / Resolved with sequelae; NRNR=Not recovered/Not resolved; F=Fatal
[c] Actions taken: DNC=Dose not changed DINC=Dose increased DR=Dose reduced DINT=Drug interrupted DPD=Drug permanently discontinued.
[d] As assessed by the investigator. IP = Investigational product NA = Not applicable NR = Not recorded.
Includes adverse events with an onset date between the date of first dose and 30 days following the date of last dose of study medication.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1 CTCAE=Common Terminology Criteria for Adverse Events(version 4).
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE180
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.4.3 Serious adverse events causally related to study treatment by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Patients with a causally related SAE [b]	1 (4.8)	2 (4.3)	3 (4.4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
PANCYTOPENIA	0 (0.0)	1 (2.1)	1 (1.5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	1 (4.8)	0 (0.0)	1 (1.5)
PYREXIA	1 (4.8)	0 (0.0)	1 (1.5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
PNEUMONITIS	0 (0.0)	1 (2.1)	1 (1.5)

[a] Number (%) of patients with a causally related SAE, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
[b] Causally related as assessed by the investigator
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
SAE Serious adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE170
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca **Page 1 of 1**

Table 11.3.5.1.1 Adverse events leading to discontinuation of fostamatinib by system organ class and preferred term (Safety analysis set)

System organ class / MedDRA Preferred term	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Patients with AE leading to discontinuation [b]	1 (4.8)	4 (8.5)	5 (7.4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	1 (4.8)	1 (2.1)	2 (2.9)
CHEST DISCOMFORT	1 (4.8)	0 (0.0)	1 (1.5)
FATIGUE	0 (0.0)	1 (2.1)	1 (1.5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	1 (4.8)	1 (2.1)	2 (2.9)
DYSPNOEA	1 (4.8)	0 (0.0)	1 (1.5)
PNEUMONITIS	0 (0.0)	1 (2.1)	1 (1.5)
CARDIAC DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
CARDIAC FAILURE CONGESTIVE	0 (0.0)	1 (2.1)	1 (1.5)
GASTROINTESTINAL DISORDERS	1 (4.8)	0 (0.0)	1 (1.5)
DYSPHAGIA	1 (4.8)	0 (0.0)	1 (1.5)
LIP SWELLING	1 (4.8)	0 (0.0)	1 (1.5)
PALATAL OEDEMA	1 (4.8)	0 (0.0)	1 (1.5)
INFECTIONS AND INFESTATIONS	0 (0.0)	1 (2.1)	1 (1.5)
PNEUMONIA	0 (0.0)	1 (2.1)	1 (1.5)
INVESTIGATIONS	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD POTASSIUM DECREASED	0 (0.0)	1 (2.1)	1 (1.5)

[a] Number (%) of patients with an AE leading to discontinuation of fostamatinib, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
[b] Action taken, fostamatinib permanently stopped.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE190
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.5.1.1 Adverse events leading to discontinuation of fostamatinib by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
METABOLISM AND NUTRITION DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
HYPOPHOSPHATAEMIA	0 (0.0)	1 (2.1)	1 (1.5)

[a] Number (%) of patients with an AE leading to discontinuation of fostamatinib, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
[b] Action taken, fostamatinib permanently stopped.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE190
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.5.1.2 Adverse Events leading to discontinuation of study treatment-key patient information
(Safety analysis set)
Arm = Fostamatinib 100mg BID

Patient Identifier	Sex/ Age (yrs)	Episode term as reported by investigator	Adverse event (MedDRA preferred term)	Time from start of treatment to onset of AE (days)/ Treatment period	Dose at time of AE	Time from start of treatment to discontinuation (days)	Maximum CTC Grade	SAE	Outcome[a]/ Received treatment for AE	Reasonable possibility AE causally related[b]
E7804003	F/84	SWOLLEN UPPER LIP	LIP SWELLING	12/On-trt	200mg BID	13	2	N	RECOVRD	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT
E7804003	F/84	SWALLOWING DIFFICULTY	DYSPHAGIA	12/On-trt	200mg BID	13	2	N	RECOVRD	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT
E7804003	F/84	CHEST TIGHTNESS	CHEST DISCOMFORT	13/On-trt	200mg QD	13	2	N	RECOVRD	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT

Age = at study entry
[a] Outcome: RECOVRD = Recovered / Resolved; RECVRNG = Recovering / Resolving; RWS = Recovered / Resolved with sequelae; NRNR=Not recovered/Not resolved; F=Fatal
[b] As assessed by the investigator.
AE Adverse event. F Female. M Male. NA Not Applicable. NR Not recorded. SAE Serious AE.
Includes adverse events with an onset date between the date of first dose and 30 days following the date of last dose of study medication.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE=Common Terminology Criteria for Adverse Events(version 4).
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE210
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.5.1.2 Adverse Events leading to discontinuation of study treatment-key patient information
(Safety analysis set)
Arm = Fostamatinib 100mg BID

Patient Identifier	Sex/ Age (yrs)	Episode term as reported by investigator	Adverse event (MedDRA preferred term)	Time from start of treatment to onset of AE (days)/ Treatment period	Dose at time of AE	Time from start of treatment to discontinuation (days)	Maximum CTC Grade	SAE	Outcome[a]/ Received treatment for AE	Reasonable possibility AE causally related[b]
E7804003	F/84	DYSPNEA	DYSPNOEA	13/On-trt	200mg QD	13	2	N	RECOVRD	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT
E7804003	F/84	UVULA SWELLING	PALATAL OEDEMA	13/On-trt	200mg QD	13	2	N	RECOVRD	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT

Age = at study entry
[a] Outcome: RECOVRD = Recovered / Resolved; RECVRNG = Recovering / Resolving; RWS = Recovered / Resolved with sequelae; NRNR=Not recovered/Not resolved; F=Fatal
[b] As assessed by the investigator.
AE Adverse event. F Female. M Male. NA Not Applicable. NR Not recorded. SAE Serious AE.
Includes adverse events with an onset date between the date of first dose and 30 days following the date of last dose of study medication.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE=Common Terminology Criteria for Adverse Events(version 4).
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE210
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.5.1.2 Adverse Events leading to discontinuation of study treatment-key patient information
(Safety analysis set)
Arm = Fostamatinib 200mg BID

Patient Identifier	Sex/ Age (yrs)	Episode term as reported by investigator	Adverse event (MedDRA preferred term)	Time from start of treatment to onset of AE (days)/ Treatment period	Dose at time of AE	Time from start of treatment to discontinuation (days)	Maximum CTC Grade	SAE	Outcome[a]/ Received treatment for AE	Reasonable possibility AE causally related[b]
E7806007	M/46	CONGESTIVE HEART FAILURE	CARDIAC FAILURE CONGESTIVE	89/On-trt	200mg BID	115	4	Y	RECVRNG	NOT RELATED
E7808007	M/70	SIGNIFICANT FATIGUE	FATIGUE	39/On-trt	200mg BID	42	2	N	RECVRNG	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT
E7808007	M/70	HYPOPHOSTPHATEMIA	HYPOPHOSPHATAEMIA	46/F-U	0mg	42	3	N	NRNR	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT

Age = at study entry
[a] Outcome: RECOVRD = Recovered / Resolved; RECVRNG = Recovering / Resolving; RWS = Recovered / Resolved with sequelae; NRNR=Not recovered/Not resolved; F=Fatal
[b] As assessed by the investigator.
AE Adverse event. F Female. M Male. NA Not Applicable. NR Not recorded. SAE Serious AE.
Includes adverse events with an onset date between the date of first dose and 30 days following the date of last dose of study medication.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE=Common Terminology Criteria for Adverse Events(version 4).
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE210
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.5.1.2 Adverse Events leading to discontinuation of study treatment-key patient information
(Safety analysis set)
Arm = Fostamatinib 200mg BID

Patient Identifier	Sex/ Age (yrs)	Episode term as reported by investigator	Adverse event (MedDRA preferred term)	Time from start of treatment to onset of AE (days)/ Treatment period	Dose at time of AE	Time from start of treatment to discontinuation (days)	Maximum CTC Grade	SAE	Outcome[a]/ Received treatment for AE	Reasonable possibility AE causally related[b]
E7808007	M/70	LOW POTASSIUM	BLOOD POTASSIUM DECREASED	46/F-U	0mg	42	2	N	NRNR	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT
E7815008	M/86	PNEUMONITIS	PNEUMONITIS	43/F-U	0mg	42	5	Y	F	REASONABLE POSSIBILITY AE WAS CAUSED BY INVESTIGATIONAL PRODUCT
E7822003	M/81	PNEUMONIA	PNEUMONIA	13/F-U	0mg	12	5	Y	F	NOT RELATED

Age = at study entry
[a] Outcome: RECOVRD = Recovered / Resolved; RECVRNG = Recovering / Resolving; RWS = Recovered / Resolved with sequelae; NRNR=Not recovered/Not resolved; F=Fatal
[b] As assessed by the investigator.
AE Adverse event. F Female. M Male. NA Not Applicable. NR Not recorded. SAE Serious AE.
Includes adverse events with an onset date between the date of first dose and 30 days following the date of last dose of study medication.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1
CTCAE=Common Terminology Criteria for Adverse Events(version 4).
There are three AEs marked serious in the clinical database that did not meet serious criteria and were not reported as Serious Adverse Events. These events were overlooked during the final safety/clinical database reconciliation.
All events have been researched and confirmed to not meet serious criteria.
E7815010: Brain Mass; E7801007: Cellulitis; E7801007: Seizure.

Program Name: RT AE210
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.5.1.3 Adverse events leading to discontinuation of fostamatinib,causally related to study treatment by system organ class and preferred term
(Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Patients with AE leading to discontinuation [b]	1 (4.8)	2 (4.3)	3 (4.4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	1 (4.8)	1 (2.1)	2 (2.9)
CHEST DISCOMFORT	1 (4.8)	0 (0.0)	1 (1.5)
FATIGUE	0 (0.0)	1 (2.1)	1 (1.5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	1 (4.8)	1 (2.1)	2 (2.9)
DYSPNOEA	1 (4.8)	0 (0.0)	1 (1.5)
PNEUMONITIS	0 (0.0)	1 (2.1)	1 (1.5)
GASTROINTESTINAL DISORDERS	1 (4.8)	0 (0.0)	1 (1.5)
DYSPHAGIA	1 (4.8)	0 (0.0)	1 (1.5)
LIP SWELLING	1 (4.8)	0 (0.0)	1 (1.5)
PALATAL OEDEMA	1 (4.8)	0 (0.0)	1 (1.5)
INVESTIGATIONS	0 (0.0)	1 (2.1)	1 (1.5)
BLOOD POTASSIUM DECREASED	0 (0.0)	1 (2.1)	1 (1.5)
METABOLISM AND NUTRITION DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
HYPOPHOSPHATAEMIA	0 (0.0)	1 (2.1)	1 (1.5)

[a] Number (%) of patients with a causally related AE leading to discontinuation of fostamatinib, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category.
Patients with events in more than 1 category are counted once in each of those categories.[b] Causally related as assessed by the investigator
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE200
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.5.2.1 Adverse Events leading to dose modification, by system organ class and preferred term (Safety analysis set)

System organ class / MedDRA Preferred term	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Patients with AE leading to dose modification of fostamatinib [b]	4 (19.0)	10 (21.3)	14 (20.6)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	2 (9.5)	2 (4.3)	4 (5.9)
NEUTROPENIA	1 (4.8)	1 (2.1)	2 (2.9)
THROMBOCYTOPENIA	1 (4.8)	1 (2.1)	2 (2.9)
INVESTIGATIONS	2 (9.5)	1 (2.1)	3 (4.4)
LIPASE INCREASED	0 (0.0)	1 (2.1)	1 (1.5)
NEUTROPHIL COUNT DECREASED	1 (4.8)	0 (0.0)	1 (1.5)
PLATELET COUNT DECREASED	1 (4.8)	0 (0.0)	1 (1.5)
WHITE BLOOD CELL COUNT DECREASED	1 (4.8)	0 (0.0)	1 (1.5)
CARDIAC DISORDERS	0 (0.0)	2 (4.3)	2 (2.9)
CARDIAC ARREST	0 (0.0)	1 (2.1)	1 (1.5)
SUPRAVENTRICULAR TACHYCARDIA	0 (0.0)	1 (2.1)	1 (1.5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	0 (0.0)	2 (4.3)	2 (2.9)
PYREXIA	0 (0.0)	2 (4.3)	2 (2.9)
INFECTIONS AND INFESTATIONS	0 (0.0)	2 (4.3)	2 (2.9)
CELLULITIS	0 (0.0)	1 (2.1)	1 (1.5)
CLOSTRIDIUM DIFFICILE INFECTION	0 (0.0)	1 (2.1)	1 (1.5)

Dose modification is an AE leading to dose change or temporary discontinuation of investigational product.
Patients may have had more than one AE leading to dose change or temporary discontinuation of investigational product.
[a] Number (%) of patients with AE leading to dose modification, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
[b] AE Action taken, fostamatinib = Dose changed or Temporary discontinuation.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE140
Cutoff Date: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.5.2.1 Adverse Events leading to dose modification, by system organ class and preferred term (Safety analysis set)

System organ class / MedDRA Preferred term	Number (%) of patients [a] 100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
BREAST PAIN	0 (0.0)	1 (2.1)	1 (1.5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
PNEUMONITIS	0 (0.0)	1 (2.1)	1 (1.5)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
ERYTHEMA	0 (0.0)	1 (2.1)	1 (1.5)
VASCULAR DISORDERS	0 (0.0)	1 (2.1)	1 (1.5)
HYPERTENSION	0 (0.0)	1 (2.1)	1 (1.5)

Dose modification is an AE leading to dose change or temporary discontinuation of investigational product.
Patients may have had more than one AE leading to dose change or temporary discontinuation of investigational product.
[a] Number (%) of patients with AE leading to dose modification, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
[b] AE Action taken, fostamatinib = Dose changed or Temporary discontinuation.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
AE Adverse event. N Number of patients in treatment group.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE140
Cutoff Date: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.5.2.2 Adverse Events leading to dose reduction, by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)
Patients with AE leading to dose reduction of fostamatinib [b]	1 (4.8)	0 (0.0)	1 (1.5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	1 (4.8)	0 (0.0)	1 (1.5)
THROMBOCYTOPENIA	1 (4.8)	0 (0.0)	1 (1.5)

Patients may have had more than one AE leading to dose reduction of investigational product.

[a] Number (%) of patients with AE leading to dose reduction, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.

Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

[b] AE Action taken, fostamatinib = Dose reduced.

Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.

AE Adverse event. N Number of patients in treatment group.

Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT AE141
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.6.1.1 Adverse Events assessed by the sponsor to be significant, by system organ class and preferred term (Safety analysis set)

	Number (%) of patients [a]		
System organ class / MedDRA Preferred term [b]	100mg BID (N=21)	200mg BID (N=47)	Total (N=68)

No Data

[a] Number (%) of patients with a significant AE, sorted by system organ class (SOC) in descending order of total frequency and preferred term (PT) within the SOC in descending order of total frequency.
Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
[b] Any AE, other than SAEs and those AEs leading to discontinuation of study treatment, which are of particular clinical importance, are identified and classified as Other Significant AEs by the sponsor.
Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
Note: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1

Program Name: RT_AE230
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time
(Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Hemoglobin	g/L	100mg BID(N=21)	BASELINE	21	111.476	16.9134	89.00	102.000	108.000	121.000	155.00
			SCREENING	21	111.857	16.6081	89.00	102.000	109.000	121.000	155.00
			WEEK 0	20	111.550	17.9897	92.00	99.000	106.000	120.500	161.00
			WEEK 1	19	116.263	19.1074	93.00	101.000	115.000	135.000	159.00
			WEEK 2	17	112.529	18.3102	89.00	100.000	112.000	120.000	162.00
			WEEK 3	15	108.000	14.1926	85.00	96.000	108.000	117.000	130.00
			WEEK 4	13	112.077	16.4998	87.00	104.000	111.000	120.000	150.00
			WEEK 8	4	117.250	4.7871	112.00	113.500	117.000	121.000	123.00
			WEEK 12	2	121.500	21.9203	106.00	106.000	121.500	137.000	137.00
			WEEK 16	2	121.000	25.4558	103.00	103.000	121.000	139.000	139.00
			WEEK 20	2	118.500	21.9203	103.00	103.000	118.500	134.000	134.00
			WEEK 24	2	125.000	21.2132	110.00	110.000	125.000	140.000	140.00
			WEEK 28	2	120.500	19.0919	107.00	107.000	120.500	134.000	134.00
			WEEK 32	2	123.500	16.2635	112.00	112.000	123.500	135.000	135.00
			WEEK 36	2	121.500	21.9203	106.00	106.000	121.500	137.000	137.00
			WEEK 40	2	123.000	24.0416	106.00	106.000	123.000	140.000	140.00
			WEEK 44	1	112.000	0.0000	112.00	112.000	112.000	112.000	112.00
			WEEK 48	1	104.000	0.0000	104.00	104.000	104.000	104.000	104.00
			DISCONTINUATION	19	108.053	22.0944	55.00	100.000	106.000	119.000	155.00
		200mg BID(N=47)	BASELINE	46	108.391	14.7490	82.00	98.000	104.500	118.000	138.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Hemoglobin	g/L	200mg BID(N=47)	SCREENING	47	108.830	14.7329	82.00	98.000	104.000	118.000	143.00
			WEEK 0	45	108.556	15.5294	82.00	94.000	107.000	120.000	141.00
			WEEK 1	45	116.356	16.8646	84.00	105.000	112.000	126.000	155.00
			WEEK 2	37	114.243	19.7124	74.00	102.000	114.000	129.000	150.00
			WEEK 3	31	111.097	21.9581	62.00	98.000	107.000	125.000	153.00
			WEEK 4	22	109.000	19.7629	72.00	92.000	113.000	123.000	151.00
			WEEK 8	3	130.000	14.1774	119.00	119.000	125.000	146.000	146.00
			WEEK 12	2	129.000	8.4853	123.00	123.000	129.000	135.000	135.00
			WEEK 16	2	128.000	14.1421	118.00	118.000	128.000	138.000	138.00
			WEEK 20	1	135.000	0.0000	135.00	135.000	135.000	135.000	135.00
			DISCONTINUATION	37	105.216	19.4638	76.00	89.000	105.000	119.000	154.00
Erythrocytes	10^12/L	100mg BID(N=21)	BASELINE	21	3.603	0.6136	2.59	3.250	3.660	3.880	5.10
			SCREENING	21	3.615	0.6031	2.59	3.250	3.660	3.890	4.90
			WEEK 0	20	3.667	0.6300	2.71	3.185	3.595	3.980	5.10
			WEEK 1	19	3.778	0.7346	2.77	3.250	3.700	4.240	5.20
			WEEK 2	17	3.612	0.6183	2.75	3.070	3.500	3.870	5.08
			WEEK 3	15	3.419	0.4951	2.60	2.940	3.490	3.700	4.22
			WEEK 4	13	3.525	0.5779	2.40	3.440	3.560	3.680	4.65
			WEEK 8	4	3.665	0.1150	3.55	3.575	3.650	3.755	3.81
		200mg BID(N=47)	BASELINE	46	3.461	0.5729	2.63	3.040	3.355	3.790	4.99

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Erythrocytes	10^12/L	100mg BID(N=21)	WEEK 12	2	3.700	0.4243	3.40	3.400	3.700	4.000	4.00
			WEEK 16	2	3.650	0.6364	3.20	3.200	3.650	4.100	4.10
			WEEK 20	2	3.550	0.4950	3.20	3.200	3.550	3.900	3.90
			WEEK 24	2	3.750	0.4950	3.40	3.400	3.750	4.100	4.10
			WEEK 28	2	3.750	0.4950	3.40	3.400	3.750	4.100	4.10
			WEEK 32	2	3.800	0.4243	3.50	3.500	3.800	4.100	4.10
			WEEK 36	2	3.800	0.5657	3.40	3.400	3.800	4.200	4.20
			WEEK 40	2	3.800	0.7071	3.30	3.300	3.800	4.300	4.30
			WEEK 44	1	3.400	0.0000	3.40	3.400	3.400	3.400	3.40
			WEEK 48	1	3.100	0.0000	3.10	3.100	3.100	3.100	3.10
			DISCONTINUATION	19	3.584	0.8472	1.60	3.120	3.540	4.310	5.20
		200mg BID(N=47)	SCREENING	46	3.487	0.5537	2.71	3.100	3.335	3.800	4.99
			WEEK 0	45	3.509	0.5786	2.50	3.150	3.400	3.800	4.93
			WEEK 1	45	3.764	0.5654	2.83	3.390	3.640	4.010	5.47
			WEEK 2	37	3.683	0.6451	2.60	3.250	3.550	4.080	5.18
			WEEK 3	31	3.592	0.6954	2.50	3.100	3.430	4.120	5.23
			WEEK 4	22	3.457	0.6008	2.40	2.950	3.595	3.800	4.40
			WEEK 8	3	4.037	0.5040	3.50	3.500	4.110	4.500	4.50
			WEEK 12	2	3.870	0.3818	3.60	3.600	3.870	4.140	4.14
			WEEK 16	2	3.840	0.6223	3.40	3.400	3.840	4.280	4.28

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Erythrocytes	10^12/L	200mg BID(N=47)	WEEK 20	1	3.900	0.0000	3.90	3.900	3.900	3.900	3.90
			DISCONTINUATION	36	3.407	0.6816	2.44	2.995	3.265	3.775	5.48
Leukocytes	10^9/L	100mg BID(N=21)	BASELINE	21	5.611	2.2539	1.90	4.400	5.100	7.400	9.40
			SCREENING	21	5.573	2.2608	1.90	4.400	5.100	7.400	9.40
			WEEK 0	20	5.886	2.2213	2.01	4.300	4.850	7.900	9.80
			WEEK 1	19	5.752	3.1241	1.30	3.100	5.000	8.300	12.10
			WEEK 2	17	5.629	2.5171	2.00	3.800	5.100	7.900	10.20
			WEEK 3	15	4.335	1.8018	1.90	2.600	4.200	5.900	7.10
			WEEK 4	13	4.182	2.0447	1.76	2.400	3.700	4.600	8.00
			WEEK 8	4	3.800	1.6872	2.10	2.650	3.500	4.950	6.10
			WEEK 12	2	4.700	0.5657	4.30	4.300	4.700	5.100	5.10
			WEEK 16	2	4.650	0.7778	4.10	4.100	4.650	5.200	5.20
			WEEK 20	2	5.650	1.3435	4.70	4.700	5.650	6.600	6.60
			WEEK 24	2	5.750	1.7678	4.50	4.500	5.750	7.000	7.00
			WEEK 28	2	3.650	1.4849	2.60	2.600	3.650	4.700	4.70
			WEEK 32	2	5.400	1.8385	4.10	4.100	5.400	6.700	6.70
			WEEK 36	2	4.950	0.3536	4.70	4.700	4.950	5.200	5.20
			WEEK 40	2	5.550	0.9192	4.90	4.900	5.550	6.200	6.20
			WEEK 44	1	5.300	0.0000	5.30	5.300	5.300	5.300	5.30
		200mg BID(N=47)	BASELINE	46	6.537	3.1090	2.01	4.200	5.550	8.200	14.70

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Leukocytes	10^9/L	100mg BID(N=21)	WEEK 48	1	6.200	0.0000	6.20	6.200	6.200	6.200	6.20
			DISCONTINUATION	19	5.209	3.7126	1.30	2.900	4.300	6.100	15.00
		200mg BID(N=47)	SCREENING	46	7.200	5.4600	2.01	4.500	5.765	8.200	37.10
			WEEK 0	45	6.840	3.4634	1.36	4.700	5.700	8.600	18.60
			WEEK 1	45	7.342	3.7755	2.60	4.600	6.500	8.800	17.90
			WEEK 2	37	6.002	2.2803	2.70	4.300	5.800	6.800	11.90
			WEEK 3	31	5.558	3.1269	2.50	3.700	4.790	6.800	16.00
			WEEK 4	22	5.112	2.8705	1.40	3.300	4.535	6.000	12.50
			WEEK 8	3	5.200	2.2517	2.90	2.900	5.300	7.400	7.40
			WEEK 12	2	5.500	2.9698	3.40	3.400	5.500	7.600	7.60
			WEEK 16	2	5.550	1.2021	4.70	4.700	5.550	6.400	6.40
			WEEK 20	1	4.900	0.0000	4.90	4.900	4.900	4.900	4.90
			DISCONTINUATION	37	6.416	4.3601	0.70	3.400	5.800	7.990	17.55
Basophils	10^9/L	100mg BID(N=21)	BASELINE	21	0.020	0.0320	0.00	0.000	0.000	0.050	0.10
			SCREENING	21	0.020	0.0320	0.00	0.000	0.000	0.050	0.10
			WEEK 0	19	0.031	0.0462	0.00	0.000	0.000	0.060	0.14
			WEEK 1	19	0.036	0.0544	0.00	0.000	0.000	0.070	0.21
			WEEK 2	17	0.014	0.0290	0.00	0.000	0.000	0.020	0.11
			WEEK 3	15	0.011	0.0194	0.00	0.000	0.000	0.020	0.06
		200mg BID(N=47)	BASELINE	44	0.029	0.0467	0.00	0.000	0.000	0.041	0.24

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Basophils	10^9/L	100mg BID(N=21)	WEEK 4	13	0.005	0.0113	0.00	0.000	0.000	0.000	0.03
			WEEK 8	4	0.003	0.0050	0.00	0.000	0.000	0.005	0.01
			WEEK 12	2	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 16	2	0.005	0.0071	0.00	0.000	0.005	0.010	0.01
			WEEK 20	2	0.010	0.0141	0.00	0.000	0.010	0.020	0.02
			WEEK 24	2	0.005	0.0071	0.00	0.000	0.005	0.010	0.01
			WEEK 28	2	0.010	0.0141	0.00	0.000	0.010	0.020	0.02
			WEEK 32	2	0.010	0.0141	0.00	0.000	0.010	0.020	0.02
			WEEK 36	2	0.005	0.0071	0.00	0.000	0.005	0.010	0.01
			WEEK 40	2	0.015	0.0212	0.00	0.000	0.015	0.030	0.03
			WEEK 44	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 48	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			DISCONTINUATION	19	0.012	0.0259	0.00	0.000	0.000	0.010	0.10
		200mg BID(N=47)	SCREENING	45	0.031	0.0475	0.00	0.000	0.000	0.042	0.24
			WEEK 0	43	0.029	0.0445	0.00	0.000	0.000	0.050	0.19
			WEEK 1	44	0.026	0.0368	0.00	0.000	0.000	0.045	0.10
			WEEK 2	36	0.024	0.0361	0.00	0.000	0.000	0.034	0.12
			WEEK 3	29	0.020	0.0308	0.00	0.000	0.010	0.020	0.10
			WEEK 4	21	0.021	0.0359	0.00	0.000	0.000	0.020	0.10
			WEEK 8	2	0.010	0.0141	0.00	0.000	0.010	0.020	0.02

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Basophils	10^9/L	200mg BID(N=47)	WEEK 12	2	0.005	0.0071	0.00	0.000	0.005	0.010	0.01
			WEEK 16	2	0.065	0.0495	0.03	0.030	0.065	0.100	0.10
			WEEK 20	1	0.020	0.0000	0.02	0.020	0.020	0.020	0.02
			DISCONTINUATION	32	0.011	0.0219	0.00	0.000	0.000	0.010	0.09
Eosinophils	10^9/L	100mg BID(N=21)	BASELINE	21	0.099	0.0814	0.00	0.040	0.100	0.150	0.30
			SCREENING	21	0.118	0.1015	0.00	0.050	0.100	0.160	0.40
			WEEK 0	18	0.142	0.1568	0.00	0.060	0.100	0.200	0.69
			WEEK 1	19	0.112	0.0784	0.00	0.062	0.100	0.200	0.30
			WEEK 2	17	0.135	0.1004	0.00	0.100	0.100	0.200	0.40
			WEEK 3	15	0.145	0.1112	0.00	0.060	0.100	0.200	0.35
			WEEK 4	13	0.129	0.1022	0.00	0.050	0.100	0.200	0.32
			WEEK 8	4	0.058	0.0506	0.00	0.015	0.065	0.100	0.10
			WEEK 12	2	0.180	0.1131	0.10	0.100	0.180	0.260	0.26
			WEEK 16	2	0.070	0.0424	0.04	0.040	0.070	0.100	0.10
			WEEK 20	2	0.135	0.0919	0.07	0.070	0.135	0.200	0.20
			WEEK 24	2	0.075	0.0354	0.05	0.050	0.075	0.100	0.10
			WEEK 28	2	0.075	0.0354	0.05	0.050	0.075	0.100	0.10
			WEEK 32	2	0.125	0.1061	0.05	0.050	0.125	0.200	0.20
			WEEK 36	2	0.070	0.0424	0.04	0.040	0.070	0.100	0.10
		200mg BID(N=47)	BASELINE	44	0.145	0.2251	0.00	0.015	0.088	0.160	1.21

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Eosinophils	10^9/L	100mg BID(N=21)	WEEK 40	2	0.065	0.0495	0.03	0.030	0.065	0.100	0.10
			WEEK 44	1	0.100	0.0000	0.10	0.100	0.100	0.100	0.10
			WEEK 48	1	0.200	0.0000	0.20	0.200	0.200	0.200	0.20
			DISCONTINUATION	19	0.053	0.0735	0.00	0.000	0.000	0.100	0.20
		200mg BID(N=47)	SCREENING	45	0.150	0.2250	0.00	0.010	0.090	0.130	1.21
			WEEK 0	44	0.130	0.1298	0.00	0.045	0.100	0.189	0.60
			WEEK 1	44	0.104	0.1011	0.00	0.049	0.090	0.132	0.50
			WEEK 2	36	0.084	0.0956	0.00	0.000	0.060	0.107	0.40
			WEEK 3	29	0.062	0.0598	0.00	0.000	0.062	0.100	0.22
			WEEK 4	21	0.082	0.0889	0.00	0.030	0.080	0.100	0.40
			WEEK 8	2	0.047	0.0092	0.04	0.040	0.047	0.053	0.05
			WEEK 12	2	0.080	0.0283	0.06	0.060	0.080	0.100	0.10
			WEEK 16	2	0.050	0.0707	0.00	0.000	0.050	0.100	0.10
			WEEK 20	1	0.200	0.0000	0.20	0.200	0.200	0.200	0.20
			DISCONTINUATION	32	0.051	0.0709	0.00	0.000	0.019	0.100	0.32
Monocytes	10^9/L	100mg BID(N=21)	BASELINE	21	0.650	0.3406	0.04	0.400	0.680	0.800	1.50
			SCREENING	21	0.645	0.3449	0.04	0.400	0.680	0.800	1.50
			WEEK 0	19	0.633	0.2352	0.30	0.400	0.660	0.800	1.13
			WEEK 1	19	0.432	0.2211	0.10	0.300	0.400	0.600	1.00
		200mg BID(N=47)	BASELINE	44	0.737	0.3607	0.14	0.470	0.700	0.945	1.60

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Monocytes	10^9/L	100mg BID(N=21)	WEEK 2	17	0.418	0.2260	0.10	0.300	0.400	0.470	1.02
			WEEK 3	15	0.315	0.1572	0.10	0.200	0.300	0.410	0.70
			WEEK 4	13	0.269	0.1666	0.10	0.180	0.200	0.300	0.70
			WEEK 8	4	0.350	0.2380	0.10	0.150	0.350	0.550	0.60
			WEEK 12	2	0.950	0.6364	0.50	0.500	0.950	1.400	1.40
			WEEK 16	2	0.500	0.0000	0.50	0.500	0.500	0.500	0.50
			WEEK 20	2	0.450	0.2121	0.30	0.300	0.450	0.600	0.60
			WEEK 24	2	0.450	0.0707	0.40	0.400	0.450	0.500	0.50
			WEEK 28	2	0.500	0.0000	0.50	0.500	0.500	0.500	0.50
			WEEK 32	2	0.400	0.0000	0.40	0.400	0.400	0.400	0.40
			WEEK 36	2	0.450	0.2121	0.30	0.300	0.450	0.600	0.60
			WEEK 40	2	0.450	0.0707	0.40	0.400	0.450	0.500	0.50
			WEEK 44	1	0.300	0.0000	0.30	0.300	0.300	0.300	0.30
			WEEK 48	1	0.300	0.0000	0.30	0.300	0.300	0.300	0.30
			DISCONTINUATION	19	0.409	0.3465	0.07	0.200	0.340	0.440	1.65
		200mg BID(N=47)	SCREENING	45	0.856	0.4526	0.14	0.600	0.730	1.140	2.59
			WEEK 0	44	0.684	0.3363	0.07	0.400	0.625	0.900	1.60
			WEEK 1	44	0.407	0.2361	0.00	0.220	0.380	0.510	0.96
			WEEK 2	36	0.326	0.1779	0.00	0.200	0.300	0.500	0.70
			WEEK 3	29	0.329	0.2080	0.09	0.200	0.260	0.480	0.80

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Monocytes	10^9/L	200mg BID(N=47)	WEEK 4	21	0.260	0.1848	0.00	0.171	0.200	0.300	0.70
			WEEK 8	3	0.675	0.5451	0.30	0.300	0.424	1.300	1.30
			WEEK 12	2	0.400	0.1414	0.30	0.300	0.400	0.500	0.50
			WEEK 16	2	0.450	0.0707	0.40	0.400	0.450	0.500	0.50
			WEEK 20	1	0.300	0.0000	0.30	0.300	0.300	0.300	0.30
			DISCONTINUATION	34	0.356	0.3051	0.00	0.121	0.295	0.500	1.17
Lymphocytes	10^9/L	100mg BID(N=21)	BASELINE	21	0.860	0.5929	0.20	0.300	0.800	1.300	2.20
			SCREENING	21	0.883	0.5792	0.20	0.322	0.800	1.300	2.20
			WEEK 0	19	0.994	0.9080	0.19	0.300	0.500	2.000	3.00
			WEEK 1	19	1.080	0.8924	0.10	0.300	0.830	1.600	2.91
			WEEK 2	17	1.198	0.8536	0.20	0.400	1.000	1.500	2.86
			WEEK 3	15	0.917	0.8409	0.10	0.400	0.800	1.070	3.50
			WEEK 4	13	0.835	0.6879	0.20	0.300	0.600	1.100	2.10
			WEEK 8	4	1.275	0.5123	0.80	0.950	1.150	1.600	2.00
			WEEK 12	2	1.400	0.4243	1.10	1.100	1.400	1.700	1.70
			WEEK 16	2	1.450	0.4950	1.10	1.100	1.450	1.800	1.80
			WEEK 20	2	1.450	0.6364	1.00	1.000	1.450	1.900	1.90
			WEEK 24	2	1.400	0.5657	1.00	1.000	1.400	1.800	1.80
			WEEK 28	2	1.250	0.3536	1.00	1.000	1.250	1.500	1.50
		200mg BID(N=47)	BASELINE	44	0.871	0.6373	0.14	0.450	0.649	1.050	3.40

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Lymphocytes	10^9/L	100mg BID(N=21)	WEEK 32	2	1.300	0.2828	1.10	1.100	1.300	1.500	1.50
			WEEK 36	2	1.450	0.3536	1.20	1.200	1.450	1.700	1.70
			WEEK 40	2	1.350	0.2121	1.20	1.200	1.350	1.500	1.50
			WEEK 44	1	1.200	0.0000	1.20	1.200	1.200	1.200	1.20
			WEEK 48	1	1.100	0.0000	1.10	1.100	1.100	1.100	1.10
			DISCONTINUATION	19	1.055	1.1283	0.20	0.300	0.500	1.800	4.35
		200mg BID(N=47)	SCREENING	45	0.933	0.6805	0.14	0.500	0.670	1.250	3.33
			WEEK 0	44	0.870	0.6371	0.10	0.450	0.700	1.100	3.40
			WEEK 1	44	1.153	1.0025	0.20	0.500	0.915	1.400	5.10
			WEEK 2	36	0.898	0.6214	0.15	0.440	0.682	1.315	2.30
			WEEK 3	30	0.801	0.5867	0.20	0.400	0.600	0.960	2.20
			WEEK 4	21	0.789	0.7763	0.00	0.300	0.600	1.100	3.60
			WEEK 8	3	1.210	1.1177	0.53	0.530	0.600	2.500	2.50
			WEEK 12	2	1.900	1.6971	0.70	0.700	1.900	3.100	3.10
			WEEK 16	2	1.350	1.2021	0.50	0.500	1.350	2.200	2.20
			WEEK 20	1	0.800	0.0000	0.80	0.800	0.800	0.800	0.80
			DISCONTINUATION	34	0.855	0.6250	0.10	0.300	0.700	1.100	2.48
Neutrophils	10^9/L	100mg BID(N=21)	BASELINE	20	3.960	2.1332	1.02	2.550	2.900	5.350	8.00
			SCREENING	20	3.875	2.0907	1.02	2.450	2.900	5.350	8.00
		200mg BID(N=47)	BASELINE	42	4.725	2.5965	1.61	2.650	4.000	6.300	11.70

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Neutrophils	10^9/L	100mg BID(N=21)	WEEK 0	19	3.980	2.1964	1.01	2.400	3.220	6.000	8.50
			WEEK 1	19	4.076	2.9689	0.83	1.700	3.550	6.400	11.20
			WEEK 2	17	3.805	2.2150	1.03	1.900	3.670	5.300	8.08
			WEEK 3	15	2.975	1.6153	0.87	1.700	3.300	4.000	6.50
			WEEK 4	13	2.920	2.0353	0.72	1.700	2.300	3.300	7.30
			WEEK 8	4	2.150	1.5286	0.80	1.100	1.750	3.200	4.30
			WEEK 12	2	2.200	1.8385	0.90	0.900	2.200	3.500	3.50
			WEEK 16	2	2.700	1.2728	1.80	1.800	2.700	3.600	3.60
			WEEK 20	2	3.600	1.9799	2.20	2.200	3.600	5.000	5.00
			WEEK 24	2	3.800	2.4042	2.10	2.100	3.800	5.500	5.50
			WEEK 28	2	1.800	1.1314	1.00	1.000	1.800	2.600	2.60
			WEEK 32	2	3.550	2.0506	2.10	2.100	3.550	5.000	5.00
			WEEK 36	2	3.000	0.8485	2.40	2.400	3.000	3.600	3.60
			WEEK 40	2	3.650	1.2021	2.80	2.800	3.650	4.500	4.50
			WEEK 44	1	3.700	0.0000	3.70	3.700	3.700	3.700	3.70
			WEEK 48	1	4.700	0.0000	4.70	4.700	4.700	4.700	4.70
			DISCONTINUATION	19	3.506	2.6622	0.40	1.500	2.700	5.300	11.40
		200mg BID(N=47)	SCREENING	43	5.398	4.6722	1.60	2.650	4.300	6.468	29.30
			WEEK 0	42	5.332	3.2472	1.10	3.200	4.295	6.610	16.93
			WEEK 1	43	5.811	3.7759	1.90	3.100	4.590	7.100	16.10

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Neutrophils	10^9/L	200mg BID(N=47)	WEEK 2	35	4.791	2.3232	1.10	3.330	4.300	5.700	10.82
			WEEK 3	30	4.405	3.0494	1.10	2.430	3.500	5.700	14.80
			WEEK 4	19	3.890	2.9017	0.97	2.000	3.200	4.000	11.99
			WEEK 8	2	2.600	0.8485	2.00	2.000	2.600	3.200	3.20
			WEEK 12	2	3.200	1.1314	2.40	2.400	3.200	4.000	4.00
			WEEK 16	2	3.650	0.0707	3.60	3.600	3.650	3.700	3.70
			WEEK 20	1	3.500	0.0000	3.50	3.500	3.500	3.500	3.50
			DISCONTINUATION	32	5.232	4.1095	0.20	1.950	4.630	7.000	15.30
Platelets	10^9/L	100mg BID(N=21)	BASELINE	21	204.524	95.2369	67.00	130.000	207.000	283.000	451.00
			SCREENING	21	205.381	95.9773	67.00	130.000	207.000	288.000	451.00
			WEEK 0	20	198.400	86.7030	72.00	122.000	194.000	261.000	386.00
			WEEK 1	19	192.737	96.3234	59.00	113.000	168.000	275.000	401.00
			WEEK 2	17	184.000	102.1886	55.00	120.000	163.000	196.000	413.00
			WEEK 3	15	170.200	100.5074	57.00	100.000	130.000	235.000	351.00
			WEEK 4	13	166.077	114.5007	43.00	96.000	109.000	261.000	382.00
			WEEK 8	4	116.500	119.7790	39.00	49.500	66.000	183.500	295.00
			WEEK 12	2	152.000	138.5929	54.00	54.000	152.000	250.000	250.00
			WEEK 16	2	171.500	142.1285	71.00	71.000	171.500	272.000	272.00
			WEEK 20	2	185.000	151.3209	78.00	78.000	185.000	292.000	292.00
		200mg BID(N=47)	BASELINE	46	195.022	97.1641	77.00	129.000	179.000	215.000	524.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Platelets	10^9/L	100mg BID(N=21)	WEEK 24	2	188.500	163.3417	73.00	73.000	188.500	304.000	304.00
			WEEK 28	2	178.500	135.0574	83.00	83.000	178.500	274.000	274.00
			WEEK 32	2	167.500	119.5010	83.00	83.000	167.500	252.000	252.00
			WEEK 36	2	176.000	141.4214	76.00	76.000	176.000	276.000	276.00
			WEEK 40	2	196.000	148.4924	91.00	91.000	196.000	301.000	301.00
			WEEK 44	1	290.000	0.0000	290.00	290.000	290.000	290.000	290.00
			WEEK 48	1	334.000	0.0000	334.00	334.000	334.000	334.000	334.00
			DISCONTINUATION	19	180.526	123.8213	38.00	94.000	132.000	249.000	437.00
		200mg BID(N=47)	SCREENING	46	190.826	78.7438	79.00	133.000	179.000	236.000	431.00
			WEEK 0	45	197.089	94.2315	77.00	127.000	191.000	244.000	478.00
			WEEK 1	45	237.822	113.2133	76.00	140.000	213.000	300.000	521.00
			WEEK 2	37	239.568	106.8118	72.00	164.000	224.000	299.000	457.00
			WEEK 3	31	204.613	89.4120	65.00	141.000	189.000	285.000	428.00
			WEEK 4	22	177.227	71.1684	66.00	110.000	175.500	234.000	334.00
			WEEK 8	3	204.333	50.8953	172.00	172.000	178.000	263.000	263.00
			WEEK 12	2	208.500	37.4767	182.00	182.000	208.500	235.000	235.00
			WEEK 16	2	213.500	60.1041	171.00	171.000	213.500	256.000	256.00
			WEEK 20	1	168.000	0.0000	168.00	168.000	168.000	168.000	168.00
			DISCONTINUATION	36	171.944	110.2579	35.00	92.500	135.500	233.500	444.00
Activated Partial Thromboplastin Time	sec	100mg BID(N=21)	BASELINE	18	30.700	4.3474	25.00	27.000	30.150	33.100	39.80

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time
(Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Activated Partial Thromboplastin Time	sec	100mg BID(N=21)	SCREENING	18	30.850	4.2129	25.00	27.500	30.150	33.100	39.80
			WEEK 0	19	30.453	3.9793	25.80	27.500	29.400	32.500	38.90
			WEEK 1	14	30.014	4.5772	24.60	27.200	27.900	34.600	38.00
			WEEK 2	16	33.213	10.9009	25.90	26.950	31.100	33.700	71.50
			WEEK 3	14	31.279	5.2879	24.40	28.500	29.300	33.700	41.90
			WEEK 4	11	29.782	4.7518	24.70	27.000	28.400	31.800	42.10
			WEEK 8	4	45.150	36.4860	24.50	25.750	28.150	64.550	99.80
			WEEK 12	1	30.400	0.0000	30.40	30.400	30.400	30.400	30.40
			WEEK 16	1	26.100	0.0000	26.10	26.100	26.100	26.100	26.10
			WEEK 20	1	29.500	0.0000	29.50	29.500	29.500	29.500	29.50
			WEEK 24	2	31.850	4.3134	28.80	28.800	31.850	34.900	34.90
			WEEK 28	2	43.800	21.0718	28.90	28.900	43.800	58.700	58.70
			WEEK 32	2	38.000	13.7179	28.30	28.300	38.000	47.700	47.70
			WEEK 36	2	31.500	3.8184	28.80	28.800	31.500	34.200	34.20
			WEEK 40	2	30.850	3.1820	28.60	28.600	30.850	33.100	33.10
			WEEK 44	1	29.600	0.0000	29.60	29.600	29.600	29.600	29.60
			DISCONTINUATION	17	29.771	4.6513	23.80	26.700	28.000	32.300	40.10
		200mg BID(N=47)	BASELINE	41	31.259	7.8226	16.50	27.500	29.500	33.600	63.00
			SCREENING	42	31.564	7.6896	16.50	27.900	30.150	33.600	63.00
			WEEK 0	37	33.030	10.7350	23.40	28.000	29.000	34.700	72.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Activated Partial Thromboplastin Time	sec	200mg BID(N=47)	WEEK 1	41	31.812	8.1106	21.00	27.000	30.200	33.400	68.00
			WEEK 2	32	32.722	8.8071	24.00	29.000	29.900	32.050	65.30
			WEEK 3	27	39.985	32.5843	24.00	28.000	30.000	33.000	180.00
			WEEK 4	20	32.485	7.7915	25.00	28.400	29.350	33.250	55.80
			WEEK 8	3	29.933	2.0648	28.50	28.500	29.000	32.300	32.30
			WEEK 12	1	30.800	0.0000	30.80	30.800	30.800	30.800	30.80
			WEEK 16	2	31.100	4.1012	28.20	28.200	31.100	34.000	34.00
			WEEK 20	1	29.400	0.0000	29.40	29.400	29.400	29.400	29.40
			DISCONTINUATION	27	36.026	14.5626	23.30	27.300	29.800	39.600	84.00
Prothrombin Intl. Normalized Ratio	[ratio]	100mg BID(N=21)	BASELINE	19	1.087	0.2495	0.90	1.000	1.000	1.100	2.01
			SCREENING	19	1.087	0.2495	0.90	1.000	1.000	1.100	2.01
			WEEK 0	19	1.057	0.2038	0.80	0.990	1.000	1.100	1.80
			WEEK 1	15	1.143	0.5893	0.80	0.950	1.000	1.040	3.25
			WEEK 2	16	1.177	0.7909	0.80	0.935	1.000	1.035	4.13
			WEEK 3	15	1.129	0.5953	0.90	0.900	1.000	1.010	3.27
			WEEK 4	11	1.101	0.3745	0.90	0.970	1.000	1.010	2.22
			WEEK 8	4	0.950	0.0577	0.90	0.900	0.950	1.000	1.00
			WEEK 12	1	0.900	0.0000	0.90	0.900	0.900	0.900	0.90
			WEEK 16	1	1.000	0.0000	1.00	1.000	1.000	1.000	1.00
		200mg BID(N=47)	BASELINE	44	1.093	0.2609	0.90	1.000	1.045	1.100	2.70

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Prothrombin Intl. Normalized Ratio	[ratio]	100mg BID(N=21)	WEEK 20	1	0.900	0.0000	0.90	0.900	0.900	0.900	0.90
			WEEK 24	2	0.900	0.1414	0.80	0.800	0.900	1.000	1.00
			WEEK 28	2	0.950	0.0707	0.90	0.900	0.950	1.000	1.00
			WEEK 32	2	0.900	0.1414	0.80	0.800	0.900	1.000	1.00
			WEEK 36	2	0.900	0.0000	0.90	0.900	0.900	0.900	0.90
			WEEK 40	2	0.850	0.0707	0.80	0.800	0.850	0.900	0.90
			WEEK 44	1	0.900	0.0000	0.90	0.900	0.900	0.900	0.90
			WEEK 48	1	0.900	0.0000	0.90	0.900	0.900	0.900	0.90
			DISCONTINUATION	18	1.071	0.2589	0.90	0.900	1.010	1.100	2.04
		200mg BID(N=47)	SCREENING	45	1.103	0.2583	0.90	1.000	1.090	1.100	2.70
			WEEK 0	37	1.118	0.3519	0.90	1.000	1.000	1.100	3.10
			WEEK 1	41	1.083	0.2399	0.90	1.000	1.000	1.100	2.30
			WEEK 2	34	1.112	0.3478	0.90	0.980	1.000	1.100	2.70
			WEEK 3	28	1.153	0.4393	0.89	0.990	1.005	1.165	3.20
			WEEK 4	20	1.140	0.4448	0.90	0.940	1.000	1.105	2.60
			WEEK 8	3	0.987	0.0321	0.95	0.950	1.000	1.010	1.01
			WEEK 12	1	1.000	0.0000	1.00	1.000	1.000	1.000	1.00
			WEEK 16	2	1.085	0.0212	1.07	1.070	1.085	1.100	1.10
			WEEK 20	1	0.900	0.0000	0.90	0.900	0.900	0.900	0.90
			DISCONTINUATION	27	1.367	0.8651	0.80	1.000	1.100	1.200	4.20

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Prothrombin Time	sec	100mg BID(N=21)	BASELINE	19	12.805	2.4710	9.60	10.600	13.100	13.700	19.30
			SCREENING	19	12.811	2.4714	9.60	10.600	13.100	13.700	19.30
			WEEK 0	19	12.332	1.7698	9.80	10.900	12.400	13.300	17.40
			WEEK 1	15	13.393	4.8716	9.40	11.600	12.700	13.400	30.40
			WEEK 2	16	13.438	6.6791	9.60	10.500	12.350	12.750	38.10
			WEEK 3	14	12.914	5.2538	9.20	10.500	12.250	12.900	30.60
			WEEK 4	11	12.245	3.3548	9.20	10.000	12.300	13.000	21.20
			WEEK 8	4	12.125	1.2339	10.30	11.400	12.600	12.850	13.00
			WEEK 12	1	12.900	0.0000	12.90	12.900	12.900	12.900	12.90
			WEEK 16	1	12.800	0.0000	12.80	12.800	12.800	12.800	12.80
			WEEK 20	1	12.800	0.0000	12.80	12.800	12.800	12.800	12.80
			WEEK 24	2	11.300	1.4142	10.30	10.300	11.300	12.300	12.30
			WEEK 28	2	11.350	2.0506	9.90	9.900	11.350	12.800	12.80
			WEEK 32	2	11.000	1.8385	9.70	9.700	11.000	12.300	12.30
			WEEK 36	2	11.250	2.7577	9.30	9.300	11.250	13.200	13.20
			WEEK 40	2	10.750	1.6263	9.60	9.600	10.750	11.900	11.90
			WEEK 44	1	9.000	0.0000	9.00	9.000	9.000	9.000	9.00
			WEEK 48	1	9.600	0.0000	9.60	9.600	9.600	9.600	9.60
			DISCONTINUATION	17	12.229	2.2290	9.30	10.900	12.100	12.500	19.60
		200mg BID(N=47)	BASELINE	44	12.923	2.5394	9.70	11.300	12.900	13.900	26.20

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Prothrombin Time	sec	200mg BID(N=47)	SCREENING	45	13.007	2.5038	9.70	11.400	12.900	13.900	26.20
			WEEK 0	37	13.295	3.0468	10.10	11.800	13.200	14.000	29.40
			WEEK 1	41	12.998	2.9935	9.50	11.300	13.000	13.700	27.90
			WEEK 2	34	13.147	3.8157	9.40	10.800	12.550	14.000	29.30
			WEEK 3	28	13.661	4.4592	10.10	10.950	13.150	14.250	33.00
			WEEK 4	20	13.680	4.6649	9.40	10.850	12.950	13.750	27.90
			WEEK 8	3	11.800	1.9079	10.60	10.600	10.800	14.000	14.00
			WEEK 12	1	13.800	0.0000	13.80	13.800	13.800	13.800	13.80
			WEEK 16	2	13.050	2.4749	11.30	11.300	13.050	14.800	14.80
			WEEK 20	1	13.500	0.0000	13.50	13.500	13.500	13.500	13.50
			DISCONTINUATION	27	15.496	7.7103	9.50	11.700	13.300	14.600	41.10
Alanine Aminotransferase	ukat/L	100mg BID(N=21)	BASELINE	21	0.441	0.2630	0.18	0.250	0.400	0.517	1.23
			SCREENING	21	0.443	0.2619	0.18	0.283	0.400	0.517	1.23
			WEEK 0	20	0.380	0.2242	0.12	0.242	0.325	0.475	1.10
			WEEK 1	19	0.452	0.3051	0.18	0.250	0.367	0.567	1.57
			WEEK 2	17	0.503	0.2321	0.22	0.333	0.450	0.667	1.03
			WEEK 3	15	0.499	0.2097	0.27	0.350	0.483	0.600	1.10
			WEEK 4	12	0.481	0.2215	0.22	0.375	0.425	0.542	1.03
			WEEK 8	4	0.850	0.7176	0.38	0.433	0.550	1.267	1.92
		200mg BID(N=47)	BASELINE	47	0.375	0.2031	0.08	0.233	0.317	0.517	0.93

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Alanine Aminotransferase	ukat/L	100mg BID(N=21)	WEEK 12	2	0.483	0.2593	0.30	0.300	0.483	0.667	0.67
			WEEK 16	2	0.658	0.3654	0.40	0.400	0.658	0.917	0.92
			WEEK 20	2	0.492	0.3654	0.23	0.233	0.492	0.750	0.75
			WEEK 24	2	0.567	0.4951	0.22	0.217	0.567	0.917	0.92
			WEEK 28	2	0.542	0.4597	0.22	0.217	0.542	0.867	0.87
			WEEK 32	2	0.558	0.3654	0.30	0.300	0.558	0.817	0.82
			WEEK 36	2	0.700	0.4479	0.38	0.383	0.700	1.017	1.02
			WEEK 40	2	0.608	0.3890	0.33	0.333	0.608	0.884	0.88
			WEEK 48	1	0.383	0.0000	0.38	0.383	0.383	0.383	0.38
			DISCONTINUATION	17	0.677	0.7994	0.28	0.383	0.483	0.567	3.73
		200mg BID(N=47)	SCREENING	46	0.375	0.2132	0.08	0.233	0.308	0.433	1.05
			WEEK 0	45	0.390	0.3453	0.05	0.233	0.267	0.467	2.05
			WEEK 1	44	0.495	0.5614	0.05	0.250	0.367	0.533	3.75
			WEEK 2	36	0.491	0.5183	0.13	0.283	0.383	0.558	3.33
			WEEK 3	31	0.583	0.5823	0.15	0.300	0.433	0.583	3.33
			WEEK 4	22	0.666	0.8350	0.12	0.283	0.458	0.700	4.20
			WEEK 8	3	0.372	0.1503	0.22	0.217	0.383	0.517	0.52
			WEEK 12	2	0.300	0.1650	0.18	0.183	0.300	0.417	0.42
			WEEK 16	2	0.217	0.0236	0.20	0.200	0.217	0.233	0.23
			WEEK 20	1	0.450	0.0000	0.45	0.450	0.450	0.450	0.45

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Alanine Aminotransferase	ukat/L	200mg BID(N=47)	DISCONTINUATION	31	0.509	0.4153	0.17	0.283	0.433	0.600	2.45
Aspartate Aminotransferase	ukat/L	100mg BID(N=21)	BASELINE	21	0.475	0.1980	0.23	0.333	0.417	0.567	1.05
			SCREENING	21	0.477	0.1949	0.23	0.350	0.417	0.533	1.05
			WEEK 0	20	0.505	0.2825	0.25	0.358	0.417	0.525	1.32
			WEEK 1	18	0.544	0.2558	0.27	0.400	0.433	0.617	1.20
			WEEK 2	17	0.519	0.1717	0.30	0.400	0.500	0.550	0.97
			WEEK 3	15	0.510	0.1511	0.30	0.400	0.467	0.617	0.80
			WEEK 4	12	0.538	0.1653	0.32	0.425	0.475	0.667	0.87
			WEEK 8	4	0.638	0.2466	0.40	0.425	0.642	0.850	0.87
			WEEK 12	2	0.458	0.0354	0.43	0.433	0.458	0.483	0.48
			WEEK 16	2	0.433	0.0000	0.43	0.433	0.433	0.433	0.43
			WEEK 20	2	0.475	0.0354	0.45	0.450	0.475	0.500	0.50
			WEEK 24	2	0.492	0.1297	0.40	0.400	0.492	0.583	0.58
			WEEK 28	2	0.433	0.1179	0.35	0.350	0.433	0.517	0.52
			WEEK 32	2	0.442	0.1061	0.37	0.367	0.442	0.517	0.52
			WEEK 36	2	0.500	0.0707	0.45	0.450	0.500	0.550	0.55
			WEEK 40	2	0.467	0.0943	0.40	0.400	0.467	0.533	0.53
			WEEK 48	1	0.450	0.0000	0.45	0.450	0.450	0.450	0.45
			DISCONTINUATION	17	0.844	0.9776	0.38	0.517	0.550	0.783	4.58
		200mg BID(N=47)	BASELINE	47	0.418	0.1994	0.13	0.283	0.367	0.500	1.22

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Aspartate Aminotransferase	ukat/L	200mg BID(N=47)	SCREENING	46	0.413	0.2000	0.13	0.283	0.350	0.500	1.22
			WEEK 0	45	0.475	0.4675	0.13	0.283	0.350	0.467	3.17
			WEEK 1	44	0.574	0.3731	0.13	0.333	0.475	0.675	1.97
			WEEK 2	36	0.570	0.3454	0.17	0.367	0.467	0.608	1.88
			WEEK 3	31	0.728	0.6689	0.18	0.417	0.483	0.683	3.32
			WEEK 4	21	0.666	0.4795	0.18	0.417	0.483	0.683	2.05
			WEEK 8	3	0.456	0.1251	0.33	0.333	0.450	0.583	0.58
			WEEK 12	2	0.425	0.1768	0.30	0.300	0.425	0.550	0.55
			WEEK 16	2	0.358	0.0825	0.30	0.300	0.358	0.417	0.42
			WEEK 20	1	0.433	0.0000	0.43	0.433	0.433	0.433	0.43
			DISCONTINUATION	32	0.836	0.9438	0.28	0.417	0.508	0.775	4.80
Alkaline Phosphatase	ukat/L	100mg BID(N=21)	BASELINE	21	2.025	2.0431	0.85	1.117	1.484	1.834	10.14
			SCREENING	21	2.029	2.0408	0.85	1.117	1.484	1.834	10.14
			WEEK 0	20	2.114	2.5704	0.80	1.084	1.350	1.700	12.20
			WEEK 1	19	1.992	1.8291	0.78	1.217	1.600	2.067	9.30
			WEEK 2	17	2.009	1.1329	1.08	1.350	1.634	2.267	5.85
			WEEK 3	15	2.078	0.9544	1.08	1.334	1.900	2.567	4.63
			WEEK 4	12	1.927	0.7384	1.08	1.325	1.675	2.692	3.15
			WEEK 8	4	1.454	0.4776	1.07	1.075	1.342	1.834	2.07
		200mg BID(N=47)	BASELINE	47	1.754	0.6097	0.70	1.317	1.667	2.034	3.97

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Alkaline Phosphatase	ukat/L	100mg BID(N=21)	WEEK 12	2	1.050	0.0471	1.02	1.017	1.050	1.084	1.08
			WEEK 16	2	1.017	0.1414	0.92	0.917	1.017	1.117	1.12
			WEEK 20	2	1.050	0.0707	1.00	1.000	1.050	1.100	1.10
			WEEK 24	2	1.150	0.1650	1.03	1.034	1.150	1.267	1.27
			WEEK 28	2	1.084	0.1179	1.00	1.000	1.084	1.167	1.17
			WEEK 32	2	1.175	0.1768	1.05	1.050	1.175	1.300	1.30
			WEEK 36	2	1.150	0.1886	1.02	1.017	1.150	1.284	1.28
			WEEK 40	2	1.225	0.2711	1.03	1.034	1.225	1.417	1.42
			WEEK 48	1	1.434	0.0000	1.43	1.434	1.434	1.434	1.43
			DISCONTINUATION	17	4.024	6.9727	1.22	1.667	1.834	2.734	30.59
		200mg BID(N=47)	SCREENING	46	1.800	0.6390	0.70	1.350	1.675	2.034	4.02
			WEEK 0	45	1.885	1.0343	0.68	1.334	1.734	2.050	6.93
			WEEK 1	44	2.071	0.6978	0.83	1.617	1.959	2.300	3.90
			WEEK 2	36	2.213	0.7967	0.95	1.692	2.050	2.551	4.70
			WEEK 3	31	2.300	0.8228	0.80	1.734	2.100	2.734	3.93
			WEEK 4	22	2.282	0.8285	1.23	1.767	2.242	2.400	4.77
			WEEK 8	3	1.900	0.4908	1.33	1.334	2.184	2.184	2.18
			WEEK 12	2	2.075	0.2947	1.87	1.867	2.075	2.284	2.28
			WEEK 16	2	2.050	0.3300	1.82	1.817	2.050	2.284	2.28
			WEEK 20	1	2.167	0.0000	2.17	2.167	2.167	2.167	2.17

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Alkaline Phosphatase	ukat/L	200mg BID(N=47)	DISCONTINUATION	31	2.666	1.6231	0.97	1.817	2.100	2.817	8.70
Protein	g/L	100mg BID(N=21)	BASELINE	21	63.048	6.4457	49.00	59.000	64.000	67.000	72.00
			SCREENING	21	63.286	6.4120	49.00	61.000	64.000	67.000	72.00
			WEEK 0	20	62.350	6.2262	50.00	60.000	63.000	67.000	72.00
			WEEK 1	19	63.526	6.8262	51.00	60.000	65.000	69.000	73.00
			WEEK 2	17	61.412	6.8653	48.00	57.000	63.000	66.000	71.00
			WEEK 3	15	61.067	5.7379	48.00	58.000	62.000	65.000	70.00
			WEEK 4	12	62.917	5.5834	51.00	61.000	64.500	66.000	71.00
			WEEK 8	4	65.500	3.5119	62.00	62.500	65.500	68.500	69.00
			WEEK 12	2	64.000	0.0000	64.00	64.000	64.000	64.000	64.00
			WEEK 16	2	64.500	0.7071	64.00	64.000	64.500	65.000	65.00
			WEEK 20	2	63.000	0.0000	63.00	63.000	63.000	63.000	63.00
			WEEK 24	2	64.000	1.4142	63.00	63.000	64.000	65.000	65.00
			WEEK 28	2	63.500	0.7071	63.00	63.000	63.500	64.000	64.00
			WEEK 32	2	64.500	3.5355	62.00	62.000	64.500	67.000	67.00
			WEEK 36	2	60.000	2.8284	58.00	58.000	60.000	62.000	62.00
			WEEK 40	2	64.000	1.4142	63.00	63.000	64.000	65.000	65.00
			WEEK 48	1	63.000	0.0000	63.00	63.000	63.000	63.000	63.00
			DISCONTINUATION	17	61.588	6.8926	48.00	55.000	62.000	66.000	72.00
		200mg BID(N=47)	BASELINE	47	63.298	6.6395	41.00	59.000	64.000	67.000	79.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Protein	g/L	200mg BID(N=47)	SCREENING	46	63.370	6.6110	41.00	59.000	64.000	67.000	79.00
			WEEK 0	45	62.311	6.1674	45.00	58.000	64.000	66.000	78.00
			WEEK 1	44	61.932	6.0325	50.00	57.000	63.000	66.000	75.00
			WEEK 2	35	60.200	6.6677	47.00	55.000	60.000	65.000	72.00
			WEEK 3	31	59.097	7.0207	47.00	52.000	61.000	64.000	71.00
			WEEK 4	22	59.182	6.8357	47.00	53.000	60.000	64.000	69.00
			WEEK 8	3	65.333	4.0415	61.00	61.000	66.000	69.000	69.00
			WEEK 12	2	61.500	2.1213	60.00	60.000	61.500	63.000	63.00
			WEEK 16	2	61.500	2.1213	60.00	60.000	61.500	63.000	63.00
			WEEK 20	1	63.000	0.0000	63.00	63.000	63.000	63.000	63.00
			DISCONTINUATION	30	58.100	7.0874	45.00	53.000	57.000	64.000	71.00
Albumin	g/L	100mg BID(N=21)	BASELINE	21	39.333	5.5166	31.00	35.000	38.000	43.000	52.00
			SCREENING	21	39.476	5.5373	31.00	35.000	39.000	43.000	52.00
			WEEK 0	20	39.000	5.8129	29.00	34.500	39.000	44.000	49.00
			WEEK 1	19	40.316	5.9726	30.00	36.000	42.000	46.000	50.00
			WEEK 2	17	37.471	6.2662	25.00	34.000	35.000	42.000	48.00
			WEEK 3	15	37.067	5.6501	25.00	33.000	37.000	40.000	48.00
			WEEK 4	12	38.000	6.6878	24.00	34.000	37.000	43.000	49.00
			WEEK 8	4	42.000	4.6188	38.00	38.000	42.000	46.000	46.00
		200mg BID(N=47)	BASELINE	47	37.830	5.3905	25.00	35.000	38.000	42.000	48.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Albumin	g/L	100mg BID(N=21)	WEEK 12	2	44.500	3.5355	42.00	42.000	44.500	47.000	47.00
			WEEK 16	2	43.500	2.1213	42.00	42.000	43.500	45.000	45.00
			WEEK 20	2	43.500	3.5355	41.00	41.000	43.500	46.000	46.00
			WEEK 24	2	44.500	3.5355	42.00	42.000	44.500	47.000	47.00
			WEEK 28	2	44.000	2.8284	42.00	42.000	44.000	46.000	46.00
			WEEK 32	2	44.500	2.1213	43.00	43.000	44.500	46.000	46.00
			WEEK 36	2	42.500	7.7782	37.00	37.000	42.500	48.000	48.00
			WEEK 40	2	42.500	4.9497	39.00	39.000	42.500	46.000	46.00
			WEEK 48	1	39.000	0.0000	39.00	39.000	39.000	39.000	39.00
			DISCONTINUATION	17	36.235	6.5530	21.00	32.000	38.000	40.000	46.00
		200mg BID(N=47)	SCREENING	46	38.000	5.5897	25.00	35.000	38.000	42.000	48.00
			WEEK 0	45	36.933	5.3657	26.00	34.000	37.000	41.000	46.00
			WEEK 1	44	36.545	5.1193	26.00	34.000	37.000	40.000	46.00
			WEEK 2	36	35.361	5.3621	24.00	31.000	35.000	40.000	45.00
			WEEK 3	31	34.387	5.6432	24.00	29.000	36.000	40.000	46.00
			WEEK 4	22	34.773	6.1018	26.00	29.000	35.500	39.000	45.00
			WEEK 8	3	40.000	3.6056	36.00	36.000	41.000	43.000	43.00
			WEEK 12	2	41.500	2.1213	40.00	40.000	41.500	43.000	43.00
			WEEK 16	2	40.500	2.1213	39.00	39.000	40.500	42.000	42.00
			WEEK 20	1	43.000	0.0000	43.00	43.000	43.000	43.000	43.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Albumin	g/L	200mg BID(N=47)	DISCONTINUATION	30	33.300	5.8022	21.00	30.000	33.500	38.000	43.00
Bilirubin	umol/L	100mg BID(N=21)	BASELINE	21	10.927	5.1131	5.00	6.840	9.000	13.680	22.23
			SCREENING	21	11.252	5.8357	3.42	6.840	9.000	13.680	22.23
			WEEK 0	20	11.267	5.7315	5.13	6.920	10.260	14.535	25.65
			WEEK 1	19	12.849	8.3754	3.42	8.550	8.550	13.680	34.20
			WEEK 2	17	12.006	5.9928	5.13	6.840	10.260	15.390	23.94
			WEEK 3	15	10.348	5.8653	5.13	6.840	8.550	10.260	25.65
			WEEK 4	12	11.758	5.6480	6.00	6.840	10.260	14.535	25.65
			WEEK 8	4	8.840	1.7067	6.84	7.420	9.130	10.260	10.26
			WEEK 12	2	9.275	1.0253	8.55	8.550	9.275	10.000	10.00
			WEEK 16	2	10.130	0.1838	10.00	10.000	10.130	10.260	10.26
			WEEK 20	2	7.920	1.5274	6.84	6.840	7.920	9.000	9.00
			WEEK 24	2	8.275	0.3889	8.00	8.000	8.275	8.550	8.55
			WEEK 28	2	7.920	1.5274	6.84	6.840	7.920	9.000	9.00
			WEEK 32	2	8.920	2.9416	6.84	6.840	8.920	11.000	11.00
			WEEK 36	2	10.775	3.1466	8.55	8.550	10.775	13.000	13.00
			WEEK 40	2	7.920	1.5274	6.84	6.840	7.920	9.000	9.00
			WEEK 48	1	5.130	0.0000	5.13	5.130	5.130	5.130	5.13
			DISCONTINUATION	17	20.881	25.7302	1.00	8.550	11.970	20.520	111.15
		200mg BID(N=47)	BASELINE	47	8.119	4.1772	1.71	5.130	6.840	10.260	23.94

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Bilirubin	umol/L	200mg BID(N=47)	SCREENING	46	8.383	4.5029	1.71	5.130	6.840	10.260	23.94
			WEEK 0	45	8.695	5.0067	3.00	5.130	7.000	10.260	30.78
			WEEK 1	44	11.121	6.9590	3.42	6.840	9.275	13.680	41.04
			WEEK 2	36	11.496	6.5211	3.42	6.840	10.260	14.535	27.36
			WEEK 3	31	12.703	7.3273	3.42	8.550	10.770	13.680	37.62
			WEEK 4	22	12.746	6.6797	4.00	8.550	10.260	15.390	35.91
			WEEK 8	3	10.410	2.8408	8.55	8.550	9.000	13.680	13.68
			WEEK 12	2	11.985	0.0212	11.97	11.970	11.985	12.000	12.00
			WEEK 16	2	11.130	1.2304	10.26	10.260	11.130	12.000	12.00
			WEEK 20	1	9.000	0.0000	9.00	9.000	9.000	9.000	9.00
			DISCONTINUATION	31	16.422	21.3451	3.42	6.840	10.260	17.100	119.70
Calcium	mmol/L	100mg BID(N=21)	BASELINE	21	2.318	0.1093	2.10	2.271	2.320	2.395	2.54
			SCREENING	21	2.321	0.1082	2.10	2.271	2.320	2.395	2.54
			WEEK 0	20	2.306	0.0970	2.12	2.221	2.333	2.370	2.50
			WEEK 1	19	2.306	0.1073	2.05	2.221	2.320	2.370	2.54
			WEEK 2	17	2.275	0.1069	2.05	2.196	2.320	2.345	2.45
			WEEK 3	14	2.316	0.0827	2.20	2.246	2.308	2.370	2.47
			WEEK 4	12	2.289	0.1182	2.12	2.183	2.295	2.370	2.52
			WEEK 8	4	2.288	0.1133	2.17	2.196	2.280	2.380	2.42
		200mg BID(N=47)	BASELINE	47	2.293	0.1267	1.97	2.221	2.320	2.395	2.52

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Calcium	mmol/L	100mg BID(N=21)	WEEK 12	2	2.278	0.0456	2.25	2.246	2.278	2.310	2.31
			WEEK 16	2	2.218	0.1020	2.15	2.146	2.218	2.290	2.29
			WEEK 20	2	2.225	0.1479	2.12	2.121	2.225	2.330	2.33
			WEEK 24	2	2.290	0.1692	2.17	2.171	2.290	2.410	2.41
			WEEK 28	2	2.318	0.1728	2.20	2.196	2.318	2.440	2.44
			WEEK 32	2	2.245	0.1056	2.17	2.171	2.245	2.320	2.32
			WEEK 36	2	2.210	0.1974	2.07	2.071	2.210	2.350	2.35
			WEEK 40	2	2.313	0.3070	2.10	2.096	2.313	2.530	2.53
			WEEK 48	1	2.121	0.0000	2.12	2.121	2.121	2.121	2.12
			DISCONTINUATION	18	2.298	0.2011	1.94	2.171	2.271	2.420	2.87
		200mg BID(N=47)	SCREENING	46	2.290	0.1264	1.97	2.190	2.320	2.370	2.52
			WEEK 0	45	2.299	0.1244	2.07	2.196	2.295	2.395	2.67
			WEEK 1	45	2.246	0.1958	1.60	2.160	2.246	2.345	3.04
			WEEK 2	37	2.213	0.1759	1.87	2.146	2.221	2.295	2.82
			WEEK 3	31	2.202	0.1601	1.85	2.110	2.221	2.295	2.52
			WEEK 4	22	2.200	0.1480	2.02	2.071	2.183	2.271	2.53
			WEEK 8	3	2.330	0.1127	2.20	2.200	2.395	2.395	2.40
			WEEK 12	2	2.268	0.1021	2.20	2.196	2.268	2.340	2.34
			WEEK 16	2	2.390	0.0849	2.33	2.330	2.390	2.450	2.45
			WEEK 20	1	2.310	0.0000	2.31	2.310	2.310	2.310	2.31

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Calcium	mmol/L	200mg BID(N=47)	DISCONTINUATION	34	2.277	0.3101	1.92	2.071	2.221	2.345	3.42
Sodium	mmol/L	100mg BID(N=21)	BASELINE	21	139.571	3.2798	133.00	138.000	139.000	142.000	146.00
			SCREENING	21	139.762	3.1766	134.00	138.000	140.000	142.000	146.00
			WEEK 0	20	138.700	2.9753	132.00	137.000	139.000	140.500	143.00
			WEEK 1	19	138.316	2.6469	133.00	136.000	138.000	140.000	145.00
			WEEK 2	17	138.706	2.8453	134.00	136.000	139.000	141.000	143.00
			WEEK 3	15	139.067	1.7512	136.00	138.000	139.000	140.000	142.00
			WEEK 4	12	139.417	1.8809	136.00	138.000	139.000	141.000	143.00
			WEEK 8	4	139.250	1.2583	138.00	138.500	139.000	140.000	141.00
			WEEK 12	2	139.500	3.5355	137.00	137.000	139.500	142.000	142.00
			WEEK 16	2	140.000	4.2426	137.00	137.000	140.000	143.000	143.00
			WEEK 20	2	140.500	2.1213	139.00	139.000	140.500	142.000	142.00
			WEEK 24	2	137.500	4.9497	134.00	134.000	137.500	141.000	141.00
			WEEK 28	2	139.500	2.1213	138.00	138.000	139.500	141.000	141.00
			WEEK 32	2	138.500	2.1213	137.00	137.000	138.500	140.000	140.00
			WEEK 36	2	141.000	2.8284	139.00	139.000	141.000	143.000	143.00
			WEEK 40	2	138.500	2.1213	137.00	137.000	138.500	140.000	140.00
			WEEK 48	1	138.000	0.0000	138.00	138.000	138.000	138.000	138.00
			DISCONTINUATION	18	138.056	3.8113	132.00	135.000	138.000	141.000	144.00
		200mg BID(N=47)	BASELINE	47	139.277	2.9833	132.00	137.000	140.000	140.000	149.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Sodium	mmol/L	200mg BID(N=47)	SCREENING	46	138.957	2.8123	132.00	137.000	139.500	140.000	146.00
			WEEK 0	45	138.689	3.0288	131.00	137.000	139.000	140.000	149.00
			WEEK 1	45	138.089	3.1825	130.00	137.000	139.000	140.000	149.00
			WEEK 2	37	136.919	3.4751	128.00	135.000	137.000	139.000	144.00
			WEEK 3	31	137.452	3.1500	131.00	136.000	137.000	140.000	143.00
			WEEK 4	22	138.000	3.1773	132.00	135.000	139.000	141.000	143.00
			WEEK 8	3	141.333	4.0415	137.00	137.000	142.000	145.000	145.00
			WEEK 12	2	143.000	5.6569	139.00	139.000	143.000	147.000	147.00
			WEEK 16	2	142.500	3.5355	140.00	140.000	142.500	145.000	145.00
			WEEK 20	1	144.000	0.0000	144.00	144.000	144.000	144.000	144.00
			DISCONTINUATION	35	136.714	3.4434	130.00	134.000	136.000	139.000	145.00
Potassium	mmol/L	100mg BID(N=21)	BASELINE	21	3.990	0.4058	3.20	3.700	4.000	4.200	4.70
			SCREENING	21	3.966	0.4063	3.20	3.700	4.000	4.190	4.70
			WEEK 0	20	4.017	0.3297	3.50	3.700	3.970	4.300	4.70
			WEEK 1	18	4.095	0.4296	3.30	3.700	4.200	4.400	4.80
			WEEK 2	17	4.161	0.5224	3.10	3.900	4.100	4.400	5.30
			WEEK 3	15	4.049	0.3492	3.50	3.800	4.000	4.300	4.80
			WEEK 4	12	4.107	0.4425	3.30	3.800	4.150	4.440	4.90
			WEEK 8	4	4.350	0.3786	4.10	4.100	4.200	4.600	4.90
		200mg BID(N=47)	BASELINE	47	4.098	0.5122	2.80	3.700	4.100	4.300	5.50

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Potassium	mmol/L	100mg BID(N=21)	WEEK 12	2	4.000	0.2828	3.80	3.800	4.000	4.200	4.20
			WEEK 16	2	3.900	0.2828	3.70	3.700	3.900	4.100	4.10
			WEEK 20	2	4.050	0.0707	4.00	4.000	4.050	4.100	4.10
			WEEK 24	2	4.000	0.4243	3.70	3.700	4.000	4.300	4.30
			WEEK 28	2	4.300	0.4243	4.00	4.000	4.300	4.600	4.60
			WEEK 32	2	3.850	0.3536	3.60	3.600	3.850	4.100	4.10
			WEEK 36	2	4.300	0.1414	4.20	4.200	4.300	4.400	4.40
			WEEK 40	2	4.300	0.4243	4.00	4.000	4.300	4.600	4.60
			WEEK 48	1	4.000	0.0000	4.00	4.000	4.000	4.000	4.00
			DISCONTINUATION	18	4.077	0.5232	3.10	3.600	4.045	4.600	5.00
		200mg BID(N=47)	SCREENING	46	4.126	0.5556	2.80	3.700	4.100	4.300	5.50
			WEEK 0	45	4.062	0.3898	3.10	3.900	4.100	4.200	5.30
			WEEK 1	45	4.209	0.4790	3.20	3.900	4.100	4.500	5.70
			WEEK 2	37	4.259	0.3730	3.60	4.000	4.300	4.400	5.10
			WEEK 3	31	4.326	0.5586	2.90	4.000	4.200	4.600	5.50
			WEEK 4	22	4.136	0.7261	2.40	3.800	4.200	4.600	5.10
			WEEK 8	3	4.800	0.9539	4.20	4.200	4.300	5.900	5.90
			WEEK 12	2	4.600	0.5657	4.20	4.200	4.600	5.000	5.00
			WEEK 16	2	4.100	0.1414	4.00	4.000	4.100	4.200	4.20
			WEEK 20	1	4.500	0.0000	4.50	4.500	4.500	4.500	4.50

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Potassium	mmol/L	200mg BID(N=47)	DISCONTINUATION	34	4.106	0.6040	2.50	3.800	4.200	4.500	5.20
Magnesium	mmol/L	100mg BID(N=21)	BASELINE	20	0.724	0.1664	0.36	0.679	0.766	0.836	0.95
			SCREENING	20	0.728	0.1689	0.36	0.679	0.766	0.857	0.95
			WEEK 0	18	0.718	0.1511	0.36	0.658	0.741	0.782	0.99
			WEEK 1	16	0.766	0.1248	0.42	0.720	0.782	0.836	0.99
			WEEK 2	16	0.739	0.1305	0.43	0.700	0.741	0.802	0.95
			WEEK 3	15	0.717	0.1590	0.40	0.699	0.700	0.823	0.95
			WEEK 4	12	0.740	0.1160	0.44	0.720	0.761	0.811	0.86
			WEEK 8	4	0.739	0.2248	0.41	0.596	0.823	0.882	0.90
			WEEK 12	2	0.600	0.2828	0.40	0.400	0.600	0.800	0.80
			WEEK 16	2	0.670	0.3253	0.44	0.440	0.670	0.900	0.90
			WEEK 20	2	0.665	0.3323	0.43	0.430	0.665	0.900	0.90
			WEEK 24	2	0.705	0.4172	0.41	0.410	0.705	1.000	1.00
			WEEK 28	2	0.710	0.4101	0.42	0.420	0.710	1.000	1.00
			WEEK 32	2	0.700	0.4243	0.40	0.400	0.700	1.000	1.00
			WEEK 36	2	0.695	0.3606	0.44	0.440	0.695	0.950	0.95
			WEEK 40	2	0.685	0.3748	0.42	0.420	0.685	0.950	0.95
			WEEK 48	1	0.950	0.0000	0.95	0.950	0.950	0.950	0.95
			DISCONTINUATION	18	0.778	0.1286	0.37	0.741	0.811	0.864	0.91
		200mg BID(N=47)	BASELINE	45	0.711	0.1783	0.24	0.650	0.741	0.823	1.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Magnesium	mmol/L	200mg BID(N=47)	SCREENING	43	0.713	0.1872	0.21	0.650	0.741	0.823	1.00
			WEEK 0	44	0.728	0.1814	0.24	0.658	0.782	0.864	1.07
			WEEK 1	44	0.764	0.1802	0.32	0.720	0.823	0.864	1.03
			WEEK 2	35	0.731	0.1993	0.30	0.658	0.782	0.864	1.03
			WEEK 3	27	0.706	0.1958	0.29	0.617	0.782	0.823	1.07
			WEEK 4	22	0.705	0.1902	0.30	0.650	0.782	0.823	0.91
			WEEK 8	3	0.676	0.2971	0.34	0.340	0.782	0.905	0.91
			WEEK 12	2	0.561	0.3697	0.30	0.300	0.561	0.823	0.82
			WEEK 16	1	0.230	0.0000	0.23	0.230	0.230	0.230	0.23
			WEEK 20	1	0.310	0.0000	0.31	0.310	0.310	0.310	0.31
			DISCONTINUATION	26	0.744	0.1827	0.32	0.658	0.782	0.864	0.99
Phosphate	mmol/L	100mg BID(N=21)	BASELINE	21	1.173	0.2254	0.84	1.066	1.130	1.227	1.87
			SCREENING	21	1.169	0.2273	0.84	1.033	1.130	1.227	1.87
			WEEK 0	17	1.099	0.1129	0.90	1.033	1.110	1.195	1.29
			WEEK 1	16	1.138	0.1907	0.84	1.033	1.098	1.195	1.68
			WEEK 2	17	1.148	0.1807	0.71	1.001	1.170	1.300	1.39
			WEEK 3	15	1.167	0.2440	0.74	1.001	1.162	1.324	1.55
			WEEK 4	12	1.096	0.2051	0.81	0.888	1.150	1.259	1.36
			WEEK 8	4	1.202	0.1757	0.97	1.079	1.225	1.324	1.39
		200mg BID(N=47)	BASELINE	44	1.147	0.2186	0.74	1.001	1.130	1.317	1.68

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Phosphate	mmol/L	100mg BID(N=21)	WEEK 12	2	1.244	0.0233	1.23	1.227	1.244	1.260	1.26
			WEEK 16	2	1.214	0.0191	1.20	1.200	1.214	1.227	1.23
			WEEK 20	2	1.355	0.2757	1.16	1.160	1.355	1.550	1.55
			WEEK 24	2	1.241	0.0718	1.19	1.190	1.241	1.292	1.29
			WEEK 28	2	1.068	0.0031	1.07	1.066	1.068	1.070	1.07
			WEEK 32	2	1.174	0.0757	1.12	1.120	1.174	1.227	1.23
			WEEK 36	2	1.079	0.0268	1.06	1.060	1.079	1.098	1.10
			WEEK 40	2	1.129	0.0439	1.10	1.098	1.129	1.160	1.16
			WEEK 48	1	1.098	0.0000	1.10	1.098	1.098	1.098	1.10
			DISCONTINUATION	17	1.101	0.1866	0.84	0.936	1.098	1.227	1.49
		200mg BID(N=47)	SCREENING	42	1.161	0.2198	0.78	1.001	1.162	1.324	1.68
			WEEK 0	43	1.125	0.2164	0.55	1.001	1.098	1.270	1.58
			WEEK 1	41	1.162	0.2157	0.71	1.020	1.195	1.292	1.58
			WEEK 2	35	1.134	0.2337	0.68	0.969	1.130	1.292	1.78
			WEEK 3	28	1.089	0.2156	0.71	0.936	1.069	1.270	1.61
			WEEK 4	22	1.031	0.2073	0.52	0.904	1.033	1.195	1.39
			WEEK 8	3	1.066	0.0566	1.00	1.001	1.098	1.100	1.10
			WEEK 12	2	1.157	0.1744	1.03	1.033	1.157	1.280	1.28
			WEEK 16	1	1.210	0.0000	1.21	1.210	1.210	1.210	1.21
			WEEK 20	1	1.320	0.0000	1.32	1.320	1.320	1.320	1.32

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Phosphate	mmol/L	200mg BID(N=47)	DISCONTINUATION	27	1.063	0.2296	0.36	0.969	1.098	1.195	1.52
Glucose	mmol/L	100mg BID(N=21)	BASELINE	21	6.010	1.8600	3.44	5.217	5.600	6.272	12.60
			SCREENING	21	5.960	1.9564	3.16	5.051	5.600	6.549	12.60
			WEEK 0	19	5.991	1.0541	4.61	5.273	5.883	6.549	8.71
			WEEK 1	19	6.337	1.7019	4.00	5.162	5.772	7.659	11.21
			WEEK 2	17	5.630	1.2679	4.10	4.773	5.495	6.216	9.49
			WEEK 3	15	5.723	1.0447	4.44	4.662	5.717	6.993	7.16
			WEEK 4	12	5.945	1.3444	4.33	4.759	5.883	6.716	8.71
			WEEK 8	4	5.493	1.8357	3.33	4.107	5.492	6.880	7.66
			WEEK 12	2	7.091	1.1179	6.30	6.300	7.091	7.881	7.88
			WEEK 16	2	5.870	1.3156	4.94	4.940	5.870	6.800	6.80
			WEEK 20	2	6.729	2.0213	5.30	5.300	6.729	8.159	8.16
			WEEK 24	2	5.537	1.0798	4.77	4.773	5.537	6.300	6.30
			WEEK 28	2	5.875	0.4596	5.55	5.550	5.875	6.200	6.20
			WEEK 32	2	5.714	1.2526	4.83	4.829	5.714	6.600	6.60
			WEEK 36	2	6.397	0.1368	6.30	6.300	6.397	6.494	6.49
			WEEK 40	2	6.524	0.7414	6.00	6.000	6.524	7.049	7.05
			WEEK 44	1	5.994	0.0000	5.99	5.994	5.994	5.994	5.99
			WEEK 48	1	6.605	0.0000	6.60	6.605	6.605	6.605	6.60
		200mg BID(N=47)	BASELINE	47	6.209	1.7533	3.94	5.051	5.828	6.771	12.43

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Glucose	mmol/L	100mg BID(N=21)	DISCONTINUATION	18	5.893	1.0840	4.72	5.273	5.522	6.000	8.60
		200mg BID(N=47)	SCREENING	46	6.042	1.5538	3.94	5.051	5.744	6.660	12.43
			WEEK 0	46	6.938	2.0248	4.27	5.606	6.272	7.937	14.15
			WEEK 1	44	6.029	1.5975	3.39	5.134	5.786	6.469	12.32
			WEEK 2	36	6.879	1.8937	4.44	5.245	6.299	8.325	12.27
			WEEK 3	31	6.729	1.6984	4.27	5.495	6.438	7.493	11.71
			WEEK 4	22	6.534	1.7671	4.33	5.495	5.908	6.605	11.82
			WEEK 8	3	5.789	0.7962	4.88	4.884	6.100	6.383	6.38
			WEEK 12	2	5.686	0.1216	5.60	5.600	5.686	5.772	5.77
			WEEK 16	2	5.803	0.9857	5.11	5.106	5.803	6.500	6.50
			WEEK 20	1	4.100	0.0000	4.10	4.100	4.100	4.100	4.10
			DISCONTINUATION	34	5.747	1.2169	3.72	5.051	5.384	6.161	9.99
Urea	mmol/L	100mg BID(N=21)	BASELINE	21	5.512	2.1143	3.57	4.100	5.355	6.069	13.21
			SCREENING	21	5.376	2.2543	2.14	3.927	5.355	6.069	13.21
			WEEK 0	20	5.462	1.4875	2.86	4.292	5.355	6.426	8.21
			WEEK 1	18	6.808	1.5971	3.93	5.712	6.742	7.854	9.64
			WEEK 2	17	5.712	1.4953	3.60	4.284	5.712	6.426	9.28
			WEEK 3	14	6.611	1.6502	3.57	5.355	6.605	7.497	10.00
			WEEK 4	11	6.916	2.0289	3.60	5.712	6.783	8.568	11.07
		200mg BID(N=47)	BASELINE	46	6.088	2.8186	1.43	3.927	5.712	7.140	14.64

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Urea	mmol/L	100mg BID(N=21)	WEEK 8	3	6.151	1.7708	4.64	4.641	5.712	8.100	8.10
			WEEK 12	2	6.963	0.7594	6.43	6.426	6.963	7.500	7.50
			WEEK 16	2	6.121	2.0923	4.64	4.641	6.121	7.600	7.60
			WEEK 20	2	7.827	0.0382	7.80	7.800	7.827	7.854	7.85
			WEEK 24	2	6.656	1.3350	5.71	5.712	6.656	7.600	7.60
			WEEK 28	2	7.442	0.9313	6.78	6.783	7.442	8.100	8.10
			WEEK 32	2	7.135	1.5068	6.07	6.069	7.135	8.200	8.20
			WEEK 36	2	7.556	0.9270	6.90	6.900	7.556	8.211	8.21
			WEEK 40	2	6.078	1.0218	5.36	5.355	6.078	6.800	6.80
			WEEK 48	1	6.783	0.0000	6.78	6.783	6.783	6.783	6.78
			DISCONTINUATION	18	6.101	2.9028	1.11	4.284	6.069	7.140	14.99
		200mg BID(N=47)	SCREENING	45	6.228	3.0114	1.43	3.927	5.712	7.140	14.99
			WEEK 0	44	6.544	2.9667	2.14	4.641	6.248	7.676	14.99
			WEEK 1	45	8.540	3.1091	2.86	6.783	8.400	9.996	17.85
			WEEK 2	37	8.595	3.4567	2.86	6.426	8.211	9.996	17.49
			WEEK 3	31	8.429	3.2863	2.14	6.426	8.211	9.996	16.78
			WEEK 4	22	8.216	3.3039	2.50	6.069	7.599	10.100	15.35
			WEEK 8	3	8.869	1.3139	7.85	7.854	8.400	10.353	10.35
			WEEK 12	2	7.506	0.9977	6.80	6.800	7.506	8.211	8.21
			WEEK 16	2	9.170	2.8709	7.14	7.140	9.170	11.200	11.20

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Urea	mmol/L	200mg BID(N=47)	WEEK 20	1	10.700	0.0000	10.70	10.700	10.700	10.700	10.70
			DISCONTINUATION	34	8.574	4.2143	2.50	5.712	6.962	11.067	21.42
Creatinine	umol/L	100mg BID(N=21)	BASELINE	21	73.553	22.8578	47.00	61.880	62.760	88.400	128.18
			SCREENING	21	73.259	23.1005	47.00	61.880	62.760	88.400	128.18
			WEEK 0	20	76.437	24.0905	44.20	61.000	70.280	93.705	126.41
			WEEK 1	19	82.000	25.4044	49.50	64.530	76.020	98.120	144.98
			WEEK 2	17	77.419	27.4639	39.00	61.880	70.720	88.400	133.48
			WEEK 3	15	74.821	24.5811	46.00	55.690	66.300	97.240	137.02
			WEEK 4	12	83.291	32.1450	43.00	59.230	73.370	104.755	152.05
			WEEK 8	4	68.885	22.2154	49.50	51.710	63.960	86.060	98.12
			WEEK 12	2	62.540	24.6922	45.08	45.080	62.540	80.000	80.00
			WEEK 16	2	65.810	24.3103	48.62	48.620	65.810	83.000	83.00
			WEEK 20	2	64.135	18.1939	51.27	51.270	64.135	77.000	77.00
			WEEK 24	2	67.135	22.4365	51.27	51.270	67.135	83.000	83.00
			WEEK 28	2	72.905	25.5902	54.81	54.810	72.905	91.000	91.00
			WEEK 32	2	61.750	17.3241	49.50	49.500	61.750	74.000	74.00
			WEEK 36	2	70.695	28.7156	50.39	50.390	70.695	91.000	91.00
			WEEK 40	2	72.460	26.2195	53.92	53.920	72.460	91.000	91.00
			WEEK 48	1	61.000	0.0000	61.00	61.000	61.000	61.000	61.00
		200mg BID(N=47)	BASELINE	47	87.629	34.4919	51.00	66.300	76.020	97.240	212.16

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Creatinine	umol/L	100mg BID(N=21)	DISCONTINUATION	18	83.984	28.1406	54.00	61.880	74.255	104.310	159.12
		200mg BID(N=47)	SCREENING	47	88.055	35.5865	44.00	66.300	78.680	99.000	221.00
			WEEK 0	45	88.645	37.0129	47.00	67.180	77.790	93.700	212.16
			WEEK 1	45	94.907	34.5417	46.00	70.720	88.400	98.000	203.32
			WEEK 2	37	96.064	35.3883	43.00	73.370	83.980	114.920	194.48
			WEEK 3	31	94.720	43.7917	53.04	67.180	79.560	114.920	234.26
			WEEK 4	22	89.422	37.7382	46.00	66.300	77.395	97.240	185.64
			WEEK 8	3	110.157	58.4936	75.00	75.000	77.790	177.680	177.68
			WEEK 12	2	81.875	5.4801	78.00	78.000	81.875	85.750	85.75
			WEEK 16	2	88.700	0.4243	88.40	88.400	88.700	89.000	89.00
			WEEK 20	1	74.000	0.0000	74.00	74.000	74.000	74.000	74.00
			DISCONTINUATION	35	100.730	47.6939	37.00	68.950	87.520	129.950	267.85
Creatine Kinase	ukat/L	100mg BID(N=21)	BASELINE	15	1.155	0.7335	0.35	0.667	0.850	1.428	2.78
			SCREENING	15	1.253	0.7730	0.35	0.667	1.084	1.832	2.78
			WEEK 0	13	0.846	0.5527	0.33	0.533	0.717	0.917	2.37
			WEEK 1	11	1.452	1.0945	0.25	0.733	1.200	1.584	3.98
			WEEK 2	13	1.636	1.2476	0.23	0.817	1.217	2.017	4.55
			WEEK 3	11	2.152	2.1767	0.30	1.150	1.217	2.734	7.90
			WEEK 4	10	2.613	2.9584	0.35	1.067	1.517	2.851	10.49
		200mg BID(N=47)	BASELINE	38	1.205	1.6087	0.23	0.433	0.800	1.334	9.47

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Creatine Kinase	ukat/L	100mg BID(N=21)	WEEK 8	3	2.484	1.9406	1.02	1.017	1.750	4.684	4.68
			WEEK 12	2	2.601	2.1925	1.05	1.050	2.601	4.151	4.15
			WEEK 16	2	2.467	2.3339	0.82	0.817	2.467	4.117	4.12
			WEEK 20	1	0.884	0.0000	0.88	0.884	0.884	0.884	0.88
			WEEK 24	2	1.817	0.8958	1.18	1.184	1.817	2.450	2.45
			WEEK 28	2	1.634	0.7544	1.10	1.100	1.634	2.167	2.17
			WEEK 32	2	2.075	1.1905	1.23	1.234	2.075	2.917	2.92
			WEEK 36	2	2.142	0.8369	1.55	1.550	2.142	2.734	2.73
			WEEK 40	2	3.242	2.6993	1.33	1.334	3.242	5.151	5.15
			WEEK 48	1	2.284	0.0000	2.28	2.284	2.284	2.284	2.28
			DISCONTINUATION	12	1.912	1.4118	0.30	1.092	1.359	2.217	4.83
		200mg BID(N=47)	SCREENING	36	1.281	1.6453	0.30	0.450	0.825	1.459	9.47
			WEEK 0	36	0.791	0.4406	0.23	0.425	0.658	1.234	1.87
			WEEK 1	38	1.722	2.8748	0.23	0.567	1.059	2.033	18.25
			WEEK 2	29	1.864	1.3267	0.40	0.867	1.334	2.784	5.67
			WEEK 3	24	1.746	1.6736	0.40	0.701	1.167	2.399	7.73
			WEEK 4	17	3.073	4.4822	0.42	0.867	2.017	2.350	18.82
			WEEK 8	3	1.873	0.7124	1.05	1.050	2.267	2.300	2.30
			WEEK 12	2	1.492	0.2475	1.32	1.317	1.492	1.667	1.67
			WEEK 16	1	0.867	0.0000	0.87	0.867	0.867	0.867	0.87

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Creatine Kinase	ukat/L	200mg BID(N=47)	WEEK 20	1	1.267	0.0000	1.27	1.267	1.267	1.267	1.27
			DISCONTINUATION	19	1.833	1.7839	0.35	0.517	1.400	2.084	5.87
Creatine Kinase MB	ug/L	200mg BID(N=47)	WEEK 0	1	41.263	0.0000	41.26	41.263	41.263	41.263	41.26
Lactate Dehydrogenase	ukat/L	100mg BID(N=21)	BASELINE	21	7.719	5.3516	2.72	3.234	6.201	9.335	23.00
			SCREENING	21	7.751	5.3244	2.72	3.684	6.201	9.335	23.00
			WEEK 0	18	7.360	5.2529	2.68	3.134	5.768	9.819	23.84
			WEEK 1	18	8.913	7.5744	2.98	4.101	6.260	10.669	34.94
			WEEK 2	17	9.848	8.7201	3.08	4.017	7.351	12.252	40.04
			WEEK 3	14	10.478	8.9215	3.15	4.384	7.993	13.453	37.74
			WEEK 4	12	10.699	10.9284	2.97	4.109	9.602	10.727	43.61
			WEEK 8	4	12.961	15.2722	4.27	4.993	5.868	20.929	35.84
			WEEK 12	2	5.409	1.2613	4.52	4.518	5.409	6.301	6.30
			WEEK 16	2	5.234	1.3438	4.28	4.284	5.234	6.185	6.18
			WEEK 20	2	5.426	1.4734	4.38	4.384	5.426	6.468	6.47
			WEEK 24	2	4.959	1.6385	3.80	3.801	4.959	6.118	6.12
			WEEK 28	2	5.051	1.9803	3.65	3.651	5.051	6.451	6.45
			WEEK 32	2	4.701	1.6738	3.52	3.517	4.701	5.885	5.88
			WEEK 36	2	5.401	1.1080	4.62	4.618	5.401	6.185	6.18
			WEEK 40	2	5.509	1.6149	4.37	4.368	5.509	6.651	6.65
		200mg BID(N=47)	BASELINE	46	8.477	12.4001	1.70	3.901	5.051	9.068	85.57

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Lactate Dehydrogenase	ukat/L	100mg BID(N=21)	DISCONTINUATION	17	12.592	8.1833	3.47	6.268	13.853	15.620	38.26
		200mg BID(N=47)	SCREENING	44	6.642	4.2800	1.70	3.442	5.309	8.252	22.85
			WEEK 0	44	8.652	9.1358	1.60	3.767	6.001	9.685	56.54
			WEEK 1	42	12.717	13.4421	1.87	4.718	8.085	13.136	70.26
			WEEK 2	35	11.751	10.3612	2.12	4.834	9.502	13.853	44.54
			WEEK 3	30	23.570	60.9472	2.00	5.634	7.927	15.336	339.80
			WEEK 4	21	14.485	17.9602	1.88	5.101	7.818	16.003	77.03
			WEEK 8	3	4.506	1.9373	2.35	2.350	5.068	6.101	6.10
			WEEK 12	2	5.809	0.0589	5.77	5.768	5.809	5.851	5.85
			WEEK 16	1	6.351	0.0000	6.35	6.351	6.351	6.351	6.35
			WEEK 20	1	6.401	0.0000	6.40	6.401	6.401	6.401	6.40
			DISCONTINUATION	25	15.420	19.5094	2.55	6.835	9.052	15.020	99.85
LDH Isoenzyme 1	ukat/L	100mg BID(N=21)	BASELINE	1	0.023	0.0000	0.02	0.023	0.023	0.023	0.02
			SCREENING	1	0.023	0.0000	0.02	0.023	0.023	0.023	0.02
			WEEK 0	1	0.014	0.0000	0.01	0.014	0.014	0.014	0.01
		200mg BID(N=47)	WEEK 1	1	7.785	0.0000	7.78	7.785	7.785	7.785	7.78
			WEEK 2	4	0.013	0.0021	0.01	0.012	0.013	0.015	0.02
			WEEK 4	2	0.014	0.0035	0.01	0.011	0.014	0.016	0.02
LDH Isoenzyme 2	ukat/L	100mg BID(N=21)	BASELINE	1	0.031	0.0000	0.03	0.031	0.031	0.031	0.03
			SCREENING	1	0.031	0.0000	0.03	0.031	0.031	0.031	0.03

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time (Safety analysis set)

					Result						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
LDH Isoenzyme 2	ukat/L	100mg BID(N=21)	WEEK 0	1	0.037	0.0000	0.04	0.037	0.037	0.037	0.04
		200mg BID(N=47)	WEEK 2	4	0.034	0.0049	0.03	0.031	0.032	0.037	0.04
			WEEK 4	2	0.034	0.0014	0.03	0.033	0.034	0.035	0.04
LDH Isoenzyme 3	ukat/L	100mg BID(N=21)	BASELINE	1	0.024	0.0000	0.02	0.024	0.024	0.024	0.02
			SCREENING	1	0.024	0.0000	0.02	0.024	0.024	0.024	0.02
			WEEK 0	1	0.027	0.0000	0.03	0.027	0.027	0.027	0.03
		200mg BID(N=47)	WEEK 2	4	0.028	0.0027	0.02	0.027	0.029	0.030	0.03
			WEEK 4	2	0.029	0.0000	0.03	0.029	0.029	0.029	0.03
LDH Isoenzyme 4	ukat/L	100mg BID(N=21)	BASELINE	1	0.009	0.0000	0.01	0.009	0.009	0.009	0.01
			SCREENING	1	0.009	0.0000	0.01	0.009	0.009	0.009	0.01
			WEEK 0	1	0.011	0.0000	0.01	0.011	0.011	0.011	0.01
		200mg BID(N=47)	WEEK 2	4	0.015	0.0035	0.01	0.012	0.015	0.018	0.02
			WEEK 4	2	0.016	0.0035	0.01	0.013	0.016	0.018	0.02
LDH Isoenzyme 5	ukat/L	100mg BID(N=21)	BASELINE	1	0.013	0.0000	0.01	0.013	0.013	0.013	0.01
			SCREENING	1	0.013	0.0000	0.01	0.013	0.013	0.013	0.01
			WEEK 0	1	0.012	0.0000	0.01	0.012	0.012	0.012	0.01
		200mg BID(N=47)	WEEK 2	4	0.010	0.0045	0.01	0.007	0.010	0.013	0.02

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.1 Haematology and clinical chemistry laboratory variables over time
(Safety analysis set)

				Result							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
			WEEK 4	2	0.008	0.0014	0.01	0.007	0.008	0.009	0.01

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile.
SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB010
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Hemoglobin	g/L	100mg BID(N=21)	WEEK 0	20	-1.450	5.9336	-16.00	-5.500	-1.000	2.500	9.00
			WEEK 1	19	3.579	9.5296	-15.00	-2.000	6.000	7.000	27.00
			WEEK 2	17	1.824	8.8193	-13.00	-4.000	3.000	7.000	20.00
			WEEK 3	15	0.067	8.2934	-14.00	-5.000	-2.000	5.000	19.00
			WEEK 4	13	1.154	11.7321	-19.00	-6.000	5.000	11.000	15.00
			WEEK 8	4	2.000	10.6145	-10.00	-6.500	2.000	10.500	14.00
			WEEK 12	2	14.500	19.0919	1.00	1.000	14.500	28.000	28.00
			WEEK 16	2	14.000	22.6274	-2.00	-2.000	14.000	30.000	30.00
			WEEK 20	2	11.500	19.0919	-2.00	-2.000	11.500	25.000	25.00
			WEEK 24	2	18.000	18.3848	5.00	5.000	18.000	31.000	31.00
			WEEK 28	2	13.500	16.2635	2.00	2.000	13.500	25.000	25.00
			WEEK 32	2	16.500	13.4350	7.00	7.000	16.500	26.000	26.00
			WEEK 36	2	14.500	19.0919	1.00	1.000	14.500	28.000	28.00
			WEEK 40	2	16.000	21.2132	1.00	1.000	16.000	31.000	31.00
			WEEK 44	1	7.000	0.0000	7.00	7.000	7.000	7.000	7.00
			WEEK 48	1	-1.000	0.0000	-1.00	-1.000	-1.000	-1.000	-1.00
			DISCONTINUATION	19	-3.895	18.8794	-51.00	-18.000	1.000	11.000	21.00
		200mg BID(N=47)	WEEK 0	38	0.158	8.5092	-14.00	-6.000	-0.500	5.000	24.00
			WEEK 1	44	8.182	8.2442	-13.00	3.000	8.500	13.000	27.00
			WEEK 2	37	3.622	10.8253	-24.00	-2.000	6.000	11.000	22.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Hemoglobin	g/L	200mg BID(N=47)	WEEK 3	31	2.161	14.6767	-44.00	-4.000	4.000	11.000	27.00
			WEEK 4	22	-1.955	12.9706	-32.00	-10.000	-0.500	5.000	21.00
			WEEK 8	3	7.667	0.5774	7.00	7.000	8.000	8.000	8.00
			WEEK 12	2	4.500	10.6066	-3.00	-3.000	4.500	12.000	12.00
			WEEK 16	2	3.500	4.9497	0.00	0.000	3.500	7.000	7.00
			WEEK 20	1	24.000	0.0000	24.00	24.000	24.000	24.000	24.00
			DISCONTINUATION	36	-1.611	14.3572	-22.00	-13.500	-3.000	9.500	38.00
Erythrocytes	10^12/L	100mg BID(N=21)	WEEK 0	20	0.004	0.2315	-0.56	-0.100	-0.005	0.125	0.51
			WEEK 1	19	0.184	0.3110	-0.53	0.010	0.200	0.290	1.11
			WEEK 2	17	0.118	0.2665	-0.39	-0.080	0.140	0.280	0.58
			WEEK 3	15	0.039	0.2201	-0.30	-0.130	0.000	0.200	0.40
			WEEK 4	13	0.066	0.3157	-0.50	-0.170	0.200	0.260	0.49
			WEEK 8	4	0.110	0.2474	-0.22	-0.080	0.180	0.300	0.30
			WEEK 12	2	0.350	0.4950	0.00	0.000	0.350	0.700	0.70
			WEEK 16	2	0.300	0.7071	-0.20	-0.200	0.300	0.800	0.80
			WEEK 20	2	0.200	0.5657	-0.20	-0.200	0.200	0.600	0.60
			WEEK 24	2	0.400	0.5657	0.00	0.000	0.400	0.800	0.80
			WEEK 28	2	0.400	0.5657	0.00	0.000	0.400	0.800	0.80
			WEEK 32	2	0.450	0.4950	0.10	0.100	0.450	0.800	0.80
			WEEK 36	2	0.450	0.6364	0.00	0.000	0.450	0.900	0.90

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Erythrocytes	10^12/L	100mg BID(N=21)	WEEK 40	2	0.450	0.7778	-0.10	-0.100	0.450	1.000	1.00
			WEEK 44	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 48	1	-0.300	0.0000	-0.30	-0.300	-0.300	-0.300	-0.30
			DISCONTINUATION	19	-0.046	0.5775	-1.30	-0.480	0.020	0.470	1.09
		200mg BID(N=47)	WEEK 0	38	0.050	0.3684	-0.43	-0.180	-0.025	0.170	1.51
			WEEK 1	44	0.320	0.2933	-0.25	0.120	0.285	0.490	1.18
			WEEK 2	37	0.174	0.3468	-0.75	-0.010	0.230	0.400	0.92
			WEEK 3	31	0.146	0.4025	-0.84	-0.060	0.150	0.490	1.03
			WEEK 4	22	-0.044	0.4219	-1.05	-0.200	-0.035	0.290	0.60
			WEEK 8	3	0.103	0.1589	-0.08	-0.080	0.190	0.200	0.20
			WEEK 12	2	-0.070	0.5233	-0.44	-0.440	-0.070	0.300	0.30
			WEEK 16	2	-0.100	0.2828	-0.30	-0.300	-0.100	0.100	0.10
			WEEK 20	1	0.600	0.0000	0.60	0.600	0.600	0.600	0.60
			DISCONTINUATION	35	0.001	0.4996	-0.90	-0.370	-0.080	0.310	1.47
Leukocytes	10^9/L	100mg BID(N=21)	WEEK 0	20	0.054	1.3997	-2.60	-0.700	-0.000	0.750	3.50
			WEEK 1	19	0.013	2.1530	-3.50	-1.100	-0.350	0.500	5.40
			WEEK 2	17	-0.008	1.5572	-2.20	-0.800	0.100	0.400	3.70
			WEEK 3	15	-1.287	1.7003	-4.40	-2.600	-0.800	0.400	0.90
			WEEK 4	13	-1.259	1.3974	-4.80	-1.400	-0.700	-0.570	0.40
			WEEK 8	4	-1.100	1.4629	-2.40	-1.950	-1.500	-0.250	1.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Leukocytes	10^9/L	100mg BID(N=21)	WEEK 12	2	-0.500	0.7071	-1.00	-1.000	-0.500	0.000	0.00
			WEEK 16	2	-0.550	0.9192	-1.20	-1.200	-0.550	0.100	0.10
			WEEK 20	2	0.450	1.4849	-0.60	-0.600	0.450	1.500	1.50
			WEEK 24	2	0.550	1.9092	-0.80	-0.800	0.550	1.900	1.90
			WEEK 28	2	-1.550	1.3435	-2.50	-2.500	-1.550	-0.600	-0.60
			WEEK 32	2	0.200	1.9799	-1.20	-1.200	0.200	1.600	1.60
			WEEK 36	2	-0.250	0.4950	-0.60	-0.600	-0.250	0.100	0.10
			WEEK 40	2	0.350	1.0607	-0.40	-0.400	0.350	1.100	1.10
			WEEK 44	1	0.200	0.0000	0.20	0.200	0.200	0.200	0.20
			WEEK 48	1	1.100	0.0000	1.10	1.100	1.100	1.100	1.10
			DISCONTINUATION	19	-0.445	3.4437	-5.10	-2.500	-0.600	0.100	8.00
		200mg BID(N=47)	WEEK 0	38	0.578	2.7293	-4.30	-0.650	0.100	1.000	10.90
			WEEK 1	44	0.866	3.1939	-8.70	-0.850	0.935	2.050	9.70
			WEEK 2	37	-0.501	2.8046	-8.50	-1.700	-0.500	0.900	9.10
			WEEK 3	31	-0.774	3.4926	-8.00	-3.000	-0.800	1.600	9.60
			WEEK 4	22	-1.016	3.4302	-7.60	-2.700	-1.450	0.600	9.70
			WEEK 8	3	-4.033	4.8645	-9.60	-9.600	-1.900	-0.600	-0.60
			WEEK 12	2	-4.750	6.1518	-9.10	-9.100	-4.750	-0.400	-0.40
			WEEK 16	2	-4.700	4.3841	-7.80	-7.800	-4.700	-1.600	-1.60
			WEEK 20	1	-7.600	0.0000	-7.60	-7.600	-7.600	-7.600	-7.60

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Leukocytes	10^9/L	200mg BID(N=47)	DISCONTINUATION	36	0.350	3.4494	-7.40	-1.850	-0.600	2.450	8.45
Basophils	10^9/L	100mg BID(N=21)	WEEK 0	19	0.009	0.0327	-0.05	0.000	0.000	0.020	0.10
			WEEK 1	19	0.014	0.0538	-0.05	0.000	0.000	0.020	0.21
			WEEK 2	17	-0.010	0.0229	-0.07	0.000	0.000	0.000	0.01
			WEEK 3	15	-0.012	0.0227	-0.06	-0.040	0.000	0.000	0.01
			WEEK 4	13	-0.009	0.0180	-0.06	-0.010	0.000	0.000	0.00
			WEEK 8	4	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 12	2	-0.005	0.0071	-0.01	-0.010	-0.005	0.000	0.00
			WEEK 16	2	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 20	2	0.005	0.0071	0.00	0.000	0.005	0.010	0.01
			WEEK 24	2	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 28	2	0.005	0.0071	0.00	0.000	0.005	0.010	0.01
			WEEK 32	2	0.005	0.0071	0.00	0.000	0.005	0.010	0.01
			WEEK 36	2	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 40	2	0.010	0.0141	0.00	0.000	0.010	0.020	0.02
			WEEK 44	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 48	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			DISCONTINUATION	19	-0.009	0.0361	-0.07	-0.040	0.000	0.000	0.10
		200mg BID(N=47)	WEEK 0	36	0.005	0.0613	-0.24	0.000	0.000	0.000	0.15
			WEEK 1	42	-0.005	0.0341	-0.14	-0.009	0.000	0.000	0.10

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Basophils	10^9/L	200mg BID(N=47)	WEEK 2	35	-0.011	0.0350	-0.14	-0.020	0.000	0.000	0.07
			WEEK 3	28	-0.023	0.0346	-0.14	-0.030	-0.010	0.000	0.00
			WEEK 4	20	-0.026	0.0394	-0.14	-0.030	-0.010	0.000	0.00
			WEEK 8	2	-0.010	0.0141	-0.02	-0.020	-0.010	0.000	0.00
			WEEK 12	2	-0.135	0.1485	-0.24	-0.240	-0.135	-0.030	-0.03
			WEEK 16	2	-0.075	0.0919	-0.14	-0.140	-0.075	-0.010	-0.01
			WEEK 20	1	-0.020	0.0000	-0.02	-0.020	-0.020	-0.020	-0.02
			DISCONTINUATION	31	-0.007	0.0405	-0.11	-0.030	0.000	0.000	0.09
Eosinophils	10^9/L	100mg BID(N=21)	WEEK 0	18	0.033	0.1459	-0.20	0.000	0.000	0.060	0.53
			WEEK 1	19	0.009	0.0588	-0.10	-0.010	0.000	0.050	0.15
			WEEK 2	17	0.019	0.0764	-0.10	-0.020	0.000	0.070	0.20
			WEEK 3	15	0.025	0.0922	-0.10	-0.030	0.000	0.060	0.25
			WEEK 4	13	0.014	0.0868	-0.10	-0.020	0.000	0.000	0.22
			WEEK 8	4	-0.078	0.0932	-0.20	-0.150	-0.055	-0.005	0.00
			WEEK 12	2	0.110	0.1556	0.00	0.000	0.110	0.220	0.22
			WEEK 16	2	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 20	2	0.065	0.0495	0.03	0.030	0.065	0.100	0.10
			WEEK 24	2	0.005	0.0071	0.00	0.000	0.005	0.010	0.01
			WEEK 28	2	0.005	0.0071	0.00	0.000	0.005	0.010	0.01
			WEEK 32	2	0.055	0.0636	0.01	0.010	0.055	0.100	0.10

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Eosinophils	10^9/L	100mg BID(N=21)	WEEK 36	2	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 40	2	-0.005	0.0071	-0.01	-0.010	-0.005	0.000	0.00
			WEEK 44	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 48	1	0.100	0.0000	0.10	0.100	0.100	0.100	0.10
			DISCONTINUATION	19	-0.049	0.0981	-0.20	-0.100	-0.050	0.000	0.19
		200mg BID(N=47)	WEEK 0	37	-0.021	0.2205	-1.21	-0.010	0.000	0.050	0.30
			WEEK 1	42	-0.046	0.2054	-1.08	-0.080	0.000	0.040	0.20
			WEEK 2	35	-0.082	0.2268	-1.21	-0.100	-0.030	0.010	0.15
			WEEK 3	28	-0.053	0.1269	-0.52	-0.100	-0.014	0.010	0.09
			WEEK 4	20	-0.059	0.1251	-0.40	-0.100	-0.041	0.020	0.10
			WEEK 8	2	-0.015	0.0064	-0.02	-0.019	-0.015	-0.010	-0.01
			WEEK 12	2	-0.305	0.4455	-0.62	-0.620	-0.305	0.010	0.01
			WEEK 16	2	-0.335	0.5445	-0.72	-0.720	-0.335	0.050	0.05
			WEEK 20	1	0.150	0.0000	0.15	0.150	0.150	0.150	0.15
			DISCONTINUATION	31	-0.093	0.2349	-1.08	-0.120	-0.050	0.000	0.23
Monocytes	10^9/L	100mg BID(N=21)	WEEK 0	19	0.020	0.3003	-0.70	-0.120	0.000	0.200	0.72
			WEEK 1	19	-0.186	0.1763	-0.56	-0.300	-0.200	-0.040	0.12
			WEEK 2	17	-0.229	0.1692	-0.50	-0.340	-0.200	-0.100	0.00
			WEEK 3	15	-0.327	0.1675	-0.65	-0.400	-0.390	-0.200	-0.08
			WEEK 4	13	-0.313	0.1529	-0.56	-0.400	-0.300	-0.200	-0.10

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Monocytes	10^9/L	100mg BID(N=21)	WEEK 8	4	-0.250	0.2380	-0.40	-0.400	-0.350	-0.100	0.10
			WEEK 12	2	0.250	0.3536	0.00	0.000	0.250	0.500	0.50
			WEEK 16	2	-0.200	0.2828	-0.40	-0.400	-0.200	0.000	0.00
			WEEK 20	2	-0.250	0.0707	-0.30	-0.300	-0.250	-0.200	-0.20
			WEEK 24	2	-0.250	0.2121	-0.40	-0.400	-0.250	-0.100	-0.10
			WEEK 28	2	-0.200	0.2828	-0.40	-0.400	-0.200	0.000	0.00
			WEEK 32	2	-0.300	0.2828	-0.50	-0.500	-0.300	-0.100	-0.10
			WEEK 36	2	-0.250	0.0707	-0.30	-0.300	-0.250	-0.200	-0.20
			WEEK 40	2	-0.250	0.2121	-0.40	-0.400	-0.250	-0.100	-0.10
			WEEK 44	1	-0.200	0.0000	-0.20	-0.200	-0.200	-0.200	-0.20
			WEEK 48	1	-0.200	0.0000	-0.20	-0.200	-0.200	-0.200	-0.20
			DISCONTINUATION	19	-0.236	0.3170	-0.80	-0.400	-0.300	-0.060	0.58
		200mg BID(N=47)	WEEK 0	37	-0.069	0.2175	-0.62	-0.200	-0.070	0.010	0.50
			WEEK 1	42	-0.331	0.2689	-1.16	-0.490	-0.277	-0.180	0.19
			WEEK 2	35	-0.380	0.2952	-1.10	-0.550	-0.300	-0.150	0.11
			WEEK 3	28	-0.350	0.2474	-1.00	-0.460	-0.335	-0.270	0.25
			WEEK 4	20	-0.337	0.2109	-0.73	-0.479	-0.285	-0.200	0.05
			WEEK 8	3	0.113	0.2686	-0.08	-0.080	0.000	0.420	0.42
			WEEK 12	2	-0.190	0.2687	-0.38	-0.380	-0.190	0.000	0.00
			WEEK 16	2	-0.140	0.4808	-0.48	-0.480	-0.140	0.200	0.20

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Monocytes	10^9/L	200mg BID(N=47)	WEEK 20	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			DISCONTINUATION	33	-0.415	0.4243	-1.20	-0.680	-0.480	-0.270	0.70
Lymphocytes	10^9/L	100mg BID(N=21)	WEEK 0	19	0.123	0.4418	-0.60	-0.200	0.000	0.400	0.90
			WEEK 1	19	0.203	0.4089	-0.20	-0.074	0.100	0.300	1.49
			WEEK 2	17	0.255	0.3766	-0.20	0.070	0.160	0.300	1.44
			WEEK 3	15	0.049	0.4837	-0.50	-0.300	0.100	0.160	1.60
			WEEK 4	13	-0.058	0.2513	-0.50	-0.180	0.000	0.100	0.50
			WEEK 8	4	0.025	0.2986	-0.30	-0.200	0.000	0.250	0.40
			WEEK 12	2	0.100	0.4243	-0.20	-0.200	0.100	0.400	0.40
			WEEK 16	2	0.150	0.3536	-0.10	-0.100	0.150	0.400	0.40
			WEEK 20	2	0.150	0.2121	0.00	0.000	0.150	0.300	0.30
			WEEK 24	2	0.100	0.2828	-0.10	-0.100	0.100	0.300	0.30
			WEEK 28	2	-0.050	0.4950	-0.40	-0.400	-0.050	0.300	0.30
			WEEK 32	2	0.000	0.5657	-0.40	-0.400	0.000	0.400	0.40
			WEEK 36	2	0.150	0.4950	-0.20	-0.200	0.150	0.500	0.50
			WEEK 40	2	0.050	0.6364	-0.40	-0.400	0.050	0.500	0.50
			WEEK 44	1	0.500	0.0000	0.50	0.500	0.500	0.500	0.50
			WEEK 48	1	0.400	0.0000	0.40	0.400	0.400	0.400	0.40
			DISCONTINUATION	19	0.242	0.7664	-0.40	-0.170	0.000	0.400	2.93
		200mg BID(N=47)	WEEK 0	37	0.009	0.3016	-0.70	-0.128	-0.010	0.200	0.50

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Lymphocytes	10^9/L	200mg BID(N=47)	WEEK 1	42	0.283	0.5196	-0.35	-0.100	0.185	0.490	2.30
			WEEK 2	35	0.013	0.4264	-1.40	-0.180	0.000	0.223	1.00
			WEEK 3	29	-0.076	0.4334	-1.80	-0.200	0.000	0.160	0.42
			WEEK 4	20	0.060	0.4715	-0.50	-0.195	-0.050	0.181	1.70
			WEEK 8	3	0.434	0.6990	-0.12	-0.118	0.200	1.220	1.22
			WEEK 12	2	1.060	1.0748	0.30	0.300	1.060	1.820	1.82
			WEEK 16	2	0.510	0.5798	0.10	0.100	0.510	0.920	0.92
			WEEK 20	1	0.400	0.0000	0.40	0.400	0.400	0.400	0.40
			DISCONTINUATION	33	-0.037	0.5731	-2.40	-0.250	-0.050	0.300	0.85
Neutrophils	10^9/L	100mg BID(N=21)	WEEK 0	18	-0.236	1.0591	-1.90	-0.800	-0.300	0.500	2.50
			WEEK 1	18	0.064	2.0603	-3.10	-1.000	-0.300	0.600	5.30
			WEEK 2	17	-0.089	1.3327	-2.00	-0.800	-0.400	0.670	3.90
			WEEK 3	15	-0.979	1.3891	-3.50	-1.900	-0.800	-0.150	1.00
			WEEK 4	13	-0.897	1.2170	-3.90	-1.100	-0.600	-0.300	0.60
			WEEK 8	4	-0.725	1.0532	-1.90	-1.500	-0.800	0.050	0.60
			WEEK 12	2	-0.900	0.9899	-1.60	-1.600	-0.900	-0.200	-0.20
			WEEK 16	2	-0.400	0.4243	-0.70	-0.700	-0.400	-0.100	-0.10
			WEEK 20	2	0.500	1.1314	-0.30	-0.300	0.500	1.300	1.30
			WEEK 24	2	0.700	1.5556	-0.40	-0.400	0.700	1.800	1.80
			WEEK 28	2	-1.300	1.9799	-2.70	-2.700	-1.300	0.100	0.10

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

				Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Neutrophils	10^9/L	100mg BID(N=21)	WEEK 32	2	0.450	1.2021	-0.40	-0.400	0.450	1.300	1.30
			WEEK 36	2	-0.100	0.0000	-0.10	-0.100	-0.100	-0.100	-0.10
			WEEK 40	2	0.550	0.3536	0.30	0.300	0.550	0.800	0.80
			WEEK 44	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 48	1	1.000	0.0000	1.00	1.000	1.000	1.000	1.00
			DISCONTINUATION	18	-0.671	2.8029	-4.40	-2.400	-0.840	-0.200	8.80
		200mg BID(N=47)	WEEK 0	35	0.728	2.5859	-3.20	-0.590	0.210	1.300	10.46
			WEEK 1	40	1.112	3.2530	-8.30	-0.480	1.050	2.189	9.60
			WEEK 2	33	0.074	2.7295	-8.30	-0.800	0.000	1.200	9.18
			WEEK 3	28	-0.095	3.3780	-8.10	-1.650	-0.350	1.100	9.65
			WEEK 4	17	-0.559	3.8456	-7.70	-2.040	-0.840	1.100	10.35
			WEEK 8	2	-5.570	5.8407	-9.70	-9.700	-5.570	-1.440	-1.44
			WEEK 12	2	-4.970	6.1235	-9.30	-9.300	-4.970	-0.640	-0.64
			WEEK 16	2	-4.520	5.0629	-8.10	-8.100	-4.520	-0.940	-0.94
			WEEK 20	1	-8.200	0.0000	-8.20	-8.200	-8.200	-8.200	-8.20
			DISCONTINUATION	30	0.741	3.1592	-7.07	-0.900	-0.010	2.160	8.02
Platelets	10^9/L	100mg BID(N=21)	WEEK 0	20	-5.100	33.0596	-65.00	-30.000	1.000	17.000	72.00
			WEEK 1	19	-2.579	48.3015	-103.00	-19.000	2.000	15.000	111.00
			WEEK 2	17	-5.941	60.9933	-183.00	-24.000	1.000	16.000	94.00
			WEEK 3	15	-17.333	47.6140	-113.00	-38.000	-10.000	10.000	61.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Platelets	10^9/L	100mg BID(N=21)	WEEK 4	13	-24.769	58.3355	-142.00	-42.000	-28.000	-8.000	92.00
			WEEK 8	4	-19.000	65.4217	-91.00	-68.000	-24.000	30.000	63.00
			WEEK 12	2	-1.500	27.5772	-21.00	-21.000	-1.500	18.000	18.00
			WEEK 16	2	18.000	31.1127	-4.00	-4.000	18.000	40.000	40.00
			WEEK 20	2	31.500	40.3051	3.00	3.000	31.500	60.000	60.00
			WEEK 24	2	35.000	52.3259	-2.00	-2.000	35.000	72.000	72.00
			WEEK 28	2	25.000	24.0416	8.00	8.000	25.000	42.000	42.00
			WEEK 32	2	14.000	8.4853	8.00	8.000	14.000	20.000	20.00
			WEEK 36	2	22.500	30.4056	1.00	1.000	22.500	44.000	44.00
			WEEK 40	2	42.500	37.4767	16.00	16.000	42.500	69.000	69.00
			WEEK 44	1	58.000	0.0000	58.00	58.000	58.000	58.000	58.00
			WEEK 48	1	102.000	0.0000	102.00	102.000	102.000	102.000	102.00
			DISCONTINUATION	19	-29.368	83.6077	-194.00	-77.000	-46.000	0.000	136.00
		200mg BID(N=47)	WEEK 0	38	2.632	40.7805	-90.00	-17.000	3.500	16.000	140.00
			WEEK 1	44	41.932	67.0562	-78.00	6.000	27.500	68.000	310.00
			WEEK 2	37	34.027	68.4903	-96.00	6.000	20.000	53.000	266.00
			WEEK 3	31	-6.387	70.0327	-186.00	-32.000	-14.000	14.000	185.00
			WEEK 4	22	-16.273	60.3057	-153.00	-40.000	-27.500	33.000	83.00
			WEEK 8	3	-23.333	135.6478	-168.00	-168.000	-3.000	101.000	101.00
			WEEK 12	2	-45.500	212.8391	-196.00	-196.000	-45.500	105.000	105.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Platelets	10^9/L	200mg BID(N=47)	WEEK 16	2	-40.500	190.2117	-175.00	-175.000	-40.500	94.000	94.00
			WEEK 20	1	91.000	0.0000	91.00	91.000	91.000	91.000	91.00
			DISCONTINUATION	35	-13.771	86.7173	-203.00	-66.000	-18.000	25.000	183.00
Activated Partial Thromboplastin Time	sec	100mg BID(N=21)	WEEK 0	17	-1.006	3.3715	-7.50	-2.300	-1.000	0.600	4.40
			WEEK 1	12	-1.508	4.3272	-9.00	-4.250	-1.350	1.250	5.90
			WEEK 2	14	2.764	11.3415	-9.00	-0.700	0.650	2.400	39.40
			WEEK 3	12	-0.025	4.4770	-9.00	-2.000	-0.800	2.550	9.80
			WEEK 4	10	-0.530	4.7126	-11.00	-1.900	-0.450	2.000	7.70
			WEEK 8	4	17.675	36.4194	-1.10	-0.800	-0.250	36.150	72.30
			WEEK 12	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 16	1	-1.400	0.0000	-1.40	-1.400	-1.400	-1.400	-1.40
			WEEK 20	1	-0.900	0.0000	-0.90	-0.900	-0.900	-0.900	-0.90
			WEEK 24	2	2.900	6.3640	-1.60	-1.600	2.900	7.400	7.40
			WEEK 28	2	14.850	23.1224	-1.50	-1.500	14.850	31.200	31.20
			WEEK 32	2	9.050	15.7685	-2.10	-2.100	9.050	20.200	20.20
			WEEK 36	2	2.550	5.8690	-1.60	-1.600	2.550	6.700	6.70
			WEEK 40	2	1.900	5.2326	-1.80	-1.800	1.900	5.600	5.60
			WEEK 44	1	2.100	0.0000	2.10	2.100	2.100	2.100	2.10
			DISCONTINUATION	16	-1.469	5.1968	-11.00	-5.300	-0.500	2.200	8.00
		200mg BID(N=47)	WEEK 0	27	1.344	11.5887	-21.70	-3.500	-0.300	2.300	47.30

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Activated Partial Thromboplastin Time	sec	200mg BID(N=47)	WEEK 1	36	-0.703	4.8938	-13.80	-2.750	0.000	2.300	8.00
			WEEK 2	28	2.889	9.6063	-11.10	-1.000	0.200	2.650	37.80
			WEEK 3	24	4.600	15.7787	-14.40	-1.500	1.750	4.550	59.30
			WEEK 4	18	2.011	7.8148	-9.60	-1.800	0.100	3.500	22.20
			WEEK 8	2	0.700	3.6770	-1.90	-1.900	0.700	3.300	3.30
			WEEK 12	1	1.800	0.0000	1.80	1.800	1.800	1.800	1.80
			WEEK 16	1	5.000	0.0000	5.00	5.000	5.000	5.000	5.00
			WEEK 20	1	0.400	0.0000	0.40	0.400	0.400	0.400	0.40
			DISCONTINUATION	23	2.787	10.6792	-9.40	-5.300	-0.200	6.700	36.20
Prothrombin Intl. Normalized Ratio	[ratio]	100mg BID(N=21)	WEEK 0	17	-0.039	0.1031	-0.26	-0.100	0.000	0.000	0.10
			WEEK 1	13	0.043	0.3687	-0.23	-0.100	0.000	0.000	1.24
			WEEK 2	14	0.113	0.5818	-0.20	-0.100	0.000	0.000	2.12
			WEEK 3	13	0.048	0.3687	-0.20	-0.100	-0.030	0.000	1.26
			WEEK 4	10	-0.014	0.1111	-0.20	-0.060	-0.020	0.010	0.21
			WEEK 8	4	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 12	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 16	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 20	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 24	2	-0.050	0.0707	-0.10	-0.100	-0.050	0.000	0.00
			WEEK 28	2	0.000	0.0000	0.00	0.000	0.000	0.000	0.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Prothrombin Intl. Normalized Ratio	[ratio]	100mg BID(N=21)	WEEK 32	2	-0.050	0.0707	-0.10	-0.100	-0.050	0.000	0.00
			WEEK 36	2	-0.050	0.0707	-0.10	-0.100	-0.050	0.000	0.00
			WEEK 40	2	-0.100	0.0000	-0.10	-0.100	-0.100	-0.100	-0.10
			WEEK 44	1	-0.100	0.0000	-0.10	-0.100	-0.100	-0.100	-0.10
			WEEK 48	1	-0.100	0.0000	-0.10	-0.100	-0.100	-0.100	-0.10
			DISCONTINUATION	17	-0.022	0.1106	-0.30	-0.030	0.000	0.030	0.11
		200mg BID(N=47)	WEEK 0	30	0.022	0.0994	-0.12	0.000	0.000	0.040	0.40
			WEEK 1	39	-0.005	0.1236	-0.40	-0.100	0.000	0.050	0.40
			WEEK 2	32	0.076	0.3405	-0.12	-0.075	0.000	0.065	1.60
			WEEK 3	27	0.113	0.4281	-0.15	-0.050	0.000	0.100	2.10
			WEEK 4	20	0.083	0.4284	-0.20	-0.100	-0.060	0.025	1.50
			WEEK 8	3	-0.057	0.0493	-0.09	-0.090	-0.080	0.000	0.00
			WEEK 12	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00
			WEEK 16	2	0.040	0.0849	-0.02	-0.020	0.040	0.100	0.10
			WEEK 20	1	-0.100	0.0000	-0.10	-0.100	-0.100	-0.100	-0.10
			DISCONTINUATION	25	0.278	0.7365	-0.20	-0.010	0.050	0.170	3.10
Prothrombin Time	sec	100mg BID(N=21)	WEEK 0	18	-0.428	1.5744	-5.30	-0.800	-0.200	0.300	2.90
			WEEK 1	14	0.371	3.5164	-5.00	-0.600	-0.200	0.300	11.10
			WEEK 2	15	1.167	4.9997	-2.10	-0.700	-0.300	0.500	18.80
			WEEK 3	13	0.592	3.3871	-1.90	-0.600	-0.300	-0.200	11.30

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Prothrombin Time	sec	100mg BID(N=21)	WEEK 4	11	-0.064	1.4479	-2.10	-0.900	-0.400	0.100	3.20
			WEEK 8	4	-0.250	0.1732	-0.40	-0.400	-0.250	-0.100	-0.10
			WEEK 12	1	0.300	0.0000	0.30	0.300	0.300	0.300	0.30
			WEEK 16	1	-0.600	0.0000	-0.60	-0.600	-0.600	-0.600	-0.60
			WEEK 20	1	0.200	0.0000	0.20	0.200	0.200	0.200	0.20
			WEEK 24	2	-1.700	1.9799	-3.10	-3.100	-1.700	-0.300	-0.30
			WEEK 28	2	-1.650	2.6163	-3.50	-3.500	-1.650	0.200	0.20
			WEEK 32	2	-2.000	2.4042	-3.70	-3.700	-2.000	-0.300	-0.30
			WEEK 36	2	-1.750	3.3234	-4.10	-4.100	-1.750	0.600	0.60
			WEEK 40	2	-2.250	2.1920	-3.80	-3.800	-2.250	-0.700	-0.70
			WEEK 44	1	-4.400	0.0000	-4.40	-4.400	-4.400	-4.400	-4.40
			WEEK 48	1	-3.800	0.0000	-3.80	-3.800	-3.800	-3.800	-3.80
			DISCONTINUATION	17	-0.553	1.4063	-5.00	-0.800	-0.200	0.000	1.20
		200mg BID(N=47)	WEEK 0	30	0.217	1.0107	-2.80	-0.100	0.050	0.400	3.20
			WEEK 1	39	0.105	1.1617	-3.20	-0.500	0.000	0.600	3.80
			WEEK 2	32	0.578	3.1749	-2.60	-0.600	-0.200	0.550	14.90
			WEEK 3	27	0.859	3.9391	-3.00	-0.500	0.300	0.800	18.60
			WEEK 4	20	0.830	3.9841	-2.90	-0.950	-0.450	0.450	13.50
			WEEK 8	3	-0.600	0.3000	-0.90	-0.900	-0.600	-0.300	-0.30
			WEEK 12	1	-0.500	0.0000	-0.50	-0.500	-0.500	-0.500	-0.50

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Prothrombin Time	sec	200mg BID(N=47)	WEEK 16	2	0.300	0.2828	0.10	0.100	0.300	0.500	0.50
			WEEK 20	1	-0.800	0.0000	-0.80	-0.800	-0.800	-0.800	-0.80
			DISCONTINUATION	25	2.520	6.3596	-1.90	-0.100	0.900	1.200	26.70
Alanine Aminotransferase	ukat/L	100mg BID(N=21)	WEEK 0	19	-0.027	0.1907	-0.52	-0.083	-0.050	0.017	0.52
			WEEK 1	19	0.041	0.2770	-0.43	-0.117	0.000	0.083	0.98
			WEEK 2	17	0.074	0.2510	-0.63	0.000	0.033	0.150	0.58
			WEEK 3	15	0.054	0.2486	-0.65	-0.017	0.067	0.100	0.47
			WEEK 4	12	0.064	0.2661	-0.60	0.017	0.075	0.167	0.58
			WEEK 8	4	0.375	0.6627	-0.02	0.025	0.075	0.725	1.37
			WEEK 12	2	0.008	0.0354	-0.02	-0.017	0.008	0.033	0.03
			WEEK 16	2	0.183	0.1414	0.08	0.083	0.183	0.283	0.28
			WEEK 20	2	0.017	0.1414	-0.08	-0.083	0.017	0.117	0.12
			WEEK 24	2	0.092	0.2711	-0.10	-0.100	0.092	0.283	0.28
			WEEK 28	2	0.067	0.2357	-0.10	-0.100	0.067	0.233	0.23
			WEEK 32	2	0.083	0.1414	-0.02	-0.017	0.083	0.183	0.18
			WEEK 36	2	0.225	0.2240	0.07	0.067	0.225	0.383	0.38
			WEEK 40	2	0.133	0.1650	0.02	0.017	0.133	0.250	0.25
			WEEK 48	1	0.067	0.0000	0.07	0.067	0.067	0.067	0.07
			DISCONTINUATION	17	0.227	0.6304	-0.67	0.017	0.100	0.300	2.50
		200mg BID(N=47)	WEEK 0	37	0.029	0.3017	-0.35	-0.100	-0.017	0.033	1.17

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

				Change from baseline							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Alanine Aminotransferase	ukat/L	200mg BID(N=47)	WEEK 1	44	0.109	0.4740	-0.38	-0.050	0.042	0.108	2.87
			WEEK 2	36	0.109	0.4523	-0.53	-0.050	0.067	0.117	2.45
			WEEK 3	31	0.192	0.5064	-0.47	-0.017	0.083	0.217	2.45
			WEEK 4	22	0.275	0.7178	-0.35	0.000	0.108	0.233	3.32
			WEEK 8	3	0.089	0.0536	0.05	0.050	0.067	0.150	0.15
			WEEK 12	2	0.058	0.0589	0.02	0.017	0.058	0.100	0.10
			WEEK 16	2	-0.025	0.0825	-0.08	-0.083	-0.025	0.033	0.03
			WEEK 20	1	0.283	0.0000	0.28	0.283	0.283	0.283	0.28
			DISCONTINUATION	31	0.150	0.4242	-0.37	-0.017	0.083	0.183	2.15
Aspartate Aminotransferase	ukat/L	100mg BID(N=21)	WEEK 0	19	0.068	0.1752	-0.07	-0.017	0.000	0.050	0.65
			WEEK 1	18	0.106	0.2056	-0.22	0.000	0.075	0.167	0.62
			WEEK 2	17	0.074	0.1855	-0.40	0.000	0.083	0.133	0.50
			WEEK 3	15	0.052	0.1622	-0.42	0.000	0.050	0.150	0.32
			WEEK 4	12	0.083	0.1921	-0.38	0.025	0.050	0.200	0.40
			WEEK 8	4	0.154	0.2175	-0.02	0.008	0.083	0.300	0.47
			WEEK 12	2	0.042	0.0354	0.02	0.017	0.042	0.067	0.07
			WEEK 16	2	0.017	0.0000	0.02	0.017	0.017	0.017	0.02
			WEEK 20	2	0.058	0.0354	0.03	0.033	0.058	0.083	0.08
			WEEK 24	2	0.075	0.1297	-0.02	-0.017	0.075	0.167	0.17
			WEEK 28	2	0.017	0.1179	-0.07	-0.067	0.017	0.100	0.10

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Aspartate Aminotransferase	ukat/L	100mg BID(N=21)	WEEK 32	2	0.025	0.1061	-0.05	-0.050	0.025	0.100	0.10
			WEEK 36	2	0.083	0.0707	0.03	0.033	0.083	0.133	0.13
			WEEK 40	2	0.050	0.0943	-0.02	-0.017	0.050	0.117	0.12
			WEEK 48	1	0.033	0.0000	0.03	0.033	0.033	0.033	0.03
			DISCONTINUATION	17	0.368	0.8391	-0.37	0.083	0.183	0.333	3.53
		200mg BID(N=47)	WEEK 0	37	0.078	0.3649	-0.40	-0.050	0.000	0.050	1.95
			WEEK 1	44	0.170	0.2926	-0.43	0.008	0.117	0.242	1.43
			WEEK 2	36	0.181	0.2720	-0.47	0.033	0.133	0.225	1.10
			WEEK 3	31	0.334	0.6097	-0.40	0.067	0.167	0.300	2.82
			WEEK 4	21	0.298	0.3713	-0.07	0.083	0.217	0.350	1.52
			WEEK 8	3	0.150	0.0333	0.12	0.117	0.150	0.183	0.18
			WEEK 12	2	0.117	0.0471	0.08	0.083	0.117	0.150	0.15
			WEEK 16	2	0.050	0.0471	0.02	0.017	0.050	0.083	0.08
			WEEK 20	1	0.217	0.0000	0.22	0.217	0.217	0.217	0.22
			DISCONTINUATION	32	0.419	0.8366	-0.42	0.042	0.183	0.383	3.58
Alkaline Phosphatase	ukat/L	100mg BID(N=21)	WEEK 0	19	0.118	0.5330	-0.33	-0.133	-0.033	0.133	2.07
			WEEK 1	19	0.341	1.0223	-0.37	-0.033	0.083	0.350	4.43
			WEEK 2	17	0.349	0.4838	-0.27	0.100	0.233	0.517	1.80
			WEEK 3	15	0.331	0.5675	-0.40	0.050	0.217	0.517	1.90
			WEEK 4	12	0.454	0.5866	-0.25	0.158	0.208	0.642	1.68

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Alkaline Phosphatase	ukat/L	100mg BID(N=21)	WEEK 8	4	0.217	0.4898	-0.42	-0.158	0.292	0.592	0.70
			WEEK 12	2	-0.183	0.4008	-0.47	-0.467	-0.183	0.100	0.10
			WEEK 16	2	-0.217	0.4951	-0.57	-0.567	-0.217	0.133	0.13
			WEEK 20	2	-0.183	0.4243	-0.48	-0.483	-0.183	0.117	0.12
			WEEK 24	2	-0.083	0.5186	-0.45	-0.450	-0.083	0.283	0.28
			WEEK 28	2	-0.150	0.4715	-0.48	-0.483	-0.150	0.183	0.18
			WEEK 32	2	-0.058	0.5304	-0.43	-0.433	-0.058	0.317	0.32
			WEEK 36	2	-0.083	0.5422	-0.47	-0.467	-0.083	0.300	0.30
			WEEK 40	2	-0.008	0.6247	-0.45	-0.450	-0.008	0.433	0.43
			WEEK 48	1	0.450	0.0000	0.45	0.450	0.450	0.450	0.45
			DISCONTINUATION	17	1.779	4.9309	-0.47	0.133	0.333	0.733	20.45
		200mg BID(N=47)	WEEK 0	37	0.143	0.8845	-0.60	-0.200	-0.067	0.167	4.90
			WEEK 1	44	0.340	0.4228	-0.45	0.100	0.292	0.533	1.85
			WEEK 2	36	0.513	0.6774	-1.30	0.133	0.350	0.800	2.52
			WEEK 3	31	0.589	0.6538	-0.38	0.100	0.483	0.950	2.12
			WEEK 4	22	0.704	0.6707	0.03	0.217	0.500	0.934	2.58
			WEEK 8	3	0.189	0.0347	0.15	0.150	0.200	0.217	0.22
			WEEK 12	2	0.067	0.2593	-0.12	-0.117	0.067	0.250	0.25
			WEEK 16	2	0.042	0.2947	-0.17	-0.167	0.042	0.250	0.25
			WEEK 20	1	0.183	0.0000	0.18	0.183	0.183	0.183	0.18

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Alkaline Phosphatase	ukat/L	200mg BID(N=47)	DISCONTINUATION	31	0.815	1.4790	-0.65	0.033	0.433	0.750	6.67
Protein	g/L	100mg BID(N=21)	WEEK 0	19	-0.737	3.0884	-4.00	-4.000	-1.000	1.000	7.00
			WEEK 1	19	0.263	3.1595	-7.00	-1.000	0.000	2.000	7.00
			WEEK 2	17	-1.706	3.5666	-9.00	-4.000	-1.000	0.000	5.00
			WEEK 3	15	-1.333	3.6580	-7.00	-3.000	0.000	1.000	5.00
			WEEK 4	12	-1.833	3.4859	-7.00	-5.500	-0.500	1.000	2.00
			WEEK 8	4	-1.000	5.9442	-9.00	-5.500	0.500	3.500	4.00
			WEEK 12	2	2.000	4.2426	-1.00	-1.000	2.000	5.000	5.00
			WEEK 16	2	2.500	3.5355	0.00	0.000	2.500	5.000	5.00
			WEEK 20	2	1.000	4.2426	-2.00	-2.000	1.000	4.000	4.00
			WEEK 24	2	2.000	2.8284	0.00	0.000	2.000	4.000	4.00
			WEEK 28	2	1.500	4.9497	-2.00	-2.000	1.500	5.000	5.00
			WEEK 32	2	2.500	0.7071	2.00	2.000	2.500	3.000	3.00
			WEEK 36	2	-2.000	7.0711	-7.00	-7.000	-2.000	3.000	3.00
			WEEK 40	2	2.000	2.8284	0.00	0.000	2.000	4.000	4.00
			WEEK 48	1	-2.000	0.0000	-2.00	-2.000	-2.000	-2.000	-2.00
			DISCONTINUATION	17	-1.412	6.2954	-17.00	-4.000	-1.000	3.000	11.00
		200mg BID(N=47)	WEEK 0	37	-0.973	3.9615	-8.00	-4.000	-1.000	2.000	7.00
			WEEK 1	44	-1.818	4.8955	-14.00	-5.000	-2.000	0.500	16.00
			WEEK 2	35	-3.657	4.6460	-12.00	-8.000	-4.000	0.000	9.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Protein	g/L	200mg BID(N=47)	WEEK 3	31	-3.806	4.8402	-20.00	-6.000	-4.000	0.000	5.00
			WEEK 4	22	-3.636	5.0667	-12.00	-7.000	-3.500	-1.000	10.00
			WEEK 8	3	0.000	6.2450	-7.00	-7.000	2.000	5.000	5.00
			WEEK 12	2	-3.000	9.8995	-10.00	-10.000	-3.000	4.000	4.00
			WEEK 16	2	-3.000	14.1421	-13.00	-13.000	-3.000	7.000	7.00
			WEEK 20	1	7.000	0.0000	7.00	7.000	7.000	7.000	7.00
			DISCONTINUATION	30	-5.300	5.7843	-19.00	-9.000	-5.000	0.000	5.00
Albumin	g/L	100mg BID(N=21)	WEEK 0	19	-0.421	2.0633	-3.00	-2.000	-1.000	1.000	4.00
			WEEK 1	19	0.737	2.6213	-3.00	-1.000	0.000	3.000	8.00
			WEEK 2	17	-1.824	2.8990	-6.00	-4.000	-1.000	0.000	4.00
			WEEK 3	15	-1.733	2.6313	-6.00	-4.000	-2.000	1.000	2.00
			WEEK 4	12	-2.000	2.7634	-7.00	-4.500	-1.000	0.000	2.00
			WEEK 8	4	0.250	3.7749	-5.00	-2.500	1.500	3.000	3.00
			WEEK 12	2	1.500	3.5355	-1.00	-1.000	1.500	4.000	4.00
			WEEK 16	2	0.500	2.1213	-1.00	-1.000	0.500	2.000	2.00
			WEEK 20	2	0.500	3.5355	-2.00	-2.000	0.500	3.000	3.00
			WEEK 24	2	1.500	3.5355	-1.00	-1.000	1.500	4.000	4.00
			WEEK 28	2	1.000	2.8284	-1.00	-1.000	1.000	3.000	3.00
			WEEK 32	2	1.500	2.1213	0.00	0.000	1.500	3.000	3.00
			WEEK 36	2	-0.500	7.7782	-6.00	-6.000	-0.500	5.000	5.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Albumin	g/L	100mg BID(N=21)	WEEK 40	2	-0.500	4.9497	-4.00	-4.000	-0.500	3.000	3.00
			WEEK 48	1	-4.000	0.0000	-4.00	-4.000	-4.000	-4.000	-4.00
			DISCONTINUATION	17	-2.294	4.4688	-11.00	-4.000	-2.000	-1.000	7.00
		200mg BID(N=47)	WEEK 0	37	-0.892	3.4543	-9.00	-3.000	-1.000	1.000	9.00
			WEEK 1	44	-1.614	3.6550	-10.00	-4.000	-1.000	1.000	9.00
			WEEK 2	36	-3.111	3.7323	-10.00	-5.500	-3.000	0.000	7.00
			WEEK 3	31	-3.839	4.6339	-17.00	-7.000	-3.000	-2.000	7.00
			WEEK 4	22	-3.818	3.9235	-11.00	-7.000	-3.500	-1.000	5.00
			WEEK 8	3	-0.333	4.1633	-5.00	-5.000	1.000	3.000	3.00
			WEEK 12	2	-1.500	4.9497	-5.00	-5.000	-1.500	2.000	2.00
			WEEK 16	2	-2.500	9.1924	-9.00	-9.000	-2.500	4.000	4.00
			WEEK 20	1	5.000	0.0000	5.00	5.000	5.000	5.000	5.00
			DISCONTINUATION	30	-4.767	5.3799	-13.00	-9.000	-5.000	-2.000	8.00
Bilirubin	umol/L	100mg BID(N=21)	WEEK 0	19	-0.217	3.2345	-6.84	-1.710	-1.000	1.710	8.55
			WEEK 1	19	2.033	4.7152	-3.42	-1.710	0.000	3.420	15.39
			WEEK 2	17	2.129	5.1357	-5.13	0.000	1.000	3.420	17.10
			WEEK 3	15	0.751	3.7534	-3.42	-1.710	0.000	1.710	11.97
			WEEK 4	12	1.793	1.5591	0.00	0.500	1.710	2.565	5.13
			WEEK 8	4	-0.250	3.7277	-3.42	-2.565	-1.355	2.065	5.13
			WEEK 12	2	-0.355	1.9163	-1.71	-1.710	-0.355	1.000	1.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Bilirubin	umol/L	100mg BID(N=21)	WEEK 16	2	0.500	0.7071	0.00	0.000	0.500	1.000	1.00
			WEEK 20	2	-1.710	2.4183	-3.42	-3.420	-1.710	0.000	0.00
			WEEK 24	2	-1.355	0.5020	-1.71	-1.710	-1.355	-1.000	-1.00
			WEEK 28	2	-1.710	2.4183	-3.42	-3.420	-1.710	0.000	0.00
			WEEK 32	2	-0.710	3.8325	-3.42	-3.420	-0.710	2.000	2.00
			WEEK 36	2	1.145	4.0376	-1.71	-1.710	1.145	4.000	4.00
			WEEK 40	2	-1.710	2.4183	-3.42	-3.420	-1.710	0.000	0.00
			WEEK 48	1	-5.130	0.0000	-5.13	-5.130	-5.130	-5.130	-5.13
			DISCONTINUATION	17	10.427	24.8884	-4.00	0.000	3.420	10.260	102.60
		200mg BID(N=47)	WEEK 0	37	0.909	2.8073	-4.00	-1.710	0.000	1.710	6.84
			WEEK 1	44	3.265	5.4437	-1.88	0.000	1.710	4.565	27.36
			WEEK 2	36	3.651	5.5562	-5.13	0.855	1.710	5.130	18.81
			WEEK 3	31	5.027	7.2551	-5.13	1.710	3.420	5.130	32.49
			WEEK 4	22	4.588	5.2173	-3.42	1.710	5.130	6.840	22.23
			WEEK 8	3	1.807	0.1674	1.71	1.710	1.710	2.000	2.00
			WEEK 12	2	5.065	0.0919	5.00	5.000	5.065	5.130	5.13
			WEEK 16	2	4.210	1.1172	3.42	3.420	4.210	5.000	5.00
			WEEK 20	1	2.000	0.0000	2.00	2.000	2.000	2.000	2.00
			DISCONTINUATION	31	8.266	18.6212	-3.42	0.000	3.000	7.000	95.76
Calcium	mmol/L	100mg BID(N=21)	WEEK 0	19	-0.006	0.0980	-0.19	-0.075	0.000	0.050	0.25

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Calcium	mmol/L	100mg BID(N=21)	WEEK 1	19	-0.011	0.1048	-0.20	-0.100	0.000	0.050	0.20
			WEEK 2	17	-0.052	0.1197	-0.33	-0.100	-0.050	0.025	0.22
			WEEK 3	14	-0.004	0.1337	-0.17	-0.050	-0.025	0.025	0.35
			WEEK 4	12	-0.039	0.1794	-0.24	-0.175	-0.062	0.050	0.40
			WEEK 8	4	-0.006	0.1124	-0.10	-0.087	-0.037	0.075	0.15
			WEEK 12	2	0.060	0.0849	0.00	0.000	0.060	0.120	0.12
			WEEK 16	2	0.000	0.1413	-0.10	-0.100	0.000	0.100	0.10
			WEEK 20	2	0.008	0.1872	-0.12	-0.125	0.008	0.140	0.14
			WEEK 24	2	0.073	0.2085	-0.07	-0.075	0.073	0.220	0.22
			WEEK 28	2	0.100	0.2121	-0.05	-0.050	0.100	0.250	0.25
			WEEK 32	2	0.028	0.1448	-0.07	-0.075	0.028	0.130	0.13
			WEEK 36	2	-0.007	0.2366	-0.17	-0.175	-0.007	0.160	0.16
			WEEK 40	2	0.095	0.3463	-0.15	-0.150	0.095	0.340	0.34
			WEEK 48	1	-0.125	0.0000	-0.12	-0.125	-0.125	-0.125	-0.12
			DISCONTINUATION	18	-0.031	0.2388	-0.44	-0.150	-0.100	0.050	0.75
		200mg BID(N=47)	WEEK 0	37	0.008	0.1186	-0.22	-0.050	0.000	0.075	0.40
			WEEK 1	45	-0.056	0.1753	-0.70	-0.110	-0.060	0.000	0.60
			WEEK 2	37	-0.076	0.1485	-0.38	-0.150	-0.100	0.000	0.42
			WEEK 3	31	-0.093	0.1599	-0.62	-0.175	-0.075	0.025	0.15
			WEEK 4	22	-0.088	0.1646	-0.32	-0.200	-0.087	-0.025	0.41

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Calcium	mmol/L	200mg BID(N=47)	WEEK 8	3	0.035	0.1427	-0.12	-0.125	0.080	0.150	0.15
			WEEK 12	2	-0.052	0.3849	-0.32	-0.324	-0.052	0.220	0.22
			WEEK 16	2	0.070	0.1980	-0.07	-0.070	0.070	0.210	0.21
			WEEK 20	1	0.190	0.0000	0.19	0.190	0.190	0.190	0.19
			DISCONTINUATION	34	-0.025	0.2917	-0.40	-0.200	-0.100	0.025	1.05
Sodium	mmol/L	100mg BID(N=21)	WEEK 0	19	-0.842	3.6096	-9.00	-3.000	-1.000	2.000	5.00
			WEEK 1	19	-1.684	2.7091	-7.00	-3.000	-2.000	0.000	3.00
			WEEK 2	17	-1.471	3.0438	-7.00	-4.000	-1.000	0.000	3.00
			WEEK 3	15	-1.600	2.9713	-7.00	-4.000	-2.000	1.000	3.00
			WEEK 4	12	-1.417	2.3916	-5.00	-3.000	-2.000	0.500	2.00
			WEEK 8	4	-1.250	1.2583	-3.00	-2.000	-1.000	-0.500	0.00
			WEEK 12	2	-0.500	0.7071	-1.00	-1.000	-0.500	0.000	0.00
			WEEK 16	2	0.000	1.4142	-1.00	-1.000	0.000	1.000	1.00
			WEEK 20	2	0.500	0.7071	0.00	0.000	0.500	1.000	1.00
			WEEK 24	2	-2.500	2.1213	-4.00	-4.000	-2.500	-1.000	-1.00
			WEEK 28	2	-0.500	0.7071	-1.00	-1.000	-0.500	0.000	0.00
			WEEK 32	2	-1.500	0.7071	-2.00	-2.000	-1.500	-1.000	-1.00
			WEEK 36	2	1.000	0.0000	1.00	1.000	1.000	1.000	1.00
			WEEK 40	2	-1.500	0.7071	-2.00	-2.000	-1.500	-1.000	-1.00
			WEEK 48	1	0.000	0.0000	0.00	0.000	0.000	0.000	0.00

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

				Change from baseline							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Sodium	mmol/L	100mg BID(N=21)	DISCONTINUATION	18	-1.500	3.9145	-9.00	-4.000	-0.500	0.000	5.00
		200mg BID(N=47)	WEEK 0	37	-0.757	2.6813	-6.00	-2.000	-1.000	1.000	5.00
			WEEK 1	45	-1.311	2.9987	-11.00	-3.000	-1.000	0.000	6.00
			WEEK 2	37	-2.838	3.3872	-13.00	-4.000	-3.000	-1.000	4.00
			WEEK 3	31	-2.387	3.1904	-9.00	-4.000	-3.000	0.000	4.00
			WEEK 4	22	-2.136	2.8668	-7.00	-5.000	-1.000	0.000	1.00
			WEEK 8	3	-0.667	3.0551	-4.00	-4.000	0.000	2.000	2.00
			WEEK 12	2	-1.500	0.7071	-2.00	-2.000	-1.500	-1.000	-1.00
			WEEK 16	2	-2.000	2.8284	-4.00	-4.000	-2.000	0.000	0.00
			WEEK 20	1	-5.000	0.0000	-5.00	-5.000	-5.000	-5.000	-5.00
			DISCONTINUATION	35	-2.086	3.7446	-11.00	-5.000	-2.000	0.000	7.00
Potassium	mmol/L	100mg BID(N=21)	WEEK 0	19	0.071	0.3754	-0.70	-0.150	0.100	0.400	0.60
			WEEK 1	18	0.068	0.3903	-0.70	-0.100	0.100	0.320	1.00
			WEEK 2	17	0.091	0.4480	-0.80	-0.100	0.100	0.400	0.80
			WEEK 3	15	0.017	0.3462	-0.70	-0.200	0.100	0.300	0.50
			WEEK 4	12	0.099	0.3663	-0.50	-0.150	0.050	0.295	0.90
			WEEK 8	4	0.325	0.4031	0.00	0.050	0.200	0.600	0.90
			WEEK 12	2	0.050	0.0707	0.00	0.000	0.050	0.100	0.10
			WEEK 16	2	-0.050	0.0707	-0.10	-0.100	-0.050	0.000	0.00
			WEEK 20	2	0.100	0.1414	0.00	0.000	0.100	0.200	0.20

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

				Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Potassium	mmol/L	100mg BID(N=21)	WEEK 24	2	0.050	0.2121	-0.10	-0.100	0.050	0.200	0.20
			WEEK 28	2	0.350	0.2121	0.20	0.200	0.350	0.500	0.50
			WEEK 32	2	-0.100	0.1414	-0.20	-0.200	-0.100	0.000	0.00
			WEEK 36	2	0.350	0.0707	0.30	0.300	0.350	0.400	0.40
			WEEK 40	2	0.350	0.2121	0.20	0.200	0.350	0.500	0.50
			WEEK 48	1	0.200	0.0000	0.20	0.200	0.200	0.200	0.20
			DISCONTINUATION	18	0.089	0.4283	-0.80	-0.100	0.050	0.400	0.70
		200mg BID(N=47)	WEEK 0	37	-0.030	0.5082	-1.20	-0.300	-0.100	0.200	1.60
			WEEK 1	45	0.107	0.5211	-1.40	-0.300	0.100	0.400	1.40
			WEEK 2	37	0.165	0.4442	-0.70	-0.100	0.100	0.400	1.20
			WEEK 3	31	0.197	0.6041	-1.20	-0.200	0.100	0.600	1.80
			WEEK 4	22	0.005	0.7397	-1.60	-0.400	0.050	0.300	1.80
			WEEK 8	3	0.400	0.5000	-0.10	-0.100	0.400	0.900	0.90
			WEEK 12	2	0.200	0.9899	-0.50	-0.500	0.200	0.900	0.90
			WEEK 16	2	-0.300	1.6971	-1.50	-1.500	-0.300	0.900	0.90
			WEEK 20	1	1.200	0.0000	1.20	1.200	1.200	1.200	1.20
			DISCONTINUATION	34	-0.026	0.5770	-1.50	-0.300	0.000	0.400	0.90
Magnesium	mmol/L	100mg BID(N=21)	WEEK 0	16	0.014	0.0866	-0.10	-0.046	0.005	0.062	0.25
			WEEK 1	16	0.048	0.0919	-0.08	0.000	0.010	0.103	0.21
			WEEK 2	16	0.012	0.0563	-0.05	-0.041	0.000	0.041	0.16

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Magnesium	mmol/L	100mg BID(N=21)	WEEK 3	15	0.031	0.0754	-0.08	-0.041	0.000	0.082	0.16
			WEEK 4	12	0.014	0.0753	-0.08	-0.041	0.000	0.046	0.21
			WEEK 8	4	0.046	0.0561	0.00	0.005	0.030	0.087	0.12
			WEEK 12	2	-0.025	0.0354	-0.05	-0.050	-0.025	0.000	0.00
			WEEK 16	2	0.045	0.0071	0.04	0.040	0.045	0.050	0.05
			WEEK 20	2	0.040	0.0141	0.03	0.030	0.040	0.050	0.05
			WEEK 24	2	0.080	0.0990	0.01	0.010	0.080	0.150	0.15
			WEEK 28	2	0.085	0.0919	0.02	0.020	0.085	0.150	0.15
			WEEK 32	2	0.075	0.1061	0.00	0.000	0.075	0.150	0.15
			WEEK 36	2	0.070	0.0424	0.04	0.040	0.070	0.100	0.10
			WEEK 40	2	0.060	0.0566	0.02	0.020	0.060	0.100	0.10
			WEEK 48	1	0.100	0.0000	0.10	0.100	0.100	0.100	0.10
			DISCONTINUATION	17	0.037	0.0708	-0.04	0.000	0.041	0.082	0.21
		200mg BID(N=47)	WEEK 0	34	0.011	0.0843	-0.16	-0.041	0.000	0.041	0.21
			WEEK 1	42	0.058	0.0660	-0.08	0.000	0.082	0.100	0.21
			WEEK 2	33	0.026	0.0619	-0.12	0.000	0.000	0.082	0.16
			WEEK 3	25	0.033	0.0641	-0.12	0.000	0.041	0.070	0.16
			WEEK 4	20	0.008	0.0592	-0.12	0.000	0.000	0.041	0.10
			WEEK 8	2	0.102	0.0307	0.08	0.080	0.102	0.123	0.12
			WEEK 12	1	0.040	0.0000	0.04	0.040	0.040	0.040	0.04

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Magnesium	mmol/L	200mg BID(N=47)	WEEK 16	1	-0.030	0.0000	-0.03	-0.030	-0.030	-0.030	-0.03
			WEEK 20	1	0.050	0.0000	0.05	0.050	0.050	0.050	0.05
			DISCONTINUATION	25	0.018	0.0686	-0.12	-0.040	0.041	0.041	0.16
Phosphate	mmol/L	100mg BID(N=21)	WEEK 0	16	-0.021	0.1320	-0.29	-0.081	-0.016	0.048	0.23
			WEEK 1	16	-0.055	0.1577	-0.42	-0.178	-0.051	0.081	0.16
			WEEK 2	17	-0.032	0.1565	-0.52	-0.065	-0.032	0.065	0.19
			WEEK 3	15	-0.030	0.1416	-0.32	-0.129	-0.065	0.040	0.25
			WEEK 4	12	-0.085	0.1970	-0.61	-0.161	-0.057	0.065	0.13
			WEEK 8	4	-0.028	0.1195	-0.19	-0.113	0.000	0.056	0.08
			WEEK 12	2	-0.038	0.2659	-0.23	-0.226	-0.038	0.150	0.15
			WEEK 16	2	-0.068	0.2235	-0.23	-0.226	-0.068	0.090	0.09
			WEEK 20	2	0.073	0.0331	0.05	0.050	0.073	0.097	0.10
			WEEK 24	2	-0.041	0.1708	-0.16	-0.162	-0.041	0.080	0.08
			WEEK 28	2	-0.214	0.2457	-0.39	-0.388	-0.214	-0.040	-0.04
			WEEK 32	2	-0.108	0.1669	-0.23	-0.226	-0.108	0.010	0.01
			WEEK 36	2	-0.203	0.2158	-0.36	-0.355	-0.203	-0.050	-0.05
			WEEK 40	2	-0.153	0.2865	-0.36	-0.355	-0.153	0.050	0.05
			WEEK 48	1	-0.355	0.0000	-0.36	-0.355	-0.355	-0.355	-0.36
			DISCONTINUATION	17	-0.067	0.1915	-0.39	-0.226	-0.032	0.065	0.26
		200mg BID(N=47)	WEEK 0	33	-0.024	0.1782	-0.48	-0.097	0.000	0.097	0.39

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

				Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Phosphate	mmol/L	200mg BID(N=47)	WEEK 1	39	0.005	0.2404	-0.65	-0.097	0.030	0.129	0.56
			WEEK 2	32	-0.039	0.2245	-0.39	-0.194	-0.097	0.077	0.55
			WEEK 3	26	-0.065	0.2418	-0.45	-0.226	-0.077	0.040	0.54
			WEEK 4	20	-0.160	0.2432	-0.61	-0.258	-0.178	-0.016	0.30
			WEEK 8	2	0.055	0.0778	0.00	0.000	0.055	0.110	0.11
			WEEK 12	1	0.290	0.0000	0.29	0.290	0.290	0.290	0.29
			WEEK 16	1	0.220	0.0000	0.22	0.220	0.220	0.220	0.22
			WEEK 20	1	0.330	0.0000	0.33	0.330	0.330	0.330	0.33
			DISCONTINUATION	25	-0.035	0.2738	-0.65	-0.162	-0.097	0.129	0.61
Glucose	mmol/L	100mg BID(N=21)	WEEK 0	18	-0.133	1.3377	-3.89	-0.721	-0.111	0.500	2.00
			WEEK 1	19	0.343	2.4080	-7.05	-0.444	0.111	1.610	4.22
			WEEK 2	17	-0.021	1.0385	-1.83	-0.611	0.100	0.500	2.39
			WEEK 3	15	0.225	0.8103	-1.05	-0.277	0.056	0.722	1.67
			WEEK 4	12	0.293	1.0839	-1.39	-0.333	0.000	0.999	2.00
			WEEK 8	4	0.625	2.6564	-2.16	-1.110	0.222	2.359	4.22
			WEEK 12	2	1.543	1.1925	0.70	0.700	1.543	2.387	2.39
			WEEK 16	2	0.322	1.2410	-0.56	-0.555	0.322	1.200	1.20
			WEEK 20	2	1.182	2.0959	-0.30	-0.300	1.182	2.664	2.66
			WEEK 24	2	-0.011	1.0052	-0.72	-0.722	-0.011	0.700	0.70
			WEEK 28	2	0.328	0.3850	0.06	0.055	0.328	0.600	0.60

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

				Change from baseline							
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Glucose	mmol/L	100mg BID(N=21)	WEEK 32	2	0.167	1.1780	-0.67	-0.666	0.167	1.000	1.00
			WEEK 36	2	0.850	0.2114	0.70	0.700	0.850	0.999	1.00
			WEEK 40	2	0.977	0.8160	0.40	0.400	0.977	1.554	1.55
			WEEK 44	1	0.499	0.0000	0.50	0.499	0.499	0.499	0.50
			WEEK 48	1	1.110	0.0000	1.11	1.110	1.110	1.110	1.11
			DISCONTINUATION	18	-0.080	2.3895	-7.88	-0.944	0.278	1.332	3.66
		200mg BID(N=47)	WEEK 0	38	0.852	1.8051	-2.05	-0.111	0.389	1.110	7.88
			WEEK 1	44	-0.245	1.7780	-5.00	-0.916	-0.139	0.527	4.38
			WEEK 2	36	0.651	1.6761	-3.77	-0.361	0.721	1.526	4.11
			WEEK 3	31	0.378	2.4227	-4.77	-1.388	0.500	1.943	5.83
			WEEK 4	22	0.344	1.7655	-3.77	-0.333	0.216	1.276	5.55
			WEEK 8	3	-0.444	1.5031	-1.50	-1.500	-1.110	1.277	1.28
			WEEK 12	2	-0.667	1.8851	-2.00	-2.000	-0.667	0.666	0.67
			WEEK 16	2	-0.550	0.7778	-1.10	-1.100	-0.550	0.000	0.00
			WEEK 20	1	-3.500	0.0000	-3.50	-3.500	-3.500	-3.500	-3.50
			DISCONTINUATION	34	-0.350	1.9864	-7.38	-1.055	-0.500	0.500	4.88
Urea	mmol/L	100mg BID(N=21)	WEEK 0	19	-0.061	2.1855	-7.14	-1.000	0.000	1.071	3.57
			WEEK 1	18	1.150	1.9228	-3.57	0.000	1.071	2.499	5.00
			WEEK 2	17	0.436	1.2377	-1.43	-0.357	0.357	0.714	3.93
			WEEK 3	14	1.505	1.6263	-0.71	-0.357	1.514	2.499	4.64

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Urea	mmol/L	100mg BID(N=21)	WEEK 4	11	1.577	2.0171	-0.50	0.000	0.714	3.213	5.71
			WEEK 8	3	0.824	0.5301	0.36	0.357	0.714	1.400	1.40
			WEEK 12	2	1.650	1.2014	0.80	0.800	1.650	2.499	2.50
			WEEK 16	2	0.807	0.1315	0.71	0.714	0.807	0.900	0.90
			WEEK 20	2	2.514	1.9990	1.10	1.100	2.514	3.927	3.93
			WEEK 24	2	1.342	0.6258	0.90	0.900	1.342	1.785	1.79
			WEEK 28	2	2.128	1.0295	1.40	1.400	2.128	2.856	2.86
			WEEK 32	2	1.821	0.4540	1.50	1.500	1.821	2.142	2.14
			WEEK 36	2	2.242	2.8878	0.20	0.200	2.242	4.284	4.28
			WEEK 40	2	0.764	0.9390	0.10	0.100	0.764	1.428	1.43
			WEEK 48	1	2.856	0.0000	2.86	2.856	2.856	2.856	2.86
			DISCONTINUATION	18	0.697	3.3488	-5.71	-0.700	0.357	2.142	10.35
		200mg BID(N=47)	WEEK 0	35	0.389	1.5690	-2.86	-0.357	0.357	1.071	5.36
			WEEK 1	44	2.443	1.9692	-3.21	1.428	2.450	3.764	7.14
			WEEK 2	36	2.195	2.1499	-2.50	1.071	2.071	2.828	8.21
			WEEK 3	30	1.910	1.7792	-3.57	0.714	2.071	3.213	5.00
			WEEK 4	21	1.383	2.3402	-5.36	0.357	1.071	2.600	5.50
			WEEK 8	3	2.814	1.8195	0.71	0.714	3.800	3.927	3.93
			WEEK 12	2	1.636	0.7983	1.07	1.071	1.636	2.200	2.20
			WEEK 16	2	3.300	4.6669	0.00	0.000	3.300	6.600	6.60

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

				Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Urea	mmol/L	200mg BID(N=47)	WEEK 20	1	6.100	0.0000	6.10	6.100	6.100	6.100	6.10
			DISCONTINUATION	33	2.623	3.4905	-2.14	0.357	1.785	3.927	12.85
Creatinine	umol/L	100mg BID(N=21)	WEEK 0	19	4.282	13.3073	-17.68	-4.420	1.770	17.680	30.94
			WEEK 1	19	7.172	9.5770	-8.84	1.760	5.300	11.490	26.52
			WEEK 2	17	3.771	9.9688	-8.84	-3.530	0.880	9.720	26.52
			WEEK 3	15	3.435	9.3328	-9.73	-1.000	0.000	11.000	27.40
			WEEK 4	12	3.645	10.5156	-8.84	-4.210	2.655	8.395	28.29
			WEEK 8	4	1.450	8.2067	-7.96	-3.980	0.880	6.880	12.00
			WEEK 12	2	6.790	15.8533	-4.42	-4.420	6.790	18.000	18.00
			WEEK 16	2	10.060	15.4715	-0.88	-0.880	10.060	21.000	21.00
			WEEK 20	2	8.385	9.3550	1.77	1.770	8.385	15.000	15.00
			WEEK 24	2	11.385	13.5977	1.77	1.770	11.385	21.000	21.00
			WEEK 28	2	17.155	16.7514	5.31	5.310	17.155	29.000	29.00
			WEEK 32	2	6.000	8.4853	0.00	0.000	6.000	12.000	12.00
			WEEK 36	2	14.945	19.8768	0.89	0.890	14.945	29.000	29.00
			WEEK 40	2	16.710	17.3807	4.42	4.420	16.710	29.000	29.00
			WEEK 48	1	11.500	0.0000	11.50	11.500	11.500	11.500	11.50
			DISCONTINUATION	18	11.487	23.6396	-17.68	1.760	7.955	10.610	97.24
		200mg BID(N=47)	WEEK 0	37	2.591	10.1948	-18.57	-2.650	0.000	8.840	32.71
			WEEK 1	45	9.453	12.5899	-16.80	0.000	8.840	17.680	36.25

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Creatinine	umol/L	200mg BID(N=47)	WEEK 2	37	8.213	16.2798	-17.68	0.000	8.840	14.140	74.26
			WEEK 3	31	6.661	26.2817	-26.52	-4.420	1.770	9.730	125.53
			WEEK 4	22	2.615	13.3445	-26.52	-6.190	0.440	12.380	26.52
			WEEK 8	3	37.410	47.4641	5.30	5.300	15.000	91.930	91.93
			WEEK 12	2	15.630	3.3517	13.26	13.260	15.630	18.000	18.00
			WEEK 16	2	22.455	9.2560	15.91	15.910	22.455	29.000	29.00
			WEEK 20	1	14.000	0.0000	14.00	14.000	14.000	14.000	14.00
			DISCONTINUATION	35	12.088	32.7707	-58.35	-1.770	5.300	14.150	149.39
Creatine Kinase	ukat/L	100mg BID(N=21)	WEEK 0	11	-0.098	0.2369	-0.42	-0.376	-0.133	0.053	0.28
			WEEK 1	11	0.323	0.8562	-0.25	-0.209	0.267	0.367	2.77
			WEEK 2	11	0.587	0.8482	-0.27	-0.050	0.383	0.807	2.52
			WEEK 3	10	1.192	2.0867	-0.14	0.128	0.342	1.500	6.69
			WEEK 4	9	1.407	2.4433	-0.36	0.217	0.650	1.434	7.70
			WEEK 8	3	1.000	0.9612	0.25	0.250	0.667	2.084	2.08
			WEEK 12	2	0.917	0.8958	0.28	0.283	0.917	1.550	1.55
			WEEK 16	2	0.783	1.0373	0.05	0.050	0.783	1.517	1.52
			WEEK 20	1	0.117	0.0000	0.12	0.117	0.117	0.117	0.12
			WEEK 24	2	0.133	0.4008	-0.15	-0.150	0.133	0.417	0.42
			WEEK 28	2	-0.050	0.5422	-0.43	-0.433	-0.050	0.333	0.33
			WEEK 32	2	0.392	0.1061	0.32	0.317	0.392	0.467	0.47

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Creatine Kinase	ukat/L	100mg BID(N=21)	WEEK 36	2	0.458	0.4597	0.13	0.133	0.458	0.783	0.78
			WEEK 40	2	1.559	1.4027	0.57	0.567	1.559	2.551	2.55
			WEEK 48	1	-0.317	0.0000	-0.32	-0.317	-0.317	-0.317	-0.32
			DISCONTINUATION	11	0.774	1.0702	-0.20	-0.050	0.417	1.017	3.36
		200mg BID(N=47)	WEEK 0	25	-0.401	1.6496	-8.10	-0.167	-0.033	0.100	0.68
			WEEK 1	35	0.533	2.7435	-8.34	-0.044	0.200	0.867	13.24
			WEEK 2	26	0.435	2.0698	-8.13	0.067	0.500	1.100	3.48
			WEEK 3	22	0.421	2.5809	-8.62	-0.167	0.350	1.184	6.22
			WEEK 4	15	1.924	3.7611	-0.65	0.067	0.483	1.950	13.80
			WEEK 8	2	0.758	0.2475	0.58	0.583	0.758	0.934	0.93
			WEEK 12	1	0.850	0.0000	0.85	0.850	0.850	0.850	0.85
			WEEK 16	1	0.400	0.0000	0.40	0.400	0.400	0.400	0.40
			WEEK 20	1	0.800	0.0000	0.80	0.800	0.800	0.800	0.80
			DISCONTINUATION	15	0.674	1.8120	-1.37	-0.433	0.050	0.800	4.82
Lactate Dehydrogenase	ukat/L	100mg BID(N=21)	WEEK 0	17	0.062	1.6563	-4.65	-0.283	-0.200	0.433	2.83
			WEEK 1	18	1.616	3.3577	-4.95	0.383	0.750	2.034	11.94
			WEEK 2	17	2.400	4.1953	-0.30	0.133	1.300	2.867	17.04
			WEEK 3	14	2.364	3.8468	-0.20	0.267	1.017	3.434	14.74
			WEEK 4	12	3.195	5.6333	-0.17	0.750	1.642	2.651	20.60
			WEEK 8	4	6.822	13.1719	-1.33	-0.258	1.059	13.903	26.51

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.2 Haematology and clinical chemistry laboratory variables, change from baseline over time (Safety analysis set)

					Change from baseline						
Laboratory variable	SI-unit	Fostamatinib assigned starting dose	Time point	n	Mean	SD	Min	Q1	Median	Q3	Max
Lactate Dehydrogenase	ukat/L	100mg BID(N=21)	WEEK 12	2	0.400	1.6267	-0.75	-0.750	0.400	1.550	1.55
			WEEK 16	2	0.225	1.5442	-0.87	-0.867	0.225	1.317	1.32
			WEEK 20	2	0.417	1.4145	-0.58	-0.583	0.417	1.417	1.42
			WEEK 24	2	-0.050	1.2495	-0.93	-0.934	-0.050	0.834	0.83
			WEEK 28	2	0.042	0.9076	-0.60	-0.600	0.042	0.683	0.68
			WEEK 32	2	-0.308	1.2141	-1.17	-1.167	-0.308	0.550	0.55
			WEEK 36	2	0.392	1.7799	-0.87	-0.867	0.392	1.650	1.65
			WEEK 40	2	0.500	1.2730	-0.40	-0.400	0.500	1.400	1.40
			DISCONTINUATION	17	4.944	4.3655	0.33	1.400	4.201	6.985	15.25
		200mg BID(N=47)	WEEK 0	36	0.070	5.8768	-29.02	-0.400	0.158	1.525	12.89
			WEEK 1	42	3.975	7.1438	-15.30	0.700	1.917	4.701	22.65
			WEEK 2	34	5.509	7.9881	-3.55	0.767	3.142	5.218	31.81
			WEEK 3	30	17.240	60.2977	-3.45	1.217	2.701	7.752	332.60
			WEEK 4	21	8.136	14.9434	-2.95	0.850	3.051	6.268	64.30
			WEEK 8	3	-0.556	2.0885	-2.97	-2.967	0.650	0.650	0.65
			WEEK 12	2	-0.934	3.3476	-3.30	-3.301	-0.934	1.434	1.43
			WEEK 16	1	-2.717	0.0000	-2.72	-2.717	-2.717	-2.717	-2.72
			WEEK 20	1	-2.667	0.0000	-2.67	-2.667	-2.667	-2.667	-2.67
			DISCONTINUATION	24	10.380	19.0251	-0.22	1.284	3.301	12.986	92.30

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.7.1.3 Haematology and clinical chemistry laboratory variables, change from baseline to maximum observation on treatment (Safety analysis set)

				Results						Change from baseline					
Laboratory variable	SI-unit	Fostamatinib assigned starting dose(mg)	Time point	n	Min	Q1	Median	Q3	Max	n	Min	Q1	Median	Q3	Max
Hemoglobin	g/L	100mg BID(N=21)	BL	21	89.00	102.00	108.00	121.00	155.00						
			MAX	21	99.00	106.00	117.00	135.00	162.00	21	-15.00	2.00	9.00	15.00	31.00
		200mg BID(N=47)	BL	46	82.00	98.00	104.50	118.00	138.00						
			MAX	47	94.00	108.00	117.00	130.00	155.00	46	-10.00	6.00	12.50	18.00	38.00
Erythrocytes	10^12/L	100mg BID(N=21)	BL	21	2.59	3.25	3.66	3.88	5.10						
			MAX	21	2.88	3.55	3.92	4.44	5.20	21	-0.53	0.10	0.36	0.49	1.11
		200mg BID(N=47)	BL	46	2.63	3.04	3.36	3.79	4.99						
			MAX	47	3.05	3.40	3.74	4.21	5.48	46	-0.25	0.26	0.48	0.60	1.51
Leukocytes	10^9/L	100mg BID(N=21)	BL	21	1.90	4.40	5.10	7.40	9.40						
			MAX	21	2.50	5.10	7.00	9.00	15.00	21	-1.00	0.40	0.90	2.10	8.00
		200mg BID(N=47)	BL	46	2.01	4.20	5.55	8.20	14.70						
			MAX	47	3.80	5.80	7.90	12.50	37.10	46	-7.60	0.50	2.10	4.50	10.90
Basophils	10^9/L	100mg BID(N=21)	BL	21	0.00	0.00	0.00	0.05	0.10						
			MAX	21	0.00	0.00	0.03	0.10	0.28	21	-0.05	0.00	0.02	0.05	0.28
		200mg BID(N=47)	BL	44	0.00	0.00	0.00	0.04	0.24						
			MAX	46	0.00	0.00	0.03	0.09	0.19	44	-0.14	0.00	0.01	0.02	0.15
Eosinophils	10^9/L	100mg BID(N=21)	BL	21	0.00	0.04	0.10	0.15	0.30						
			MAX	21	0.00	0.10	0.19	0.30	0.69	21	-0.10	0.00	0.10	0.19	0.53
		200mg BID(N=47)	BL	44	0.00	0.02	0.09	0.16	1.21						

NC = Not calculated
BL Baseline. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015_MAX
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.3 Haematology and clinical chemistry laboratory variables, change from baseline to maximum observation on treatment (Safety analysis set)

				Results						Change from baseline					
Laboratory variable	SI-unit	Fostamatinib assigned starting dose(mg)	Time point	n	Min	Q1	Median	Q3	Max	n	Min	Q1	Median	Q3	Max
			MAX	46	0.00	0.10	0.13	0.22	0.50	44	-1.08	0.00	0.06	0.10	0.34
Monocytes	10^9/L	100mg BID(N=21)	BL	21	0.04	0.40	0.68	0.80	1.50						
			MAX	21	0.20	0.60	0.70	0.90	1.65	21	-0.80	-0.10	0.08	0.20	0.72
		200mg BID(N=47)	BL	44	0.14	0.47	0.70	0.95	1.60						
			MAX	46	0.13	0.60	0.77	1.17	2.59	44	-0.49	-0.10	0.00	0.30	0.80
Lymphocytes	10^9/L	100mg BID(N=21)	BL	21	0.20	0.30	0.80	1.30	2.20						
			MAX	21	0.30	0.50	1.10	2.10	4.35	21	-0.10	0.16	0.30	0.60	2.93
		200mg BID(N=47)	BL	44	0.14	0.45	0.65	1.05	3.40						
			MAX	46	0.37	0.60	1.01	1.61	5.10	44	-0.25	0.16	0.32	0.67	2.30
Neutrophils	10^9/L	100mg BID(N=21)	BL	20	1.02	2.55	2.90	5.35	8.00						
			MAX	21	1.03	3.30	5.70	6.67	11.40	20	-1.00	-0.20	0.73	2.00	8.80
		200mg BID(N=47)	BL	42	1.61	2.65	4.00	6.30	11.70						
			MAX	45	2.05	4.40	6.20	11.41	29.30	42	-7.70	0.76	2.05	4.80	10.46
Platelets	10^9/L	100mg BID(N=21)	BL	21	67.00	130.00	207.00	283.00	451.00						
			MAX	21	83.00	157.00	235.00	330.00	437.00	21	-38.00	14.00	16.00	72.00	136.00
		200mg BID(N=47)	BL	46	77.00	129.00	179.00	215.00	524.00						
			MAX	47	106.00	145.00	240.00	335.00	669.00	46	-35.00	19.00	49.00	92.00	310.00

NC = Not calculated
BL Baseline. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015_MAX
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.3 Haematology and clinical chemistry laboratory variables, change from baseline to maximum observation on treatment (Safety analysis set)

				Results						Change from baseline					
Laboratory variable	SI-unit	Fostamatinib assigned starting dose(mg)	Time point	n	Min	Q1	Median	Q3	Max	n	Min	Q1	Median	Q3	Max
Activated Partial Thromboplastin Time	sec	100mg BID(N=21)	BL	18	25.00	27.00	30.15	33.10	39.80						
			MAX	20	26.90	29.20	31.95	38.25	99.80	18	-7.50	0.00	2.70	5.40	72.30
		200mg BID(N=47)	BL	41	16.50	27.50	29.50	33.60	63.00						
			MAX	46	21.00	29.80	33.60	41.00	180.00	40	-9.60	-0.10	2.70	10.55	59.30
Prothrombin Intl. Normalized Ratio	[ratio]	100mg BID(N=21)	BL	19	0.90	1.00	1.00	1.10	2.01						
			MAX	21	0.90	1.00	1.08	1.10	4.13	19	-0.23	0.00	0.00	0.10	2.12
		200mg BID(N=47)	BL	44	0.90	1.00	1.05	1.10	2.70						
			MAX	46	0.90	1.05	1.10	1.20	4.20	43	-0.12	0.03	0.10	0.20	3.10
Prothrombin Time	sec	100mg BID(N=21)	BL	19	9.60	10.60	13.10	13.70	19.30						
			MAX	20	9.90	12.00	13.05	13.45	38.10	19	-5.00	-0.40	0.30	0.90	18.80
		200mg BID(N=47)	BL	44	9.70	11.30	12.90	13.90	26.20						
			MAX	46	9.60	12.20	13.70	14.80	41.10	43	-2.60	0.30	0.70	1.70	26.70
Alanine Aminotransferase	ukat/L	100mg BID(N=21)	BL	21	0.18	0.25	0.40	0.52	1.23						
			MAX	21	0.28	0.48	0.58	0.73	3.73	21	-0.43	0.10	0.28	0.38	2.50
		200mg BID(N=47)	BL	47	0.08	0.23	0.32	0.52	0.93						
			MAX	47	0.15	0.35	0.50	0.73	6.62	47	-0.35	0.08	0.17	0.28	6.33

NC = Not calculated
BL Baseline. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015_MAX
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.3 Haematology and clinical chemistry laboratory variables, change from baseline to maximum observation on treatment (Safety analysis set)

				Results						Change from baseline					
Laboratory variable	SI-unit	Fostamatinib assigned starting dose(mg)	Time point	n	Min	Q1	Median	Q3	Max	n	Min	Q1	Median	Q3	Max
Aspartate Aminotransferase	ukat/L	100mg BID(N=21)	BL	21	0.23	0.33	0.42	0.57	1.05						
			MAX	21	0.43	0.53	0.68	0.90	4.58	21	-0.22	0.15	0.30	0.47	3.53
		200mg BID(N=47)	BL	47	0.13	0.28	0.37	0.50	1.22						
			MAX	47	0.18	0.47	0.68	1.22	4.80	47	-0.40	0.13	0.28	0.68	3.82
Alkaline Phosphatase	ukat/L	100mg BID(N=21)	BL	21	0.85	1.12	1.48	1.83	10.14						
			MAX	21	1.08	1.62	1.90	2.90	31.14	21	-0.22	0.23	0.52	0.75	21.00
		200mg BID(N=47)	BL	47	0.70	1.32	1.67	2.03	3.97						
			MAX	47	0.97	2.03	2.38	3.40	8.70	47	-0.32	0.37	0.67	1.33	6.67
Protein	g/L	100mg BID(N=21)	BL	21	49.00	59.00	64.00	67.00	72.00						
			MAX	21	51.00	63.00	66.00	69.00	73.00	21	-4.00	-1.00	2.00	5.00	11.00
		200mg BID(N=47)	BL	47	41.00	59.00	64.00	67.00	79.00						
			MAX	47	45.00	60.00	65.00	69.00	78.00	47	-5.00	-2.00	1.00	3.00	16.00
Albumin	g/L	100mg BID(N=21)	BL	21	31.00	35.00	38.00	43.00	52.00						
			MAX	20	30.00	38.00	42.00	46.00	50.00	20	-2.00	-0.50	1.00	3.50	8.00
		200mg BID(N=47)	BL	47	25.00	35.00	38.00	42.00	48.00						
			MAX	46	27.00	36.00	39.00	42.00	46.00	46	-6.00	-2.00	0.00	2.00	9.00
Bilirubin	umol/L	100mg BID(N=21)	BL	21	5.00	6.84	9.00	13.68	22.23						
			MAX	21	6.84	11.97	13.68	22.23	119.70	21	-1.71	1.71	5.13	10.26	111.15

NC = Not calculated
BL Baseline. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015_MAX
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.3 Haematology and clinical chemistry laboratory variables, change from baseline to maximum observation on treatment (Safety analysis set)

				Results						Change from baseline					
Laboratory variable	SI-unit	Fostamatinib assigned starting dose(mg)	Time point	n	Min	Q1	Median	Q3	Max	n	Min	Q1	Median	Q3	Max
		200mg BID(N=47)	BL	47	1.71	5.13	6.84	10.26	23.94						
			MAX	47	5.13	10.26	13.68	18.81	119.70	47	-1.71	3.42	5.13	11.00	95.76
Calcium	mmol/L	100mg BID(N=21)	BL	21	2.10	2.27	2.32	2.40	2.54						
			MAX	21	2.20	2.30	2.37	2.42	2.87	21	-0.18	0.00	0.02	0.12	0.75
		200mg BID(N=47)	BL	47	1.97	2.22	2.32	2.40	2.52						
			MAX	47	2.07	2.22	2.37	2.42	4.02	47	-0.12	-0.02	0.05	0.10	1.65
Sodium	mmol/L	100mg BID(N=21)	BL	21	133.00	138.00	139.00	142.00	146.00						
			MAX	21	134.00	139.00	141.00	143.00	145.00	21	-5.00	-1.00	1.00	4.00	5.00
		200mg BID(N=47)	BL	47	132.00	137.00	140.00	140.00	149.00						
			MAX	47	135.00	139.00	140.00	142.00	149.00	47	-6.00	-1.00	1.00	2.00	8.00
Potassium	mmol/L	100mg BID(N=21)	BL	21	3.20	3.70	4.00	4.20	4.70						
			MAX	21	3.70	4.10	4.30	4.70	5.30	21	-0.70	0.10	0.50	0.70	1.00
		200mg BID(N=47)	BL	47	2.80	3.70	4.10	4.30	5.50						
			MAX	47	3.50	4.10	4.50	5.00	6.40	47	-0.50	0.20	0.40	0.80	2.20
Magnesium	mmol/L	100mg BID(N=21)	BL	20	0.36	0.68	0.77	0.84	0.95						
			MAX	21	0.44	0.78	0.82	0.86	1.00	20	-0.04	0.04	0.08	0.12	0.25
		200mg BID(N=47)	BL	45	0.24	0.65	0.74	0.82	1.00						
			MAX	47	0.33	0.75	0.86	0.91	1.07	45	-0.05	0.04	0.08	0.12	0.21

NC = Not calculated
BL Baseline. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015_MAX
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.3 Haematology and clinical chemistry laboratory variables, change from baseline to maximum observation on treatment (Safety analysis set)

				Results						Change from baseline					
Laboratory variable	SI-unit	Fostamatinib assigned starting dose(mg)	Time point	n	Min	Q1	Median	Q3	Max	n	Min	Q1	Median	Q3	Max
Phosphate	mmol/L	100mg BID(N=21)	BL	21	0.84	1.07	1.13	1.23	1.87						
			MAX	21	1.00	1.13	1.23	1.32	1.68	21	-0.23	0.03	0.10	0.19	0.26
		200mg BID(N=47)	BL	44	0.74	1.00	1.13	1.32	1.68						
			MAX	47	0.78	1.19	1.30	1.39	1.78	44	-0.23	0.00	0.10	0.32	0.61
Glucose	mmol/L	100mg BID(N=21)	BL	21	3.44	5.22	5.60	6.27	12.60						
			MAX	21	4.77	6.27	7.16	8.16	11.21	21	-3.89	0.50	1.33	1.89	4.22
		200mg BID(N=47)	BL	47	3.94	5.05	5.83	6.77	12.43						
			MAX	47	4.94	6.49	7.27	9.05	14.15	47	-1.55	0.17	1.28	2.22	7.88
Urea	mmol/L	100mg BID(N=21)	BL	21	3.57	4.10	5.36	6.07	13.21						
			MAX	21	3.93	6.78	7.85	8.93	18.92	21	-3.57	0.71	2.14	3.93	14.28
		200mg BID(N=47)	BL	46	1.43	3.93	5.71	7.14	14.64						
			MAX	47	2.86	7.85	10.00	11.80	21.42	46	-2.14	2.50	3.59	5.36	12.85
Creatinine	umol/L	100mg BID(N=21)	BL	21	47.00	61.88	62.76	88.40	128.18						
			MAX	21	54.00	69.84	82.21	104.31	212.16	21	-8.84	7.08	9.72	26.52	150.28
		200mg BID(N=47)	BL	47	51.00	66.30	76.02	97.24	212.16						
			MAX	47	54.00	80.44	95.47	140.56	267.85	47	-11.49	8.84	17.00	29.00	149.39
Creatine Kinase	ukat/L	100mg BID(N=21)	BL	15	0.35	0.67	0.85	1.43	2.78						
			MAX	17	0.23	1.20	1.73	2.40	10.49	15	-0.63	0.32	0.88	2.52	7.70
		200mg BID(N=47)	BL	38	0.23	0.43	0.80	1.33	9.47						

NC = Not calculated
BL Baseline. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015_MAX
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.3 Haematology and clinical chemistry laboratory variables, change from baseline to maximum observation on treatment (Safety analysis set)

				Results						Change from baseline					
Laboratory variable	SI-unit	Fostamatinib assigned starting dose(mg)	Time point	n	Min	Q1	Median	Q3	Max	n	Min	Q1	Median	Q3	Max
Lactate Dehydrogenase	ukat/L	100mg BID(N=21)	MAX	45	0.20	0.73	1.48	2.31	18.82	38	-8.10	0.12	0.50	1.52	13.80
			BL	21	2.72	3.23	6.20	9.34	23.00						
			MAX	20	3.47	5.88	12.24	15.99	43.61	20	0.33	1.54	4.10	8.39	26.51
		200mg BID(N=47)	BL	46	1.70	3.90	5.05	9.07	85.57						
			MAX	44	2.55	7.08	10.59	27.96	339.80	43	-15.30	2.50	5.20	20.20	332.60

NC = Not calculated
BL Baseline. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB015_MAX
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Hemoglobin	100mg(N=21)	0	2 (10.53)	2 (10.53)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		1	17 (89.47)	0 (0.00)	17 (89.47)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	19 (100.00)	2 (10.53)	17 (89.47)	0 (0.00)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		1	45 (100.00)	3 (6.67)	42 (93.33)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	45 (100.00)	3 (6.67)	42 (93.33)	0 (0.00)	0 (0.00)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Program Name: RT_TLAB020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Leukocytes	100mg(N=21)	0	13 (68.42)	6 (31.58)	2 (10.53)	2 (10.53)	2 (10.53)	1 (5.26)
		1	4 (21.05)	0 (0.00)	3 (15.79)	0 (0.00)	1 (5.26)	0 (0.00)
		2	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)	1 (5.26)	0 (0.00)
		3	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)	1 (5.26)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	19 (100.00)	6 (31.58)	5 (26.32)	2 (10.53)	5 (26.32)	1 (5.26)
	200mg(N=47)	0	32 (71.11)	17 (37.78)	9 (20.00)	3 (6.67)	2 (4.44)	1 (2.22)
		1	9 (20.00)	0 (0.00)	3 (6.67)	3 (6.67)	1 (2.22)	2 (4.44)
		2	4 (8.89)	1 (2.22)	1 (2.22)	1 (2.22)	1 (2.22)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	45 (100.00)	18 (40.00)	13 (28.89)	7 (15.56)	4 (8.89)	3 (6.67)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Lymphocytes	100mg(N=21)	0	7 (36.84)	2 (10.53)	2 (10.53)	0 (0.00)	2 (10.53)	1 (5.26)
		1	3 (15.79)	0 (0.00)	0 (0.00)	2 (10.53)	1 (5.26)	0 (0.00)
		2	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)	1 (5.26)	0 (0.00)
		3	8 (42.11)	0 (0.00)	0 (0.00)	1 (5.26)	5 (26.32)	2 (10.53)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	19 (100.00)	2 (10.53)	2 (10.53)	3 (15.79)	9 (47.37)	3 (15.79)
	200mg(N=47)	0	12 (27.91)	5 (11.63)	3 (6.98)	4 (9.30)	0 (0.00)	0 (0.00)
		1	5 (11.63)	1 (2.33)	0 (0.00)	3 (6.98)	1 (2.33)	0 (0.00)
		2	16 (37.21)	0 (0.00)	2 (4.65)	6 (13.95)	4 (9.30)	4 (9.30)
		3	9 (20.93)	0 (0.00)	0 (0.00)	1 (2.33)	4 (9.30)	4 (9.30)
		4	1 (2.33)	0 (0.00)	0 (0.00)	0 (0.00)	1 (2.33)	0 (0.00)
		Total evaluable	43 (100.00)	6 (13.95)	5 (11.63)	14 (32.56)	10 (23.26)	8 (18.60)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Neutrophils	100mg(N=21)	0	16 (88.89)	9 (50.00)	2 (11.11)	2 (11.11)	1 (5.56)	2 (11.11)
		1	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	2 (11.11)	0 (0.00)	0 (0.00)	0 (0.00)	2 (11.11)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	18 (100.00)	9 (50.00)	2 (11.11)	2 (11.11)	3 (16.67)	2 (11.11)
	200mg(N=47)	0	39 (95.12)	29 (70.73)	3 (7.32)	4 (9.76)	0 (0.00)	3 (7.32)
		1	2 (4.88)	2 (4.88)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	41 (100.00)	31 (75.61)	3 (7.32)	4 (9.76)	0 (0.00)	3 (7.32)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Platelets	100mg(N=21)	0	12 (63.16)	6 (31.58)	4 (21.05)	1 (5.26)	1 (5.26)	0 (0.00)
		1	6 (31.58)	1 (5.26)	3 (15.79)	0 (0.00)	2 (10.53)	0 (0.00)
		2	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)	1 (5.26)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	19 (100.00)	7 (36.84)	7 (36.84)	1 (5.26)	4 (21.05)	0 (0.00)
	200mg(N=47)	0	31 (68.89)	18 (40.00)	8 (17.78)	3 (6.67)	1 (2.22)	1 (2.22)
		1	14 (31.11)	0 (0.00)	7 (15.56)	4 (8.89)	2 (4.44)	1 (2.22)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	45 (100.00)	18 (40.00)	15 (33.33)	7 (15.56)	3 (6.67)	2 (4.44)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Activated Partial Thromboplastin Time	100mg(N=21)	0	16 (100.00)	14 (87.50)	1 (6.25)	1 (6.25)	0 (0.00)	0 (0.00)
		1	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	16 (100.00)	14 (87.50)	1 (6.25)	1 (6.25)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	33 (86.84)	28 (73.68)	3 (7.89)	2 (5.26)	0 (0.00)	0 (0.00)
		1	4 (10.53)	2 (5.26)	1 (2.63)	1 (2.63)	0 (0.00)	0 (0.00)
		2	1 (2.63)	0 (0.00)	0 (0.00)	1 (2.63)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	38 (100.00)	30 (78.95)	4 (10.53)	4 (10.53)	0 (0.00)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Alanine Aminotransferase	100mg(N=21)	0	16 (88.89)	11 (61.11)	5 (27.78)	0 (0.00)	0 (0.00)	0 (0.00)
		1	2 (11.11)	1 (5.56)	0 (0.00)	0 (0.00)	1 (5.56)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	18 (100.00)	12 (66.67)	5 (27.78)	0 (0.00)	1 (5.56)	0 (0.00)
	200mg(N=47)	0	42 (91.30)	31 (67.39)	9 (19.57)	1 (2.17)	1 (2.17)	0 (0.00)
		1	4 (8.70)	1 (2.17)	2 (4.35)	0 (0.00)	1 (2.17)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	46 (100.00)	32 (69.57)	11 (23.91)	1 (2.17)	2 (4.35)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Program Name: RT_TLAB020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Aspartate Aminotransferase	100mg(N=21)	0	12 (66.67)	2 (11.11)	10 (55.56)	0 (0.00)	0 (0.00)	0 (0.00)
		1	6 (33.33)	0 (0.00)	5 (27.78)	0 (0.00)	1 (5.56)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	18 (100.00)	2 (11.11)	15 (83.33)	0 (0.00)	1 (5.56)	0 (0.00)
	200mg(N=47)	0	35 (76.09)	13 (28.26)	19 (41.30)	0 (0.00)	3 (6.52)	0 (0.00)
		1	11 (23.91)	1 (2.17)	6 (13.04)	3 (6.52)	1 (2.17)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	46 (100.00)	14 (30.43)	25 (54.35)	3 (6.52)	4 (8.70)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Program Name: RT_TLAB020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Alkaline Phosphatase	100mg(N=21)	0	14 (77.78)	9 (50.00)	4 (22.22)	1 (5.56)	0 (0.00)	0 (0.00)
		1	3 (16.67)	0 (0.00)	2 (11.11)	1 (5.56)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	1 (5.56)	0 (0.00)	0 (0.00)	0 (0.00)	1 (5.56)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	18 (100.00)	9 (50.00)	6 (33.33)	2 (11.11)	1 (5.56)	0 (0.00)
	200mg(N=47)	0	32 (69.57)	11 (23.91)	20 (43.48)	1 (2.17)	0 (0.00)	0 (0.00)
		1	14 (30.43)	0 (0.00)	10 (21.74)	4 (8.70)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	46 (100.00)	11 (23.91)	30 (65.22)	5 (10.87)	0 (0.00)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Program Name: RT_TLAB020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Albumin	100mg(N=21)	0	14 (77.78)	10 (55.56)	4 (22.22)	0 (0.00)	0 (0.00)	0 (0.00)
		1	4 (22.22)	0 (0.00)	2 (11.11)	2 (11.11)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	18 (100.00)	10 (55.56)	6 (33.33)	2 (11.11)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	37 (80.43)	15 (32.61)	14 (30.43)	8 (17.39)	0 (0.00)	0 (0.00)
		1	5 (10.87)	0 (0.00)	1 (2.17)	4 (8.70)	0 (0.00)	0 (0.00)
		2	4 (8.70)	0 (0.00)	0 (0.00)	4 (8.70)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	46 (100.00)	15 (32.61)	15 (32.61)	16 (34.78)	0 (0.00)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Bilirubin	100mg(N=21)	0	17 (94.44)	12 (66.67)	3 (16.67)	1 (5.56)	1 (5.56)	0 (0.00)
		1	1 (5.56)	0 (0.00)	0 (0.00)	1 (5.56)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	18 (100.00)	12 (66.67)	3 (16.67)	2 (11.11)	1 (5.56)	0 (0.00)
	200mg(N=47)	0	45 (97.83)	36 (78.26)	6 (13.04)	3 (6.52)	0 (0.00)	0 (0.00)
		1	1 (2.17)	0 (0.00)	0 (0.00)	0 (0.00)	1 (2.17)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	46 (100.00)	36 (78.26)	6 (13.04)	3 (6.52)	1 (2.17)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Calcium (low)	100mg(N=21)	0	19 (100.00)	18 (94.74)	0 (0.00)	1 (5.26)	0 (0.00)	0 (0.00)
		1	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	19 (100.00)	18 (94.74)	0 (0.00)	1 (5.26)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	44 (95.65)	32 (69.57)	1 (2.17)	10 (21.74)	1 (2.17)	0 (0.00)
		1	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	2 (4.35)	2 (4.35)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	46 (100.00)	34 (73.91)	1 (2.17)	10 (21.74)	1 (2.17)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Calcium (high)	100mg(N=21)	0	19 (100.00)	18 (94.74)	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)
		1	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	19 (100.00)	18 (94.74)	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	41 (95.35)	38 (88.37)	1 (2.33)	0 (0.00)	0 (0.00)	2 (4.65)
		1	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	2 (4.65)	2 (4.65)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	43 (100.00)	40 (93.02)	1 (2.33)	0 (0.00)	0 (0.00)	2 (4.65)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Sodium (low)	100mg(N=21)	0	15 (78.95)	8 (42.11)	7 (36.84)	0 (0.00)	0 (0.00)	0 (0.00)
		1	4 (21.05)	2 (10.53)	2 (10.53)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	19 (100.00)	10 (52.63)	9 (47.37)	0 (0.00)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	39 (84.78)	21 (45.65)	17 (36.96)	0 (0.00)	1 (2.17)	0 (0.00)
		1	7 (15.22)	2 (4.35)	5 (10.87)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	46 (100.00)	23 (50.00)	22 (47.83)	0 (0.00)	1 (2.17)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Sodium (high)	100mg(N=21)	0	14 (82.35)	12 (70.59)	2 (11.76)	0 (0.00)	0 (0.00)	0 (0.00)
		1	3 (17.65)	2 (11.76)	1 (5.88)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	17 (100.00)	14 (82.35)	3 (17.65)	0 (0.00)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	39 (86.67)	35 (77.78)	4 (8.89)	0 (0.00)	0 (0.00)	0 (0.00)
		1	6 (13.33)	5 (11.11)	1 (2.22)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	45 (100.00)	40 (88.89)	5 (11.11)	0 (0.00)	0 (0.00)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Potassium (low)	100mg(N=21)	0	17 (89.47)	16 (84.21)	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)
		1	2 (10.53)	1 (5.26)	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	19 (100.00)	17 (89.47)	2 (10.53)	0 (0.00)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	41 (89.13)	32 (69.57)	5 (10.87)	0 (0.00)	4 (8.70)	0 (0.00)
		1	4 (8.70)	3 (6.52)	0 (0.00)	0 (0.00)	1 (2.17)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	1 (2.17)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (2.17)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	46 (100.00)	35 (76.09)	5 (10.87)	0 (0.00)	5 (10.87)	1 (2.17)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Potassium (high)	100mg(N=21)	0	17 (89.47)	16 (84.21)	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)
		1	2 (10.53)	2 (10.53)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	19 (100.00)	18 (94.74)	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	41 (89.13)	34 (73.91)	6 (13.04)	0 (0.00)	1 (2.17)	0 (0.00)
		1	4 (8.70)	2 (4.35)	0 (0.00)	2 (4.35)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	1 (2.17)	1 (2.17)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	46 (100.00)	37 (80.43)	6 (13.04)	2 (4.35)	1 (2.17)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Magnesium (low)	100mg(N=21)	0	15 (83.33)	15 (83.33)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		1	1 (5.56)	1 (5.56)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	1 (5.56)	0 (0.00)	0 (0.00)	1 (5.56)	0 (0.00)	0 (0.00)
		3	1 (5.56)	0 (0.00)	0 (0.00)	0 (0.00)	1 (5.56)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	18 (100.00)	16 (88.89)	0 (0.00)	1 (5.56)	1 (5.56)	0 (0.00)
	200mg(N=47)	0	34 (77.27)	32 (72.73)	2 (4.55)	0 (0.00)	0 (0.00)	0 (0.00)
		1	5 (11.36)	3 (6.82)	2 (4.55)	0 (0.00)	0 (0.00)	0 (0.00)
		2	2 (4.55)	0 (0.00)	0 (0.00)	1 (2.27)	1 (2.27)	0 (0.00)
		3	2 (4.55)	0 (0.00)	0 (0.00)	0 (0.00)	2 (4.55)	0 (0.00)
		4	1 (2.27)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (2.27)
		Total evaluable	44 (100.00)	35 (79.55)	4 (9.09)	1 (2.27)	3 (6.82)	1 (2.27)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Magnesium (high)	100mg(N=21)	0	15 (93.75)	15 (93.75)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		1	1 (6.25)	1 (6.25)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	16 (100.00)	16 (100.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	34 (89.47)	33 (86.84)	1 (2.63)	0 (0.00)	0 (0.00)	0 (0.00)
		1	4 (10.53)	4 (10.53)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	38 (100.00)	37 (97.37)	1 (2.63)	0 (0.00)	0 (0.00)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Program Name: RT_TLAB020
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Phosphate	100mg(N=21)	0	18 (100.00)	16 (88.89)	0 (0.00)	2 (11.11)	0 (0.00)	0 (0.00)
		1	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	18 (100.00)	16 (88.89)	0 (0.00)	2 (11.11)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	41 (95.35)	31 (72.09)	0 (0.00)	8 (18.60)	2 (4.65)	0 (0.00)
		1	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	2 (4.65)	0 (0.00)	0 (0.00)	1 (2.33)	1 (2.33)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	43 (100.00)	31 (72.09)	0 (0.00)	9 (20.93)	3 (6.98)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Glucose (low)	100mg(N=21)	0	11 (61.11)	11 (61.11)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		1	6 (33.33)	6 (33.33)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	1 (5.56)	1 (5.56)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	18 (100.00)	18 (100.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	27 (62.79)	25 (58.14)	2 (4.65)	0 (0.00)	0 (0.00)	0 (0.00)
		1	12 (27.91)	12 (27.91)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		2	4 (9.30)	4 (9.30)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	43 (100.00)	41 (95.35)	2 (4.65)	0 (0.00)	0 (0.00)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Glucose (high)	100mg(N=21)	0	12 (63.16)	6 (31.58)	6 (31.58)	0 (0.00)	0 (0.00)	0 (0.00)
		1	6 (31.58)	0 (0.00)	5 (26.32)	1 (5.26)	0 (0.00)	0 (0.00)
		2	1 (5.26)	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	19 (100.00)	7 (36.84)	11 (57.89)	1 (5.26)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	30 (65.22)	9 (19.57)	17 (36.96)	4 (8.70)	0 (0.00)	0 (0.00)
		1	12 (26.09)	2 (4.35)	7 (15.22)	3 (6.52)	0 (0.00)	0 (0.00)
		2	4 (8.70)	0 (0.00)	1 (2.17)	3 (6.52)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	46 (100.00)	11 (23.91)	25 (54.35)	10 (21.74)	0 (0.00)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Creatinine	100mg(N=21)	0	17 (89.47)	14 (73.68)	2 (10.53)	1 (5.26)	0 (0.00)	0 (0.00)
		1	2 (10.53)	0 (0.00)	2 (10.53)	0 (0.00)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	19 (100.00)	14 (73.68)	4 (21.05)	1 (5.26)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	35 (76.09)	28 (60.87)	5 (10.87)	2 (4.35)	0 (0.00)	0 (0.00)
		1	9 (19.57)	0 (0.00)	4 (8.70)	5 (10.87)	0 (0.00)	0 (0.00)
		2	2 (4.35)	0 (0.00)	1 (2.17)	1 (2.17)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	46 (100.00)	28 (60.87)	10 (21.74)	8 (17.39)	0 (0.00)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.4 Haematology and clinical chemistry, CTCAE grade change from baseline to maximum value during treatment (Safety analysis set)

				Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Patients at baseline[b]	0	1	2	3	4
Creatine Kinase	100mg(N=21)	0	11 (91.67)	9 (75.00)	1 (8.33)	1 (8.33)	0 (0.00)	0 (0.00)
		1	1 (8.33)	0 (0.00)	0 (0.00)	1 (8.33)	0 (0.00)	0 (0.00)
		2	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	12 (100.00)	9 (75.00)	1 (8.33)	2 (16.67)	0 (0.00)	0 (0.00)
	200mg(N=47)	0	34 (94.44)	26 (72.22)	6 (16.67)	2 (5.56)	0 (0.00)	0 (0.00)
		1	1 (2.78)	0 (0.00)	0 (0.00)	0 (0.00)	1 (2.78)	0 (0.00)
		2	1 (2.78)	1 (2.78)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		3	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		4	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
		Total evaluable	36 (100.00)	27 (75.00)	6 (16.67)	2 (5.56)	1 (2.78)	0 (0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.5 Clinical Chemistry, CTCAE grade change from baseline to maximum value during treatment for electrolytes (Safety analysis set)

					Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Criteria Low/High	Patients at baseline[b]	0	1	2	3	4
Calcium (low)	100mg(N=21)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		19(100.00)	18(94.74)	0(0.00)	1(5.26)	0(0.00)	0(0.00)
		1	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		19(100.00)	18(94.74)	0(0.00)	1(5.26)	0(0.00)	0(0.00)
Calcium (high)	100mg(N=21)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		19(100.00)	18(94.74)	1(5.26)	0(0.00)	0(0.00)	0(0.00)
		1	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		19(100.00)	18(94.74)	1(5.26)	0(0.00)	0(0.00)	0(0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade (low/high) - patients with no low/high graded assessments during treatment are excluded.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.5 Clinical Chemistry, CTCAE grade change from baseline to maximum value during treatment for electrolytes (Safety analysis set)

					Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Criteria Low/High	Patients at baseline[b]	0	1	2	3	4
Calcium (low)	200mg(N=47)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	2(4.35)	2(4.35)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		44(95.65)	32(69.57)	1(2.17)	10(21.74)	1(2.17)	0(0.00)
		1	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		46(100.00)	34(73.91)	1(2.17)	10(21.74)	1(2.17)	0(0.00)
Calcium (high)	200mg(N=47)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	2(4.65)	2(4.65)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		41(95.35)	38(88.37)	1(2.33)	0(0.00)	0(0.00)	2(4.65)
		1	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		43(100.00)	40(93.02)	1(2.33)	0(0.00)	0(0.00)	2(4.65)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade (low/high) - patients with no low/high graded assessments during treatment are excluded.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.5 Clinical Chemistry, CTCAE grade change from baseline to maximum value during treatment for electrolytes (Safety analysis set)

					Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Criteria Low/High	Patients at baseline[b]	0	1	2	3	4
Sodium (low)	100mg(N=21)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	2(10.53)	0(0.00)	2(10.53)	0(0.00)	0(0.00)	0(0.00)
		0		15(78.95)	8(42.11)	7(36.84)	0(0.00)	0(0.00)	0(0.00)
		1	High	2(10.53)	2(10.53)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		19(100.00)	10(52.63)	9(47.37)	0(0.00)	0(0.00)	0(0.00)
Sodium (high)	100mg(N=21)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	1(5.88)	1(5.88)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		14(82.35)	12(70.59)	2(11.76)	0(0.00)	0(0.00)	0(0.00)
		1	High	2(11.76)	1(5.88)	1(5.88)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		17(100.00)	14(82.35)	3(17.65)	0(0.00)	0(0.00)	0(0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade (low/high) - patients with no low/high graded assessments during treatment are excluded.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.5 Clinical Chemistry, CTCAE grade change from baseline to maximum value during treatment for electrolytes (Safety analysis set)

					Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Criteria Low/High	Patients at baseline[b]	0	1	2	3	4
Sodium (low)	200mg(N=47)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	4(8.70)	1(2.17)	3(6.52)	0(0.00)	0(0.00)	0(0.00)
		0		39(84.78)	21(45.65)	17(36.96)	0(0.00)	1(2.17)	0(0.00)
		1	High	3(6.52)	1(2.17)	2(4.35)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		46(100.00)	23(50.00)	22(47.83)	0(0.00)	1(2.17)	0(0.00)
Sodium (high)	200mg(N=47)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	3(6.67)	3(6.67)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		39(86.67)	35(77.78)	4(8.89)	0(0.00)	0(0.00)	0(0.00)
		1	High	3(6.67)	2(4.44)	1(2.22)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		45(100.00)	40(88.89)	5(11.11)	0(0.00)	0(0.00)	0(0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade (low/high) - patients with no low/high graded assessments during treatment are excluded.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.5 Clinical Chemistry, CTCAE grade change from baseline to maximum value during treatment for electrolytes (Safety analysis set)

					Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Criteria Low/High	Patients at baseline[b]	0	1	2	3	4
Potassium (low)	100mg(N=21)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	2(10.53)	1(5.26)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		17(89.47)	16(84.21)	1(5.26)	0(0.00)	0(0.00)	0(0.00)
		1	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		19(100.00)	17(89.47)	2(10.53)	0(0.00)	0(0.00)	0(0.00)
Potassium (high)	100mg(N=21)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	2(10.53)	2(10.53)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		17(89.47)	16(84.21)	1(5.26)	0(0.00)	0(0.00)	0(0.00)
		1	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		19(100.00)	18(94.74)	1(5.26)	0(0.00)	0(0.00)	0(0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade (low/high) - patients with no low/high graded assessments during treatment are excluded.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.5 Clinical Chemistry, CTCAE grade change from baseline to maximum value during treatment for electrolytes (Safety analysis set)

					Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Criteria Low/High	Patients at baseline[b]	0	1	2	3	4
Potassium (low)	200mg(N=47)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	1(2.17)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	1(2.17)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	2(4.35)	1(2.17)	0(0.00)	0(0.00)	1(2.17)	0(0.00)
		0		41(89.13)	32(69.57)	5(10.87)	0(0.00)	4(8.70)	0(0.00)
		1	High	2(4.35)	2(4.35)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		46(100.00)	35(76.09)	5(10.87)	0(0.00)	5(10.87)	1(2.17)
Potassium (high)	200mg(N=47)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	1(2.17)	1(2.17)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	2(4.35)	2(4.35)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		41(89.13)	34(73.91)	6(13.04)	0(0.00)	1(2.17)	0(0.00)
		1	High	2(4.35)	0(0.00)	0(0.00)	2(4.35)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		46(100.00)	37(80.43)	6(13.04)	2(4.35)	1(2.17)	0(0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade (low/high) - patients with no low/high graded assessments during treatment are excluded.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.5 Clinical Chemistry, CTCAE grade change from baseline to maximum value during treatment for electrolytes (Safety analysis set)

					Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Criteria Low/High	Patients at baseline[b]	0	1	2	3	4
Magnesium (low)	100mg(N=21)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	1(5.56)	0(0.00)	0(0.00)	0(0.00)	1(5.56)	0(0.00)
		2	Low	1(5.56)	0(0.00)	0(0.00)	1(5.56)	0(0.00)	0(0.00)
		1	Low	1(5.56)	1(5.56)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		15(83.33)	15(83.33)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		18(100.00)	16(88.89)	0(0.00)	1(5.56)	1(5.56)	0(0.00)
Magnesium (high)	100mg(N=21)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	1(6.25)	1(6.25)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		15(93.75)	15(93.75)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		16(100.00)	16(100.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade (low/high) - patients with no low/high graded assessments during treatment are excluded.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.5 Clinical Chemistry, CTCAE grade change from baseline to maximum value during treatment for electrolytes (Safety analysis set)

					Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Criteria Low/High	Patients at baseline[b]	0	1	2	3	4
Magnesium (low)	200mg(N=47)	4	Low	1(2.27)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	1(2.27)
		3	Low	2(4.55)	0(0.00)	0(0.00)	0(0.00)	2(4.55)	0(0.00)
		2	Low	2(4.55)	0(0.00)	0(0.00)	1(2.27)	1(2.27)	0(0.00)
		1	Low	5(11.36)	3(6.82)	2(4.55)	0(0.00)	0(0.00)	0(0.00)
		0		34(77.27)	32(72.73)	2(4.55)	0(0.00)	0(0.00)	0(0.00)
		1	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		44(100.00)	35(79.55)	4(9.09)	1(2.27)	3(6.82)	1(2.27)
Magnesium (high)	200mg(N=47)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	4(10.53)	4(10.53)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		34(89.47)	33(86.84)	1(2.63)	0(0.00)	0(0.00)	0(0.00)
		1	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		38(100.00)	37(97.37)	1(2.63)	0(0.00)	0(0.00)	0(0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade (low/high) - patients with no low/high graded assessments during treatment are excluded.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.5 Clinical Chemistry, CTCAE grade change from baseline to maximum value during treatment for electrolytes (Safety analysis set)

					Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Criteria Low/High	Patients at baseline[b]	0	1	2	3	4
Glucose (low)	100mg(N=21)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	1(5.56)	1(5.56)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		11(61.11)	11(61.11)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	High	5(27.78)	5(27.78)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	1(5.56)	1(5.56)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		18(100.00)	18(100.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
Glucose (high)	100mg(N=21)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	1(5.26)	0(0.00)	1(5.26)	0(0.00)	0(0.00)	0(0.00)
		0		12(63.16)	6(31.58)	6(31.58)	0(0.00)	0(0.00)	0(0.00)
		1	High	5(26.32)	0(0.00)	4(21.05)	1(5.26)	0(0.00)	0(0.00)
		2	High	1(5.26)	1(5.26)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		19(100.00)	7(36.84)	11(57.89)	1(5.26)	0(0.00)	0(0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade (low/high) - patients with no low/high graded assessments during treatment are excluded.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.5 Clinical Chemistry, CTCAE grade change from baseline to maximum value during treatment for electrolytes (Safety analysis set)

					Maximum overall CTCAE grade during treatment (%) [c]				
Parameter	Fostamatinib assigned starting dose (mg)	Baseline CTCAE grade[a]	Criteria Low/High	Patients at baseline[b]	0	1	2	3	4
Glucose (low)	200mg(N=47)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		27(62.79)	25(58.14)	2(4.65)	0(0.00)	0(0.00)	0(0.00)
		1	High	12(27.91)	12(27.91)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	High	4(9.30)	4(9.30)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		43(100.00)	41(95.35)	2(4.65)	0(0.00)	0(0.00)	0(0.00)
Glucose (high)	200mg(N=47)	4	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		3	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		2	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		1	Low	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		0		30(65.22)	9(19.57)	17(36.96)	4(8.70)	0(0.00)	0(0.00)
		1	High	12(26.09)	2(4.35)	7(15.22)	3(6.52)	0(0.00)	0(0.00)
		2	High	4(8.70)	0(0.00)	1(2.17)	3(6.52)	0(0.00)	0(0.00)
		3	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		4	High	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
		Total evaluable		46(100.00)	11(23.91)	25(54.35)	10(21.74)	0(0.00)	0(0.00)

[a] Baseline is defined as the last result obtained prior to the start of study treatment
[b] Patients with a baseline value and at least one on-treatment value. Percentages have been calculated using the number of patients with a baseline value and a post baseline value.
[c] Derived from Lab assessments between the start of treatment and 30 days following the date of last dose of study medication and is the maximum CTCAE grade (low/high) - patients with no low/high graded assessments during treatment are excluded.
CTCAE Common Terminology Criteria for Adverse Events v4.0.

Table 11.3.7.1.6 Urinalysis laboratory variables over time
(Safety analysis set)

Laboratory variable	SI-unit	Fostamatinib assignedstarting dose	Time point	Result							
				n	Mean	SD	Min	Q1	Median	Q3	Max
Albumin	mg/L	100mg BID(N=21)	BASELINE	7	9.54	5.948	4.0	4.60	7.70	14.00	20.0
			SCREENING	8	8.35	6.458	0.0	4.30	6.35	12.75	20.0
			WEEK 0	1	50.80	0.000	50.8	50.80	50.80	50.80	50.8
		200mg BID(N=47)	BASELINE	21	1536.17	6300.883	0.0	7.00	12.60	62.30	29000.0
			SCREENING	21	1536.17	6300.883	0.0	7.00	12.60	62.30	29000.0
			WEEK 1	1	53.50	0.000	53.5	53.50	53.50	53.50	53.5
			DISCONTINUATION	3	8.23	7.366	0.0	0.00	10.50	14.20	14.2
Creatinine	mmol/L	100mg BID(N=21)	BASELINE	14	10.02	5.262	3.2	5.20	9.02	13.84	19.3
			SCREENING	14	10.02	5.262	3.2	5.20	9.02	13.84	19.3
			WEEK 0	1	2.99	0.000	3.0	2.99	2.99	2.99	3.0
			DISCONTINUATION	1	13.17	0.000	13.2	13.17	13.17	13.17	13.2
		200mg BID(N=47)	BASELINE	34	11.53	6.198	0.1	7.60	10.67	15.10	32.4
			SCREENING	35	11.75	6.241	0.1	7.60	10.70	15.56	32.4
			WEEK 1	1	25.46	0.000	25.5	25.46	25.46	25.46	25.5
			DISCONTINUATION	5	9.82	6.641	1.3	5.20	10.60	14.21	17.8

NC = Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SD Standard deviation. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RT_TLAB040
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.2 ALT or AST, and bilirubin, elevations at any time - individual patient data
(Safety analysis set)

Fostamatinib assigned starting dose (mg)	Patient Identifier	Sex	Age [a] (years)	Day study treatment discont-inued	Time point (study day)	ALT (U/L)	ALT xULN	AST (U/L)	AST xULN	Total bilirubin (umol/L)	Total bilirubin xULN	ALP (U/L)	ALP xULN
100mg	E7814002	M	52	7	-13	74.00	1.85	63.00	2.10	8.55	0.41	608.00	5.07
					1	43.00	1.08	79.00	2.63	11.97	0.57	732.00	6.10
					7	224.00	5.60	275.00	9.17	111.15	5.29	1835.00	15.29
					8	199.00	4.98	237.00	7.90	116.28	5.54	1868.00	15.57
					9	189.00	4.73	226.00	7.53	119.70	5.70	1756.00	14.63
200mg	E7801008	M	60	28	-4	35.00	0.88	30.00	1.00	10.26	0.49	113.00	0.94
					8	24.00	0.60	26.00	0.87	18.81	0.90	119.00	0.99
					15	25.00	0.63	30.00	1.00	10.26	0.49	121.00	1.01
					22	47.00	1.18	199.00	6.63	11.97	0.57	146.00	1.22
	E7808003	M	70	8	-14	18.00	0.45	73.00	2.43	23.94	1.14	122.00	1.02
					1	88.00	2.20	190.00	6.33	30.78	1.47	416.00	3.47
					8	147.00	3.68	288.00	9.60	119.70	5.70	522.00	4.35
	E7809004	M	75	34	-9	53.00	1.33	32.00	1.07	3.42	0.16	95.00	0.79
					1	123.00	3.08	71.00	2.37	3.42	0.16	105.00	0.88
					8	225.00	5.63	118.00	3.93	5.13	0.24	150.00	1.25
					8	200.00	5.00	92.00	3.07	5.13	0.24	142.00	1.18
					9								
					10								
					15	189.00	4.73	77.00	2.57	6.84	0.33	144.00	1.20
					22	200.00	5.00	85.00	2.83	8.55	0.41	133.00	1.11
					28	252.00	6.30	123.00	4.10	8.55	0.41	148.00	1.23

[a] Age at study entry
ALP Alkaline phosphatase. ALT Alanine aminotransferase. AST Aspartate aminotransferase. F Female. M Male. ULN Upper limit of normal.
Note: Table includes all patients who have ALT or AST>3xULN and total bilirubin >2xULN, at any time during the study (ie, not necessarily at the same time).
Reference ranges: ALP 30-120; ALT 10-40; AST 10-30; Total bilirubin 5-21.

Program Name: RT_TLAB050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.7.2 ALT or AST, and bilirubin, elevations at any time - individual patient data
(Safety analysis set)

Fostamatinib assigned starting dose (mg)	Patient Identifier	Sex	Age [a] (years)	Day study treatment discont-inued	Time point (study day)	ALT (U/L)	ALT xULN	AST (U/L)	AST xULN	Total bilirubin (umol/L)	Total bilirubin xULN	ALP (U/L)	ALP xULN
200mg	E7812001	F	52	42	-7	17.00	0.43	20.00	0.67	8.55	0.41	131.00	1.09
					1	16.00	0.40	20.00	0.67	6.84	0.33	123.00	1.03
					8	30.00	0.75	36.00	1.20	15.39	0.73	183.00	1.53
					15	46.00	1.15	51.00	1.70	18.81	0.90	282.00	2.35
					17	27.00	0.68	38.00	1.27	11.97	0.57	224.00	1.87
					22	33.00	0.83	65.00	2.17	15.39	0.73	290.00	2.42
					29	44.00	1.10	51.00	1.70	15.39	0.73	286.00	2.38
					42	51.00	1.28	81.00	2.70	15.39	0.73	322.00	2.68
					45	74.00	1.85	82.00	2.73	13.68	0.65	252.00	2.10
					50	397.00	9.93	217.00	7.23	13.68	0.65	201.00	1.68
					52	378.00	9.45	118.00	3.93	10.26	0.49	273.00	2.28
					57	151.00	3.78	41.00	1.37	10.26	0.49	206.00	1.72
					64	54.00	1.35	23.00	0.77	11.97	0.57	137.00	1.14
	E7822005	M	64	26	-3	26.00	0.65	24.00	0.80	5.13	0.24	120.00	1.00
					1	20.00	0.50	20.00	0.67	6.84	0.33	98.00	0.82
					8	27.00	0.68	28.00	0.93	5.13	0.24	129.00	1.08
					15	21.00	0.53	32.00	1.07	6.84	0.33	133.00	1.11
					18	18.00	0.45	34.00	1.13	10.26	0.49	111.00	0.93
					22	25.00	0.63	80.00	2.67	10.26	0.49	124.00	1.03
					25	31.00	0.78	194.00	6.47	11.97	0.57	100.00	0.83
					26	38.00	0.95	253.00	8.43	17.10	0.81	115.00	0.96

[a] Age at study entry
ALP Alkaline phosphatase. ALT Alanine aminotransferase. AST Aspartate aminotransferase. F Female. M Male. ULN Upper limit of normal.
Note: Table includes all patients who have ALT or AST>3xULN and total bilirubin >2xULN, at any time during the study (ie, not necessarily at the same time).
Reference ranges: ALP 30-120; ALT 10-40; AST 10-30; Total bilirubin 5-21.

Program Name: RT_TLAB050
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.1.1 Vital signs variables over time
(Safety analysis set)

Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Result Min	Q1	Median	Q3	Max
Systolic Blood Pressure	mmHg	100mg(N=21)	SCREENING	20	102	114.5	123.0	134.5	149
			WEEK 0	21	101	111.5	117.8	124.0	144
			WEEK 1	19	109	113.5	118.0	126.0	155
			WEEK 2	15	106	108.3	117.3	122.3	133
			WEEK 3	14	103	112.5	117.8	127.0	157
			WEEK 4	12	92	110.0	112.5	122.0	133
			WEEK 8	4	111	111.0	115.8	126.5	133
			WEEK 12	2	118	118.0	121.0	124.0	124
			WEEK 16	2	116	116.0	124.3	132.5	133
			WEEK 20	2	133	132.5	133.3	134.0	134
			WEEK 24	2	124	123.5	126.0	128.5	129
			WEEK 28	2	106	105.5	118.8	132.0	132
			WEEK 32	2	110	110.0	123.3	136.5	137
			WEEK 36	2	116	116.0	131.3	146.5	147
			WEEK 40	2	111	111.0	125.0	139.0	139
			WEEK 44	1	146	145.5	145.5	145.5	146
			WEEK 48	1	138	138.0	138.0	138.0	138
			DISCONTINUATION	17	101	116.5	122.0	126.0	133
		200mg(N=47)	SCREENING	45	86	114.0	119.0	130.0	150
			WEEK 0	44	92	106.5	116.5	127.5	156

Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.

Table 11.3.8.1.1 Vital signs variables over time
(Safety analysis set)

Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Result Min	Q1	Median	Q3	Max
Systolic Blood Pressure	mmHg	200mg(N=47)	WEEK 1	45	101	117.5	130.8	139.5	171
			WEEK 2	36	96	117.0	127.0	139.5	148
			WEEK 3	30	98	115.0	127.0	135.0	162
			WEEK 4	20	91	106.5	125.3	139.0	154
			WEEK 8	3	132	132.0	135.0	138.0	138
			WEEK 12	2	113	112.5	121.3	130.0	130
			WEEK 16	2	124	124.0	124.0	124.0	124
			WEEK 20	1	152	151.5	151.5	151.5	152
			DISCONTINUATION	34	82	115.5	127.0	131.0	142
Diastolic Blood Pressure	mmHg	100mg(N=21)	SCREENING	20	60	66.5	74.0	84.5	94
			WEEK 0	21	58	69.0	71.0	75.0	87
			WEEK 1	19	67	72.0	74.5	79.5	89
			WEEK 2	15	59	69.8	73.5	77.3	87
			WEEK 3	14	63	66.0	74.3	80.5	90
			WEEK 4	12	61	62.5	77.5	82.5	89
			WEEK 8	4	61	65.5	71.3	77.0	82
			WEEK 12	2	57	57.0	68.3	79.5	80
			WEEK 16	2	64	63.5	69.5	75.5	76
			WEEK 20	2	60	59.5	73.5	87.5	88
			WEEK 24	2	58	58.0	70.8	83.5	84

Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.

Table 11.3.8.1.1 Vital signs variables over time (Safety analysis set)

Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Result Min	Q1	Median	Q3	Max
Diastolic Blood Pressure	mmHg	100mg(N=21)	WEEK 28	2	63	62.5	69.5	76.5	77
			WEEK 32	2	61	61.0	69.0	77.0	77
			WEEK 36	2	70	69.5	73.5	77.5	78
			WEEK 40	2	63	63.0	72.0	81.0	81
			WEEK 44	1	72	71.5	71.5	71.5	72
			WEEK 48	1	67	66.5	66.5	66.5	67
			DISCONTINUATION	17	57	65.0	75.0	80.0	81
		200mg(N=47)	SCREENING	45	54	62.0	73.0	79.0	97
			WEEK 0	44	51	62.0	70.5	76.5	92
			WEEK 1	45	61	72.0	81.3	88.0	114
			WEEK 2	36	56	72.5	80.0	88.0	102
			WEEK 3	30	57	67.5	78.5	87.5	98
			WEEK 4	20	52	67.0	78.0	84.8	102
			WEEK 8	3	78	77.5	79.0	80.5	81
			WEEK 12	2	80	80.0	85.0	90.0	90
			WEEK 16	2	74	73.5	73.5	73.5	74
			WEEK 20	1	87	86.5	86.5	86.5	87
			DISCONTINUATION	34	54	69.0	71.0	79.0	92
Pulse Rate	BEATS/MIN	100mg(N=21)	SCREENING	20	69	77.0	84.5	93.0	116
			WEEK 0	21	63	76.0	81.0	93.5	114

Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.

Table 11.3.8.1.1 Vital signs variables over time
(Safety analysis set)

Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Result Min	Q1	Median	Q3	Max
Pulse Rate	BEATS/MIN	100mg(N=21)	WEEK 1	19	52	69.0	75.8	88.0	109
			WEEK 2	15	65	65.0	83.0	92.5	108
			WEEK 3	14	65	68.5	82.8	90.0	110
			WEEK 4	12	64	74.0	81.3	84.0	92
			WEEK 8	4	71	72.8	79.0	84.0	85
			WEEK 12	2	65	64.5	70.0	75.5	76
			WEEK 16	2	67	67.0	71.0	75.0	75
			WEEK 20	2	63	63.0	66.3	69.5	70
			WEEK 24	2	65	64.5	67.3	70.0	70
			WEEK 28	2	67	67.0	73.3	79.5	80
			WEEK 32	2	72	72.0	76.3	80.5	81
			WEEK 36	2	70	70.0	71.8	73.5	74
			WEEK 40	2	72	72.0	73.8	75.5	76
			WEEK 44	1	69	69.0	69.0	69.0	69
			WEEK 48	1	68	68.0	68.0	68.0	68
			DISCONTINUATION	17	65	74.0	85.0	94.0	102
		200mg(N=47)	SCREENING	45	56	77.0	87.0	96.0	125
			WEEK 0	44	48	71.5	81.8	89.5	129
			WEEK 1	45	53	66.5	80.5	94.5	147
			WEEK 2	36	49	73.5	83.5	99.5	119

Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.

Program Name: RTVIT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.8.1.1 Vital signs variables over time
(Safety analysis set)

Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Result Min	Q1	Median	Q3	Max
Pulse Rate	BEATS/MIN	200mg(N=47)	WEEK 3	30	60	79.0	89.5	100.0	120
			WEEK 4	20	62	68.0	79.3	95.0	126
			WEEK 8	3	59	58.5	75.5	92.5	93
			WEEK 12	2	61	61.0	85.0	109.0	109
			WEEK 16	2	52	52.0	52.0	52.0	52
			WEEK 20	1	53	53.0	53.0	53.0	53
			DISCONTINUATION	34	52	80.0	93.0	104.5	120
Weight	kg	100mg(N=21)	SCREENING	19	48	64.4	78.9	91.8	106
			WEEK 0	20	51	63.2	72.6	86.0	102
			WEEK 1	19	50	61.5	77.3	89.4	101
			WEEK 2	15	56	66.0	83.0	91.9	106
			WEEK 3	14	56	71.8	81.6	91.7	101
			WEEK 4	12	54	63.8	78.6	90.3	106
			WEEK 8	4	57	64.9	77.9	87.6	92
			WEEK 12	2	75	75.0	83.8	92.5	93
			WEEK 16	2	75	75.2	83.8	92.4	92
			WEEK 20	2	77	76.7	84.7	92.7	93
			WEEK 24	2	77	76.7	84.8	92.9	93
			WEEK 28	2	79	78.8	85.3	91.8	92
			WEEK 32	2	79	78.6	84.9	91.1	91

Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.

Program Name: RTVIT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.8.1.1 Vital signs variables over time (Safety analysis set)

Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Result Min	Q1	Median	Q3	Max
Weight	kg	100mg(N=21)	WEEK 36	2	80	79.7	85.7	91.7	92
			WEEK 40	2	80	79.7	85.5	91.3	91
			WEEK 44	1	79	78.5	78.5	78.5	79
			WEEK 48	1	82	81.8	81.8	81.8	82
			DISCONTINUATION	17	55	61.0	73.9	88.8	102
		200mg(N=47)	SCREENING	46	47	66.9	79.2	93.3	139
			WEEK 0	44	47	67.4	78.8	93.8	139
			WEEK 1	45	46	66.0	77.7	88.7	140
			WEEK 2	36	46	70.9	78.5	92.5	146
			WEEK 3	30	45	67.4	78.1	91.2	140
			WEEK 4	20	44	69.5	79.3	102.9	137
			WEEK 8	3	69	68.7	135.8	143.7	144
			WEEK 12	2	67	67.1	67.1	67.1	67
			WEEK 16	2	64	64.4	104.0	143.5	144
			WEEK 20	1	146	145.8	145.8	145.8	146
			DISCONTINUATION	34	47	66.2	78.3	86.5	138

Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.

Program Name: RTVIT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.1.2 Vital signs variables, change from baseline over time
(Safety analysis set)

				Change from baseline					
Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
Systolic Blood Pressure	mmHg	100mg(N=21)	WEEK 0	20	-25	-17.0	-5.5	0.0	28
			WEEK 1	18	-29	-14.0	-4.0	5.0	22
			WEEK 2	14	-27	-12.0	-7.0	2.0	25
			WEEK 3	13	-20	-6.0	-2.0	8.0	31
			WEEK 4	11	-28	-19.0	-11.0	-6.0	27
			WEEK 8	3	-18	-11.0	0.0	12.0	20
			WEEK 12	2	-4	0.0	7.0	14.0	18
			WEEK 16	2	0	0.0	10.0	17.0	25
			WEEK 20	2	14	17.0	19.0	21.0	31
			WEEK 24	2	-7	4.0	11.5	18.0	20
			WEEK 28	2	-9	-8.0	1.0	12.0	18
			WEEK 32	2	-5	-1.0	12.0	20.0	23
			WEEK 36	2	1	5.0	21.0	31.0	36
			WEEK 40	2	-6	-3.0	7.5	28.0	31
			WEEK 44	1	25	25.0	27.0	32.0	32
			WEEK 48	1	7	7.0	20.0	22.0	22
			DISCONTINUATION	16	-29	-11.0	-3.0	7.5	32
		200mg(N=47)	WEEK 0	44	-35	-11.0	-1.0	7.0	32
			WEEK 1	45	-33	-3.0	10.0	22.0	49
			WEEK 2	36	-31	-3.0	8.5	16.0	44

NC=Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTVIT015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.1.2 Vital signs variables, change from baseline over time
(Safety analysis set)

				Change from baseline					
Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
Systolic Blood Pressure	mmHg	200mg(N=47)	WEEK 3	30	-27	1.0	7.0	15.0	67
			WEEK 4	20	-27	-2.0	6.0	14.0	36
			WEEK 8	3	-28	-21.0	4.0	6.0	15
			WEEK 12	2	-3	-3.0	7.0	10.0	11
			WEEK 16	2	-9	-9.0	-7.5	0.0	6
			WEEK 20	1	14	14.0	16.0	21.0	21
			DISCONTINUATION	33	-45	-12.0	4.0	12.0	46
Diastolic Blood Pressure	mmHg	100mg(N=21)	WEEK 0	20	-25	-14.0	-5.5	0.0	7
			WEEK 1	18	-23	-8.0	-0.5	7.0	23
			WEEK 2	14	-35	-12.5	-2.5	6.5	16
			WEEK 3	13	-31	-7.0	1.0	6.0	13
			WEEK 4	11	-33	-12.0	-7.0	0.0	10
			WEEK 8	3	-32	-28.0	-11.0	8.0	10
			WEEK 12	2	-37	-35.0	-20.5	-4.0	-3
			WEEK 16	2	-31	-30.0	-18.5	-9.0	-8
			WEEK 20	2	-40	-38.0	-14.5	7.0	11
			WEEK 24	2	-39	-36.0	-20.5	-2.0	1
			WEEK 28	2	-33	-30.0	-19.5	-7.0	-4
			WEEK 32	2	-34	-30.0	-18.5	-8.0	-6
			WEEK 36	2	-34	-28.0	-14.0	-4.0	-1

NC=Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTVIT015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.8.1.2 Vital signs variables, change from baseline over time (Safety analysis set)

Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	Change from baseline n	Min	Q1	Median	Q3	Max
Diastolic Blood Pressure	mmHg	100mg(N=21)	WEEK 40	2	-31	-29.0	-13.5	-5.0	-1
			WEEK 44	1	-22	-22.0	-22.0	-21.0	-21
			WEEK 48	1	-33	-33.0	-27.0	-26.0	-26
			DISCONTINUATION	16	-13	-4.0	2.5	8.0	16
		200mg(N=47)	WEEK 0	44	-32	-9.0	0.0	4.0	31
			WEEK 1	45	-17	-1.0	8.0	15.0	39
			WEEK 2	36	-24	-1.0	6.0	13.0	37
			WEEK 3	30	-18	2.0	6.0	11.0	37
			WEEK 4	20	-13	0.0	4.0	11.0	29
			WEEK 8	3	-7	-2.0	3.0	4.0	11
			WEEK 12	2	13	13.0	14.0	17.0	19
			WEEK 16	2	-7	-3.5	7.5	17.5	20
			WEEK 20	1	7	7.0	8.0	11.0	11
			DISCONTINUATION	33	-32	-3.0	2.0	10.0	24
Pulse Rate	BEATS/MIN	100mg(N=21)	WEEK 0	20	-19	-13.0	-5.0	6.0	29
			WEEK 1	18	-28	-14.5	-4.0	4.5	20
			WEEK 2	13	-23	-8.0	-4.0	9.0	16
			WEEK 3	13	-21	-11.0	-7.0	9.0	32
			WEEK 4	10	-16	-13.0	-8.0	-2.0	5
			WEEK 8	3	-22	-14.0	-11.0	-10.0	-5

NC=Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTVIT015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.8.1.2 Vital signs variables, change from baseline over time (Safety analysis set)

				Change from baseline					
Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
Pulse Rate	BEATS/MIN	100mg(N=21)	WEEK 12	2	-30	-29.0	-19.5	-8.0	-7
			WEEK 16	2	-26	-25.0	-18.5	-8.0	-3
			WEEK 20	2	-29	-29.0	-22.5	-14.0	-13
			WEEK 24	2	-27	-24.0	-20.5	-20.0	-17
			WEEK 28	2	-26	-24.0	-11.5	-1.0	-1
			WEEK 32	2	-24	-21.0	-12.5	1.0	3
			WEEK 36	2	-21	-19.0	-16.5	-11.0	-2
			WEEK 40	2	-21	-20.0	-13.0	-9.0	-8
			WEEK 44	1	-15	-15.0	-13.0	-13.0	-13
			WEEK 48	1	-16	-16.0	-14.0	-13.0	-13
			DISCONTINUATION	16	-33	-7.5	0.5	11.5	32
		200mg(N=47)	WEEK 0	44	-65	-12.0	-3.0	3.0	23
			WEEK 1	44	-35	-13.0	-5.5	4.0	65
			WEEK 2	34	-24	-8.0	-1.5	8.0	25
			WEEK 3	30	-28	-7.0	4.0	13.0	36
			WEEK 4	20	-23	-10.0	-3.0	3.0	34
			WEEK 8	3	-2	-1.0	6.0	9.0	27
			WEEK 12	2	0	2.0	14.5	28.0	30
			WEEK 16	2	-9	-8.0	-6.5	15.0	36
			WEEK 20	1	-7	-7.0	-7.0	-5.0	-5

NC=Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTVIT015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.1.2 Vital signs variables, change from baseline over time (Safety analysis set)

				Change from baseline					
Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
Pulse Rate	BEATS/MIN	200mg(N=47)	DISCONTINUATION	31	-33	-6.0	1.0	9.0	30
Weight	kg	100mg(N=21)	WEEK 0	17	-1	0.0	0.3	0.9	4
			WEEK 1	15	-3	-0.9	-0.1	0.5	3
			WEEK 2	14	-1	-0.7	0.5	1.1	10
			WEEK 3	12	-2	-0.7	0.3	1.9	3
			WEEK 4	11	-3	-1.6	0.2	2.4	3
			WEEK 8	3	-1	-0.8	3.5	4.5	5
			WEEK 12	2	5	4.8	5.3	5.7	6
			WEEK 16	2	5	4.7	5.3	5.9	6
			WEEK 20	2	5	5.0	6.2	7.4	7
			WEEK 24	2	5	5.2	6.3	7.4	7
			WEEK 28	2	4	4.1	6.8	9.5	10
			WEEK 32	2	3	3.4	6.3	9.3	9
			WEEK 36	2	4	4.0	7.2	10.4	10
			WEEK 40	2	4	3.6	7.0	10.4	10
			WEEK 44	1	9	9.2	9.2	9.2	9
			WEEK 48	1	13	12.5	12.5	12.5	13
			DISCONTINUATION	14	-4	-0.1	0.8	1.7	6
		200mg(N=47)	WEEK 0	43	-6	-1.0	0.0	0.6	7
			WEEK 1	43	-6	-1.9	-0.5	0.2	11

NC=Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTVIT015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.1.2 Vital signs variables, change from baseline over time
(Safety analysis set)

				Change from baseline					
Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
Weight	kg	200mg(N=47)	WEEK 2	34	-6	-1.3	-0.5	1.0	18
			WEEK 3	26	-5	-2.7	-0.5	1.7	12
			WEEK 4	19	-6	-2.8	-0.5	1.7	8
			WEEK 8	3	-4	-3.5	1.9	15.5	16
			WEEK 12	1	0	0.3	0.3	0.3	0
			WEEK 16	2	-2	-2.4	6.5	15.3	15
			WEEK 20	1	18	17.6	17.6	17.6	18
			DISCONTINUATION	32	-10	-4.1	-0.9	0.6	14

NC=Not calculated
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTVIT015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.1.3 Vital signs variables, change from baseline to maximum value during treatment (Safety analysis set)

				Result						Change from baseline				
Vital signs Variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max	n	Min	Q1	Median	Q3	Max
Systolic Blood Pressure	mmHg	100mg(N=21)	BL	20	102	114.5	123.0	134.5	149						
			Max	21	104	127.0	138.0	153.0	160	18	-15	0.0	8.5	25.0	36
		200mg(N=47)	BL	47	86	114.0	119.0	130.0	150						
			Max	47	104	130.0	142.0	151.0	194	45	-12	11.0	21.0	30.0	67
Diastolic Blood Pressure	mmHg	100mg(N=21)	BL	20	60	66.5	74.0	84.5	94						
			Max	21	68	78.0	84.0	89.0	106	16	-15	2.0	9.5	12.5	23
		200mg(N=47)	BL	47	53	62.0	73.0	79.0	97						
			Max	47	57	77.0	89.0	97.0	134	45	-6	11.0	14.0	20.0	39
Pulse Rate	BEATS/MIN	100mg(N=21)	BL	20	69	77.0	84.5	93.0	116						
			Max	21	66	86.0	96.0	105.0	130	18	-13	0.0	9.5	16.0	32
		200mg(N=47)	BL	47	56	76.0	87.0	97.0	125						
			Max	47	61	87.0	100.0	116.0	147	44	-25	4.5	13.0	23.0	65
Weight	kg	100mg(N=21)	BL	19	48	64.4	78.9	91.8	106						
			Max	21	51	64.5	79.6	92.9	106	19	-0	0.7	1.2	3.6	13
		200mg(N=47)	BL	47	47	66.8	78.8	93.3	139						
			Max	47	47	68.3	79.3	93.9	146	46	-5	-0.7	0.4	1.8	18

NC=Not calculated
BL Baseline. Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group.
Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTVIT015_max.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.1.4 Vital sign variables,changes outside predefined criteria
(Safety analysis set)

		Number(%) of patients	
		100mg BID (N=21)	200mg BID (N=47)
Systolic BP(mmHg)	<=100	7 (33.3)	19 (40.4)
	>150	5 (23.8)	8 (17.0)
	Change > 30[a]	2 (9.5)	9 (19.1)
	<=100 and change > 30[a]	0 (00.0)	1 (2.1)
	>150 and change > 30[a]	4 (19.0)	6 (12.8)
Diastolic BP(mmHg)	>90	1 (4.8)	4 (8.5)
	Change > 30[a]	1 (4.8)	4 (8.5)
	>90 and change > 30[a]	0 (00.0)	2 (4.3)
Pulse rate (beats/min)	<40	0 (00.0)	0 (00.0)
	>100	6 (28.6)	18 (38.3)
	Change > 20[a]	6 (28.6)	20 (42.6)
	<40 and change > 20[a]	0 (00.0)	0 (00.0)
	>100 and change > 20[a]	3 (14.3)	10 (21.3)

[a] Change from baseline to any observation on treatment.
Baseline is defined as the last result obtained prior to the start of study treatment.
On treatment is defined as assessments between the start of treatment and 30 days following the date of last dose of study medication.

Program Name: RTVIT999.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.2.1 ECG variables over time
(Safety analysis set)

				Result					
ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
Heart Rate	beats/min	100mg BID (N=21)	BASELINE	21	58	70.0	74.0	85.0	109
			SCREENING	21	58	70.0	74.0	85.0	109
			WEEK 0	21	58	69.0	78.0	90.0	118
			WEEK 4	12	52	64.5	73.0	79.5	89
			WEEK 8	4	64	66.5	74.0	81.0	83
			WEEK 12	2	61	61.0	65.0	69.0	69
			WEEK 16	2	64	64.0	69.0	74.0	74
			WEEK 20	2	61	61.0	65.5	70.0	70
			WEEK 24	2	62	62.0	65.5	69.0	69
			WEEK 28	2	59	59.0	70.0	81.0	81
			WEEK 32	2	64	64.0	74.5	85.0	85
			WEEK 36	2	63	63.0	68.5	74.0	74
			WEEK 40	2	62	62.0	64.5	67.0	67
			WEEK 44	1	68	68.0	68.0	68.0	68
			WEEK 48	1	67	67.0	67.0	67.0	67
			DISCONTINUATION	11	59	66.0	80.0	95.0	121
		200mg BID (N=47)	BASELINE	46	50	67.0	80.5	91.0	118
			SCREENING	47	50	67.0	81.0	93.0	118
			WEEK 0	44	52	69.5	79.5	88.0	121
			WEEK 4	23	44	64.0	70.0	89.0	126
			WEEK 8	3	62	62.0	80.0	107.0	107
			WEEK 12	1	63	63.0	63.0	63.0	63

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.2.1 ECG variables over time
(Safety analysis set)

ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	Result					
				n	Min	Q1	Median	Q3	Max
Heart Rate	beats/min	200mg BID (N=47)	WEEK 16	2	52	52.0	85.0	118.0	118
			WEEK 20	1	49	49.0	49.0	49.0	49
			DISCONTINUATION	22	52	79.0	84.5	98.0	120
PR Interval	ms	100mg BID (N=21)	BASELINE	21	0	142.0	156.0	176.0	191
			SCREENING	21	0	142.0	156.0	176.0	191
			WEEK 0	21	0	138.0	156.0	171.0	198
			WEEK 4	12	124	144.0	172.5	178.0	188
			WEEK 8	4	144	146.0	157.0	171.0	176
			WEEK 12	2	152	152.0	168.5	185.0	185
			WEEK 16	2	148	148.0	164.0	180.0	180
			WEEK 20	2	146	146.0	164.5	183.0	183
			WEEK 24	2	160	160.0	166.0	172.0	172
			WEEK 28	2	164	164.0	174.0	184.0	184
			WEEK 32	2	180	180.0	180.0	180.0	180
			WEEK 36	2	120	120.0	144.0	168.0	168
			WEEK 40	2	156	156.0	164.0	172.0	172
			WEEK 44	1	144	144.0	144.0	144.0	144
			WEEK 48	1	152	152.0	152.0	152.0	152
			DISCONTINUATION	10	128	132.0	162.0	197.0	214
		200mg BID (N=47)	BASELINE	44	84	134.0	154.0	170.0	254
			SCREENING	45	84	134.0	152.0	170.0	254

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.8.2.1 ECG variables over time
(Safety analysis set)

ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	Result					
				n	Min	Q1	Median	Q3	Max
PR Interval	ms	200mg BID (N=47)	WEEK 0	43	112	136.0	154.0	172.0	268
			WEEK 4	23	112	154.0	164.0	188.0	228
			WEEK 8	3	118	118.0	168.0	204.0	204
			WEEK 12	1	180	180.0	180.0	180.0	180
			WEEK 16	2	118	118.0	171.0	224.0	224
			WEEK 20	1	184	184.0	184.0	184.0	184
			DISCONTINUATION	21	100	136.0	154.0	174.0	216
QT Interval	ms	100mg BID (N=21)	BASELINE	21	320	380.0	395.0	402.0	452
			SCREENING	21	320	380.0	395.0	402.0	452
			WEEK 0	21	300	380.0	392.0	426.0	453
			WEEK 4	12	346	386.0	399.0	419.0	448
			WEEK 8	4	380	386.0	393.0	411.0	428
			WEEK 12	2	396	396.0	413.5	431.0	431
			WEEK 16	2	392	392.0	408.0	424.0	424
			WEEK 20	2	392	392.0	416.5	441.0	441
			WEEK 24	2	404	404.0	410.0	416.0	416
			WEEK 28	2	372	372.0	400.0	428.0	428
			WEEK 32	2	388	388.0	402.0	416.0	416
			WEEK 36	2	368	368.0	396.0	424.0	424
			WEEK 40	2	404	404.0	406.0	408.0	408
			WEEK 44	1	384	384.0	384.0	384.0	384
			WEEK 48	1	396	396.0	396.0	396.0	396

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.8.2.1 ECG variables over time
(Safety analysis set)

ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	Result					
				n	Min	Q1	Median	Q3	Max
QT Interval	ms	100mg BID (N=21)	DISCONTINUATION	11	320	368.0	380.0	418.0	438
		200mg BID (N=47)	BASELINE	46	312	360.0	392.0	418.0	465
			SCREENING	47	312	352.0	392.0	418.0	465
			WEEK 0	44	320	362.0	382.0	415.0	452
			WEEK 4	23	284	372.0	400.0	432.0	482
			WEEK 8	3	338	338.0	410.0	432.0	432
			WEEK 12	1	452	452.0	452.0	452.0	452
			WEEK 16	2	306	306.0	405.0	504.0	504
			WEEK 20	1	464	464.0	464.0	464.0	464
			DISCONTINUATION	22	306	332.0	358.0	388.0	468
QRS Duration	ms	100mg BID (N=21)	BASELINE	21	73	84.0	86.0	96.0	138
			SCREENING	21	73	84.0	86.0	96.0	138
			WEEK 0	21	72	83.0	88.0	98.0	134
			WEEK 4	12	74	79.0	88.0	94.5	142
			WEEK 8	4	72	85.5	103.5	120.0	132
			WEEK 12	2	98	98.0	120.5	143.0	143
			WEEK 16	2	96	96.0	116.0	136.0	136
			WEEK 20	2	94	94.0	119.0	144.0	144
			WEEK 24	2	95	95.0	115.5	136.0	136
			WEEK 28	2	96	96.0	116.0	136.0	136

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.8.2.1 ECG variables over time
(Safety analysis set)

ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	Result					
				n	Min	Q1	Median	Q3	Max
QRS Duration	ms	100mg BID (N=21)	WEEK 32	2	98	98.0	122.0	146.0	146
			WEEK 36	2	99	99.0	120.5	142.0	142
			WEEK 40	2	98	98.0	117.0	136.0	136
			WEEK 44	1	94	94.0	94.0	94.0	94
			WEEK 48	1	98	98.0	98.0	98.0	98
			DISCONTINUATION	11	72	78.0	88.0	94.0	120
		200mg BID (N=47)	BASELINE	46	68	82.0	90.0	102.0	156
			SCREENING	47	68	82.0	90.0	102.0	156
			WEEK 0	44	70	81.0	89.0	98.0	164
			WEEK 4	23	74	82.0	94.0	114.0	160
			WEEK 8	3	104	104.0	118.0	158.0	158
			WEEK 12	1	118	118.0	118.0	118.0	118
			WEEK 16	2	94	94.0	103.0	112.0	112
			WEEK 20	1	114	114.0	114.0	114.0	114
			DISCONTINUATION	22	66	76.0	88.0	108.0	156
RR Interval	ms	100mg BID (N=21)	BASELINE	21	550.459	705.8824	810.8108	857.1429	1034.483
			SCREENING	21	550.459	705.8824	810.8108	857.1429	1034.483
			WEEK 0	21	508.475	666.6667	769.2308	869.5652	1034.483
			WEEK 4	12	674.157	754.7468	822.0721	930.2885	1153.846
			WEEK 8	4	722.892	741.1926	814.5294	903.5326	937.500
			WEEK 12	2	869.565	869.5652	926.5859	983.6066	983.607

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.8.2.1 ECG variables over time
(Safety analysis set)

ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	Result					
				n	Min	Q1	Median	Q3	Max
RR Interval	ms	100mg BID (N=21)	WEEK 16	2	810.811	810.8108	874.1554	937.5000	937.500
			WEEK 20	2	857.143	857.1429	920.3747	983.6066	983.607
			WEEK 24	2	869.565	869.5652	918.6536	967.7419	967.742
			WEEK 28	2	740.741	740.7407	878.8449	1016.9492	1016.949
			WEEK 32	2	705.882	705.8824	821.6912	937.5000	937.500
			WEEK 36	2	810.811	810.8108	881.5959	952.3810	952.381
			WEEK 40	2	895.522	895.5224	931.6322	967.7419	967.742
			WEEK 44	1	882.353	882.3529	882.3529	882.3529	882.353
			WEEK 48	1	895.522	895.5224	895.5224	895.5224	895.522
			DISCONTINUATION	11	495.868	631.5789	750.0000	909.0909	1016.949
		200mg BID (N=47)	BASELINE	46	508.475	659.3407	745.3704	895.5224	1200.000
			SCREENING	47	508.475	645.1613	740.7407	895.5224	1200.000
			WEEK 0	44	495.868	681.8182	754.7468	863.3540	1153.846
			WEEK 4	23	476.190	674.1573	857.1429	937.5000	1363.636
			WEEK 8	3	560.748	560.7477	750.0000	967.7419	967.742
			WEEK 12	1	952.381	952.3810	952.3810	952.3810	952.381
			WEEK 16	2	508.475	508.4746	831.1604	1153.8462	1153.846
			WEEK 20	1	1224.490	1224.4898	1224.4898	1224.4898	1224.490
			DISCONTINUATION	22	500.000	612.2449	710.6812	759.4937	1153.846
QTcF	ms	100mg BID (N=21)	BASELINE	21	387.07	417.960	425.362	440.217	473.56
			SCREENING	21	387.07	417.960	425.362	440.217	473.56

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.2.1 ECG variables over time
(Safety analysis set)

ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	Result					
				n	Min	Q1	Median	Q3	Max
QTcF	ms	100mg BID (N=21)	WEEK 0	21	375.86	419.095	440.141	446.316	469.36
			WEEK 4	12	380.82	417.719	424.723	432.960	444.29
			WEEK 8	4	410.69	413.594	426.901	438.157	439.01
			WEEK 12	2	414.89	414.885	424.133	433.381	433.38
			WEEK 16	2	420.38	420.384	426.802	433.220	433.22
			WEEK 20	2	412.67	412.669	428.053	443.437	443.44
			WEEK 24	2	420.57	420.572	421.919	423.267	423.27
			WEEK 28	2	411.14	411.138	418.373	425.609	425.61
			WEEK 32	2	425.05	425.046	430.407	435.767	435.77
			WEEK 36	2	394.65	394.646	412.799	430.952	430.95
			WEEK 40	2	412.48	412.484	415.810	419.137	419.14
			WEEK 44	1	400.36	400.360	400.360	400.360	400.36
			WEEK 48	1	410.84	410.837	410.837	410.837	410.84
			DISCONTINUATION	11	387.31	404.292	431.493	435.854	442.90
		200mg BID (N=47)	BASELINE	46	353.59	407.433	425.204	439.531	503.12
			SCREENING	47	353.59	407.433	425.046	439.531	503.12
			WEEK 0	44	361.89	404.350	415.695	434.515	461.65
			WEEK 4	23	363.68	410.837	431.618	447.415	489.68
			WEEK 8	3	409.88	409.884	436.748	451.263	451.26
			WEEK 12	1	459.41	459.411	459.411	459.411	459.41
			WEEK 16	2	383.38	383.382	431.953	480.523	480.52
			WEEK 20	1	433.71	433.710	433.710	433.710	433.71
			DISCONTINUATION	21	350.00	398.054	408.214	431.247	475.78

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.2.2 ECG variables, change from baseline over time
(Safety analysis set)

				Change from baseline					
ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
Heart Rate	beats/min	100mg BID (N=21)	WEEK 0	21	-11	-2.0	1.0	5.0	18
			WEEK 4	12	-21	-10.5	-4.0	-0.5	6
			WEEK 8	4	-11	-8.5	-6.0	1.5	9
			WEEK 12	2	-14	-14.0	-10.0	-6.0	-6
			WEEK 16	2	-11	-11.0	-6.0	-1.0	-1
			WEEK 20	2	-14	-14.0	-9.5	-5.0	-5
			WEEK 24	2	-13	-13.0	-9.5	-6.0	-6
			WEEK 28	2	-16	-16.0	-5.0	6.0	6
			WEEK 32	2	-11	-11.0	-0.5	10.0	10
			WEEK 36	2	-12	-12.0	-6.5	-1.0	-1
			WEEK 40	2	-13	-13.0	-10.5	-8.0	-8
			WEEK 44	1	-7	-7.0	-7.0	-7.0	-7
			WEEK 48	1	-8	-8.0	-8.0	-8.0	-8
			DISCONTINUATION	11	-14	2.0	6.0	13.0	22
		200mg BID (N=47)	WEEK 0	43	-24	-6.0	1.0	6.0	32
			WEEK 4	23	-26	-10.0	2.0	9.0	28
			WEEK 8	3	1	1.0	7.0	8.0	8
			WEEK 12	1	8	8.0	8.0	8.0	8
			WEEK 16	2	-3	-3.0	8.0	19.0	19
			WEEK 20	1	-6	-6.0	-6.0	-6.0	-6
			DISCONTINUATION	21	-15	1.0	7.0	21.0	33

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.2.2 ECG variables, change from baseline over time
(Safety analysis set)

				Change from baseline					
ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
PR Interval	ms	100mg BID (N=21)	WEEK 0	21	-30	-4.0	-2.0	14.0	20
			WEEK 4	12	-26	-2.0	5.0	11.0	18
			WEEK 8	4	-16	-14.0	-7.0	9.0	20
			WEEK 12	2	-8	-8.0	10.5	29.0	29
			WEEK 16	2	-12	-12.0	6.0	24.0	24
			WEEK 20	2	-14	-14.0	6.5	27.0	27
			WEEK 24	2	0	0.0	8.0	16.0	16
			WEEK 28	2	4	4.0	16.0	28.0	28
			WEEK 32	2	20	20.0	22.0	24.0	24
			WEEK 36	2	-40	-40.0	-14.0	12.0	12
			WEEK 40	2	-4	-4.0	6.0	16.0	16
			WEEK 44	1	-16	-16.0	-16.0	-16.0	-16
			WEEK 48	1	-8	-8.0	-8.0	-8.0	-8
			DISCONTINUATION	10	-16	-6.0	-3.0	18.0	32
		200mg BID (N=47)	WEEK 0	41	-22	-4.0	2.0	10.0	44
			WEEK 4	23	-12	-8.0	0.0	12.0	47
			WEEK 8	3	2	2.0	6.0	23.0	23
			WEEK 12	1	-1	-1.0	-1.0	-1.0	-1
			WEEK 16	2	6	6.0	24.5	43.0	43
			WEEK 20	1	3	3.0	3.0	3.0	3
			DISCONTINUATION	20	-14	-9.0	5.0	8.0	32

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.2.2 ECG variables, change from baseline over time
(Safety analysis set)

				Change from baseline					
ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
QT Interval	ms	100mg BID (N=21)	WEEK 0	21	-38	-8.0	4.0	12.0	40
			WEEK 4	12	-18	-1.0	8.0	14.0	46
			WEEK 8	4	-20	-8.0	6.0	20.0	32
			WEEK 12	2	8	8.0	21.5	35.0	35
			WEEK 16	2	4	4.0	16.0	28.0	28
			WEEK 20	2	4	4.0	24.5	45.0	45
			WEEK 24	2	8	8.0	18.0	28.0	28
			WEEK 28	2	-16	-16.0	8.0	32.0	32
			WEEK 32	2	0	0.0	10.0	20.0	20
			WEEK 36	2	-20	-20.0	4.0	28.0	28
			WEEK 40	2	12	12.0	14.0	16.0	16
			WEEK 44	1	-4	-4.0	-4.0	-4.0	-4
			WEEK 48	1	8	8.0	8.0	8.0	8
			DISCONTINUATION	11	-62	-16.0	-12.0	0.0	36
		200mg BID (N=47)	WEEK 0	43	-76	-18.0	-4.0	14.0	48
			WEEK 4	23	-60	-22.0	-4.0	28.0	60
			WEEK 8	3	-50	-50.0	-30.0	-8.0	-8
			WEEK 12	1	-10	-10.0	-10.0	-10.0	-10
			WEEK 16	2	-82	-82.0	-20.0	42.0	42
			WEEK 20	1	2	2.0	2.0	2.0	2
			DISCONTINUATION	21	-96	-46.0	-20.0	2.0	28

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.2.2 ECG variables, change from baseline over time
(Safety analysis set)

				Change from baseline					
ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
QRS Duration	ms	100mg BID (N=21)	WEEK 0	21	-8	-4.0	0.0	2.0	12
			WEEK 4	12	-10	-5.0	0.0	3.0	10
			WEEK 8	4	-10	-5.0	0.0	1.5	3
			WEEK 12	2	2	2.0	6.5	11.0	11
			WEEK 16	2	0	0.0	2.0	4.0	4
			WEEK 20	2	-2	-2.0	5.0	12.0	12
			WEEK 24	2	-1	-1.0	1.5	4.0	4
			WEEK 28	2	0	0.0	2.0	4.0	4
			WEEK 32	2	2	2.0	8.0	14.0	14
			WEEK 36	2	3	3.0	6.5	10.0	10
			WEEK 40	2	2	2.0	3.0	4.0	4
			WEEK 44	1	-2	-2.0	-2.0	-2.0	-2
			WEEK 48	1	2	2.0	2.0	2.0	2
			DISCONTINUATION	11	-18	-6.0	0.0	7.0	10
		200mg BID (N=47)	WEEK 0	43	-34	-6.0	0.0	6.0	10
			WEEK 4	23	-10	-2.0	2.0	4.0	8
			WEEK 8	3	2	2.0	4.0	8.0	8
			WEEK 12	1	4	4.0	4.0	4.0	4
			WEEK 16	2	-2	-2.0	-2.0	-2.0	-2
			WEEK 20	1	0	0.0	0.0	0.0	0
			DISCONTINUATION	21	-18	-10.0	2.0	6.0	8

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.8.2.2 ECG variables, change from baseline over time
(Safety analysis set)

				Change from baseline					
ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
RR Interval	ms	100mg BID (N=21)	WEEK 0	21	-158.637	-41.9841	-10.5263	26.7380	110.599
			WEEK 4	12	-71.542	5.8685	44.6130	103.3935	331.928
			WEEK 8	4	-97.649	-24.4575	59.1497	103.5326	137.500
			WEEK 12	2	69.565	69.5652	126.5859	183.6066	183.607
			WEEK 16	2	10.811	10.8108	74.1554	137.5000	137.500
			WEEK 20	2	57.143	57.1429	120.3747	183.6066	183.607
			WEEK 24	2	69.565	69.5652	118.6536	167.7419	167.742
			WEEK 28	2	-59.259	-59.2593	78.8449	216.9492	216.949
			WEEK 32	2	-94.118	-94.1176	21.6912	137.5000	137.500
			WEEK 36	2	10.811	10.8108	81.5959	152.3810	152.381
			WEEK 40	2	95.522	95.5224	131.6322	167.7419	167.742
			WEEK 44	1	82.353	82.3529	82.3529	82.3529	82.353
			WEEK 48	1	95.522	95.5224	95.5224	95.5224	95.522
			DISCONTINUATION	11	-212.565	-95.7290	-60.8108	-28.4091	195.031
		200mg BID (N=47)	WEEK 0	43	-367.816	-58.4795	-9.4937	53.6113	248.920
			WEEK 4	23	-163.683	-138.5281	-14.4928	143.6782	278.224
			WEEK 8	3	-123.167	-123.1672	-45.3129	-9.4937	-9.494
			WEEK 12	1	-138.528	-138.5281	-138.5281	-138.5281	-138.528
			WEEK 16	2	-97.586	-97.5860	-17.3245	62.9371	62.937
			WEEK 20	1	133.581	133.5807	133.5807	133.5807	133.581
			DISCONTINUATION	21	-340.909	-173.0769	-95.0704	-4.2729	143.678

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.2.2 ECG variables, change from baseline over time
(Safety analysis set)

				Change from baseline					
ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max
QTcF	ms	100mg BID (N=21)	WEEK 0	21	-14.59	-4.191	6.177	15.285	46.45
			WEEK 4	12	-20.65	-6.843	0.187	6.020	10.81
			WEEK 8	4	-7.27	-5.931	-2.903	4.760	10.73
			WEEK 12	2	-3.08	-3.075	1.864	6.803	6.80
			WEEK 16	2	2.42	2.424	4.533	6.642	6.64
			WEEK 20	2	-5.29	-5.292	5.783	16.858	16.86
			WEEK 24	2	-3.31	-3.311	-0.350	2.611	2.61
			WEEK 28	2	-6.82	-6.822	-3.896	-0.969	-0.97
			WEEK 32	2	-1.53	-1.532	8.137	17.807	17.81
			WEEK 36	2	-23.31	-23.314	-9.470	4.374	4.37
			WEEK 40	2	-14.09	-14.094	-6.459	1.177	1.18
			WEEK 44	1	-17.60	-17.601	-17.601	-17.601	-17.60
			WEEK 48	1	-7.12	-7.123	-7.123	-7.123	-7.12
			DISCONTINUATION	11	-31.36	-3.318	0.316	6.396	21.71
		200mg BID (N=47)	WEEK 0	43	-57.44	-13.438	-2.044	8.421	27.92
			WEEK 4	23	-41.44	-9.709	0.775	11.599	64.64
			WEEK 8	3	-48.60	-48.602	-12.045	-6.880	-6.88
			WEEK 12	1	10.62	10.618	10.618	10.618	10.62
			WEEK 16	2	-75.10	-75.104	-21.687	31.731	31.73
			WEEK 20	1	-15.08	-15.083	-15.083	-15.083	-15.08
			DISCONTINUATION	20	-60.32	-18.637	-4.623	2.003	27.45

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG015.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.2.3 ECG variables, change from baseline to maximum value during treatment (Safety analysis set)

ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	Result n	Result Min	Result Q1	Result Median	Result Q3	Result Max	Change from baseline n	Change from baseline Min	Change from baseline Q1	Change from baseline Median	Change from baseline Q3	Change from baseline Max
Heart Rate	beats/min	100mg BID (N=21)	Baseline	21	58	70.0	74.0	85.0	109						
			Max	21	65	74.0	83.0	95.0	121	21	-11	2.0	6.0	12.0	22
		200mg BID (N=47)	Baseline	46	50	67.0	80.5	91.0	118						
			Max	47	52	75.0	87.0	98.0	126	46	-24	0.0	6.5	17.0	33
PR Interval	ms	100mg BID (N=21)	Baseline	21	0	142.0	156.0	176.0	191						
			Max	21	0	154.0	168.0	180.0	214	21	-20	-2.0	8.0	20.0	32
		200mg BID (N=47)	Baseline	44	84	134.0	154.0	170.0	254						
			Max	46	112	140.0	155.0	182.0	268	44	-22	0.0	6.0	11.0	47
QT Interval	ms	100mg BID (N=21)	Baseline	21	320	380.0	395.0	402.0	452						
			Max	21	320	380.0	402.0	432.0	453	21	-22	-3.0	7.0	28.0	46
		200mg BID (N=47)	Baseline	46	312	360.0	392.0	418.0	465						
			Max	47	284	366.0	394.0	416.0	504	46	-76	-14.0	0.0	28.0	60

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG015_MAX.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.2.3 ECG variables, change from baseline to maximum value during treatment (Safety analysis set)

				Result						Change from baseline					
ECG variable	SI-unit	Fostamatinib, assigned starting dose	Time point	n	Min	Q1	Median	Q3	Max	n	Min	Q1	Median	Q3	Max
QRS Duration	ms	100mg BID (N=21)	Baseline	21	73	84.0	86.0	96.0	138						
			Max	21	72	84.0	92.0	98.0	146	21	-8	-1.0	2.0	4.0	14
		200mg BID (N=47)	Baseline	46	68	82.0	90.0	102.0	156						
			Max	47	70	82.0	90.0	100.0	164	46	-34	-4.0	1.0	6.0	10
RR Interval	ms	100mg BID (N=21)	Baseline	21	550.5	705.88	810.81	857.14	1034.5						
			Max	21	508.5	740.74	845.07	952.38	1153.8	21	-105.9	-20.16	11.74	82.82	331.9
		200mg BID (N=47)	Baseline	46	508.5	659.34	745.37	895.52	1200.0						
			Max	47	476.2	681.82	769.23	909.09	1363.6	46	-175.3	-56.43	0.00	107.66	278.2
QTcF	ms	100mg BID (N=21)	Baseline	21	387.1	417.96	425.36	440.22	473.6						
			Max	21	395.3	419.09	441.12	446.32	469.4	21	-11.4	-3.04	10.88	15.75	46.5
		200mg BID (N=47)	Baseline	46	353.6	407.43	425.20	439.53	503.1						
			Max	47	361.9	405.04	424.93	449.34	489.7	46	-57.4	-8.86	3.72	16.94	64.6

NC = Not calculated.
Max Maximum. Min Minimum. n Number of patients included in analysis. N Number of patients in treatment group. Q1 1st quartile. Q3 3rd quartile. SI International System of Units.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RTTECG015_MAX.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Table 11.3.8.2.4 QTcF and QTcF intervals, at any observation on treatment
(Safety analysis set)

	Number (%) of patients	
	100mg BID (N=21)	200mg BID (N=47)
QTcF value above xxx ms at any time during treatment		
> 450 (ms)	1 (4.8)	13 (27.7)
> 480 (ms)	0 (0.0)	2 (4.3)
QTcF increase [a] by more than yy ms at any time during treatment		
> 30 (ms)	1 (4.8)	1 (2.1)
> 60 (ms)	0 (0.0)	1 (2.1)
QTcF value above xxx ms and QTcF increase [a] by more than yy ms at any time during treatment		
Value >450 (ms) and increase >30 (ms)	0 (0.0)	1 (2.1)

[a] Change from baseline to any observation on treatment.
Baseline is defined as the last result obtained prior to the start of study treatment.
On treatment is defined as assessments between the start of treatment and 30 days following the date of last dose of study medication.
Fridericia's correction has been used for QTc.

Program Name: RTTECG021.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013

Table 11.3.8.3 WHO Performance status,baseline versus last observation on treatment-shift table (Safety analysis set)

			Assessment at end of treatment					
Fostamatinib, assigned starting dose	Baseline assessment	n	0-Normal activity	1-Restricted activity	2-In bed <=50% of the time	3-In bed >50% of the time	4-100% bedridden	Not done
100mg BID (N=21)	0-Normal activity	9	6(66.7)	3(33.3)	0(0.0)	0(0.0)	0(0.0)	0(0.0)
	1-Restricted activity	11	0(0.0)	10(90.9)	1(9.1)	0(0.0)	0(0.0)	0(0.0)
	2-In bed <=50% of the time	0	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)
	3-In bed >50% of the time	0	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)
	4-100% bedridden	0	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)
	Not done	1	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	1(100.0)
	Total	21	6(28.6)	13(61.9)	1(4.8)	0(0.0)	0(0.0)	1(4.8)
200mg BID (N=47)	0-Normal activity	9	5(55.6)	3(33.3)	0(0.0)	0(0.0)	0(0.0)	1(11.1)
	1-Restricted activity	36	3(8.3)	22(61.1)	5(13.9)	2(5.6)	1(2.8)	3(8.3)
	2-In bed <=50% of the time	0	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)
	3-In bed >50% of the time	0	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)
	4-100% bedridden	0	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)
	Not done	2	0(0.0)	0(0.0)	1(50.0)	0(0.0)	0(0.0)	1(50.0)
	Total	47	8(17.0)	25(53.2)	6(12.8)	2(4.3)	1(2.1)	5(10.6)

n Number of patients in baseline category
Baseline is defined as the last result obtained prior to the start of study treatment.
% calculated using each baseline assessment n as denominator
On treatment is defined as assessments between the start of treatment and 30 days following the date of last dose of study medication.

Program Name: RTPSTAT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.1 Plot of geometric mean (+/- SD) plasma concentrations (ng/mL) of fostamatinib (metabolite R406) versus time for 100mg and 200mg
PK analysis set

Analysis Relative Day=1



Program Name: RF2PC301
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.1 Plot of geometric mean (+/- SD) plasma concentrations (ng/mL) of fostamatinib (metabolite R406) versus time for 100mg and 200mg
PK analysis set

Analysis Relative Day=8



Program Name: RF2PC301
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.1 Plot of geometric mean (+/- SD) plasma concentrations (ng/mL) of fostamatinib (metabolite R406) versus time for 100mg and 200mg
PK analysis set

Analysis Relative Day=29



Program Name: RF2PC301
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E2S13002 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E2S14001 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E7601001 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E7601003 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E7306003 Day=1



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E7306003 Day=8



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E7306003 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E7306005 Day=1



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E7306005 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E7308001 Day=8



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E7308001 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E7[illegible]5 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=100mg SUBJID=E7[illegible] Day=8



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=100mg SUBJID=E7[illegible] Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=100mg SUBJID=E7810002 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=100mg SUBJID=E7815004 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=100mg SUBJID=E7822002 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E2S13001 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E2S13005 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E2S13006 Day=1



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E2S13007 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E2S13008 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7801006 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7801007 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7[illegible] Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7804002 Day=8



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7306007 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7[illegible]2 Day=8



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7[illegible]2 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7[illegible]007 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7809001 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7809004 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7810001 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7810004 Day=8



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7810004 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7812001 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7815001 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7815008 Day=1



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7815008 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7815012 Day=1



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7817005 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7817006 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7819002 Day=8



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7819002 Day=29



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7522003 Day=8



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)

Treatment Arm=200mg SUBJID=E7522004 Day=1



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)

Treatment Arm=200mg SUBJID=E7522004 Day=8



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatirib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.1.2 Plot of individual plasma concentrations (ng/mL) of fostamatinib (metabolite R406)



Program Name: RF2PC300
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.2.2.1 Progression-free survival, Kaplan-Meier plot
(Full analysis set)



Program Name: RFTEFF030_PFS.sas
Data Cutoff: 30OCT2013
Report Produced: December 10, 2013
SCRI for AstraZeneca

Figure 11.2.2.2 Target Lesion size, percentage change waterfall plot
(Full analysis set)



Best change in target lesion size is the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction

Program Name: RFZeff030
Data Cutoff: 300CT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.1.1 Haematology data, box plot of Hemoglobin absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.1.2 Haematology data, box-plot of Hemoglobin change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.1.3 Hemoglobin, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.2.1 Haematology data, box plot of Erythrocytes absolute values (Safety analysis set)

Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.2.2 Haematology data, box-plot of Erythrocytes change from baseline (Safety analysis set)

Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.2.3 Erythrocytes, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.3.1 Haematology data, box plot of Leukocytes absolute values (Safety analysis set)

Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.3.2 Haematology data, box-plot of Leukocytes change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.3.3 Leukocytes, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.4.1 Haematology data, box plot of Basophils absolute values (Safety analysis set)

Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.4.2 Haematology data, box-plot of Basophils change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.4.3 Basophils, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.5.1 Haematology data, box plot of Eosinophils absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.5.2 Haematology data, box-plot of Eosinophils change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.5.3 Eosinophils, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.6.1 Haematology data, box plot of Monocytes absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.6.2 Haematology data, box-plot of Monocytes change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.6.3 Monocytes, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.7.1 Haematology data, box plot of Lymphocytes absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.7.2 Haematology data, box-plot of Lymphocytes change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.7.3 Lymphocytes, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.8.1 Haematology data, box plot of Neutrophils absolute values (Safety analysis set)

Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.8.2 Haematology data, box-plot of Neutrophils change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.8.3 Neutrophils, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.9.1 Haematology data, box plot of Platelets absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.9.2 Haematology data, box-plot of Platelets change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.9.3 Platelets, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.10.1 Haematology data, box plot of Activated Partial Thromboplastin Time absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.10.2 Haematology data, box-plot of Activated Partial Thromboplastin Time change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.10.3 Activated Partial Thromboplastin Time, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.11.1 Haematology data, box plot of Prothrombin Intl. Normalized Ratio absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.11.2 Haematology data, box-plot of Prothrombin Intl. Normalized Ratio change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.11.3 Prothrombin Intl. Normalized Ratio, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.12.1 Haematology data, box plot of Prothrombin Time absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.12.2 Haematology data, box-plot of Prothrombin Time change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.12.3 Prothrombin Time, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.13.1 Clinical chemistry data, box plot of Alanine Aminotransferase absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.13.2 Clinical chemistry data, box-plot of Alanine Aminotransferase change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.13.3 Alanine Aminotransferase, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.14.1 Clinical chemistry data, box plot of Aspartate Aminotransferase absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.14.2 Clinical chemistry data, box-plot of Aspartate Aminotransferase change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.14.3 Aspartate Aminotransferase, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.15.1 Clinical chemistry data, box plot of Alkaline Phosphatase absolute values
(Safety analysis set)

Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.15.2 Clinical chemistry data, box-plot of Alkaline Phosphatase change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.15.3 Alkaline Phosphatase, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.16.1 Clinical chemistry data, box plot of Protein absolute values
(Safety analysis set)

Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.16.2 Clirical chemistry data, box-plot of Protein change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.16.3 Protein, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.17.1 Clinical chemistry data, box plot of **Albumin** absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.17.2 Clirical chemistry data, box-plot of Albumin change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.17.3 Albumin, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.18.1 Clirical chemistry data, box plot of Bilirubin absoluto valuo
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.18.2 Clirical chemistry data, box-plot of Bilirubin change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.18.3 Bilirubin, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.19.1 Clirical chemistry data, box plot of Calcium absolute values
(Safety analysis set)

Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.19.2 Clinical chemistry data, box-plot of Calcium change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.19.3 Calcium, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.20.1 Clirical chemistry data, box plot of Sodium absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.20.2 Clirical chemistry data, box-plot of Sodium change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.20.3 Sodium, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.21.1 Clirical chemistry data, box plot of Potassium absolute values
(Safety analysis set)

Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.21.2 Clirical chemistry data, box-plot of Potassium change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.21.3 Potassium, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.22.1 Clirical chemistry data, box plot of Magnesium absoluto values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.22.2 Clinical chemistry data, box-plot of Magnesium change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.22.3 Magnesium, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.23.1 Clirical chemistry data, box plot of Phosphate absoluto valuo
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.23.2 Clinical chemistry data, box-plot of Phosphate change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.23.3 Phosphate, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.24.1 Clinical chemistry data, box plot of Glucose absoluto values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.24.2 Clinical chemistry data, box-plot of Glucose change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.24.3 Glucose, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.25.1 Clinical chemistry data, box plot of Urea absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.25.2 Clirical chemistry data, box-plot of Urea change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.25.3 Urea, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.26.1 Clirical chemistry data, box plot of Creatirine absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.26.2 Clinical chemistry data, box-plot of Creatinine change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.26.3 Creatinine, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.27.1 Clinical chemistry data, box plot of Creatine Kinase absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.27.2 Clinical chemistry data, box-plot of Creatine Kinase change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.27.3 Creatine Kinase, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.1.26.1 Clinical chemistry data, box plot of Lactate Dehydrogenase absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Dotted lines represent project lab reference ranges.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.26.2 Clinical chemistry data, box-plot of Lactate Dehydrogenase change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZLAB010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.7.1.28.3 Lactate Dehydrogenase, baseline versus maximum observation on treatment - shift plot (Safety analysis set)



Dotted lines represent JAMA standard refernce ranges
Baseline is defined as the last result obtained prior to the start of study treatment

Program Name: RFZLAB050
Data Cutoff: 30OCT2013
SCRI for AstraZeneca

Figure 11.3.7.2 ALT versus total bilirubin, expressed as multiples of ULN
(Safety analysis set)



ALT Alanine aminotransferase ULN Upper limit of normal.
Vertical Reference line value: 3 & 5. Horizontal reference line value: 2
Upper limit values: ALT=0.68 Bili = 21

Program Name: RFZLAB030
Data Cutoff: 30OCT2013
SCRI for: AstraZeneca

Figure 11.3.7.3 AST versus total bilirubin, expressed as multiples of ULN
(Safety analysis set)



AST Aspartate aminotransferase ULN Upper limit of normal.
Vertical Reference line value: 3 & 5. Horizontal reference line value: 2
Upper limit values: AST=0.51 Bili = 21

Program Name: RFZLAB030
Data Cutoff: 30OCT2013
SCRI for: AstraZeneca

Figure 11.3.7.4 Liver biochemistry test results over time - patients with elevated ALT or AST, and elevated total bilirubin, at any time
(Safety analysis set)

Subject Identifier for the Study=E7501.005



ALP Alkaline phosphatase. ALT Alanine aminotransferase. AST Aspartate aminotransferase.
ULN Upper limit of normal.
Reference ranges: ALP 30-120; ALT 10-40; AST 10-30; total bilirubin 5-21.
Program Name: RF2LAB040
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca.

Figure 11.3.7.4 Liver biochemistry test results over time - patients with elevated ALT or AST, and elevated total bilirubin, at any time
(Safety analysis set)

Subject Identifier for the Study=E7####3



ALP Alkaline phosphatase. ALT Alanine aminotransferase. AST Aspartate aminotransferase.
ULN Upper limit of normal.
Reference ranges: ALP 30-120; ALT 10-40; AST 10-30; total bilirubin 5-21.
Program Name: RF2LAB040
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca.

Figure 11.3.7.4 Liver biochemistry test results over time - patients with elevated ALT or AST, and elevated total bilirubin, at any time
(Safety analysis set)

Subject Identifier for the Study=E7809004



ALP Alkaline phosphatase. ALT Alanine aminotransferase. AST Aspartate aminotransferase.
ULN Upper limit of normal.
Reference ranges: ALP 30-120; ALT 10-40; AST 10-30; total bilirubin 5-21.
Program Name: RF2LAB040
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca.

Figure 11.3.7.4 Liver biochemistry test results over time - patients with elevated ALT or AST, and elevated total bilirubin, at any time
(Safety analysis set)

Subject Identifier for the Study=E7$L2001



ALP Alkaline phosphatase. ALT Alanine aminotransferase. AST Aspartate aminotransferase.
ULN Upper limit of normal.
Reference ranges: ALP 30-120; ALT 10-40; AST 10-30; total bilirubin 5-21.
Program Name: RF2LAB040
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca.

Figure 11.3.7.4 Liver biochemistry test results over time - patients with elevated ALT or AST, and elevated total bilirubin, at any time
(Safety analysis set)

Subject Identifier for the Study=E7381.4002



ALP Alkaline phosphatase. ALT Alanine aminotransferase. AST Aspartate aminotransferase.
ULN Upper limit of normal.
Reference ranges: ALP 30-120; ALT 10-40; AST 10-30; total bilirubin 5-21.
Program Name: RF2LAB040
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca.

Figure 11.3.7.4 Liver biochemistry test results over time - patients with elevated ALT or AST, and elevated total bilirubin, at any time
(Safety analysis set)

Subject Identifier for the Study=E7522005



ALP Alkaline phosphatase. ALT Alanine aminotransferase. AST Aspartate aminotransferase.
ULN Upper limit of normal.
Reference ranges: ALP 30-120; ALT 10-40; AST 10-30; total bilirubin 5-21.
Program Name: RF2LAB040
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca.

Figure 11.3.8.1.5.1 Vital signs data, box plot of Weight absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.

Program Name: RFZVT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for: AstraZeneca

Figure 11.3.8.1.5.2 Vital signs data, box-plot of Weight change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZVT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.1.6.1 Vital signs data, box plot of Systolic Blood Pressure absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.

Program Name: RFZVT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for: AstraZeneca

Figure 11.3.8.1.6.2 Vital signs data, box-plot of Systolic Blood Pressure change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZVT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.1.7.1 Vital signs data, box plot of Diastolic Blood Pressure absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.

Program Name: RFZVT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for: AstraZeneca

Figure 11.3.8.1.7.2 Vital signs data, box-plot of Diastolic Blood Pressure change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZVT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.1.8.1 Vital signs data, box plot of Pulse Rate absolute values (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.

Program Name: RFZVT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for: AstraZeneca

Figure 11.3.8.1.8.2 Vital signs data, box-plot of Pulse Rate change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile.
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZVT010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.2.1 ECG data, box plot of QT Interval absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile

Program Name: RFZECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.2.2 ECG data, box-plot of QT Interval change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.3.1 ECG data, box plot of Heart Rate absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile

Program Name: RFZECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.3.2 ECG data, box-plot of Heart Rate change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.4.1 ECG data, box plot of PR Interval absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile

Program Name: RFZECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.4.2 ECG data, box-plot of PR Interval change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.5.1 ECG data, box plot of RR Interval absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile

Program Name: RFZECG01.0.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.5.2 ECG data, box-plot of RR Interval change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.6.1 ECG data, box plot of QRS Duration absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile

Program Name: RFZECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.6.2 ECG data, box-plot of QRS Duration change from baseline (Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.7.1 ECG data, box plot of QTcF absolute values
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile

Program Name: RFZECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Figure 11.3.8.7.2 ECG data, box-plot of QTcF change from baseline
(Safety analysis set)



Horizontal line: median, Box: Q1 - Q3
Whiskers extend to the most extreme observation within 1.5 times the interquartile range from the nearest quartile
Baseline is defined as the last result obtained prior to the start of study treatment.

Program Name: RFZECG010.sas
Data Cutoff: 30OCT2013
Report Produced: 10DEC2013
SCRI for AstraZeneca

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	2813001
Age/Gender	76/Male
Date of first treatment dose	28 Nov 2012
Date of last treatment dose	05 Jan 2013
Event/Grade/Date:	Fatigue/Grade 3/05 Jan 2013
Outcome/Causality/Date:	Resolved/Unrelated/08 Jan 2013
Relevant medical history	Diarrhea (Grade 2) that began on 02 Dec 2012. Abdominal Discomfort, Appetite loss, Diarrhea, Reflux, Constipation, Dry mouth and Hypertension. Of note, the onset date for Fatigue on the report is indicated as UN Sep 2012, which is before the patient signed consent.
On study concomitant medications	Folic acid, Omeprazole, Domperidone, Paracetamol, Difflam mouthwash, Ensure, Loperamide, Cyclizine and Codeine phosphate

This 76 year old male with DLBCL was hospitalization for increasing fatigue (Grade 3) on 05 Jan 2013 after receiving study drug for 5 weeks. The patient had a history of fatigue prior to initiating study drug. Upon hospitalization the patient's labs revealed HgB 8.0 (Grade 3 anemia), and the patient received a blood transfusion on 06 Jan 2013. He was discharged stable from the hospital on 08 Jan 2013.

Treatment was temporarily discontinued for this event.

This patient's fatigue were considered a worsening of the patient's pre-existing lymphoma-related symptoms, and **unrelated to treatment with fostamatinib** by a physician at the site.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	2813005
Age/Gender	70/Male
Date of first treatment dose	15 May 2013
Date of last treatment dose	12 Aug 2013
Event/Grade/Date:	VF Cardiac Arrest/Grade 4/12 Aug 2013
Outcome/Causality/Date:	Resolved/Unrelated/23 Aug 2013
Relevant medical history	Postural dizziness since 25 Dec 2013 Constipation, Hypokalemia, Gout, Right ear deafness, Perthes' disease (as a child). No history of cardiovascular disease.
On study concomitant medications	Omeprazole, Acyclovir, Chlorhexidine, Nystatin, Allopurinol and Furosemide

This 70 year old male with refractory DLBCL lost consciousness outside of the hospital and was found to be in ventricular fibrillation. He was resuscitated, including cardioversion, and hospitalized on 12 Aug 2013. Angiogram performed on 13 Aug 2013 revealed occlusion of the left anterior descending artery (LAD) with collateralization via the right coronary artery (RCA) without requiring stent insertion. ECHO on16 Aug 2013 revealed dilated LV with estimated severely impaired LV systolic function (LVEF 23%) moderate mitral regurgitation and dilated right heart with mild impaired systolic function. TTE and synchrony studies 20 Aug 2013 revealed evidence of Antero-septal scar which supported the existence of a previous myocardial infarction, and implied that there was a chronic component to the event. He was started on low molecular weight heparin (LMWH), Aspirin and B-blocker and a dual chamber ICD implantation was performed on 22 Aug 2013. He was reviewed by the heart failure specialists and was advised medical management for left ventricular systolic dysfunction. His low LVEF was attributed partly to his recent resuscitation. At the time of his discharge, he was clinically improved, without any evidence of CHF; however, a follow-up echocardiogram was not performed.

The patient began fostamatinib on 15 May 2013 and continued through 12 Aug 2013 the day of this event. The study drug was temporarily discontinued due to this event.

His spontaneous ventricular arrhythmia is attributed to underlying ischemic heart disease, and is **unrelated to treatment with fostamatinib**.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	2818001
Age/Gender	54/Female
Date of first treatment dose	21 Jan 2013
Date of last treatment dose	04 Mar 2013
Event/Grade/Date:	Neutropenic Sepsis/Grade 3/10 Mar 2013
Outcome/Causality/Date:	Resolved/Unrelated/19 Mar 2013
Relevant medical history	Spinal cord compression, irritable bowel syndrome, bilateral deafness, abdominal pain, abdominal tenderness on palpitation, night sweats, anorexia, abdominal cramps, indigestion, yawning and hiccoughing, and anemia.
On study concomitant medications	Omeprazole. On 04 Mar 2013 the patient started the following regimen for DLBCL: Cyclophosphamide, Etoposide, Prednisolone and Dexamethasone

This 54 year old female patient with advanced DLBCL received 6 week fostamatinib and was removed from study on 04 Mar 2013 because of disease progression. The patient was immediately started on cyclophosphamide, etoposide, prednisolone, and dexamathoasone. The patient was admitted to the hospital on 06 Mar 2013 due to anemia and neurological symptoms. The patient was scheduled to be discharged, but developed pyrexia along with an ANC of 0.2 on 10 March 2013. She was given IV Tazocin without response and was changed to IV Meropenam. She was then switched to oral antibiotics and discharged on 19 Mar 2013.

The Investigator has assessed the neutropenic sepsis as **unrelated to fostamatinib** and related to patient's new DLBCL myelosuppressive chemotherapy regimen previously described.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7801007
Age/Gender	81/Female
Date of first treatment dose	13 Aug 2013
Date of last treatment dose	19 Aug 2013
Event/Grade/Date:	Vasovagal Syncope/Grade 3/20 Aug 2013
Outcome/Causality/Date:	Resolved/Unrelated/24 Aug 2013
Relevant medical history	Hyperlipidemia, Bilateral numbness to fingertips
On study concomitant medications	Roxicodone, Xanax, Claritin, Pravastatin, Vitamin B6, Calcium, Vitamin B12, Magnesium, Vitamin C, and Osteo Bi-Flex.

This 81 year old patient had received fostamatinib for 6 days when she returned to the clinic for follow-up and had severe vomiting while there followed by syncope and seizure-like activity on 20 Aug 2013. She was admitted to the hospital for evaluation. CT Head showed new parietal white matter parenchymal hypodensity, possibly ischemic, but location was thought to be unusual for lucunar infarct. MRI of the brain also showed small vessel ischemic changes. The patient had no signs of infection and she was started on IV fluids and antiemetics. She was evaluated by the neurology team who felt that since she had spells of abnormal involuntary movements after vomiting, she most likely had vasovagal syncope and had provoked seizure activity due to a temporary decrease in brain perfusion. It was felt that this could possibly be convulsive syncope and that the patient did not required antiepileptic therapy. Nausea and vomiting resolved, and the patient was discharged on 24 Aug 2012. The patient did not have any additional episodes of vasovagal syncope. Of note, the site has confirmed the diagnosis of vasovagal syncope. Study drug was temporarily held during this event.

Patient began study drug on 13 Aug 2012 with last administered date of Fostamatinib disodium on 19 Aug 2012. The study drug was temporarily discontinued in response to this event.

The event was considered **unrelated to treatment** with fostamatinib.

Reason for narrative	**Serious adverse event leading to death**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7806007
Age/Gender	46/Male
Date of first treatment dose	23 April 2013
Date of last treatment dose	14 August 2013
Event/Grade/Date:	Congestive heart failure/Grade 3/19 July 2013 and 12 August 2013
Outcome/Causality/Date:	Death/Unrelated/30 August 2013
Relevant medical history	Congestive heart failure, Nonrheumatic Aortic valve disorder, Mitral stenosis, Mitral regurgitation, Aortic stenosis, and recent hospitalization for pleural effusions.
On study concomitant medications	Sertraline, Gabapentin, Valacyclovir, Lorazepam and Hydrocodone-acetaminophen

This 46-year-old male subject with refractory diffuse large B-cell lymphoma (DLBCL) returned to the outpatient clinic on 12 August 2013 for consideration of Cycle 5 Day 1 of fostamatinib. The subject was last seen in the hospital on 19 July 2013 with congestive heart failure that responded well to IV Lasix. An ECHO performed on 23 July 2013 showed an LVEF of 30%. He was prescribed Lisinopril 2.5 mg qd and was discharged to home in stable condition on 24 July 2013.

A chest x-ray at this visit (12 August 2013) showed worsening congestive heart failure. The subject was admitted to the hospital and started on antibiotics on 12 August 2013. Blood culture results were negative, and antibiotics were discontinued on 13 August 2013. His left ventricular ejection fraction (LVEF) was 15%. Study drug was discontinued on 14 August 2013. Pleural fluid from thoracentesis performed on 14 August 2013 was negative for lymphoma.

On 19 August 2013 a coronary angiogram confirmed the presence of chronic total occlusion of the mid left anterior descending coronary artery with evidence of left-to-let collaterals and a 70% area of stenosis of the right coronary artery. Patient was started on dobutamine on 15 August 2013 and initiated on afterload reduction agents. The afterload agents were discontinued because of hypotension and dobutamine was discontinued on 21 August 2013. The patient continued to become progressively more hypotensive and developed acute transaminitis secondary to low flow and shock liver. Balloon aortic valvulopasty and impella placement were performed on 23 August 2013.

The patient continued to decline, he received home hospice care, and expired on 28 September 2013.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Subject number	7806008
Age/Gender	62/Female
Date of first treatment dose	08 May 2013
Date of last treatment dose	19 May 2013
Event/Grade/Date:	Clostridium Difficile Infection/Grade 3/20 May 2013
Outcome/Causality/Date:	Not Recovered-Not Resolved/Unrelated/ 27 May 2013
Relevant medical history	Hyperlipidemia, Hypertension, Diabetes Mellitus Type II, Gastroesophageal reflux disease, Left pleural effusion, Pericardial Effusion
On study concomitant medications	Atorvastatin Calcium; Folic Acid; Lisinopril; Metformin; Sulfamethoxazole/Trimethoprim

This 62-year-old female subject with refractory diffuse large B-cell lymphoma (DLBCL) began fostamatinib 200 mg bid on 08 May 2013. On 20 May 2013, the subject went to the emergency room (ER) and was admitted to the hospital for nausea, vomiting, diarrhoea, shortness of breath (SOB), and severe weakness. The subject had recently had fluid removed from the left lung on 15 May 2013. A chest x-ray on 21 May 2013 showed rapid development of the mediastinal mass known to be related to lymphoma that accounted for the subject's SOB. Clostridium difficile (C. diff) per rectal culture taken 21 May 2013 was positive and Trop - 0.062, and she was started on vancomycin. The subject had one previous episode of C.diff and had been taking Bactrim® for infection prophylaxis since 06 March 2013. The subject was removed from the study on 24 May 2013 due to progressive disease and she expired on 11 June 2013 at a local hospital.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7808001
Age/Gender	71/Female
Date of first treatment dose	07 August 2012
Date of last treatment dose	28 March 2013
Event/Grade/Date:	Pain, back/Grade 3/29 Mar 2013
Outcome/Causality/Date:	Resolved/Unrelated/17 May 2013
Relevant medical history	Hyperlipidemia, Hypertension, Diabetes Mellitus Type II, Gastroesophageal reflux disease, Left pleural effusion, Pericardial Effusion
On study concomitant medications	Atorvastatin Calcium; Folic Acid; Lisinopril; Metformin; Sulfamethoxazole/Trimethoprim

This 71 year-old female with diffuse large B-cell lymphoma (DLBCL) was hospitalised for back pain on 29 March 2013. A magnetic resonance imaging (MRI) scan was performed and showed no progression of lymphoma; it did however show degenerative disk disease. No study drug action was taken in response to this event.

Relevant concomitant medications were: Sinemet®, fentanyl transdermal patch, and Vicodin®.

Subsequent to physical therapy and massage therapy, the patient noted that the pain had completely resolved as of 17 May 2013.

Per site, the back pain was **not related to study drug treatment** but related to intercurrent illness of degenerative disk disease.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7809001
Age/Gender	71/Female
Date of first treatment dose	05 September 2012
Date of last treatment dose	30 October 2012
Event/Grade/Date:	Progressive Deterioration (cytopenia)/Grade 1/12 Nov 2012
Outcome/Causality/Date:	Resolved/Related/ 15 Nov 2012
Relevant medical history	Hypertension, Diabetes, Hypercholesteremia
On study concomitant medications	Starlix, Metformin, Losartan, Zocor, Prevacid, HCTZ, Prednisone, and Duragesic

This 71 year old female received fostamatinib for diffuse large B-cell lymphoma (DLBCL) and was removed from the study due to progressive disease on 30 October 2012 after approximately 2 months of treatment. The patient was seen on 08 Nov 2012 with moderate cytopenia, maculopapular pruritic rash, and frontal headaches. She was started on steroids and a Fentanyl patch, and she improved until the patch was discontinued and she was tapered off steroids. Four days later, the patient returned with a persistent rash, headache, and worsening of cytopenias, to Grade 3, and was admitted to the hospital. CT scans were similar to previous scans and the MRI of the head was negative. She received empiric antibiotics, and when her cultures returned negative, she was switched to oral antibiotics. Her bone marrow showed no evidence of disease. Her symptoms improved on tapering dose of steroids and Fentanyl patch and she was discharged on 15 Nov 2012.

The patient was off study drug at the time of this event but within the 30-day window.

The site investigator assessed progressive deterioration **as possibly related to fostamatinib**. Per the Investigator Brochure for fostamatinib, this was an unexpected event.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Subject number	7809002
Age/Gender	61/Female
Date of first treatment dose	14 Sept 2012
Date of last treatment dose	08 Nov 2012
Event/Grade/Date:	Fever/Grade 1/13 Nov 2012
Outcome/Causality/Date:	Resolved/Related/ 20 Nov 2012
Relevant medical history	Hepatitis C, but currently inactive
On study concomitant medications	Calcium MVI, Magnesium MVI, B Complex Vitamin, Miralax OTC.

This 61-year-old female subject reported having a fever of 102°F at home on 13 Nov 2012. When the subject presented to the clinic on 16 Nov 2012, she had a temperature of 99.6°F and ANC 1.2 and she was admitted to the hospital. The subject was started on Fortaz, Vancomycin and Acetaminophen. Blood cultures were negative, and no source of infection was noted. The highest temperature recorded during the hospitalization was 101.7°F. Her fever resolved with the administration of antibiotics, and she was discharged on 20 Nov 2012.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7809004
Age/Gender	75/Male
Date of first treatment dose	28Mar 2013
Date of last treatment dose	03 April 2013
Event/Grade/Date:	Fever/Grade 1/04 Apr 2013
Outcome/Causality/Date:	Resolved/Unrelated/06 Apr 2013
Relevant medical history	Auto-transplant Oct/2010, Heart failure during induction to stem cell transplant, Diabetes Mellitus, Hypertension
On study concomitant medications	Glimepiride, Losartan, Atenolol, Levothyroxine, Finasteride, Tamsulosin, Simvastatin, Isosorbide dinitrate, Aspirin, Ceftriaxone

This 75 year old male went to clinic for Visit 3 Day 8, on April 4, 2013. Upon arrival patients temperature was 101F. Blood cultures were drawn and patient was admitted to the hospital for fever and to rule out possible sepsis. CXR was negative.

Relevant Lab Tests:

Baseline (19 Mar 2013): ANC- 4.6, AST- 32, ALT- 53

04 Apr 2013: ANC- 6.4, AST- 118, ALT- 225, Alk Phos – 142, T bili – 0.3

05 Apr 2013: ANC – 2.6, WBC - 3.1, Hgb – 9.2, Plt – 122, Creatinine – 1.7

06 Apr 2103: ANC – 2.25, WBC – 2.6, Hgb – 8.2, Plt – 114, Creatinine – 1.7, Blood Cultures – no growth after 3 days

Patient became afebrile and cultures were negative. He was discharged on 06 Apr 2013 on Ciprofloxacin 500mg po bid.

Study drug was temporarily discontinued due to this event.

The fever is judged to be related to infection, and **unrelated to treatment** with fostamatinib.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7810001
Age/Gender	74/Male
Date of first treatment dose	6 Sept 2013
Date of last treatment dose	13 Sept 2013
Event/Grade/Date:	Supraventricular Tachycardia/Grade 3/13 Sept 2013
Outcome/Causality/Date:	Resolved/Unrelated/17 Sept 2013
Relevant medical history	Atrial Fibrillation (11/Jan/2012 to present), Hypertension, Hypercholesterolemia, DMII, CAD s/p MI w/multiple stents placed (1996), Paroxysmal Afib
On study concomitant medications	Ambien, Colace, Duragesic, Folic acid, Humulin, Metoprolol tartrate, Naprosyn, Novolog FlexPen, Oxycodone, Pravastatin, Prilosec, Vitamin D2 and Zyloprim

This 74 year old male had a history of atrial fibrillation, first documented in January 2012. He had received 7 days of fostamatanib when he was found to have a heart rate of 150 at the Cycle 1 Day 8 visit. An ECG showed a **supraventricular tachycardia**, rate 150, resulting in hospitalization for heart rate reduction. Fostamatinib was temporarily discontinued. His arrhythmia was converted to sinus rhythm at a normal rate in the hospital, following treatment with amiodarone. Other concurrent cardiac events were ruled out.

Relevant tests are as follows:
13 Sept 2012: EKG – Supraventricular tachycardia, CTA – Increased size of bilateral pulmonary nodules but otherwise normal, CXR – normal, CK – 23, CK-MB – 2.0, LDH – 267, Troponin-T – 0.02, TSH – normal. 14 Sep 2012: CT – Tachycardia, ECHO – LVEF 55-60%, CK – 30, Troponin T - 0.02

His tachycardia stabilized and he was restarted fostamatinib on 15 Sept 2012. The subject's HCT was decreased throughout the hospitalization (**anaemia**) which appeared to delay discharge from the hospital until 17 Sep 2012.

The Site Investigator has assessed the event of supraventricular tachycardia as **not related** to protocol therapy, and related to history of atrial fibrillation.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7812003 (1)
Age/Gender	53/Male
Date of first treatment dose	20 Jun 2013
Date of last treatment dose	29 Jun 2013
Event/Grade/Date:	Hyponatremia/Grade 3/29 Jun 2013
Outcome/Causality/Date:	Resolved/Unrelated/30 Jun 2013
Relevant medical history	Insomnia
On study concomitant medications	Dilaudid, Fentanyl patch, Omeprazole, Ranitidine, Dexamethasone

This 53 year old man with refractory DLBCL had received fostamatinib for 9 days when he required hospitalization for hyponatremia (Na 126), which was accompanied by weakness, dizziness, and dehydration. The patient also reported taking Dilaudid 2mg every 1-2hrs for pain control when hospitalized. He was treated with normal saline, and quickly normalized his sodium to 137. The dehydration and poor oral intake were thought to be related to his underlying lymphoma, and unrelated to treatment with fostamatinib.

No study drug action has been taken in response to this event.

Per the site, hyponatremia was **not related to protocol treatment**, and likely related to dehydration.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7812003 (2)
Age/Gender	53/Male
Date of first treatment dose	20 Jun 2013
Date of last treatment dose	17 Jul 2013
Event/Grade/Date:	Pneumonia/Grade 3/20 Jul 2013
Outcome/Causality/Date:	Resolved/Unrelated/12 Aug 2013
Relevant medical history	Abdominal Pain, Decreased appetite, Grade 1 Constipation, Back Pain, Anxiety, Esophagitis, Gastritis, Weight loss, Fatigue and Grade 3 Thrombocytopenia on 18 Jul 2013.
On study concomitant medications	Acyclovir, Colace, Levoflaxacin, Lorazepam, Omeprazole, Ranitidine, Fentanyl patch, Dilaudid, Miralax and Tylenol Treatment medications for pneumonia: Levaquin, Meropenem 500mg IV q8hrs and Vancomycin

This 53 year old man with refractory DLBCL returned to the clinic on 18 Jul 2013 for Cycle 2 Day 1 fostamatinib but study drug was held due to Grade 3 thrombocytopenia. Two days later the patient presented to the ER with complaints of abdominal pain, fatigue, and generalized weakness. His temperature was 101.8, Chest X-Ray and Chest CT revealed right lower lobe pneumonia and ascites in the upper abdomen. He was admitted to the hospital on 20 Jul 2013 for IV antibiotics and observation. He was found to have progressive lymphoma, with increasing size of abdominal masses and ascites required repeated paracentesis. The patient was anemic and was given 2 units of packed red blood cells. Ascites was confirmed as disease progression and the patient underwent radiation from 07 Aug 2013 to 09 Aug 2013 for the bulky lymphoma mass in the abdomen and pelvis. The pneumonia in this patient was felt to be an accompaniment of his general decline due to progressive lymphoma, and unrelated to treatment with fostamatinib.

On 12 Aug 2013, the patient expired due to progression of disease and not pneumonia.

The subject began fostamatinib on 20 Jun 2013. The patient permanently discontinued from study on 18 Jul 2013 due to progression of disease. Per the site Investigator, pneumonia is not related to fostamatinib, but related to progression of DLBCL.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7815008 (1)
Age/Gender	76/Male
Date of first treatment dose	26 Apr 2013
Date of last treatment dose	27 May 2013
Event/Grade/Date:	Pneumonitis/Grade 3/26 May 2013
Outcome/Causality/Date:	Resolved/Related/ 05 Jun 2013
Relevant medical history	GERD, Hyperlipidemia, Hypertension
On study concomitant medications	Simvastatin, Omeprazole, Valtrex Allopurinol, Amlodipine

This 86 year old male presented to clinic to start Cycle 2 fostamatinib on 24 May 2013 reporting a Grade 1 cough, and night sweats for several days. CT Chest scan noted ground glass changes but no evidence of progressive adenopathy. Cycle 2 was initiated and the patient was empirically treated with Moxifloxacin 400 mg IV in the clinic and given Levofloxacin 750 mg QD to take at home. On 26 May 2013 the patient's daughter called and reported the patient had a fever of 100.2°F. They were advised to go to the ER. The patient was admitted to a local hospital on 27 May 2013. He was started on IV Cefepime with overnight. The patient's ANC was 2.2, platelets 104K and UA was negative on admission. CT Chest scan showed nonspecific interstitial pneumonitis. CXR was stable without acute process and blood cultures showed no growth after 5 days. He also experienced symptoms of urinary urgency and incontinence, but urine culture was negative. Patient became afebrile and was discharged home on oral Levaquin on 30 May 2013. At discharge the patient's ANC = 2.7 and platelets were 58K.

Study drug was temporarily discontinued due to this event and restarted after completion of antibiotics on 05 Jun 2013. The pneumonitis was considered possibly related to treatment with fostamatinib.

Reason for narrative	**Serious adverse event leading to death**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7815008 (2)
Age/Gender	76/Male
Date of first treatment dose	26 Apr 2013
Date of last treatment dose	7 June 2013
Event/Grade/Date:	Pneumonitis/Grade 5/07 Jun 2013
Outcome/Causality/Date:	Death/Related/ 17 Jun 2013
Relevant medical history	Gastroesophageal Reflux Disease (GERD), Hyperlipidemia, Hypertension
On study concomitant medications	Simvastatin, Omeprazole, Valtrex Allopurinol, Amlodipine

This 86-year-old male subject was hospitalized (27 May 2013) and treated for pneumonitis – Grade 3. Fostamatinib was held for approximately 10 days and restarted on 05 Jun 2013. The subject went to local Emergency Room (ER) on 07 June 2013 for complaints of shortness of breath, fatigue, fever and chills. Vital signs upon arrival were temperature 98.9, P 91, R 22, BP 100/61 and O2 saturation 94 on room air. The subject was treated with IV Vancomycin, Cefepime, Levaquin, Tobramycin and steroids. He was also evaluated for cardiomegaly detected on Chest X-ray (CXR). CT Chest revealed significant adenopathy consistent with known lymphoma with minimal progression and congestive heart failure (CHF). A bronchoscopy with RLL bronchoalveolar lavage revealed no significant diagnostic entities. Echocardiogram (ECHO) showed left ventricular ejection fraction (LVEF) of 40%, anterior wall hypokinesis and pulmonary hypertension with right ventricular systolic pressures of 50-60. He developed progressive hypoxemia that was unresponsive to IV diuretics. Pneumonia was ruled out and the subject was diagnosed with pneumonitis. The subject entered hospice on 15 Jun 2013 and expired on 17 Jun 2013.

The investigator assessed the cause of the subject's death to be pneumonitis related to fostamatinib.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7817005
Age/Gender	56/Male
Date of first treatment dose	29 May 2013
Date of last treatment dose	15 Jul 2013
Event/Grade/Date:	Sinus Ventricular Tachycardia/Grade 3/17 Jul 2013
Outcome/Causality/Date:	Resolved/Unrelated/ 19 Jul 2013
Relevant medical history	Atrial Fibrillation (Sep 2012 – controlled with Metoprolol and Digoxin without incident since diagnosis), Cataracts, Sinus Headaches, Hypertension, Arthritis, Hypercholesterolemia, Intermittent Constipation, Vocal Cord Paralysis
On study concomitant medications	Acetaminophen, Aspirin 1 Fluticasone nasal, Zetia, Digoxin, Lopressor, Esgic-plus, Cymetra and Dexamethasone.

This 56 year old male had been experiencing hoarseness since 15 May 2013 and was diagnosed with left vocal cord paralysis. On 24 Jun 2013 his ENT physician performed a vocal fold injection of Cymetra followed by a course of Dexamethasone 4mg bid for 7 days with improvement. However, on 15 Jul 2013 the patient experienced a sudden loss of voice and was diagnosed with bilateral vocal cord paralysis. The ENT physician advised the patient to have a percutaneous endoscopic gastrostomy (PEG) placed to prevent dehydration and malnutrition, which he underwent on 17 Jul 2013. Immediately post-surgery, the patient had period of Sinus Ventricular Tachycardia (SVT) which did not subside with adenosine and required cardioversion. He was admitted to the critical care unit (CCU) for observation on 17 Jul 2013 and was given Lopressor and digoxin, but continued to have intermittent A-Fib. ECHO showed moderate – severe pulmonary hypertension and small pericardial effusion, but normal LVEF (50-55%). His cardiologist felt the arrhythmias were caused by the mediastinal mass impeding on the pericardium. The patient continued to improve on medication and was discharged on 19 Jul 2013. The study drug was permanently discontinued due to this event.

Per the site Investigator, SVT was not related to fostamatinib and was related to predisposing risk factors related to the procedure (PEG placement).

Please note this event meets criteria for cardiac adjudication.

Reason for narrative	**Serious adverse event**
Investigational product/Study	Fostamatinib disodium /D4302C00001
Patient number	7822003
Age/Gender	81/Male
Date of first treatment dose	20 Mar 2013
Date of last treatment dose	01 Apr 2013
Event/Grade/Date:	Pneumonia/Grade 5/01 Apr 2013
Outcome/Causality/Date:	Resolved/Unrelated/07 Apr 2013
Relevant medical history	COPD, DM Type II, Hx of MI with CABG x 4 vessels, Systemic hypertension, Barrett's esophagus, Chronic atrial fibrillation on rate control/anticoagulation, Asthma
On study concomitant medications	Albuterol, Aspirin, Lipitor, Cardizem and Warfarin Per initial consultation note from 04/Feb/2013, the patient was taking Lantus, Symbicort, Flomax, Coreg, Percocet, Ramipril, Omeprazole, KCl PO, Crestor, Spiriva, Senna, Altace and Magnesium, but it is unclear if the subject was still on all of these at the time of the event.

This 81 year old male presented to clinic for Cycle 1 Day 15 visit with complaints of shortness of breath, dizziness, light headedness, confusion, and low blood pressure. His O2 sats were 83% on room air and blood pressure was 76/53 on presentation. The patient was transported to the hospital via ambulance for admission. His BUN /Cr was noted to be 60/3.0, respectively and Glucose was low at 50. He was treated with IV fluids and O2 for pneumonia and subendocardial demand ischemia. On 02 Apr 2013 the patient was transferred to the ICU due to persistent hypotensive with increased pressor needs despite dopamine drip. Hospital notes indicated the patient was diagnosed with right heart failure with hypotension and left pleural effusion (both unclear if new or old at this time). ER note also indicated acute encephalopathy, NSTEMI and acute renal failure. Notes also indicate that V/Q scan to rule out Pulmonary Embolism and thoracentesis for left pleural effusion were planned. We learned the patient expired on 07 Apr 2013 while in the hospital.

Updated information, including the assessment of the investigator, indicates that the cause of death as infection/sepsis. Fostamatinib is **unlikely** to have contributed to the hospitalization or subsequent death.